﻿<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><link>http://newsroom.ucla.edu/portal/ucla</link><language>en-us</language><pubDate>Wed, 01 Jul 2009 17:00:00 GMT</pubDate><title>Health Sciences: UCLA Newsroom</title><description /><copyright>UCLA Newsroom</copyright><generator>iPressroom.com</generator><item><author>Mark Wheeler</author><title>UCLA collaboration identifies immune system link to schizophrenia</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-collaboration-finds-immune-95099.aspx?link_page_rss=95099</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-collaboration-finds-immune-95099.aspx</guid><description><![CDATA[<P class=MsoNormal style="MARGIN: 0in 0in 0pt">Schizophrenia is a devastating mental disease, thought to be caused by the interaction of both genetic and environmental factors. Because there is no biochemical test that can identify the disorder, physicians rely upon the recognition of its symptoms — which can include auditory hallucinations and paranoia — in order to make their diagnosis.<?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="mso-spacerun: yes">&nbsp;</SPAN><o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">Now following on their earlier work that identified three gene locations that may be implicated in schizophrenia, researchers at UCLA and colleagues from around the world have, for the first time, identified additional genes that confirm what scientists have long suspected — that the immune system may play a role in the development of the disorder. Further, they have also identified genetic anomalies that disrupt the cellular pathways involved in brain development, memory and cognition, all markers of schizophrenia.<o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><o:p>&nbsp;</o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">The research appears in the July 1 online edition of the journal Nature.<o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="mso-spacerun: yes">&nbsp;</SPAN><o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">Roel Ophoff, the co-lead author and an assistant professor at the Center for Neurobehavioral Genetics at the UCLA Semel Institute for Neuroscience and Human Behavior, and his collaborators from nearly 50 institutions worldwide, performed a genome-wide scan of 2,663 people diagnosed with schizophrenia and 13,498 controls from eight European locations<SPAN class=MsoCommentReference><SPAN style="DISPLAY: none; mso-ansi-font-size: 10.0pt; mso-hide: all">.</SPAN></SPAN> They were looking for single nucleotide polymorphisms (SNP), genetic variations that are commonly present in the general population but more often present in those suffering from the disorder. In total, nearly 314,000 SNPs were included in their analysis.<o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="mso-spacerun: yes">&nbsp;</SPAN><o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">They found significant associations with genetic markers on the Major Histocompatibility Complex (MHC), a group of genes that controls several aspects of the immune response. Further, they discovered additional variations in two other genes, called NRGN and TCF4, which points to perturbation of pathways involved in brain development, memory and cognition.<o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="mso-spacerun: yes">&nbsp;</SPAN><o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">"This is another step forward in understanding the biological basis of this disorder, one that robs people of their lives," said Ophoff, who holds a joint appointment at the University of Utrecht, The Netherlands. "It also shows the importance of worldwide collaborations for the study of schizophrenia genetics, because it allows us to do very large numbers of scans." 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="mso-spacerun: yes">&nbsp;</SPAN><o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">The findings are significant yet not without challenge, said Ophoff, since the study aimed at the "common variants" in the human genome. "In other words," he said, "these are not rare mutations present in only a few individuals, but these genetic variants are abundantly present in the population. Anybody could carry this variant, but that doesn't mean they will necessarily develop the disease. Yet, when you look at the population at large, these variants are more often present in patients than in healthy control subjects." 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="mso-spacerun: yes">&nbsp;</SPAN><o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">And that’s important, he noted, in developing new techniques to thwart the disease. "Knowing these specific genes are involved in the pathway leading to schizophrenia provides unique clues as to which molecular mechanisms are involved," he said.<o:p></o:p>&nbsp; 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="mso-spacerun: yes">&nbsp;</SPAN><o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">While the association between schizophrenia and the immune system has long been suspected, the evidence for it has, until now, been mostly circumstantial. And impaired cognitive and memory functions are increasingly being recognized as core features of schizophrenia, which are poorly addressed by current medications.<o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="mso-spacerun: yes">&nbsp;</SPAN><o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">"The three common genetic variants we describe, then, which we feel predisposes certain individuals to schizophrenia, have the potential to be translated into targets for the development of new and novel medications," Ophoff said.<o:p></o:p>&nbsp; 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="mso-spacerun: yes">&nbsp;</SPAN><o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">Some 40 other authors and institutions contributed to the paper, and there were multiple funding sources; for UCLA, funding was provided by the National Institute of Mental Health. Other UCLA authors included Dr. Nelson Freimer, director of the Center for Neurobehavioral Genetics and professor of psychiatry, and Rita Cantor, professor of human genetics, both members of the <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><st1:place w:st="on"><st1:PlaceName w:st="on">David</st1:PlaceName> <st1:PlaceName w:st="on">Geffen</st1:PlaceName> <st1:PlaceType w:st="on">School</st1:PlaceType></st1:place> of Medicine. The UCLA authors report no conflicts of interest.<o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="mso-spacerun: yes">&nbsp;</SPAN><o:p></o:p> 
<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt"><STRONG>The Semel Institute for Neuroscience and Human Behavior </STRONG>is an interdisciplinary research and education institute devoted to the understanding of complex human behavior, including the genetic, biological, behavioral and sociocultural underpinnings of normal behavior, and the causes and consequences of neuropsychiatric disorders. In addition to conducting fundamental research, the institute faculty seeks to develop effective treatments for neurological and psychiatric disorders, improve access to mental health services and shape national health policy regarding neuropsychiatric disorders.</DIV>
<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt">&nbsp;</DIV>
<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt">For more news, see <A href="http://newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=155829" height="1" width="1" />]]></description><pubDate>Wed, 01 Jul 2009 17:00:00 GMT</pubDate></item><item><author>Sarah Anderson</author><title>Conversing helps language development more than reading alone</title><link>http://newsroom.ucla.edu/portal/ucla/conversing-with-child-more-effective-94603.aspx?link_page_rss=94603</link><guid>http://newsroom.ucla.edu/portal/ucla/conversing-with-child-more-effective-94603.aspx</guid><description><![CDATA[<DIV>Adult-child conversations have a more significant impact on language development than exposing children to language through one-on-one reading alone, according to a new study in the July issue of <I>Pediatrics</I>, the journal of the American Academy of Pediatrics.</DIV>
<DIV> </DIV>
<DIV>"Pediatricians and others have encouraged parents to provide language input through reading, storytelling and simple narration of daily events," explains study's lead author, Dr. Frederick J. Zimmerman, associate professor in the Department of Health Services in the UCLA School of Public Health. "Although sound advice, this form of input may not place enough emphasis on children's role in language-based exchanges and the importance of getting children to speak as much as possible."</DIV>
<DIV> </DIV>
<DIV>The study of 275 families of children ages 0-4 was designed to test factors that contribute to language development of infants and toddlers. Participants' exposure to adult speech, child speech and television was measured using a small digital language recorder or processor known as the LENA System. This innovative technology allowed researchers to hear what was truly going on in a child's language environment, facilitating access to valuable new insights.</DIV>
<DIV> </DIV>
<DIV>The study found that back-and-forth conversation was strongly associated with future improvements in the child's language score. Conversely, adult monologueing, such as monologic reading, was more weakly associated with language development. TV viewing had no effect on language development, positive or negative.</DIV>
<DIV> </DIV>
<DIV>Zimmerman adds, "What's new here is the finding that the effect of adult-child conversations was roughly <I>six times</I> as potent at fostering good language development as adult speech input alone."</DIV>
<DIV> </DIV>
<DIV>Each day, children hear an average of some 13,000 words spoken to them by adults and participate in about 400 conversational turns with adults. More conversations mean more opportunities for mistakes and therefore more opportunities for valuable corrections. Furthermore, they also provide an opportunity for children to practice new vocabulary.</DIV>
<DIV> </DIV>
<DIV>Parents should be encouraged not only to provide language input to their children through reading or storytelling but also to engage their children in two-sided conversations, the study concludes.</DIV>
<DIV> </DIV>
<DIV>"Talk is powerful, but what's even more powerful is engaging a child in meaningful interactions — the 'give and take' that is so important to the social, emotional and cognitive development of infants and toddlers," says Dr. Jill Gilkerson, language research director at LENA Foundation and a study co-author.</DIV>
<DIV> </DIV>
<DIV>"It is not enough to speak to children," Zimmerman adds. "Parents should also engage them in conversation. Kids love to hear you speak, but they thrive on trying speech out for themselves. Give them a chance to say what's on their minds, even if it's 'goo goo gah.'"</DIV>
<DIV> </DIV>
<DIV><STRONG>The UCLA School of Public Health</STRONG> is dedicated to enhancing the public's health by conducting innovative research; training future leaders and health professionals; translating research into policy and practice; and serving local, national and international communities. For more information, see <A href="http://www.ph.ucla.edu/">http://www.ph.ucla.edu/</A>.</DIV>
<DIV> </DIV>
<DIV>For more news, see <A href="http://newsroom.ucla.edu/" target=_self>UCLA Newsroom</A><SPAN style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">.<SPAN style="mso-spacerun: yes">  </SPAN></SPAN><SPAN style="LINE-HEIGHT: 115%; mso-bidi-font-size: 12.0pt"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=155404" height="1" width="1" />]]></description><pubDate>Mon, 29 Jun 2009 16:15:00 GMT</pubDate></item><item><author>UCLA Newsroom</author><title>Statement on the death of Michael Jackson at UCLA Medical Center</title><link>http://newsroom.ucla.edu/portal/ucla/media-reports-that-michael-jackson-94914.aspx?link_page_rss=94914</link><guid>http://newsroom.ucla.edu/portal/ucla/media-reports-that-michael-jackson-94914.aspx</guid><description><![CDATA[<div><span style="font-style: italic;">The family of Michael Jackson made this brief statement available on June 25 at Ronald Reagan UCLA Medical Center:</span><br><br>The legendary King of Pop, Michael Jackson, passed away on Thursday, June 25, 2009, at 2:26 p.m. It is believed he suffered cardiac arrest in his home. However, the cause of his death is unknown until results of the autopsy are known.</div>
<div>&nbsp;</div>
<div>His personal physician, who was with him at the time, attempted to resuscitate Jackson, as did paramedics who transported him to Ronald Reagan UCLA Medical Center. Upon arriving at the hospital at approximately 1:14 p.m., a team of doctors, including emergency physicians and cardiologists, attempted to resuscitate him for a period of more than one hour but were unsuccessful.</div>
<div>&nbsp;</div>
<div>Jackson’s family requests that the media respect their privacy during this tragic period of time.</div>
<div>&nbsp;</div>
<div><em>Video:&nbsp;<a href="http://www.newsroom.ucla.edu/portal/ucla/electronicplay.aspx?fid=73027&amp;id=E0C5478" target="_blank">Jermaine Jackson reading statement and Michael Jackson's personal physician</a>.</em></div>
<div>&nbsp;</div>
<div><span style="font-style: italic;">For more news, visit the </span><a style="font-style: italic;" href="http://newsroom.ucla.edu/" target="_self">UCLA Newsroom</a>.</div> <img src="http://newsroom.ucla.edu/rss.ashx?id=155349" height="1" width="1" />]]></description><pubDate>Fri, 26 Jun 2009 02:05:41 GMT</pubDate></item><item><author>Stuart Wolpert</author><title>Remembering what to remember and what to forget</title><link>http://newsroom.ucla.edu/portal/ucla/remembering-what-to-remember-and-94861.aspx?link_page_rss=94861</link><guid>http://newsroom.ucla.edu/portal/ucla/remembering-what-to-remember-and-94861.aspx</guid><description><![CDATA[<DIV>People in very early stages of Alzheimer’s disease already have trouble focusing on what is important to remember, a UCLA psychologist and colleagues report. <BR><BR>"One of the first telltale signs of Alzheimer’s disease may be not memory problems, but failure to control attention," said Alan Castel, UCLA assistant professor of psychology and lead author of the study. <BR><BR>The study consisted of three groups: 109 healthy older adults (68 of them female), with an average age of just under 75; 54 older adults (22 of them female) with very mild Alzheimer’s disease, who were functioning fine in their daily lives, with an average age of just under 76; and 35 young adults, with an average age of 19. <BR><BR>They were presented with eight lists of 12 words, one word at a time, each paired with a point value from 1 to 12. A new word with its value was presented on a screen every second. The words were common, like "table," "wallet" and "apple." They were given 30 seconds to recall the words, and were told to maximize their scores, by focusing on remembering the high-value words. <BR><BR>The young adults were selective, remembering more of the high-value words than the low-value words. They recalled an average of 5.7 words out of 12. The healthy older adults remembered fewer words, an average of 3.5, but were equally selective in recalling the high-value words. <BR><BR>"It’s not surprising that the older adults recalled fewer words," Castel said. "Memory capacity declines with age. However, the older adults were just as selective as the younger adults."<BR><BR>The people with very mild Alzheimer’s disease recalled an average of just 2.8 words and had some trouble in focusing on just the high-value words, recalling some lower-value words. <BR><BR>"They recall fewer words and their ability to be selective is worse," Castel said. "They understand that they should attend to the high-value words, but they can’t do it as well." <BR><BR>What are the implications of this study? <BR><BR>"Memory can be a limited resource," Castel said. "If we can recall only so much information, we need to be selective in old age. A trick for successful aging is to know what the important things are and to remember those things. Many older adults learn to be more selective because they know they can’t remember everything. The ability to be selective might decline when our attention is divided and in the early stages of Alzheimer’s disease."<BR><BR>Castel, who conducts research on human memory and aging, including how memory changes as we get older, suggests that older adults focus on fewer, important things. <BR><BR>"If you can remember only a few things before you travel, for example, you might want to remember to take your wallet, your plane ticket and your passport," he said. "If you forget your handkerchief and your comb, those aren’t so important." <BR><BR>Castel has conducted similar studies in which some words have negative point values; if you recall them, your score will decrease. <BR><BR>"Healthy older adults are good at not recalling them," he said. (He has not done that study with people in early stages of Alzheimer’s disease.) <BR><BR>If you don’t want to remember something, he said, the best thing to do is not to pay attention to it. <BR><BR>The research was published in the May issue of the journal Neuropsychology. It was federally funded by the National Institute on Aging, part of the National Institutes of Health. Co-authors are David Balota, professor of psychology and neurology at Washington University in St. Louis; and David McCabe, assistant professor of psychology at Colorado State University. <BR><BR>Castel, 33, follows his own advice.<BR><BR>"I can’t remember everything," he said. "I’m learning to be more strategic. I ask myself, what are the three most important things I need to do today. It’s about prioritizing." <BR><BR><STRONG>UCLA </STRONG>is California's largest university, with an enrollment of nearly 38,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 323 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=155341" height="1" width="1" />]]></description><pubDate>Thu, 25 Jun 2009 17:40:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>UCLA study reveals how tiny levels of carbon monoxide could damage fetal brains</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-study-uncovers-how-chronic-94824.aspx?link_page_rss=94824</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-study-uncovers-how-chronic-94824.aspx</guid><description><![CDATA[<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt">A&nbsp;UCLA study has discovered that chronic exposure during pregnancy to miniscule levels of carbon monoxide damages the cells of the fetal brain, resulting in permanent impairment.&nbsp;The journal BMC (BioMed Central ) Neuroscience published the findings June 22 in its online edition.<SPAN style="mso-spacerun: yes">&nbsp; </SPAN></DIV>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p>&nbsp;</o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">"We expected the placenta to protect fetuses from the mother’s exposure to tiny amounts of carbon monoxide,” said John Edmond, professor emeritus of biological chemistry at the David Geffen School of Medicine at UCLA. "But we found that not to be the case." 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><o:p>&nbsp;</o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">The researchers exposed pregnant rats to 25 parts per million carbon monoxide in the air, an exposure level established as safe by Cal/OSHA, <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><st1:place w:st="on"><st1:State w:st="on">California</st1:State></st1:place>’s division of occupational health and safety. <SPAN style="mso-spacerun: yes">&nbsp;</SPAN> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><o:p>&nbsp;</o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">Dr. Ivan Lopez, UCLA associate professor of head and neck surgery, tested the rats’ litters 20 days after birth.<SPAN style="mso-spacerun: yes">&nbsp;</SPAN>Rats born to animals who had inhaled the gas suffered chronic oxidative stress, a harmful condition caused by an excess of harmful free radicals or insufficient antioxidants.<SPAN style="mso-spacerun: yes">&nbsp; </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><o:p>&nbsp;</o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">"Oxidative stress damaged the baby rats’ brain cells, leading to a drop in proteins essential for proper function," said Lopez. "Oxidative stress is a risk factor linked to many disorders, including autism, cancer, Alzheimer’s, Parkinson’s, Lou Gehrig’s disease, multiple sclerosis and cardiovascular disease.<SPAN style="mso-spacerun: yes">&nbsp;</SPAN>We know that it exacerbates disease.”<o:p></o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><o:p>&nbsp;</o:p> 
<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt">"We believe that the minute levels of carbon monoxide in the mother rats’ environment made their offspring more vulnerable to illness," added <st1:City w:st="on"><st1:place w:st="on">Edmond</st1:place></st1:City>.<SPAN style="mso-spacerun: yes"> "</SPAN>Our findings highlight the need for policy makers to tighten their regulation of carbon monoxide." </DIV>
<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt">&nbsp;</DIV>
<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt">Tobacco smoke, gas heaters, stoves and ovens all emit carbon monoxide, which can rise to high concentrations in well-insulated homes. Infants and children are particularly vulnerable to carbon monoxide exposure because they spend a great deal of time in the home.&nbsp; </DIV>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><o:p>&nbsp;</o:p> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt">No policies exist to regulate the gas in the home.<SPAN style="mso-spacerun: yes">&nbsp;</SPAN>Most commercial home monitors sound an alarm only hours after concentrations reaches 70 parts per million — nearly three times the 25 parts per million limit set by Cal/OSHA.<SPAN style="mso-spacerun: yes">&nbsp; </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><o:p>&nbsp;</o:p> 
<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt">A grant from the <st1:place w:st="on"><st1:PlaceType w:st="on">University</st1:PlaceType> of <st1:PlaceName w:st="on">California</st1:PlaceName></st1:place>’s Tobacco-related Disease Research Program supported the research.</DIV>
<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt">&nbsp;</DIV>
<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt">For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self><SPAN style="COLOR: #0000ff; TEXT-DECORATION: underline">UCLA Newsroom</SPAN></A>.</DIV>
<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt">&nbsp;</DIV>
<DIV class=MsoNormal style="MARGIN: 0in 0in 0pt">&nbsp;</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=155332" height="1" width="1" />]]></description><pubDate>Thu, 25 Jun 2009 16:10:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>First direct visualization of memory formation in the brain</title><link>http://newsroom.ucla.edu/portal/ucla/first-direct-visualization-of-94669.aspx?link_page_rss=94669</link><guid>http://newsroom.ucla.edu/portal/ucla/first-direct-visualization-of-94669.aspx</guid><description><![CDATA[<B></B>
<DIV><STRONG>FINDINGS:</STRONG> </DIV>
<DIV>UCLA and McGill University researchers have, for the first time, "photographed" a memory in the making. The study clarifies one of the ways in which connections in the brain between nerve cells, called synapses, can be changed with experience. The phenomenon is called "synaptic plasticity," and is the foundation for how we learn and remember. As we learn, the memories are stored in changes in the strength and/or number of synaptic connections between nerve cells in our brain. Long-lasting changes in synaptic connections are required for long-term memories. This is the first study to use fluorescent imaging to directly visualize protein synthesis - the making of a memory - at individual synapses during learning-related synaptic plasticity. </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>IMPACT</STRONG>: </DIV>
<DIV>Understanding how synapses can change with experience is critical to understanding behavioral plasticity and to understanding diseases in which learning and experience-dependent behaviors are impaired. Such diseases include mental retardation and Alzheimer's disease and anxiety and mood disorders. It also can elucidate potential strategies for improving normal cognition and behavioral plasticity. </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>JOURNAL</STRONG>: </DIV>
<DIV>The research appears in the June 19 edition of the journal Science. </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>AUTHORS</STRONG>: </DIV>
<DIV>Senior author Kelsey Martin, associate professor of psychiatry and biological chemistry; Dan Ohtan Wang, Sang Mok Kim, Yali Zhao, Hongik Hwang, Satoru K. Miura, all of UCLA; and Wayne S. Sossin, McGill University. </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>HOW</STRONG>: </DIV>
<DIV>The researchers used sensory and motor neurons from the sea slug <I>Aplysia Californica</I> that can form connections in culture. The neurons were stimulated with serotonin, which strengthens the synapses, and allowed them to detect new protein synthesis using a "translational reporter," a fluorescent protein that can be easily detected and tracked. </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>MORE</STRONG>: </DIV>
<DIV>This is the first study to directly visualize protein synthesis at individual synapses during a long-lasting form of synaptic plasticity. The studies revealed an exquisite level of control over the specificity of regulation of new protein synthesis. "While this was not really surprising to us given the complexity of information processing in the brain," said Martin, "visualizing the process of protein synthesis at individual synapses, and beginning to discern the elegance of its regulation, leaves us, as biologists, with a wonderful sense of awe." </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>FUNDING</STRONG>: </DIV>
<DIV>This study was funded by the National Institutes of Health, the W.M. Keck Foundation, and the Canadian Institutes of Health Research. The authors report no conflict of interest.</DIV>
<DIV>&nbsp;</DIV>
<DIV>
<DIV><STRONG>MEDIA CONTACT:</STRONG></DIV>
<DIV>Mark Wheeler | 310-794-2265 | <A href="mailto:mwheeler@mednet.ucla.edu"><SPAN style="COLOR: #0000ff; TEXT-DECORATION: underline">mwheeler@mednet.ucla.edu</SPAN></A> </DIV><!--END PRINT--></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=155273" height="1" width="1" />]]></description><pubDate>Mon, 22 Jun 2009 23:25:00 GMT</pubDate></item><item><author>Amy Albin</author><title>Mattel Children's Hospital UCLA ranked among nation's best pediatric hospitals</title><link>http://newsroom.ucla.edu/portal/ucla/mattel-children-s-hospital-ucla-94629.aspx?link_page_rss=94629</link><guid>http://newsroom.ucla.edu/portal/ucla/mattel-children-s-hospital-ucla-94629.aspx</guid><description><![CDATA[<DIV>Mattel Children's Hospital UCLA ranks among the nation's top pediatric hospitals, according to the U.S. News Media Group's annual survey of the finest pediatric facilities in the United States.</DIV>
<DIV> </DIV>
<DIV>The 2009 edition of "<A href="http://www.usnews.com/childrenshospitals" target=_self>America's Best Children's Hospitals</A>" is currently available online and will be published in the August issue of U.S. News & World Report, on newsstands July 21.</DIV>
<DIV> </DIV>
<DIV>The survey is the most extensive listing of its kind and includes hospital rankings in 10 pediatric specialties. Nationally, Mattel Children's Hospital was recognized for excellence in nine of the 10 categories, including kidney disorders (ranked No. 3), digestive disorders (8), neurology and neurosurgery (12), heart and heart surgery (14), diabetes and endocrine disorders (15), urology (16), cancer (16), neonatal care (21), and orthopedics (26).</DIV>
<DIV> </DIV>
<DIV>"By combining the overall scores of each category for all hospitals ranked in the survey, we also calculated that Mattel Children's Hospital UCLA ranked 12th in the nation and second in the state of California," said the hospital's physician-in-chief, Dr. Edward R.B. McCabe, who holds the Mattel Executive Endowed Chair in the UCLA Department of Pediatrics. "We are especially proud that two of our programs — kidney disorders and digestive disorders — were ranked the highest on the West Coast and our neurology and neurosurgery program was ranked the highest in the state. Great care is delivered to the children and families at Mattel Children's Hospital every day, and these rankings are a salute to our dedicated doctors, nurses and staff."</DIV>
<DIV> </DIV>
<DIV>This year's rankings weighed a three-part blend of reputation, outcomes and care-related measures such as nursing care, advanced technology, credentialing and other factors. Hospitals were judged based on a combination of opinions from pediatric specialists about hospitals they would recommend for the sickest children and data gathered in a 65-page survey covering important hospital information, ranging from surgical death rates to whether pediatric anesthesiologists and other subspecialists are on staff. The U.S. News & World Report website offers a detailed description of the <A href="http://health.usnews.com/articles/health/best-childrens-hospitals/2009/06/17/behind-the-best-childrens-hospitals-rankings.html" target=_blank>methodology</A>.</DIV>
<DIV> </DIV>
<DIV>Ranking-eligible facilities were largely drawn from two membership categories of the National Association of Children's Hospitals and Related Institutions (NACHRI): free-standing children's hospitals and large, multidisciplinary pediatric departments within medical centers. Several non-NACHRI members were added to the rankings because of known expertise or because they were recommended by experts. Of the 160 children's hospitals invited to complete the 65-page survey, 98 responded. The survey was created and administered by RTI International, which also collects the data and oversees the methodology for the annual "Best Hospitals" rankings in U.S. News & World Report.</DIV>
<DIV> </DIV>
<DIV>"While they might be a small percentage of all hospital patients, a large number of children every year need high-quality hospital care," said U.S. News' health rankings editor Avery Comarow. "The objective of the 'Best Children's Hospitals' rankings is to help children with uniquely challenging medical needs, and for these special patients, it is essential they seek treatment at pediatric facilities with deep expertise. With this year's rankings, we are providing important information on the best of the best."</DIV>
<DIV> </DIV>
<DIV><B><A href="http://www.uclahealth.org/mattel" target=_self>Mattel Children's Hospital UCLA</A></B>, one of the highest-rated children's hospitals in California, is a vital component of Ronald Reagan UCLA Medical Center, ranked by U.S. News & World Report as the No. 3 hospital in nation and best in the Western United States. Mattel Children's Hospital offers a full spectrum of primary and specialized medical care for infants, children and adolescents. The hospital's mission is to provide state-of-the-art treatment for children in a compassionate atmosphere and to improve the understanding and treatment of pediatric diseases. </DIV>
<DIV> </DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=155240" height="1" width="1" />]]></description><pubDate>Fri, 19 Jun 2009 19:10:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Alterations in brain's white matter key to schizophrenia, UCLA study shows</title><link>http://newsroom.ucla.edu/portal/ucla/alterations-in-brain-s-white-matter-94666.aspx?link_page_rss=94666</link><guid>http://newsroom.ucla.edu/portal/ucla/alterations-in-brain-s-white-matter-94666.aspx</guid><description><![CDATA[<DIV>Schizophrenia, a chronic and debilitating disorder marked in part by auditory hallucinations and paranoia, can strike in late adolescence or early adulthood at a time when people are ready to stand on their own two feet as fully independent adults.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Now scientists at UCLA think they are beginning to understand one important piece of this puzzle. In the first study of its kind, the researchers used a novel form of brain imaging to discover that white matter in the brains of adolescents at risk of developing schizophrenia does not develop at the same rate as healthy people. Further, the extent of these alterations can be used to predict how badly patients will or will not deteriorate functionally over time.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Reporting in the online edition of the journal Biological Psychiatry, lead author Katherine Karlsgodt, a postdoctoral fellow in UCLA's Department of Psychology, and senior authors Tyrone Cannon and Carrie Bearden, professors&nbsp;at the UCLA Semel Institute for Neuroscience and Human Behavior, focused on the brain's white matter — which forms the major connections between different brain regions&nbsp;— because it is known that white matter is disrupted in people who already have schizophrenia.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We found that healthy subjects showed a normal and expected increase in measures indexing white matter integrity in the temporal lobe as they age," said Karlsgodt, "but young people at high-risk for psychosis showed no such increase — that is, they fail to show the normal developmental pattern."</DIV>
<DIV>&nbsp;</DIV>
<DIV>While there is growing evidence that schizophrenics show changes in white matter, and there is increasing evidence that white matter connectivity may be highly relevant to the development of psychosis, there is very little known about how these changes arise, said Karlsgodt. Historically, looking at white matter has been hard to do. But in recent years, she said, researchers have begun to use a relatively new technique, diffusion tensor imaging (DTI) that uses the movement of water molecules along white matter tracts to map out the brain's pathways. In the last few years, these techniques have been applied to research schizophrenia and other disorders.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers studied a control group of 25 healthy&nbsp;individuals&nbsp;and 36 teens and young adults, aged 12 to 26, at very high risk for developing schizophrenia, and followed them over a two-year period. The adolescents were identified as high risk due to genetic factors (i.e., being close relatives of someone with schizophrenia), or because they showed very early clinical symptoms of the disease. All of the subjects underwent a DTI scan at the start of the trial, along with clinical and functional assessments. Follow-up assessments of clinical and functional outcome were done at different periods over the next two years.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Failing to find a normal increase in white matter integrity over time in the at-risk subjects, said Karlsgodt, "suggests there is a fundamental difference in how typically developing young people and high-risk adolescents develop during this period right before the disease would be expected to manifest. Something may go awry with the developmental process during this period that might contribute to the onset of the disorder."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The other important finding, she said, was that by looking at white matter integrity in the temporal lobe at people's first appointment, "we could predict how well they would be functioning 15 months later at work, school and home.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This is a very exciting finding, because it means we might be closer to being able to identify people who will need more or different treatments in the future, so that we can get them the help they need."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Research was carried out in the Clinical Neuroscience Lab of Tyrone D. Cannon of UCLA, with additional contribution from co-author Tara A. Niendam of the University of California, Davis. Research was supported by the National Institutes of Health, the National Alliance for Research on Schizophrenia and Affective Disorders, and a gift to UCLA by Garen and Shari Staglin. The authors reported no known biomedical financial interests or other potential conflicts of interest.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Karlsgodt, Bearden and Cannon are members of the Center for the Assessment and Prevention of Prodromal States (CAPPS) at the Semel Institute. CAPPS provides clinical, psychosocial and neuropsychological assessments, and psychological and psychiatric treatment. It also conducts other research aimed at early identification and prevention of these at-risk mental states. </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.semel.ucla.edu/" target=_self>The Semel Institute for Neuroscience and Human Behavior</A></STRONG> is a world-leading, interdisciplinary research and education institute devoted to the understanding of complex human behavior and the causes and consequences of neuropsychiatric disorders.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://newsroom.ucla.edu/portal/ucla/default.aspx" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=155253" height="1" width="1" />]]></description><pubDate>Fri, 19 Jun 2009 18:01:25 GMT</pubDate></item><item><author>Jennifer Marcus</author><title>Research explores interactions between nanomaterials, biological systems</title><link>http://newsroom.ucla.edu/portal/ucla/exploring-the-world-of-nanomaterial-94257.aspx?link_page_rss=94257</link><guid>http://newsroom.ucla.edu/portal/ucla/exploring-the-world-of-nanomaterial-94257.aspx</guid><description><![CDATA[<DIV>The recent explosion in the development of nanomaterials with enhanced performance characteristics for use in commercial and medical applications has increased the likelihood of people coming into direct contact with these materials. <BR><BR>There are currently more than 800 products on the market — including clothes, skin lotions and cleaning products — claiming to have at least one nanocomponent, and therapeutic nanocarriers have been designed for targeted drug delivery inside the human body. Human exposure to nanomaterials, which are smaller than one one-thousandth the diameter of a human hair, raises some important questions, including whether these "nano-bio" interactions could have adverse health effects.</DIV>
<DIV> </DIV>
<DIV>Now, researchers at UCLA and the California NanoSystems Institute (CNSI), along with colleagues in academia and industry, have taken a proactive role in examining the current understanding of the nano-bio interface to identify the potential risks of engineered nanomaterials and to explore design methods that will lead to safer and more effective nanoparticles for use in a variety of treatments and products.</DIV>
<DIV> </DIV>
<DIV>In a research review published in the July issue of the journal<SPAN style="FONT-STYLE: italic"> </SPAN>Nature Materials (and currently available <A href="http://www.nature.com/nmat/journal/vaop/ncurrent/full/nmat2442.html" target=_blank>online</A>)<SPAN style="FONT-STYLE: italic"></SPAN>, the team provides a comprehensive overview of current knowledge on the physical and chemical properties of nanomaterials that allow them to undergo interactions with biological molecules and bioprocesses.<SPAN id=pr_TEXT1 onmouseover="top.hlElement(1,'text',1,2,window.name)" onclick="top.editElement('text',1,2,window.name)" onmouseout="top.hlElement(0,'text',1,2,window.name)"></SPAN><BR><BR>"What we have established here is a blueprint that will serve to educate the first generation of nanobiologists," said Dr. Andre Nel, leader of the team and chief of the division of nanomedicine at the David Geffen School of Medicine at UCLA and the California NanoSystems Institute.</DIV>
<DIV> </DIV>
<DIV>Despite remarkable advances in nanoscience, relatively little is known about the intracellular activity and function of engineered nanomaterials, an area of study particularly important for the development of effective and safe nanoparticle drug-delivery systems. Much of the current knowledge derives from the study of tagged or labeled nanoparticles and their effects on cells after cellular uptake — without any detailed understanding of what these interactions may lead to, good or bad.</DIV>
<DIV> </DIV>
<DIV>The review article examines the variety of ways in which nanomaterials interface with biological systems and presents a roadmap of the physical and chemical properties of the materials that could lead to potentially hazardous or advantageous interactions at the nano-bio interface. A better understanding of the biological impact, combined with appropriate stewardship, will allow for more informed decisions about design features for the safe use of nanotechnology. </DIV>
<DIV> </DIV>
<DIV>In addition to Nel, the team included Tian Xia, a researcher in UCLA's nanomedicine division, UCLA associate professor of civil and environmental engineering Eric Hoek, Lutz Mädler of the University of Bremen, Darrell Velegol of Penn State University, Ponisseril Somasundaran of Columbia University, Fred Klessig of Pennsylvania Bio Systems, Vince Castranova of the National Institute for Occupational Safety and Health, and Mike Thompson of FEI Co.</DIV>
<DIV> </DIV>
<DIV>"We are committed to ensuring that nanotechnology is introduced and implemented in a responsible and safe manner," said Nel, who also directs the Center for Environmental Implications of Nanotechnology, which is funded by the National Science Foundation and the Environmental Protection Agency and is headquartered at the CNSI. <BR><BR>"Based on our rapidly improving understanding of nano-bio interactions, we have done a thorough examination of the literature and our own research progress to identify measures that could be taken for safe design of nanomaterials," he said. "Not only will this improve the implementation and acceptance of this technology, but it will also provide the cornerstone of developing new and improved nanoscale therapeutic devices, such as drug-delivering nanoparticles."<BR><BR>The review article spotlighted several important research advancements:</DIV>
<DIV> </DIV>
<UL>
<LI>A classification of the interactions when nanomaterials contact and bind to biological systems will help scientists understand how man-made materials may react when exposed to cells, tissues and various life forms in different natural environmental contexts.</LI></UL>
<DIV> </DIV>
<UL>
<LI>When nanomaterials enter a biological fluid — for example, blood, plasma or interstitial fluid — the materials' surface may be coated with proteins. Understanding how these protein layers change the properties of the nanomaterials and the ways in which they interact in the body can provide valuable information on how to alter the protein coatings to allow for targeted delivery of nanomaterials to specific tissues, such as in cancer treatments.</LI></UL>
<DIV> </DIV>
<UL>
<LI>Physicochemical properties such as size, charge, shape and other characteristics could greatly affect the ability of nanomaterials to enter a cell; this could determine whether a material can be useful in nanomedicine applications or could cause harm if taken in by life forms in an ecosystem or food chain.</LI></UL>
<DIV> </DIV>
<UL>
<LI>Nanoparticles can elicit a wide range of intracellular responses, depending on their properties, concentrations and interactions with biological molecules. These properties and their relationships to cellular function can induce cellular damage or induce advantageous cellular responses, such as increased energy production and growth.</LI></UL>
<DIV> </DIV>
<DIV> </DIV>
<DIV>Based on the link between certain nanomaterial properties and potential toxic effects, the team asserts that scientists can reengineer specific nanomaterial properties that are hazardous while maintaining catalytically useful function for industrial use. </DIV>
<DIV> </DIV>
<DIV>As an example of a safe design feature, some nanoparticles now receive a surface coating designed to improve safety by preventing bioreactivity. Nanoparticles in cosmetic formulations such as suntan lotions, for instance, may be coated with a water-repelling polymer to reduce direct contact with human skin. An extension of this principle uses polymers and detergents to decrease cellular uptake. However, there is the potential that when the coating wears off, the material may become hazardous. It is therefore important to consider improving the stability of coating substances. Coating nanoparticles with protective shells is also an effective means of preventing the breakup of materials that could release toxic substances upon dissolution.</DIV>
<DIV> </DIV>
<DIV>"Instead of waiting for knowledge to unfold randomly, we can already begin to view the events at nano-bio interface as a discoverable scientific platform that can be used for setting up a deliberate inorganic-organic roadmap to new, better and safer products," Nel said. "What we can identify by understanding the rules that shape the nano-bio interface will have a massive impact on the ability to develop safe nanomaterials in the future."</DIV>
<DIV> </DIV>
<DIV><SPAN style="FONT-WEIGHT: bold"><A href="http://www.cnsi.ucla.edu/" target=_blank>The California NanoSystems Institute</A></SPAN> (CNSI) is an integrated research center operating jointly at UCLA and UC Santa Barbara whose mission is to foster interdisciplinary collaborations for discoveries in nanosystems and nanotechnology; train the next generation of scientists, educators and technology leaders; and facilitate partnerships with industry, fueling economic development and the social well-being of California, the United States and the world. The CNSI was established in 2000 with $100 million from the state of California and an additional $250 million in federal research grants and industry funding. At the institute, scientists in the areas of biology, chemistry, biochemistry, physics, mathematics, computational science and engineering are measuring, modifying and manipulating the building blocks of our world — atoms and molecules. These scientists benefit from an integrated laboratory culture enabling them to conduct dynamic research at the nanoscale, leading to significant breakthroughs in the areas of health, energy, the environment and information technology.</DIV>
<DIV> </DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=155235" height="1" width="1" />]]></description><pubDate>Fri, 19 Jun 2009 16:55:00 GMT</pubDate></item><item><author>Gwen Driscoll</author><title>Long-term care costs exceed yearly income for many Calif. seniors living alone</title><link>http://newsroom.ucla.edu/portal/ucla/out-of-reach-long-term-care-costs-94165.aspx?link_page_rss=94165</link><guid>http://newsroom.ucla.edu/portal/ucla/out-of-reach-long-term-care-costs-94165.aspx</guid><description><![CDATA[<DIV><EM>(To see the data, visit <A href="http://www.healthpolicy.ucla.edu/news_06182009b.html">www.healthpolicy.ucla.edu/news_06182009b.html</A>.) </EM></DIV>
<DIV>&nbsp;</DIV>
<DIV>In Los Angeles County, being disabled can cost a year's income. That's because the annual cost of in-home care services for seniors living alone is now $319 more than this group's&nbsp;median income of $17,029.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Combine&nbsp;long-term care expenses with other basic expenses, such as food and rent, and a Los Angeles senior living alone will need twice the median income to survive, according to new data released today by the UCLA Center for Health Policy Research and the Insight Center for Community Economic Development.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In all 58 California counties, long-term health care is far out of reach for the state's most vulnerable citizens: seniors living alone who are disabled. Yet even as costs soar, Gov. Arnold Schwarzenegger has proposed the elimination of Medi-Cal–funded in-home supportive services for up to 400,000 seniors as a means of closing the state's budget gap.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"In all 58 counties, long-term care paired with basic living expenses exceeds median income," said Jenny Chung, attorney and program manager&nbsp;at the Insight Center. "Seniors can't afford care as it is. How are they going to cope with cuts?"</DIV>
<DIV>&nbsp;</DIV>
<DIV>In 33 counties (57 percent of all California counties), the cost of long-term health care for elderly single women&nbsp;— who are more likely than men to use long-term care&nbsp;—&nbsp;exceeds the median income for single Californians aged 65 or older. In 38 counties (65.5 percent of all counties), the cost of&nbsp;long-term care combined with basic living expenses is at least two times the<I> </I>median income for this group. And in all 58 California counties, long-term care paired with basic living expenses far exceeds median income.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"When getting help at home costs a year's income, something's wrong," said Steven P. Wallace, associate director of the Center for Health Policy Research. "It means that extended families will be stretched thin to provide care or that the elderly will bankrupt themselves to pay for a service provider."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The new data provides county-by-county estimates of long-term care costs, as well as&nbsp;long-term care costs paired with basic living expenses. These basic living expenses are estimated using the Elder Economic Security Standard Index, or Elder Index, a tool that measures the actual costs of basic necessities for older adults in each of California's counties.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers have created&nbsp;an accompanying table in which these&nbsp;costs are paired with median income&nbsp;— a measure of Social Security, pensions and other income for retired Californians age 65 and older who are living alone. The table, which can be sorted, can be&nbsp;accessed on the websites&nbsp;of the <A href="http://www.healthpolicy.ucla.edu/" target=_blank>Center for Health Policy Research</A> and the <A href="http://www.insightcced.org/?page=ecounty" target=_self>Insight Center</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Researchers found that the cost of a "medium" amount of long-term care — 16 hours a week —&nbsp;was often equal to or greater than the median income that single female&nbsp;seniors receive from Social Security, pensions and other sources.</DIV>
<DIV>&nbsp;</DIV>
<DIV>When other basic living expenses were factored in, total costs nearly doubled or tripled.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Researchers used&nbsp;the "medium" level of long-term care as a measure because it&nbsp;is the most representative amount of care used by seniors in California. Female seniors living alone are the group most likely to need paid in-home assistance when they become disabled.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Approximately 973,000 California seniors live alone. Of these, 50 percent do not have enough income to meet basic expenses, as defined by the Elder Index.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Long-term care is not covered by most insurance policies. Only the lowest-income seniors in California can receive in-home care services&nbsp;through the state's Medi-Cal program. However, due to the state budget crisis, services for all but the most severely disabled may soon be cut.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The only alternative, that no one wants, is going to a nursing home where Medi-Cal will eventually pick up the cost," Wallace said. "But Medi-Cal will only pay if a senior is extremely poor. Which means many seniors are caught in the middle&nbsp;—&nbsp;with too little money&nbsp;to afford in-home services and too&nbsp;much to qualify for a Medi-Cal nursing home."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Among the researchers' findings:</DIV>
<DIV style="FONT-SIZE: 4px">&nbsp;</DIV>
<UL>
<LI>Contra Costa and San Francisco counties have the highest long-term care costs: $21,043 and $21,011, respectively. Yet the median income&nbsp;for single seniors living alone&nbsp;is $23,985 in Contra Costa County&nbsp;and $16,792 in San Francisco County. </LI></UL>
<DIV style="FONT-SIZE: 4px">&nbsp;</DIV>
<UL>
<LI>The cost of long-term care paired with basic living expenses is highest in San Francisco and San Mateo counties: $48,446 and $48,441, respectively.</LI></UL>
<DIV style="FONT-SIZE: 4px">&nbsp;</DIV>
<UL>
<LI>In 38 counties (65.5 percent of all counties), the cost of&nbsp;long-term care paired with basic living&nbsp;expenses is&nbsp;twice the median income. In at least one county, Alpine,&nbsp;these costs are three times the median income.</LI></UL>
<DIV style="FONT-SIZE: 4px">&nbsp;</DIV>
<UL>
<LI>Orange County ranked the&nbsp;lowest of all 58 counties in terms of long-term care costs: $17,136. However, when long-term care costs are paired with basic living expenses, Orange County becomes one of the most expensive places for seniors. Long-term care costs plus basic living&nbsp;expenses&nbsp;are $42,603, raising Orange County to 11th out of 58 counties and illustrating the toll that rents and other necessities exact on seniors in expensive areas.</LI></UL>
<DIV>&nbsp;</DIV>
<DIV>The Elder Economic Security Standard Index quantifies the actual costs of meeting basic necessities for older adults in each California county. The Elder Index is currently under consideration by the California Legislature as a planning tool for state aging-services programs. For more information on the Elder Standard Index, click <A href="http://www.insightcced.org/communities/cfess/cal-eesi.html" target=_blank>here</A>. </DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.insightcced.org/"><STRONG>The Insight Center for Community Economic Development</STRONG></A> is a 40-year-old national research, consulting and legal organization dedicated to building economic health in vulnerable communities.<BR><BR><A href="http://www.healthpolicy.ucla.edu/"><STRONG>The UCLA Center for Health Policy Research</STRONG></A>&nbsp;is one of the nation's leading health policy research centers and the premier source of health-related information on Californians.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=155212" height="1" width="1" />]]></description><pubDate>Thu, 18 Jun 2009 16:00:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>UCLA leads nation in protecting med students from drug industry influence</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-leads-nation-in-protecting-94399.aspx?link_page_rss=94399</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-leads-nation-in-protecting-94399.aspx</guid><description><![CDATA[<div>The David Geffen School of Medicine at UCLA is one of only nine medical schools out of 149 to earn an 'A' grade in a nationwide survey by the <span id="pr_TEXT1" onmouseover="top.hlElement(1,'text',1,2,window.name)" onmouseout="top.hlElement(0,'text',1,2,window.name)" onclick="top.editElement('text',1,2,window.name)" contenteditable="true">American Medical Students Association of educational policies governing </span>students' contact with the pharmaceutical industry.</div>
<div> </div>
<div>"We are proud to be in the top 6 percent of medical schools addressing this important issue," said Dr. Andrew Leuchter, associate dean of the Geffen School of Medicine. "It is crucial that our nation's physicians be trained to make decisions in the best interests of their patients, free of influence from private industry."</div>
<div> </div>
<div>UCLA was one of the first U.S. medical schools to adopt tough industry-relations guidelines. In November 2006, UCLA prohibited all industry gifts to faculty, staff and students; banned industry advertising materials and sales calls in patient care areas; and limited the use of drug samples to circumstances in the best interests of patients, such as cases of financial need.</div>
<div> </div>
<div>In July 2007, UCLA's guidelines were incorporated into the policy for the entire University of California system. In addition, UCLA now requires annual reporting by faculty members of all financial relationships with health care vendors.</div>
<div> </div>
<div>Developed with the Pew Prescription Project, the 2009 scorecard (<a href="http://www.amsascorecard.org/">www.amsascorecard.org</a>) evaluated each medical school's policies in 11 areas, including restrictions on gifts, free meals and drug samples; paid promotional presentations; interaction with sales representatives; and industry-funded education. The results provide a school-by-school analysis of policies that govern the pharmaceutical industry's interaction with faculty and students. </div>
<div> </div>
<div>In addition to UCLA, top-ranked schools included Mount Sinai School of Medicine in New York; the University of Pittsburgh Medical Center; the University of Pennsylvania School of Medicine; the University of California, Davis, School of Medicine; the University of California, San Francisco, School of Medicine; the University of Texas Medical Branch at Galveston; Johns Hopkins School of Medicine; and the Mayo Medical School.</div>
<div> </div>
<div>Pharmaceutical marketing to physicians has been estimated at up to $46 billion annually — roughly $35,000 per physician each year. These figures do not factor in promotion by the medical device industry. More than 100,000 pharmaceutical sales representatives visit U.S. doctors, often providing free lunches, gifts, drug samples and promotional medical literature.</div>
<div> </div>
<div>The David Geffen School of Medicine tightly regulates interactions between private industry representatives and faculty, staff and students. For a detailed description of UCLA's industry-relations policies, see <a href="http://dgsom.healthsciences.ucla.edu/administration/guidelinesMain">http://dgsom.healthsciences.ucla.edu/administration/guidelinesMain</a>.</div>
<div> </div>
<div>For more news, visit the <a href="http://www.newsroom.ucla.edu/" target="_self">UCLA Newsroom</a>.</div> <img src="http://newsroom.ucla.edu/rss.ashx?id=155176" height="1" width="1" />]]></description><pubDate>Wed, 17 Jun 2009 16:35:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Study IDs protein assemblies that may be key factor in causing Alzheimer's</title><link>http://newsroom.ucla.edu/portal/ucla/alzheimer-s-assemblies-identified-94284.aspx?link_page_rss=94284</link><guid>http://newsroom.ucla.edu/portal/ucla/alzheimer-s-assemblies-identified-94284.aspx</guid><description><![CDATA[<DIV><B>FINDINGS:</B> </DIV>
<DIV>Alzheimer's disease is the leading cause of late-life dementia. An increasing body of evidence has linked&nbsp;assemblies of a common peptide,&nbsp;the amyloid-β protein, to&nbsp;the disease. While plaques formed from large assemblies of this protein&nbsp;are known to be the eventual result of Alzheimer's, recent evidence suggests that small assemblies —&nbsp;or oligomers —&nbsp;of amyloid-β are the toxic agents responsible for the disease symptoms.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In this research, scientists used mass spectrometry&nbsp;to study the mixture of oligomers formed by the&nbsp;amyloid-β42 protein. While many types of amyloid-β assemblies have been described, the researchers&nbsp;found that&nbsp;oligomers made up of 12 units of amyloid-β42&nbsp;appear to be a key neurotoxic agent in the development of Alzheimer's.</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>IMPACT:</B> </DIV>
<DIV>Discovering the pathways of assembly may be critical&nbsp;in determining&nbsp;therapeutic targets for Alzheimer's. The identification of such a key, specific toxic assembly could pave the way for treatments that target the disease in the early stages of development.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>AUTHOR:</B></DIV>
<DIV>UCLA neurology professor David Teplow, a member of the research team, is available for interviews.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>JOURNAL:</B> </DIV>
<DIV>The research appears online this week in the journal Nature Chemistry.</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><STRONG>BACKGROUND</STRONG>: </DIV>
<DIV>The researchers used a&nbsp;technique&nbsp;known as&nbsp;electrospray-ionization ion-mobility mass spectrometry to study the mixture of oligomers formed by amyloid-β42 and some closely related proteins that do not result in disease.&nbsp;The technique allowed the team to observe&nbsp;both the mass and geometry of the oligomers formed.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>FUNDING: </B></DIV>
<DIV>Funding from<B> </B>the National Institutes of Health, the National Science Foundation, the Alfred P. Sloan Foundation, the David and Lucile Packard Foundation, and the Biotechnology and Biological Sciences Research Council supported this work.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>MEDIA CONTACT:</STRONG></DIV>
<DIV>Mark Wheeler | 310-794-2265 | <A href="mailto:mwheeler@mednet.ucla.edu">mwheeler@mednet.ucla.edu</A> </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=155162" height="1" width="1" />]]></description><pubDate>Wed, 17 Jun 2009 00:10:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Depression may increase Alzheimer's risk in people with memory problems</title><link>http://newsroom.ucla.edu/portal/ucla/depression-may-increase-risk-of-94104.aspx?link_page_rss=94104</link><guid>http://newsroom.ucla.edu/portal/ucla/depression-may-increase-risk-of-94104.aspx</guid><description><![CDATA[<DIV>People with memory problems who are depressed are more likely to develop Alzheimer's disease than those who aren't depressed, according to a new UCLA study. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Researchers also found, however,&nbsp;that the popular Alzheimer's drug donepezil may help delay the progression to Alzheimer's in depressed individuals&nbsp;who suffer from mild cognitive impairment or memory problems.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Mild cognitive impairment is&nbsp;the transition&nbsp;period between the cognitive decline of normal aging and Alzheimer's disease. People with&nbsp;mild cognitive&nbsp;impairment experience memory problems that are greater than expected from normal aging but do not show other symptoms of Alzheimer's, such as difficulties completing everyday activities.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study appears in the June 16 issue of Neurology, the medical journal of the American Academy of Neurology.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The three-year study followed 756 people between the ages of 55 and 91 who had mild cognitive impairment. Of those, 208 were diagnosed with depression using a test that measures the severity and intensity of depressive symptoms. For every one-point increase on the test, a participant's risk of developing Alzheimer's went up by&nbsp;3 percent.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Our longer-term findings add to the body of evidence that suggests depression is a major risk factor for Alzheimer's disease," said Po H. Lu, an assistant professor of neurology and a member of the UCLA Mary S. Easton Center for Alzheimer's Disease Research. "Since the drug donepezil has been shown to improve the behavioral symptoms of Alzheimer's disease, our study also tested whether the drug would delay the progression to Alzheimer's disease in people with memory problems."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Study participants were given either vitamin E, donepezil or a placebo pill. Researchers found that among depressed people with mild cognitive impairment, 11 percent of those taking donepezil developed Alzheimer's disease at 1.7 years, compared with 25 percent of those who took vitamin E or the placebo. At 2.2 years, 14 percent of the donepezil group had developed Alzheimer's, compared with 29 percent of the vitamin E and placebo groups. Donepezil had little effect in the group of people who were not depressed.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"If we can delay the progression of this disease for even two years, it could significantly improve the quality of life for many people dealing with memory loss," Lu said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Donepezil is not approved by the Food and Drug Administration for use in treating mild cognitive impairment.&nbsp;The drug&nbsp;is indicated for mild-to-moderate and severe Alzheimer's disease.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study was supported by the National Institute on Aging, the Alzheimer's Association, an Alzheimer's Disease Cooperative Study grant, the Alzheimer's Disease Research Center, Jim Easton and the Sidell Kagan Foundation.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Other authors included J.L. Cummings, E. Teng and K. Tingus of UCLA; S.D. Edland of the University of California, San Diego; and R.C. Petersen of the Mayo Clinic College of Medicine.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Dr. Petersen has served as a paid consultant to GE Healthcare and has served on safety monitoring committees for Elan Pharmaceuticals and Wyeth; Dr. Cummings has served as a paid consultant to Abbott, Acadia, Accera, ADAMAS, Astellas, Avanir, Bristol-Myers Squibb, CoMentis, Eisai, En-Vivo, Forest, Janssen, Lilly, Lundbeck, Medivation, Merck, Merz, Myriad, Neuren, Novartis, Pfizer, Prana, Schering Plough, Sonexa, Takeda, Toyama and Wyeth.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>The Mary S. Easton Center for Alzheimer's Disease Research</STRONG> is part of the <A href="http://www.neurology.ucla.edu/" target=_blank>UCLA Department of Neurology</A>, which encompasses more than a dozen research, clinical and teaching programs. These programs cover brain mapping and neuroimaging, movement disorders, Alzheimer's disease and other dementias, multiple sclerosis, neurogenetics, nerve and muscle disorders, epilepsy, neuro-oncology, neurotology, neuropsychology, headaches and migraines, neurorehabilitation, and neurovascular disorders. The department has ranked No. 1 among its peers nationwide in National Institutes of Health funding for the last seven years (2002–08).</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=155000" height="1" width="1" />]]></description><pubDate>Mon, 15 Jun 2009 20:00:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Two altruistic donors launch rare kidney transplant chains at UCLA</title><link>http://newsroom.ucla.edu/portal/ucla/two-altruistic-donors-launch-rare-94189.aspx?link_page_rss=94189</link><guid>http://newsroom.ucla.edu/portal/ucla/two-altruistic-donors-launch-rare-94189.aspx</guid><description><![CDATA[<DIV>One is a Michigan firefighter who wanted to honor the memory of his son, who died at age 24 in a tragic snowmobile accident. The other is an Air Force technical sergeant from Iowa who specializes in intelligence analysis. Besides their public service and Midwest origins, they&nbsp;have one other thing in common: They each donated a kidney to a complete stranger. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Harry Damon, the firefighter from Grand Rapids, Mich., and Nicole Lanstrum, who was born and raised in rural Iowa, initiated two kidney transplant chains last week at Ronald Reagan UCLA Medical Center that freed at least six kidney patients — four at UCLA and two in San Francisco — from lives on dialysis. And because their generosity helped initiate similar chains at other transplant centers, the lives of many others will be restored.</DIV>
<DIV>&nbsp;</DIV>
<DIV>A "donor chain" creates opportunities for endless donor-recipient pairings. It starts with an altruistic donor — someone who wants to donate a kidney out of the goodness of his or her heart. That kidney is transplanted into a recipient who had a donor willing to give a kidney but whose kidney was not a match. To keep the chain going, the incompatible donor gives a kidney to another patient, unknown to him or her, who has been identified as a match, essentially "paying it forward." A specialized computer program matches donors and recipients across the country.</DIV>
<DIV>&nbsp;</DIV>
<DIV>(View a <A href="http://streaming.uclahealth.org/kidneyexchange-br" target=_blank><STRONG>video</STRONG></A> on these donor chains.)</DIV>
<DIV>&nbsp;</DIV>
<DIV>Because kidneys can remain outside the body for 24 to 48 hours between removal and transplant, these chains enable donors to give kidneys to strangers of various races and ethnicities&nbsp;across the country.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Nearly 80,000 people are on the kidney transplant waiting list in the United States, according to the United Network for Organ Sharing. California alone has more than 16,000 people on the list.</DIV>
<DIV>&nbsp;</DIV>
<DIV>These are the second and third chains at UCLA, which helped <A href="http://newsroom.ucla.edu/portal/ucla/the-first-new-york-to-los-angeles-54901.aspx" target=_blank>perform the first such transplant chain</A> in the western United States in July 2008. The first chain in the United States was led by Dr. Michael Rees at the University of Toledo in Ohio. Overall, kidney transplant chains are rare.</DIV>
<DIV>&nbsp;</DIV>
<DIV>To mark the generous organ donations from Damon and Lanstrum, the chains have been named the Nick Damon Transplant Chain, in honor of Harry Damon's deceased son, and the Service Before Self Transplant Chain, reflecting one of the three core values of the U.S. Air Force.</DIV>
<DIV>&nbsp;</DIV>
<DIV>One transplant chain took place on&nbsp;Monday, June 8, and the second on Tuesday, June 9. The two chains will continue at California Pacific Medical Center in San Francisco and at the University of California, San Francisco, where still more renal failure patients will have life-changing transplants.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The donors and recipients from the UCLA chain met as a group for the first time June 15. Damon, whose son died three years ago, had been working with the National Kidney Registry to find someone who needed a kidney.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"For me, I'm doing this to have new beginnings in my own life," he&nbsp;said. "If I can help create new beginnings for someone else, it's all the better."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Damon&nbsp;was eventually matched with patient Sheila Whitney of Compton, Calif., who has been on dialysis for more than six years and whose son, Reginal Griffin, couldn't donate to his mother because she was highly sensitized — that is, she developed strong antibodies to her son's blood during her pregnancy, a common occurrence.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Reginal Griffin, a Long Beach, Calif.,&nbsp;resident who is roughly the same age as Nick Damon was when the latter died, instead donated his kidney&nbsp;to Keenan Cheung, a father of three from La Canada, Calif., whose wife, Jeanne, has an incompatible blood type and was ruled out as a donor to her husband. With the gift from Reginal, Keenan ends&nbsp;four-and-a-half years of dialysis.</DIV>
<DIV>&nbsp;</DIV>
<DIV>This gift freed Jeanne, who juggles family and a part-time job, to donate to Sonia Valencia, a resource teacher who lives in Commerce, Calif., and has been on dialysis for six years. Sonia was initially set to receive a kidney from her friend Celia Contreras, a kindergarten teacher from Pico Rivera, Calif., but they, too, had incompatible blood types.</DIV>
<DIV>&nbsp;</DIV>
<DIV>As a result, Celia's "left-over" kidney went to California Pacific Medical Center to a recipient whose brother will then serve as the bridge donor kicking off another chain in a few weeks.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Nicole Lanstrum, whose gift initiated the June 9 chain, had wanted to donate a kidney since high school in Clarion, Iowa — just a few miles from her hometown of Dows — and had sought out the National Kidney Registry for this purpose. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Lanstrum, who has never known anyone on dialysis, is hoping that her donation will inspire others in the military to do the same.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"I just feel we're all put on this earth to make it better and no one has the same game plan," said Lanstrum, who is stationed in Tucson, Ariz. "I think this is something that God supports me in."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Lanstrum's kidney went to Valinda Jones, a registered nurse from Woodland Hills, Calif., who&nbsp;was to have&nbsp;received a donation from a friend&nbsp;in Indiana who is also a nurse and prefers to remain unnamed. That match didn't work out because of&nbsp;incompatibility.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Indiana nurse's kidney was instead shipped to UCSF for transplantation into a woman whose sister will serve as the bridge to a new chain.</DIV>
<DIV>&nbsp;</DIV>
<DIV>At the June 15 gathering, all the exchange donors received special lapel pins in an engraved box honoring them as "Everyday Heroes."</DIV>
<DIV>&nbsp;</DIV>
<DIV>OneLegacy,&nbsp;a nonprofit organ and tissue recovery organization serving the greater Los Angeles area, facilitated the chains by coordinating interstate transport of the kidneys. As coordinators of transplants from deceased donors, organizations like OneLegacy very rarely participate in the living donation process, given that the latter are coordinated in-house by the transplant centers. However, with UCLA's living donor chains involving transplant centers in different cities, OneLegacy was asked to participate by Dr. Jeffrey Veale, director of the donor exchange program and assistant professor of urology at the David Geffen School of Medicine at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>OneLegacy ensured that operating room procedures were followed during the kidneys' packaging for transportation and that the surgeons at the receiving transplant centers hundreds of miles away knew the quality and characteristics of the kidneys on arrival. A courier was on hand outside the operating room to deliver the kidneys to the airport for transportation on a commercial airline.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This is a procedure we do every day with deceased donors but seldom with living donors," said Thomas Mone, CEO and executive vice president of OneLegacy. "We applied the same high standards to make sure the donation chain is a success."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Veale had nothing but praise for Damon and Lanstrum, whose generosity is improving so many lives.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"About 30 to 40 percent of the people who have a willing living donor don't match that person," Veale said. "With this innovative program we can greatly expand the donor pool."</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.kidneyregistry.org/" target=_blank><STRONG>The National Kidney Registry</STRONG></A> is a nonprofit organization with the mission&nbsp;of saving&nbsp;and improving the lives of people facing kidney failure by increasing the quality, speed and number of living donor transplants in the world.&nbsp;The registry&nbsp;matches donors and recipients&nbsp;using a specialized computer program developed by businessman and registry founder Garet Hil. Hil started the registry when his youngest daughter needed a transplant and tests revealed that her body would have rejected his kidney, as well as kidneys from other donors. </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://transplants.ucla.edu/body.cfm?id=34&amp;oTopID=34" target=_blank>The UCLA Kidney&nbsp;and Pancreas Transplant Program</A></STRONG> performed its first kidney transplant in 1957 and for the past 50 years has continued to be a national leader in both clinical research and academic excellence. UCLA is the second-largest kidney transplant program in the country and the largest in Southern California, performing hundreds of adult and pediatric transplants each year. The program has some of the best outcomes in the country, according to the Scientific Registry of Transplant Recipients, a national database of organ transplant statistics. UCLA's program has helped pioneer the use of minimally invasive laparoscopic surgery to remove kidneys from living donors. </DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=154941" height="1" width="1" />]]></description><pubDate>Mon, 15 Jun 2009 19:00:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>New 'Idol' grabs spotlight: Study IDs enzyme that controls 'bad' cholesterol</title><link>http://newsroom.ucla.edu/portal/ucla/new-idol-grabs-spotlight-ucla-94162.aspx?link_page_rss=94162</link><guid>http://newsroom.ucla.edu/portal/ucla/new-idol-grabs-spotlight-ucla-94162.aspx</guid><description><![CDATA[<DIV>UCLA scientists have discovered a new mechanism that controls cells' production of low-density lipoprotein (LDL), the so-called "bad" cholesterol that is often linked to medical problems like heart disease, stroke and clogged arteries. </DIV>
<DIV> </DIV>
<DIV>In the body, cells in the liver produce a specific receptor that sticks to LDL and removes it from the blood, lowering cholesterol levels. Statin drugs also reduce LDL cholesterol levels by boosting cells' production of the receptor.</DIV>
<DIV> </DIV>
<DIV>In research published in the June 11 online edition of the journal Science, the UCLA team used a mouse model to identify an enzyme called "Idol" that destroys the receptor, permitting more LDL cholesterol to circulate in the blood. By blocking Idol's activity, the researchers induced cells to produce more of the receptor and absorb more cholesterol from the body.</DIV>
<DIV> </DIV>
<DIV>"We only know of three pathways that regulate the LDL receptor. The first two are already targeted by existing drugs," said principal investigator Dr. Peter Tontonoz, a professor of pathology and laboratory medicine at the David Geffen School of Medicine at UCLA and a Howard Hughes Medical Institute investigator. "Idol is the first mechanism discovered in several years that may lead to a new medication designed to control cholesterol levels."</DIV>
<DIV><B></B> </DIV>
<DIV>The findings suggest that development of a drug that interferes with Idol's activity could influence cholesterol metabolism and lower levels of bad cholesterol. Doctors could prescribe the new medication in conjunction with statin drugs, which also cut cholesterol levels by targeting a different enzyme linked to the LDL receptor. This could benefit patients who cannot tolerate statin-related side effects.</DIV>
<DIV><B></B> </DIV>
<DIV>Tontonoz collaborated with UCLA's Noam Zelcer, Cynthia Hong and Rima Boyadjian on the research, which was funded by the Howard Hughes Medical Institute and the National Heart, Lung and Blood Institute. </DIV>
<DIV> </DIV>
<DIV>The university has filed a patent related to the research findings.</DIV>
<DIV> </DIV>
<DIV><STRONG>UCLA</STRONG> is California's largest university, with an enrollment of nearly 38,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 323 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize.</DIV>
<DIV> </DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV>
<DIV> </DIV>
<DIV> </DIV>
<DIV>
<DIV><B></B></DIV></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=154715" height="1" width="1" />]]></description><pubDate>Fri, 12 Jun 2009 18:50:00 GMT</pubDate></item><item><author>Rachel Champeau</author><title>Leading UCLA researchers present latest findings on aging, age-related issues</title><link>http://newsroom.ucla.edu/portal/ucla/leading-ucla-researchers-present-94153.aspx?link_page_rss=94153</link><guid>http://newsroom.ucla.edu/portal/ucla/leading-ucla-researchers-present-94153.aspx</guid><description><![CDATA[<DIV><STRONG>WHAT:</STRONG> </DIV>
<DIV>At a special conference sponsored by the UCLA Center on Aging and the UCLA Multicampus Program in Geriatric Medicine and Gerontology, UCLA researchers will present their latest findings on age-related issues, including Alzheimer's disease, diet and nutrition, exercise, breast cancer, fall-prevention, dementia, and much more. For information and a full program schedule, visit <A href="http://www.aging.ucla.edu/AnnResearchCon2007.html" target=_blank>www.aging.ucla.edu/AnnResearchCon2007.html</A>.</DIV>
<DIV> </DIV>
<DIV><STRONG>WHO:</STRONG></DIV>
<DIV>Speakers: Lynn Daucher, the director of the California Department of Aging will deliver the conference's keynote address, "Research Network to Aging Network." Other conference speakers include:</DIV>
<DIV style="FONT-SIZE: 4px"> </DIV>
<UL>
<LI>Lynn Vavreck, UCLA assistant professor of political science: "Ageism in the 2008 Election" 
<LI>Steven Clarke, UCLA professor of chemistry and biochemistry: "Strategies for Stopping Aging Chemistry in Its Tracks" 
<LI>Lene Levy Storms, UCLA associate professor of social welfare: "Teaching Good Bedside Manners to Nursing Home Staff"</LI></UL>
<DIV> </DIV>
<DIV>Panel: The conference's panel, "Nutrition and Aging: Fact vs. Fiction," will include the following participants:</DIV>
<DIV style="FONT-SIZE: 4px"> </DIV>
<UL>
<LI>Zhaoping Li (moderator), UCLA professor of clinical medicine 
<LI>Catherine F. Clarke, UCLA professor of chemistry and biochemistry 
<LI>Sally Frautschy, UCLA associate professor-in-residence of medicine 
<LI>Fernando Gomez-Pinilla, UCLA professor of physiological science 
<LI>Stephen R. Spindler, UC Riverside professor of biochemistry</LI></UL>
<DIV> </DIV>
<DIV><STRONG>WHEN: </STRONG></DIV>
<DIV>8 a.m.–12:30 p.m., Tuesday, June 16</DIV>
<DIV style="FONT-SIZE: 4px"> </DIV>
<UL>
<LI>8 a.m.: Registration</LI>
<LI>
<DIV>8:20–9 a.m.: Poster session</DIV>
<LI>
<DIV>9–10:15 a.m.: Program speakers (Vavreck, Clarke, Levy-Storms)</DIV>
<LI>
<DIV>10:15–11 a.m.: Poster session</DIV>
<LI>
<DIV>11–11:40 a.m.: Panel discussion </DIV>
<LI>
<DIV>11:40 a.m.–12:30 p.m.: Keynote speaker Lynn Daucher</DIV></LI></UL>
<DIV><STRONG></STRONG> </DIV>
<DIV><STRONG>WHERE: </STRONG></DIV>
<DIV>UCLA Faculty Center (<A href="http://www.maps.ucla.edu/campus?cpoint=6428675.4864426,1848276.93577647&level=3&a_layers=Base%20Map&s_resource=Base%20Map&s_layer=Campus%20Building&s_field=SDE.CMPS_BLDG_AREA.OBJECTID&s_value=7" target=_blank>map</A>)</DIV>
<DIV><STRONG></STRONG> </DIV>
<DIV><STRONG>MEDIA CONTACT: </STRONG></DIV>
<DIV>Rachel Champeau, UCLA Health Sciences Media Relations, 310-794-0777</DIV>
<DIV> </DIV>
<DIV><STRONG>PARKING:</STRONG></DIV>
<DIV>
<DIV>For parking, enter the campus on Westholme Avenue, just off of Hilgard Avenue. The parking kiosk will have parking information.</DIV></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=154704" height="1" width="1" />]]></description><pubDate>Thu, 11 Jun 2009 23:20:00 GMT</pubDate></item><item><author>Sarah Anderson</author><title>Air pollution from freeway extends further than previously thought</title><link>http://newsroom.ucla.edu/portal/ucla/air-pollution-from-freeway-extends-93857.aspx?link_page_rss=93857</link><guid>http://newsroom.ucla.edu/portal/ucla/air-pollution-from-freeway-extends-93857.aspx</guid><description><![CDATA[<DIV>Environmental health researchers&nbsp;from UCLA, the University of Southern California and the California Air Resources Board have found that during the hours before sunrise, freeway air pollution extends much further than previously thought.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Air pollutants from Interstate 10&nbsp;in Santa Monica extend as far as 2,500 meters —&nbsp;more than 1.5 miles —&nbsp;downwind, based on recent measurements from a research team headed by Dr. Arthur Winer, a professor of environmental health sciences&nbsp;at the UCLA School of Public Health. This distance&nbsp;is&nbsp;10 times greater than&nbsp;previously measured daytime pollutant impacts from roadways and has significant exposure implications, since most people are in their homes during the hours before sunrise and outdoor pollutants penetrate into indoor environments.&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study was published last month&nbsp;in the journal Atmospheric Environment, with Dr. Shishan Hu, a postdoctoral&nbsp;scholar at the UCLA School of Public Health,&nbsp;as lead author.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"To measure the pollution levels, we equipped an electric vehicle with no emissions of its own with fast-response instruments for gaseous and particulate air pollutants, a GPS and video monitor, and instruments to measure temperature and winds," Winer said. "In both winter and summer of 2008, we drove toward and away from Interstate 10 on a route perpendicular to the freeway in Santa Monica between the hours of 4 a.m. and 7 a.m."</DIV>
<DIV>&nbsp;</DIV>
<DIV>A second striking finding of the study was that although traffic volumes are lower in the pre-sunrise hours, the air pollution concentrations measured by the team were higher than even those during daytime traffic congestion peaks. Concentrations are higher before sunrise even though emissions are lower because of the unique weather conditions. In the pre-sunrise hours, wind speeds are generally very low, and while the wind direction is somewhat variable, the predominant direction is from the northeast in the winter months and the northwest in the summer months. </DIV>
<DIV>&nbsp;</DIV>
<DIV>This means that&nbsp;areas south of&nbsp;Interstate 10 are generally downwind in the pre-sunrise hours and areas north of the freeway are generally upwind; this is consistent with the observation that vehicle-related pollutants are found much further from the freeway on the south side in the pre-sunrise hours, compared with the north side.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Our research shows that under the low wind speeds and shallow temperature inversions during the early morning, before sunrise, air pollution from freeways is trapped near the surface, limiting dilution and creating a zone of influence many times greater than during the day," said Dr. Suzanne Paulson, a professor in the UCLA Department of&nbsp;Atmospheric and Oceanic Sciences and a co-principal investigator of the study. "These meteorological conditions are very common in the hours before sunrise."</DIV>
<DIV>&nbsp;</DIV>
<DIV>In comparing the winter and summer early mornings, researchers&nbsp;found much higher levels of air pollution in the winter. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"This is because the sun rises later in the winter, so the early morning period captures more of the early morning rush hour," Paulsen said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Our findings confirm previous work showing peak levels of ultrafine particles (UFP) immediately adjacent to the freeway, but we found high concentrations persisted for up to 1.5 miles downwind of the freeway during the pre-sunrise hours," said Dr. Scott Fruin of the USC Keck School of Medicine. "Elevated UFP concentrations also extended up to 600 meters upwind of the freeway, another strong difference from daytime observations, which typically show little or no vehicle-related pollution directly upwind from freeways."</DIV>
<DIV>&nbsp;</DIV>
<DIV>In the present study, other pollutants, including nitric oxide and particle-bound polycyclic aromatic hydrocarbons, also extended far from the freeway during the pre-sunrise hours. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Other members of the research team included Dr. Kathleen Kozawa and Steve Mara of the California Air Resources Board, which sponsored the study.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The study raises more questions about the significant health outcomes caused or exacerbated by freeway traffic," Winer said. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Numerous epidemiologic studies have already shown that traffic-related pollution is linked to increased risk of asthma, respiratory illness, cardiovascular disease and premature mortality.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers recommend that&nbsp;residents living near freeways should consider keeping their windows closed at night and minimize outdoor exercise near major roadways in the hours before sunrise.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=154614" height="1" width="1" />]]></description><pubDate>Wed, 10 Jun 2009 16:15:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>UCLA named state lead center in new effort to combat pediatric brain injury</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-named-as-lead-center-for-93847.aspx?link_page_rss=93847</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-named-as-lead-center-for-93847.aspx</guid><description><![CDATA[<DIV>The UCLA Brain Injury Research Center, together with Mattel Children's Hospital UCLA, will serve as California's lead center for research on pediatric brain injuries as part of a new national network announced June 5 in Washington, D.C.</DIV>
<DIV> </DIV>
<DIV>In what is being called one of the largest collaborative efforts in pediatric medicine, UCLA will join with 51 other health care institutions representing states across the country to address issues related to the treatment of brain injury, the number one cause of death and disability in children and young adults in the United States.</DIV>
<DIV> </DIV>
<DIV>The collaboration is the work of the Sarah Jane Brain Project, a nonprofit organization founded in 2007 by Patrick Donohue, whose baby daughter was shaken so hard by a caregiver that she suffered a severe brain injury. </DIV>
<DIV> </DIV>
<DIV>In January, more than 60 of the top pediatric neurologists in the country, including UCLA's Dr. Christopher Giza, came together to draft the National Pediatric Acquired Brain Injury Plan, which called for the development of a national collaborative network to address the issue.</DIV>
<DIV> </DIV>
<DIV>Member centers in the new network will share information and research findings on pediatric brain injuries in an effort to establish a standardized national medical plan for dealing with these injuries. As a state lead center, UCLA will be responsible for developing a master plan of care for children and young adults with brain injuries in California.</DIV>
<DIV> </DIV>
<DIV>"We are so honored to have UCLA's Mattel Children's Hospital as the state lead center for California and as part of this national network of the best health care institutions in the country," Donohue said.</DIV>
<DIV> </DIV>
<DIV>"It is shocking to realize that despite brain injury being the leading killer and disabler of our children, nothing has ever before been done to develop a nationally standardized medical, or even an educational, plan to address it," Donohue added. "Very little public awareness exists of pediatric brain injury."</DIV>
<DIV> </DIV>
<DIV>"We are proud to be given this designation by the Sarah Jane Brain Project and to be affiliated with the foundation," said Giza, an associate professor of neurosurgery and pediatric neurology and a member of the Sarah Jane Brain Project's medical advisory board. "Most disorders of the brain, whether multiple sclerosis, Alzheimer's or autism, have strong and vocal advocacy groups. But traumatic brain injury remains a silent epidemic, affecting over 1.5 million people each year in the U.S. So I applaud the foundation for becoming a strong voice for research into pediatric brain injury and for being the driving force behind this plan."</DIV>
<DIV> </DIV>
<DIV>It is estimated that the National Pediatric Acquired Brain Injury Plan will cost $125 million annually to implement across the country. The plan will address all important aspects of brain injuries and brain injury treatment, including prevention, acute care, rehabilitation, adult transition, rural/telehealth and mild traumatic brain injury.</DIV>
<DIV> </DIV>
<DIV><A href="http://www.neurosurgery.ucla.edu/"><STRONG>The UCLA Department of Neurosurgery</STRONG></A> is committed to providing excellence in leadership in the major disciplines of neurosurgery. Centers of Excellence in neurosurgery have been established at UCLA in brain injury, brain tumors, epilepsy surgery, neurovascular surgery, pediatric neurosurgery, spinal and peripheral nerve surgery, and stereotactic and functional neurosurgery. Other departmental programs in development include neuroendoscopy, hydrocephalus, interventional MR surgery and neurological critical care. </DIV>
<DIV> </DIV>
<DIV><STRONG><A href="http://www.mattel.ucla.edu/" target=_blank>Mattel Children's Hospital UCLA</A></STRONG> is a vital part of Ronald Reagan UCLA Medical Center, which is consistently ranked the best hospital in the western United States by U.S. News & World Report. Mattel hospital offers a full spectrum of primary and specialized medical care for infants, children and adolescents, with the mission of providing state-of-the-art treatment for children in a compassionate atmosphere, as well as improving the understanding and treatment of pediatric diseases. </DIV>
<DIV> </DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=154552" height="1" width="1" />]]></description><pubDate>Wed, 10 Jun 2009 00:00:00 GMT</pubDate></item><item><author>Amy Albin</author><title>Run-walk event to benefit pediatric cancer program at UCLA</title><link>http://newsroom.ucla.edu/portal/ucla/dad-s-day-dash-to-benefit-pediatric-93763.aspx?link_page_rss=93763</link><guid>http://newsroom.ucla.edu/portal/ucla/dad-s-day-dash-to-benefit-pediatric-93763.aspx</guid><description><![CDATA[<DIV><B>WHAT: </B></DIV>
<DIV>The San Fernando Valley Bruins are&nbsp;marking Father's Day a week early&nbsp;this year with the annual Dad's Day Dash, a run/walk event in which all proceeds go to benefit the pediatric cancer program at Mattel Children's Hospital UCLA. The dash will feature a 5K and 10K run/walk and a 1K "fun run" for kids. The event is presented in conjunction with the Optimist clubs of the San Fernando Valley and Westwood/UCLA Hospital.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>WHEN: </B></DIV>
<DIV>7:30 a.m., Saturday, June 13</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>WHERE: </B></DIV>
<DIV>Warner Center Park,&nbsp;21820 Califa Ave., Woodland Hills, Calif.&nbsp;91367</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>INFORMATION: </B></DIV>
<DIV>For more information, to register, or to make a donation, visit <A href="http://www.w2promotions.com/">www.w2promotions.com</A>.</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>BACKGROUND: </B></DIV>
<DIV>The pediatric cancer program at Mattel Children's Hospital UCLA is ranked among the nation's best by U.S. News &amp; World Report. In addition to providing ongoing treatment and support for young cancer patients and their families,&nbsp;program physicians are involved in cutting-edge research to find new ways to treat pediatric cancers. <A href="https://www.uclahealth.org/mattel" target=_blank>Mattel Children's Hospital UCLA</A>, a vital component of UCLA Medical Center, offers a full spectrum of primary and specialized medical care for infants, children and adolescents. The hospital's mission is to provide state-of-the-art treatment for children in a compassionate atmosphere and&nbsp;to improve the understanding and treatment of pediatric diseases. </DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>MEDIA CONTACT: </B></DIV>
<DIV>Fay Bevans, San Fernando Valley Bruins, <A href="mailto:fbevans@conet.ucla.edu">fbevans@conet.ucla.edu</A></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=154335" height="1" width="1" />]]></description><pubDate>Mon, 08 Jun 2009 19:55:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>UCLA neurosurgeons discuss new trends in treatment of traumatic head injury</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-experts-to-discuss-the-treatment-93562.aspx?link_page_rss=93562</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-experts-to-discuss-the-treatment-93562.aspx</guid><description><![CDATA[<DIV><B>WHAT: </B></DIV>
<DIV>Researchers from the UCLA Brain Injury Research Center (BIRC) will discuss their latest research and insights into the treatment of traumatic brain injury, focusing on three specific groups: professional athletes, active-duty military personnel, and children and teenagers. The event will include representatives from the U.S. Department of Defense and the World Boxing Council.</DIV>
<DIV> </DIV>
<DIV>Treating brain injuries quickly and effectively can mean the difference between recovery and death or permanent disability. While physicians have long believed that the injured brain lies in a docile state and requires very little energy for recovery, UCLA researchers have found that recovery requires significant amounts of "fuel." Determining what type of fuel — glucose, pyruvate, lactate, ketones or other naturally occurring compounds — works best in which patients is the next step, and the BIRC has been awarded a prestigious grant from the National Institutes of Health to pursue this research on optimal treatments.</DIV>
<DIV><STRONG></STRONG>  </DIV>
<DIV><B>WHO:</B></DIV>
<DIV>Participants will include: </DIV>
<BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px">
<DIV><STRONG>Dr. Neil Martin</STRONG>, M.D. </DIV>
<DIV>Chair of the UCLA Department of Neurosurgery and co-director of the UCLA Stroke Center</DIV>
<DIV> </DIV>
<DIV><STRONG>David Hovda</STRONG>, Ph.D.</DIV>
<DIV>Director of the UCLA Brain Injury Research Center and professor of neurosurgery</DIV></BLOCKQUOTE>
<DIV><B>WHEN: </B></DIV>
<DIV>5 p.m., Monday, June 8</DIV>
<DIV><B></B> </DIV>
<DIV><B>WHERE: </B></DIV>
<DIV>Ronald Reagan UCLA Medical Center (B-Level), 757 Westwood Blvd., Los Angeles 90095 (<A href="http://www.maps.ucla.edu/campus?cpoint=6426492.99400661,1846883.13426619&level=3&a_layers=Base%20Map&s_resource=Base%20Map&s_layer=Campus%20Building&s_field=SDE.CMPS_BLDG_AREA.OBJECTID&s_value=112" target=_blank>map</A>)</DIV>
<DIV><B></B> </DIV>
<DIV><B>BACKGROUND: </B></DIV>
<DIV>Each year, some 1.5 million Americans suffer traumatic brain injuries (TBI) — more than are stricken annually by breast and pediatric cancers, Alzheimer's and Parkinson's diseases, HIV/AIDS, and West Nile Virus combined. Despite the numbers, and the trauma and deaths such injuries cause, TBI has received comparatively little media coverage and research funding. </DIV>
<DIV> </DIV>
<DIV><B>MEDIA CONTACT: </B></DIV>
<DIV>Mark Wheeler, Health Sciences Media Relations, 310-794-2265</DIV>
<DIV><A href="mailto:mwheeler@mednet.ucla.edu">mwheeler@mednet.ucla.edu</A></DIV>
<DIV> </DIV>
<DIV><STRONG>PARKING:</STRONG></DIV>
<DIV>Press should call media contact to arrange parking.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=154012" height="1" width="1" />]]></description><pubDate>Wed, 03 Jun 2009 22:40:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Could standard treatment for traumatic brain injury be wrong?</title><link>http://newsroom.ucla.edu/portal/ucla/could-conventional-treatment-for-93476.aspx?link_page_rss=93476</link><guid>http://newsroom.ucla.edu/portal/ucla/could-conventional-treatment-for-93476.aspx</guid><description><![CDATA[<DIV>Traumatic brain injury — not heart disease, stroke or cancer — is the number one cause of death and disability in people under 45. Each year, some 1.5 million Americans, including soldiers, athletes, the elderly and children, sustain head injuries, and nearly half of them will be hospitalized and treated in an emergency room or intensive care unit.</DIV>
<DIV> </DIV>
<DIV>But what if they are treated incorrectly?</DIV>
<DIV> </DIV>
<DIV>The Brain Injury Research Center (BIRC) in the UCLA Department of Neurosurgery has been awarded a $4.2 million grant from the National Institutes of Health to research new ways to heal the brain after a traumatic brain injury, or TBI. Specifically, researchers will be looking at how to best feed the brain the nutrients it needs to optimize recovery.</DIV>
<DIV> </DIV>
<DIV>The standard thinking for many years has been that after a TBI, the brain lies in a docile state or coma and thus requires very little energy. But research from the BIRC now shows that the brain's response to trauma requires enormous amounts of energy.</DIV>
<DIV> </DIV>
<DIV>"Many patients with a traumatic brain injury exhibit hyperglycemia — high blood sugar — by the time they arrive in the ER," said David Hovda, professor of neurosurgery and director of the BIRC. "So the standard protocol was to give the patient insulin to tightly control the levels of glucose that would take them to normal. For many regions of the injured brain, this may be the wrong thing to do."</DIV>
<DIV> </DIV>
<DIV>In fact, the brain needs fuel to initiate the healing process — and not just glucose, Hovda suspects. Because they have found that the way glucose is used by the brain changes after a TBI, researchers believe other naturally used compounds, including pyruvate, beta-hydroxybutyrate, lactate and ketones, should be considered in treatment. Hovda and his colleagues think that each of these fuels may serve a different purpose, depending on the severity of the injury and whether the injured individual is an adult or adolescent. The goal, therefore, is to identify the optimal brain fuels for different age groups that will improve recovery.</DIV>
<DIV> </DIV>
<DIV>"Our work is challenging because we're questioning a standard protocol," said Dr. Christopher Giza, UCLA associate professor of neurosurgery and a co-investigator on the NIH grant. "If the brain is actually asking for fuel (glucose), that means that after trauma, Mother Nature is shifting gears and changing the chemistry of the brain. These concepts and constructs are what we're going to be examining closely."</DIV>
<DIV> </DIV>
<DIV>"The majority of head injuries are called mild traumatic brain injuries," Hovda said. "But what we've discovered is the path of physiological consequences measured in severe head injuries also occurs in mild traumatic head injuries as well. So this research might just change what's put in the IV bag at the onset of treatment."</DIV>
<DIV> </DIV>
<DIV>Over the past 20 years, there have been more than 75 clinical trials for traumatic brain injury, but none have resulted in a standard treatment for TBI. The current grant will have both a research and a clinical component: The research will look at the use of alternative fuels and how these fuels enter the brain and contribute to the healing process, while the clinical aspect will test alternative fuels and examine the possible threat to recovery after TBI when hyperglycemia is stopped.</DIV>
<DIV> </DIV>
<DIV>Interest in continuing research on head trauma recovery is widespread and is supported by, among others, Major League Baseball, the National Football League, the World Boxing Council and the U.S. Department of Defense.</DIV>
<DIV> </DIV>
<DIV>"We wish there was a cure for TBI," Hovda said. "But for now all that's available is rehabilitation therapy. Patients diagnosed with epilepsy or depression have medications that may help. But as of now there is no cocktail remedy for TBI. Our hope is to change that."</DIV>
<DIV> </DIV>
<DIV><STRONG><A href="http://neurosurgery.ucla.edu/body.cfm?id=621" target=_blank>The UCLA Brain Injury Research Center</A></STRONG> maintains a comprehensive basic and clinical scientific program in the field of traumatic brain injury. Its scientists conduct research into imaging, neurophysiology, molecular biology, modeling, and behavioral neuroscience in order to apply this knowledge toward understanding the neurobiology of human TBI.</DIV>
<DIV> </DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>. </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=153818" height="1" width="1" />]]></description><pubDate>Tue, 02 Jun 2009 21:25:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>Even with no treatment available, cancer patients want to know metastasis risk</title><link>http://newsroom.ucla.edu/portal/ucla/cancer-patients-want-genetic-testing-93297.aspx?link_page_rss=93297</link><guid>http://newsroom.ucla.edu/portal/ucla/cancer-patients-want-genetic-testing-93297.aspx</guid><description><![CDATA[<DIV>If you had cancer and a genetic test could predict the risk of the tumor spreading aggressively, would you want to know&nbsp;— even if no treatments existed to help you?</DIV>
<DIV>&nbsp;</DIV>
<DIV>An overwhelming majority of eye cancer patients&nbsp;would, according to a new UCLA study published in the June edition of the Journal of Genetic Counseling.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Our goal was to explore what people with cancer want,"&nbsp;said Dr. Tara McCannel, director of the Ophthalmic Oncology Center at UCLA's Jules Stein Eye Institute and a researcher at UCLA's Jonsson Comprehensive Cancer Center. "We learned that patients want to know their prognosis, good or bad, even when there are no treatments at present for their condition."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The UCLA study surveyed 99 patients who had been diagnosed with ocular melanoma, which develops in the pigmented layers under the retina. Half the patients had undergone localized radiation to shrink the tumor. The rest of the group also underwent radiation but first had cells from their tumors biopsied. These cells were grown in culture and studied for a missing copy of chromosome 3 — the genetic marker most strongly linked to rapid metastatic disease.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Patients whose tumors contain the genetic marker have at least a 50 percent chance of death within five years, due to swift spreading of the tumor to the liver and other organs. Aggressive cases can result in blindness and death in as&nbsp;little as a year.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In the UCLA study, all the patients were asked to evaluate their interest in receiving genetic testing results related to prognosis.&nbsp;Of the 99 patients,&nbsp;98 responded that they would have wanted predictive testing at the time of their treatment; only one would have declined.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Additionally, 98 percent of the respondents&nbsp;stated that supportive counseling should be offered when patients receive their test results.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We were surprised to see such a unanimous response," McCannel said. "We expected some patients would prefer not to know, but the numbers consistently said otherwise."</DIV>
<DIV>&nbsp;</DIV>
<DIV>"People understand that no good treatment currently exists after their cancer spreads. Everyone wants to know what their risk is for metastasis," said co-author Annette Stanton, a UCLA professor of psychology, psychiatry and biobehavioral sciences. "If the risk is low, it's a huge relief and emotional burden off patients' shoulders. If the risk is high, it enables patients to plan arrangements for their family and finances and make the most of their time alive."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The UCLA survey also measured quality of life and depression symptoms in patients who received genetic test results and compared their rankings to those of untested patients.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Regardless of their test result, all of the patients rated themselves about the same in terms of quality of life and emotional well-being," Stanton said. "We hope that these findings reduce clinical resistance and pave the way for prognostic testing to become the standard of care in the management of ocular melanoma."</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The issue of genetic testing has been a huge source of clinical controversy," McCannel said. "People want information; they have a lot of things they still want to do in life. Knowing their prognosis offers a tool that helps them plan their lives. Our research demonstrates that it's valuable to give people these details, even when their disease is not presently treatable."</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Our results emphasize how important it is for patients to be treated in a full-service hospital research center that offers genetic testing and counseling and treats the whole patient, not just their disease," said Stanton, who is also a member of UCLA's&nbsp;Jonsson Cancer Center.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Tumor biopsy also helps researchers search for key genes that play a role in aggressive metastasis, improving clinicians' ability to provide the best care.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"After analyzing the tumor specimens, we grow the biopsied cells in a culture dish and can add drugs to test which ones block cancer growth," McCannel said. "That is how we're going to beat this cancer. Developing drugs to target these genes will one day result in therapies and a cure."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The technique of fine-needle aspiration biopsy for collecting cancer cells from the living eye has been utilized at the Jules Stein Eye Institute since 2004 but has been adopted by only a handful of other ophthalmic centers in the nation.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Although rare, ocular melanoma is the most common eye cancer to strike adults. The National Eye Institute reports some 2,000 newly diagnosed cases of the cancer&nbsp;— roughly seven in 1 million people&nbsp;— per year. The disease spans the age and ethnic spectrum and is not hereditary.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study's UCLA co-authors included first author Tammy Beran, Dr. Bradley Straatsma and Barry Burgess. The research was supported by funding from UCLA's Jonsson Comprehensive Cancer Center.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=153632" height="1" width="1" />]]></description><pubDate>Mon, 01 Jun 2009 22:00:00 GMT</pubDate></item><item><author>Gwen Driscoll</author><title>Dental paradox: Calif. has most dentists, yet shortages exist in certain locations</title><link>http://newsroom.ucla.edu/portal/ucla/california-s-dental-paradox-state-92484.aspx?link_page_rss=92484</link><guid>http://newsroom.ucla.edu/portal/ucla/california-s-dental-paradox-state-92484.aspx</guid><description><![CDATA[<DIV>Drive the length of Alpine County in northeastern California and you will see snow-covered peaks, alpine meadows and verdant forests. What you won't see: a dentist.</DIV>
<DIV> </DIV>
<DIV>Alpine County has no actively practicing dentists. In San Benito and Inyo counties, there is one dentist for every 5,000 residents. Imperial and Colusa counties have one for every 4,000 residents.</DIV>
<DIV> </DIV>
<DIV>In contrast, San Francisco County has 6.1 licensed dentists for every 5,000 residents, and neighboring Placer County and Marin County have 5.2 and 5.0 per 5,000, respectively.</DIV>
<DIV> </DIV>
<DIV>The differences demonstrate that "if you don't live in a city or a major urban area, you may have a long drive to treat a toothache," said Nadereh Pourat, director of research planning at the UCLA Center for Health Policy Research and the author of a new fact sheet on dentists in California, "<A href="http://www.healthpolicy.ucla.edu/">Distribution and Characteristics of Dentists Licensed to Practice in California, 2008.</A>"</DIV>
<DIV> </DIV>
<DIV>The fact sheet quantifies the number of dentists statewide and in each county, as well as the proportion of dentists to residents and the number of areas where shortages of dentists exist.</DIV>
<DIV> </DIV>
<DIV>Pourat found that California has nearly 32,000 licensed dentists, or approximately 14 percent of the total number of dentists nationwide — the largest percentage of any state.</DIV>
<DIV> </DIV>
<DIV>California also has 233 dental health professional shortage areas (DHPSAs). These are smaller areas within counties that have a dentist-to-population ratio of one-to-5,000 or less, or that have a population with unusually high needs or insufficient capacity for care among existing dentists.</DIV>
<DIV> </DIV>
<DIV>"There's a lot of demand and not a lot of dentists," Pourat said. "And if you have to travel an hour to see a dentist, that's a serious obstacle to care."</DIV>
<DIV> </DIV>
<DIV>Shortage areas are further challenged by a growing wave of retirement-age dentists. Statewide, only 15 percent of active dentists received their license within the past five years, while 20 percent have been licensed for 30 or more years.</DIV>
<DIV> </DIV>
<DIV>Among the other findings:</DIV>
<DIV style="FONT-SIZE: 4px"> </DIV>
<UL>
<LI>Los Angeles County has the largest total number of licensed dentists, with 7,854, but also the largest number of dental health professional shortage areas, with 37.</LI></UL>
<UL>
<LI>Dentists in rural counties more often divide their time between multiple locations. This may mean longer wait times to see the dentist in some areas.</LI></UL>
<UL>
<LI>Many rural areas do not have access to dental care provided in publicly funded community clinics. In those areas, free or low-cost dental care may not be available. </LI></UL>
<UL>
<LI>45 percent of newly licensed dentists are female. This is a significant change in dentist demographics: Only 4 percent of dentists nearing retirement are female.</LI></UL>
<UL></UL>
<DIV> </DIV>
<DIV>Funding for this fact sheet was provided by the California HealthCare Foundation, an independent philanthropy committed to improving the way health care is delivered and financed in California.</DIV>
<DIV><B></B> </DIV>
<DIV><STRONG><A href="http://www.healthpolicy.ucla.edu/" target=_self>The UCLA Center for Health Policy Research</A></STRONG> is one of the nation's leading health policy research centers and the premier source of health-related information on Californians.</DIV>
<DIV> </DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=153172" height="1" width="1" />]]></description><pubDate>Thu, 28 May 2009 16:00:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Menopause transition may cause trouble learning</title><link>http://newsroom.ucla.edu/portal/ucla/menopause-transition-may-cause-92903.aspx?link_page_rss=92903</link><guid>http://newsroom.ucla.edu/portal/ucla/menopause-transition-may-cause-92903.aspx</guid><description><![CDATA[<DIV><B></B></DIV>
<DIV><B></B></DIV>
<DIV>The largest study of its kind to date shows that women may not be able to learn as well shortly before menopause, compared with other stages in their lives.</DIV>
<DIV> </DIV>
<DIV>The research was published in the May 26 print issue of <A href="http://www.neurology.org/cgi/content/abstract/72/21/1850" target=_blank>Neurology</A>, the medical journal of the American Academy of Neurology.  </DIV>
<DIV> </DIV>
<DIV>Over four years, the researchers studied 2,362 women who were between the ages of 42 and 52 and had had at least one menstrual period in the three months before the study started.</DIV>
<DIV> </DIV>
<DIV>The women were given three tests: verbal memory, working memory and a test that measured the speed at which they processed information. Scientists tested the women throughout the four stages of the menopause transition: premenopause (no change in menstrual periods), early perimenopause (menstrual irregularity but no gaps of three months), late perimenopause (having no period for three to 11 months) and postmenopause (no period for 12 months).</DIV>
<DIV> </DIV>
<DIV>The researchers found that processing speed improved with repeated testing during premenopause, early perimenopause and postmenopause, but that scores during late perimenopause did not show the same degree of improvement. Improvements in processing speed during late perimenopause were only 28 percent as large as improvements observed in premenopause. </DIV>
<DIV> </DIV>
<DIV>For verbal memory performance, improvement was not as strong during early and late perimenopause, compared with premenopause. Improvements in verbal memory during early perimenopause were 29 percent as large as improvements observed in premenopause. During late perimenopause, verbal memory improvement was 7 percent as large as in premenopause. </DIV>
<DIV> </DIV>
<DIV>Combined, these findings suggest that during the early and late perimenopause, women do not learn as well as they do during other menopausal transition stages.</DIV>
<DIV> </DIV>
<DIV>"These perimenopausal test results concur with prior self-reported memory difficulties — 60 percent of women state that they have memory problems during the menopause transition," said Dr. Gail Greendale, a professor of medicine in the division of geriatrics at the David Geffen School of Medicine at UCLA and the study's primary investigator. "The good news is that the effect of perimenopause on learning seems to be temporary. Our study found that the amount of learning improved back to premenopausal levels during the postmenopausal stage."</DIV>
<DIV> </DIV>
<DIV>The study also found that taking estrogen or progesterone hormones before menopause helped verbal memory and processing speed. In contrast, taking these hormones after the final menstrual period had a negative effect: Postmenopausal women using hormones showed no improvement in either processing speed or verbal memory, unlike postmenopausal women not taking hormones.</DIV>
<DIV> </DIV>
<DIV>"Our results suggest that the 'critical period' for estrogen or progesterone's benefits on the brain may be prior to menopause, but the findings should be interpreted with caution," Greendale said.</DIV>
<DIV> </DIV>
<DIV>Other researchers on this study were M.-H. Huang, R.G. Wight, T. Seeman and A.S. Karlamangla of UCLA; C. Luetters of the University of California, Irvine; N.E. Avis of Wake Forest University; and J. Johnston of the Alaska Native Tribal Health Consortium.</DIV>
<DIV> </DIV>
<DIV>The National Institutes of Health (NIH), the National Institute on Aging, the National Institute of Nursing Research and the NIH Office of Research on Women's Health supported the study.</DIV>
<DIV> </DIV>
<DIV><STRONG><A href="http://www.aan.com/" target=_blank>The American Academy of Neurology</A></STRONG>, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to improving patient care through education and research. Neurologists have undergone specialized training in diagnosing, treating and managing disorders of the brain and nervous system, such as multiple sclerosis, Alzheimer's disease, narcolepsy and stroke. </DIV>
<DIV> </DIV>
<DIV><B></B></DIV>
<DIV><STRONG><A href="http://www.uclahealth.org/body.cfm?id=307&action=detail&limit_department=15&limit_division=1027&CFID=18470268&CFTOKEN=69564304" target=_blank>The UCLA Division of Geriatrics</A></STRONG> within the department of medicine at the David Geffen School of Medicine at UCLA offers comprehensive outpatient and inpatient services at several convenient locations and works closely with other UCLA programs to improve and maintain the quality of life of seniors. UCLA geriatricians are specialists in managing the overall health of people age 65 and older and treating medical disorders that frequently affect the elderly, including falls and immobility, urinary incontinence, memory loss and dementia, arthritis, high blood pressure, heart disease, osteoporosis, and diabetes. UCLA geriatricians can knowledgably consider and address a broad spectrum of health-related factors — including medical, psychological and social — when treating patients. </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=153057" height="1" width="1" />]]></description><pubDate>Wed, 27 May 2009 16:10:00 GMT</pubDate></item><item><author>Office of Media Relations</author><title>Chancellor Block 'greatly concerned' about budget deficit</title><link>http://newsroom.ucla.edu/portal/ucla/chancellor-block-on-budget-93202.aspx?link_page_rss=93202</link><guid>http://newsroom.ucla.edu/portal/ucla/chancellor-block-on-budget-93202.aspx</guid><description><![CDATA[<DIV><EM>This is a statement from UCLA Chancellor Gene Block released May 26, regarding the campus budget.</EM></DIV>
<DIV>&nbsp;</DIV>
<DIV>To the Campus Community:</DIV>
<P>In the wake of last Tuesday's election, we are all greatly concerned about the budget deficit and its impact on the University of California and UCLA. You may have read that the state Legislative Analyst's Office has increased, yet again, the projected budget shortfall — from $21 billion, contemplated at the time of last Tuesday's election, to $24 billion.</P>
<P>There will be three levels of decision-making in the coming months that affect the severity and nature of cuts to the university: state government (legislature and governor), UC system (President Yudof and the Regents) and UCLA. We do know that the cuts will be severe, and there is no question that we are facing difficult and painful choices.</P>
<P>We are in no position at this time, however, to predict the level and extent of cuts to the university that may impact our current planning levels. Right now, I encourage you to visit <A title=http://newsroom.ucla.edu/portal/ucla/campus-budget.aspx href="http://newsroom.ucla.edu/portal/ucla/campus-budget.aspx">http://newsroom.ucla.edu/portal/ucla/campus-budget.aspx</A> for up-to-date information about the state deficit, and UC and UCLA actions.</P>
<P>As the governor and state legislature negotiate next year's budget, UC and UCLA will advocate for our critical needs and priorities, such as the Cal Grants program. Recently, as you may know, the media reported that the governor is proposing the potential elimination of Cal Grants, which would greatly reduce low-income families’ access to the University of California. I am deeply concerned about these recent reports. President Yudof has expressed similar sentiment.</P>
<P>Nevertheless, we face a difficult period of uncertainty. As we move through this process, please do what you can to stay informed, help the campus achieve cost efficiencies and continue to lend your voice as an ambassador for public higher education in California.</P>
<P>Sincerely,</P>
<P>Gene D. Block<BR>Chancellor</P> <img src="http://newsroom.ucla.edu/rss.ashx?id=153034" height="1" width="1" />]]></description><pubDate>Wed, 27 May 2009 00:07:22 GMT</pubDate></item><item><author>Enrique Rivero</author><title>UCLA conference explores impact of economic crisis on human trafficking</title><link>http://newsroom.ucla.edu/portal/ucla/iris-cantor-ucla-women-s-health-92883.aspx?link_page_rss=92883</link><guid>http://newsroom.ucla.edu/portal/ucla/iris-cantor-ucla-women-s-health-92883.aspx</guid><description><![CDATA[<DIV><STRONG>WHAT:</STRONG></DIV>
<DIV>As the economic crisis worsens, reports of human trafficking have&nbsp;increased in Los Angeles, with documented cases of slave labor in restaurants, hotels, the garment industry, agriculture, child and elder care, and construction. "Impact of the Economic Crisis: Increase in Reports of Human Trafficking in L.A. County and Globally," a breakfast and briefing for the media and women's health experts, brings together health and law enforcement officials and human trafficking survivors to outline the local and global impact of this situation.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The event is sponsored by the Iris Cantor–UCLA Women's Health Center, with generous support from the David and Lucile Packard Foundation, the Coalition to Abolish Slavery and Trafficking, the Annenberg Foundation, and the Weingart Foundation.</DIV>
<DIV><BR></DIV>
<DIV><STRONG>WHO:</STRONG></DIV>
<DIV>Participants will include:</DIV>
<BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px">
<DIV><STRONG>Kay Buck</STRONG><BR>Executive director of the Coalition to Abolish Slavery and Trafficking</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>Kimberly Agbonkpolor</STRONG></DIV>
<DIV>Los Angeles Police Department's L.A. Metropolitan Task Force on Human Trafficking</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>Terri Thorfinnson</STRONG></DIV>
<DIV>Chief of the California Department of Health Services' Office of Women's Health</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>Susie Baldwin</STRONG></DIV>
<DIV>Chief of the health assessment unit&nbsp;of the Los Angeles County Department of Public Health's Office of Health Assessment and Epidemiology</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>Human trafficking survivors</STRONG></DIV></BLOCKQUOTE>
<DIV><STRONG>WHEN:</STRONG></DIV>
<DIV>Friday, May 29</DIV>
<UL>
<LI>
<DIV>8:45 a.m.: Breakfast and check-in</DIV>
<LI>
<DIV>9:30–10:30 a.m.: Program</DIV>
<LI>
<DIV>10:30–11 a.m.: Q&amp;A with presenters and panelists</DIV>
<LI>
<DIV>11–11:30 a.m.: One-on-one interview opportunities</DIV></LI></UL>
<DIV><STRONG></STRONG>&nbsp;</DIV>
<DIV><STRONG>WHERE:</STRONG></DIV>
<DIV>Covel Commons, on the UCLA campus (<A href="http://www.maps.ucla.edu/campus?cpoint=6425407.9944348,1849266.74482048&amp;level=3&amp;a_layers=Base%20Map&amp;s_resource=Base%20Map&amp;s_layer=Campus%20Building&amp;s_field=SDE.CMPS_BLDG_AREA.OBJECTID&amp;s_value=88">map</A>)</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>BACKGROUND:</STRONG></DIV>
<DIV>According to the United Nations' International Labor Organization, more than 12 million people worldwide are currently victims of human trafficking; the U.S. Department of Justice says the U.S. is a destination country for thousands of victims. Slave laborers rescued in Los Angeles have been documented to be citizens of Mexico, the United States, and countries in Central and South America, Asia, and Africa.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>R.S.V.P. &amp; INFORMATION:</STRONG></DIV>
<DIV>R.S.V.P. is required. For reservations, directions and parking information, please contact Robin Lam at 310-794-8063 or <A href="mailto:robinlam@mednet.ucla.edu">robinlam@mednet.ucla.edu</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>MEDIA CONTACT:</STRONG></DIV>
<DIV>Enrique Rivero, UCLA Health Sciences Media Relations, 310-794-2273</DIV>
<DIV><A href="mailto:erivero@mednet.ucla.edu">erivero@mednet.ucla.edu</A></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=152619" height="1" width="1" />]]></description><pubDate>Fri, 22 May 2009 18:45:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Limiting medical residents' work hours would cost $1.6 billion annually</title><link>http://newsroom.ucla.edu/portal/ucla/limiting-work-hours-for-medical-92820.aspx?link_page_rss=92820</link><guid>http://newsroom.ucla.edu/portal/ucla/limiting-work-hours-for-medical-92820.aspx</guid><description><![CDATA[<DIV>New recommendations by the national Institute of Medicine to limit the work hours of medical residents and improve their educational conditions would cost the nation's teaching hospitals about $1.6 billion annually to hire substitute workers, according to a new report from the RAND Corp. and UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>While society may benefit if such changes reduce medical errors, as intended, limiting trainee workloads would create a substantial new expense for academic medical centers, according to the study, published in the May 21 edition of the New England Journal of Medicine.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Adopting new restrictions on the work hours of physicians in training would impose a substantial new cost on the nation's 8,500 physician training programs," said lead author Dr. Teryl K. Nuckols, assistant professor of medicine in the division of general internal medicine and health services research at the David Geffen School of Medicine at UCLA and a researcher at RAND, a nonprofit research organization. "There is no obvious way to pay for these changes, so that's one major issue that must be addressed."</DIV>
<DIV>&nbsp;</DIV>
<DIV>In December 2008, the Institute of Medicine released a report calling for revisions to medical residents' workloads and schedules to decrease the chances of fatigue-related medical errors and to enhance the learning environment. Recommendations included requiring time for sleep during prolonged shifts, reducing shifts to 16 hours if residents do not have time for sleep, reducing residents' workloads and increasing the number of days residents must have off.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Graduate medical education programs traditionally have required residents to work long hours, often more than 100 per week. Such training programs generally run three to seven years following medical school.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study by RAND Health and UCLA provides new details about the potential costs and clinical implications of the Institute of Medicine recommendations, expanding upon a cost analysis described in the original report.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Should the recommendations be adopted, researchers say teaching hospitals would need to make up for residents' shorter work hours by either hiring other providers, such as physician assistants, to do the work or by expanding the number of residency positions.</DIV>
<DIV>&nbsp;</DIV>
<DIV>While adding residency slots could help ease physician shortages in some specialties, it also could lead to oversupply in others, according to the study. Researchers estimate that residency positions would need to grow by about 8 percent overall to meet staffing needs under the Institute of Medicine recommendations.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The trainees who are working more than the proposed limits would allow are not necessarily in the specialties where more physicians are needed," Nuckols said. "For example, pediatric residents work a lot of hours, but there is no evidence that there are too few pediatricians."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Researchers estimate that adopting the Institute of Medicine's recommendations would cost each major teaching hospital about $3.2 million annually on average. That figure is higher than some proven quality-improvement efforts for hospitals, such as computerized physician order entry and medication bar-coding systems. But it would be less expensive than other proposals, such as requiring that there be one nurse for every four patients.</DIV>
<DIV>&nbsp;</DIV>
<DIV>One study of shorter work shifts suggests that reducing resident work hours could cut serious medical errors by 25 percent in medical intensive care units. But few errors cause injury, and the effects could be different in other clinical settings, according to the study. In addition, revising work rules could prompt other types of medical errors as the care of hospitalized patients is more frequently handed from one provider to another.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Researchers say adopting the work hours and workload recommendations of the Institute of Medicine report would be more expensive for teaching hospitals than a major revision of resident work hours adopted by training programs six years ago. Those rules say that residents should not work more than an average of 80 hours per week, among other limits. Nearly a quarter of the costs estimated by the researchers would be necessary, however, just to bring residents into compliance with those current rules.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Residency programs already have picked much of the low-hanging fruit by reducing the non-educational duties placed on residents," Nuckols said. "Further changes will require that hospitals hire professionals with high levels of training, such as nurse practitioners and physicians, and that will be expensive."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Other authors of the study are Dr. Jose J. Escarce of RAND and UCLA; Dr. Jay Bhattacharya of Stanford University, who is a member of the Institute of Medicine committee that issued the report; and Dianne Miller Wolman and Cheryl Ulmer of the Institute of Medicine.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Support for the study was provided by the Institute of Medicine, under contract to the federal Agency for Healthcare Research and Quality.</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.rand.org/health/"><STRONG>RAND Health</STRONG></A>, a division of the RAND Corp., is the nation's largest independent health policy research program, with a broad research portfolio that focuses on quality, costs, health services delivery, and health promotion and disease prevention, among other topics. RAND Health is the creator of COMPARE (Comprehensive Assessment of Reform Efforts), a one-of-a-kind online resource that provides objective analysis about national health care reform proposals. Visit <A href="http://www.randcompare.org/">www.randcompare.org</A> to learn more.</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://gim.med.ucla.edu/index.php"><STRONG>The General Internal Medicine and Health Services Research Divison</STRONG></A> in the department of medicine at the David Geffen School of Medicine at UCLA provides a unique interactive environment for collaborative efforts between health services researchers and clinical experts with experience in evidence-based work. The division's 100-plus clinicians and researchers are engaged in a wide variety of projects that examine issues related to access to care, quality of care, health measurement, physician education, clinical ethics and doctor-patient communication. Researchers in the division have close working relationships with economists, statisticians, social scientists and other specialists throughout UCLA and frequently collaborate with their counterparts at the RAND Corp. and the Charles Drew University of Medicine and Science.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=152617" height="1" width="1" />]]></description><pubDate>Fri, 22 May 2009 18:15:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Elderly women with 'dowager's hump' may be at higher risk of earlier death</title><link>http://newsroom.ucla.edu/portal/ucla/hyperkyphosis-may-predict-earlier-92475.aspx?link_page_rss=92475</link><guid>http://newsroom.ucla.edu/portal/ucla/hyperkyphosis-may-predict-earlier-92475.aspx</guid><description><![CDATA[<DIV><B></B></DIV>
<DIV>Hyperkyphosis, or "dowager's hump"&nbsp;— the exaggerated forward curvature of the upper spine seen&nbsp;commonly in elderly&nbsp;women&nbsp;— may predict earlier death in women whether or not they have vertebral osteoporosis, UCLA&nbsp;researchers have found.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In a study published in the May 19 issue of Annals of Internal Medicine, researchers found that older white women with both vertebral fractures and the increased spinal curvature that results in the bent-over posture characteristic of hyperkyphosis had an elevated risk for earlier death.&nbsp;The finding&nbsp;was independent of other factors that included age and underlying spinal osteoporosis.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Women who had only hyperkyphosis, without vertebral fractures,&nbsp;did not show an increased risk for premature death. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Hyperkyphosis can be caused by a number of factors besides osteoporosis, including habitual poor posture and degenerative diseases of the muscles and intervertebral discs.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Just being bent forward may be an important clinical finding that should serve as a trigger to seek medical evaluation for possible spinal osteoporosis, as vertebral fractures more often than not are a silent disease," said Dr. Deborah Kado, an associate professor of orthopedic surgery and medicine at the David Geffen School of Medicine at UCLA and the study's primary investigator. "We demonstrated that having this age-related postural change is not a good thing. It could mean you're likely to die sooner."</DIV>
<DIV>&nbsp;</DIV>
<DIV>For the study, the researchers reviewed data&nbsp;on&nbsp;610 women, age 67 to 93, from a cohort of 9,704 participants in the Study of Osteoporotic Fractures. The participants were&nbsp;recruited between 1986 and 1988 in Baltimore, Md.; Minneapolis, Minn.; Portland, Ore.; and&nbsp;Pennsylvania's Monongahela Valley. Researchers&nbsp;measured spinal curvature with a flexicurve and assessed vertebral fractures from spinal radiographs; they assessed mortality&nbsp;based on&nbsp;follow-ups averaging 13.5 years.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Adjusting for age, as well as osteoporosis-related factors such as low bone density, moderate and severe vertebral fractures, and the number of prevalent vertebral fractures, the researchers found that women with previous vertebral fractures and increasing degrees of spinal curvature were at increased mortality risk from the spinal condition, regardless of age, smoking, spinal bone-mineral density, or the number and severity of their spinal fractures.</DIV>
<DIV>&nbsp;</DIV>
<DIV>These study findings provide evidence that it is not just vertebral fracture alone but the associated increased spinal curvature that may be most predictive of adverse health outcomes. Other studies linking hyperkyphosis to poor health, such as impaired physical function, increased fall risk, fractures and mortality, have been unable to exclude the possibility that vertebral fractures alone were the underlying explanation for the findings.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B></B></DIV>
<DIV>The researchers note several caveats. This study focused on women, though hyperkyphosis also affects men; measurements for vertebral fractures were based only on height ratios, which could lead to misclassification of other causes of height ratio decreases, such as Scheuermann disease; and the timing of the assessments could have affected the results, though it's unlikely to have made much difference.</DIV>
<DIV>&nbsp;</DIV>
<DIV>However, this study demonstrates a possible association between hyperkyphosis and increased risk for earlier death independent of the number and severity of vertebral fractures or osteoporosis in older women, the researchers write.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"These results add to the growing literature that suggests that hyperkyphosis is a clinically important finding. Because it is readily observed and is associated with ill health in older persons, hyperkyphosis should be recognized as a geriatric syndrome — a 'multifactorial health condition that occurs when the accumulated effect of impairments in multiple systems renders a person vulnerable to situational challenges.'"</DIV>
<DIV>&nbsp;</DIV>
<DIV>Study co-authors include Arun S. Karlamangla of UCLA; Li-Yung Lui and Steven R. Cummings of the California Pacific Medical Center Research Institute; and Kristine E. Ensrud and Howard A. Fink of the University of Minnesota.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The National Institute of Arthritis and Musculoskeletal and Skin Diseases and the National Institute on Aging funded this study.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B></B></DIV>
<DIV>
<DIV><STRONG><A href="http://www.uclahealth.org/body.cfm?id=307&amp;action=detail&amp;ref=20" target=_self>The UCLA Department of Orthopaedic Surgery</A></STRONG> provides consultation and treatment for disorders of the musculoskeletal system.&nbsp;Department faculty members provide comprehensive services for such specialties as joint replacement and reconstructive surgery, microvascular surgery, sports medicine, arthroscopy, foot and ankle surgery, hand surgery, pediatric orthopedics, spinal diseases, orthopedic trauma, orthopedic oncology, and metabolic bone disease. In 1998, UCLA and Los Angeles Orthopaedic Hospital formed a strategic alliance through which Orthopaedic Hospital was integrated with UCLA in the replacement facility for Santa Monica–UCLA Medical Center and Orthopaedic Hospital.</DIV></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=152529" height="1" width="1" />]]></description><pubDate>Thu, 21 May 2009 16:20:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>UCLA scientists identify new gene linked to autism risk</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-identify-new-gene-92513.aspx?link_page_rss=92513</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-identify-new-gene-92513.aspx</guid><description><![CDATA[<DIV>UCLA scientists have discovered a variant of a gene called CACNA1G that may increase&nbsp;children's risk of developing&nbsp;autism, particularly&nbsp;boys. The journal Molecular Psychiatry publishes the findings in its May 19 advance online edition.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Classic autism strikes&nbsp;four times as many boys as girls. When including the entire spectrum of autism disorders, such as the milder Asperger syndrome, boys are 10 times more&nbsp;likely to be diagnosed&nbsp;than girls.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This is a strong finding," said Dr. Stanley Nelson, professor of human genetics at the David Geffen School of Medicine at UCLA and the study's principal investigator. "No one has scrutinized the role that CACNA1G plays in autism.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We found that a common form of the gene occurs more frequently in the DNA of families that have two or more sons affected by autism but no affected daughters," he said. "Our study may explain why boys are more susceptible to the disorder than girls."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Nelson and his colleagues zeroed in on a region of chromosome 17 that previous studies have tied to autism. The research team scoured the DNA of 1,046 members of families with at least two sons affected by autism for common gene variants.</DIV>
<DIV>&nbsp;</DIV>
<DIV>A variant is a gene that has undergone subtle changes from the normal DNA yet is shared by a significant portion of the population.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers used tools of the Human Genome Project to scan thousands of variants across all genes in the suspicious region of the chromosome and to pluck out the most common forms.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We wanted to identify what was happening in this region of chromosome 17 that boosts autism risk," Nelson said. "When the same genetic markers kept cropping up in a single region of the DNA, we knew we had uncovered a big clue."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers traced the genetic markers to CACNA1G, which helps move calcium between cells. They discovered that the gene has a common variant that appears in the DNA of nearly 40 percent of the population.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This alternate form of CACNA1G consistently increased the correlation to autism spectrum disorders, suggesting that inheriting the gene may heighten a child's risk of developing autism," Nelson said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>How the gene contributes to higher autism risk remains unclear, but Nelson emphasized that it cannot be considered a risk factor on its own.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This variant is a single piece of the puzzle," he said. "We need a larger sample size to identify all of the genes involved in autism and to solve the whole puzzle of this disease."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The UCLA team's next step will be to sequence the gene in people who possess the altered variant in order to identify the exact change that increases autism risk. These subtle variations offer potential markers for the real mutation causing greater susceptibility to the disease.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Nelson's co-authors included Samuel Strom, Jennifer Stone, John ten Bosch, Barry Merriman, Rita Cantor and Daniel Geschwind, all of UCLA. The study was funded by the National Institute of Mental Health and Cure Autism Now, which merged with Autism Speaks in 2007.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The DNA samples and clinical data were provided by families who donated blood to the Los Angeles–based Autism Genetic Resource Exchange (AGRE), a program created and funded by Cure Autism Now.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"When parents like me first formed AGRE, this was our dream, that talented scientists would use our gene bank to collaborate and bring us closer to understanding autism," said Jon Shestack, co-founder of Cure Autism Now and a board member of Autism Speaks. "AGRE has played an important role in almost every major autism genetics paper in the past five years."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Autism is a complex brain disorder that strikes in early childhood. The condition disrupts a child's ability to communicate and develop social relationships and is often accompanied by acute behavioral challenges. The Centers for Disease Control and Prevention reports that one in 150 American children is diagnosed with an autism spectrum disorder. The diagnosis of autism has expanded tenfold in the last decade.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV>
<DIV>&nbsp;</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=152410" height="1" width="1" />]]></description><pubDate>Tue, 19 May 2009 21:20:00 GMT</pubDate></item><item><author>Sandra Shagat</author><title>Dental researchers ID new target in fight against osteoporosis, periodontitis</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-dental-school-researchers-91633.aspx?link_page_rss=91633</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-dental-school-researchers-91633.aspx</guid><description><![CDATA[<DIV>Osteoporosis and periodontitis are common diseases whose sufferers must cope with weakness, injury and reduced function as they lose bone more quickly than it is formed. While the mechanism of bone destruction in these diseases is understood, scientists have had less information about how bone formation is impaired.</DIV>
<DIV> </DIV>
<DIV>Now, researchers at the UCLA School of Dentistry, working with scientists at the University of Michigan and the University of California, San Diego, have identified a potential new focus of treatments for osteoporosis, periodontitis and similar diseases.</DIV>
<DIV> </DIV>
<DIV>In a paper published May 17 in the online edition of the journal Nature Medicine, Cun-Yu Wang, who holds UCLA's No-Hee Park Endowed Chair in the dental school's division of oral biology and medicine, and colleagues suggest that inhibiting nuclear factor-kB (NF-kB), a master protein that controls genes associated with inflammation and immunity, can prevent disabling bone loss by maintaining bone formation.</DIV>
<DIV> </DIV>
<DIV>The findings could offer new hope to millions who struggle with osteoporosis and periodontitis each year. The National Institutes of Health estimates that in the United States alone, more than 10 million people have osteoporosis, and many more have low bone mass, putting them at risk for the disease, as well as for broken bones. According to the American Academy of Periodontology, mild to moderate periodontitis affects a majority of adults, with between 5 and 20 percent of the population suffering from a more severe stage of the disease. </DIV>
<DIV> </DIV>
<DIV>The NF-kB protein, a culprit in inflammatory and immune disorders, plays a major role in both osteoporosis and periodontitis, disrupting the healthy balance of bone destruction and formation. It is this balance that Wang and his fellow scientists seek to restore, and perhaps even improve upon, by finding new ways to promote net bone accumulation.</DIV>
<DIV> </DIV>
<DIV>"Most studies focus on the part that NF-kB plays in the regulation of osteoclasts — bone-resorbing cells. For the past five years, we looked closely at the effect of NF-kB on osteoblasts — bone-forming cells," said Wang, the study's principal investigator and a member of UCLA's Jonsson Comprehensive Cancer Center. "We knew that NF-kB promoted resorption. What we discovered in our in vitro and in vivo studies is that this protein also inhibits new bone formation, giving us a fuller picture of its role in inflammation and immune responses." </DIV>
<DIV> </DIV>
<DIV>"This landmark paper by Dr. Wang and his colleagues is not only top-notch molecular science, but it also holds promise for clinicians trying to provide the most enlightened treatment of women with postmenopausal osteoporosis," said John Adams, a UCLA professor of orthopedic surgery. "The paper shows how the molecular manipulation of a previously unsuspected pro-inflammatory pathway in the bone-forming cell, the osteoblast, can regulate the capacity of that cell to make new bone." </DIV>
<DIV> </DIV>
<DIV>Many currently available treatments work to prevent further bone loss but are not able to increase bone mass. Wang's research results support the idea that a new drug that prevents the action of NF-kB in cells may represent a major therapeutic advance.</DIV>
<DIV> </DIV>
<DIV>"Although it has been known for some time that inflammation inhibits bone formation, the groundbreaking work by Dr. Wang and his colleagues elucidates the critical role of NF-kB in the mechanism that underlies this phenomenon," said Philip Stashenko, a professor at the Harvard School of Dental Medicine and president and CEO of the Forsyth Institute, an oral health treatment and research organization. "Many drugs that block NF-kB are in development, and these findings suggest that new treatments to preserve bone in periodontitis, osteoporosis and related bone diseases are imminent."</DIV>
<DIV> </DIV>
<DIV>As a next step, Wang and his research team are planning to test small molecules that inhibit the specific bone-resorption and bone-inhibition actions of NF-kB in osteoporosis and periodontitis.</DIV>
<DIV> </DIV>
<DIV>The study was supported by grants from the National Institute of Dental and Craniofacial Research and the National Institute of Diabetes and Digestive and Kidney Diseases. </DIV>
<DIV> </DIV>
<DIV>An abstract of the paper is available at <A href="http://dx.doi.org/10.1038/nm.1954" target=_blank>http://dx.doi.org/10.1038/nm.1954</A>.</DIV>
<DIV> </DIV>
<DIV><B><A href="http://www.dentistry.ucla.edu/" target=_blank>The UCLA School of Dentistry</A></B> is dedicated to improving the oral health of the people of California, the nation and the world through its teaching, research, patient care and public service initiatives. The school provides education and training programs that develop leaders in dental education, research, the profession and the community; conducts research programs that generate new knowledge, promote oral health and investigate the cause, prevention, diagnosis and treatment of oral disease; and delivers patient-centered oral health care to the community and state. </DIV>
<DIV> </DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=152182" height="1" width="1" />]]></description><pubDate>Mon, 18 May 2009 21:40:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>UCLA study shows traumatic brain injury haunts children for years</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-study-shows-traumatic-brain-91513.aspx?link_page_rss=91513</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-study-shows-traumatic-brain-91513.aspx</guid><description><![CDATA[<DIV>Traumatic brain injury is the single most common cause of death and disability in children and adolescents, according to the national Centers for Disease Control and Prevention. Now, UCLA researchers have found that the effects of a blow to the head, whether it's mild or a concussion, can linger for years.</DIV>
<DIV> </DIV>
<DIV>Talin Babikian, lead study author and a UCLA postdoctoral fellow in psychiatry and biobehavioral sciences, and senior author Robert Asarnow, a UCLA professor of psychiatry, analyzed 28 selected articles about traumatic brain injury, or TBI, published between 1988 and 2007, quantifying for the first time all of the available literature on the effects of TBI on the developing brains of children and adolescents. Their findings appear in the May issue of the journal Neuropsychology.</DIV>
<DIV> </DIV>
<DIV>The key, and most surprising, finding, the authors say, was that over time, children and adolescents with a severe TBI appear to fall even farther behind their peers than was previously thought, making intervention and monitoring especially important in this group.</DIV>
<DIV> </DIV>
<DIV>Various levels of TBI in children were included in the studies that were reviewed. The extent of a brain injury is typically based on the Glasgow Coma Scale, a standard clinical tool used to measure the severity of these injuries. The scale measures a person's eye/pupil response, motor response and verbal communication to determine whether a TBI is mild, moderate or severe. </DIV>
<DIV> </DIV>
<DIV>Children in the studies were sorted by TBI severity and the time since their injury. All three severity levels were examined, and follow-up exams were done, on average, 0–5 months, 6–23 months or 24-plus months after injury for 14 key aspects of neurocognition.</DIV>
<DIV> </DIV>
<DIV>Additional key findings of the study:</DIV>
<DIV style="FONT-SIZE: 3px"> </DIV>
<UL>
<LI>Time didn’t heal all wounds — the worse the injury, the worse the neurocognitive outcome over time, especially on measures of general intellectual functioning and brain processing speed. The moderate and severe TBI groups were similarly impaired after examination at 24-plus months. While there was modest recovery in intellectual functioning and attention, weaknesses in many children with even moderate TBI persisted even two years after the injury, compared with children in control groups. 
<LI>For children diagnosed with severe TBI, more help was needed. They showed significant problems within months on IQ, executive functioning (processing speed, attention), and verbal memory (both immediate and delayed) measures. After two or more years, all areas studied were impaired.</LI></UL>
<DIV> </DIV>
<DIV>"The good news is that the studies showed that children with mild traumatic brain injuries and concussions may show some difficulties in cognition initially, but the effects are subtle and typically diminish over time," Babikian said. "The bad news, though, is the existence of a subgroup of patients who show persistent neurocognitive problems and need to be screened and followed.</DIV>
<DIV> </DIV>
<DIV>"And because younger children have more development ahead of them, the same injury can affect a 4-year-old and a 12-year-old very differently," she said. "Further, children who suffer a severe brain injury may show a slower rate of development as a group, highlighting the importance of targeted treatment developed specifically for children with severe TBI."</DIV>
<DIV> </DIV>
<DIV>Equally important, Babikian said, is the take-home message of prevention. </DIV>
<DIV> </DIV>
<DIV>"Because younger children with a traumatic brain injury seem to generally do worse than their older counterparts," she said, "the public health implication of this research is a reminder of the importance of the use of protective measures to minimize the effects of a brain injury when one does occur, as well as prevention through consistent use of helmets and seat belts."</DIV>
<DIV> </DIV>
<DIV>The research was funded by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, and by the Della Martin Foundation. The authors report no conflict of interest.</DIV>
<DIV> </DIV>
<DIV><STRONG><A href="http://www.psychiatry.ucla.edu/" target=_blank>The UCLA Department of Psychiatry and Biobehavioral Sciences</A></STRONG> is the home within the David Geffen School of Medicine at UCLA for faculty who are experts in the origins and treatment of disorders of complex human behavior. The department is part of the Semel Institute for Neuroscience and Human Behavior, a world-leading interdisciplinary research and education institute devoted to the understanding of complex human behavior and the causes and consequences of neuropsychiatric disorders.</DIV>
<DIV> </DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=151976" height="1" width="1" />]]></description><pubDate>Thu, 14 May 2009 21:55:00 GMT</pubDate></item><item><author>Phil Hampton</author><title>Businessman convicted in scheme to sell body parts</title><link>http://newsroom.ucla.edu/portal/ucla/businessman-convicted-in-scheme-91701.aspx?link_page_rss=91701</link><guid>http://newsroom.ucla.edu/portal/ucla/businessman-convicted-in-scheme-91701.aspx</guid><description><![CDATA[A Los Angeles County jury today found a Rancho Cucamonga businessman guilty of grand theft by embezzlement, tax evasion and other felonies in connection with a scheme to sell body parts donated to UCLA's medical school.<br><br>Ernest V. Nelson, was found guilty of selling body parts to medical and pharmaceutical research companies without permission from the campus. His conspirator, Henry Reid, the former director of UCLA's donated body program, <a target="_blank" href="http://www.today.ucla.edu/portal/ut/willed-body-program-defendent-80211.aspx">pleaded guilty and was sentenced</a> in January to more than four years in prison and ordered to pay $500,000 in compensation to the David Geffen School of Medicine.<br><br>When the scheme came to light in 2004, the campus voluntarily shut down the program and instituted a comprehensive series of strategies designed to enhance security, build in transparency and widen oversight. Medical school officials said the new program is running smoothly and that they are confident the measures will ensure that donated bodies are used only to advance scientific research and the education of medical students.<br><br>UCLA police Chief Karl Ross praised the work of his detectives. "The work of the UCLA investigators in this complex, multi-state investigation was the key component in ensuring a successful prosecution and sentencing," said Ross. "I want to acknowledge their excellent work for almost five years to ensure that justice was served." <img src="http://newsroom.ucla.edu/rss.ashx?id=151975" height="1" width="1" />]]></description><pubDate>Thu, 14 May 2009 21:33:48 GMT</pubDate></item><item><author>Mark Wheeler</author><title>How to build a bigger brain</title><link>http://newsroom.ucla.edu/portal/ucla/how-to-build-a-bigger-brain-91273.aspx?link_page_rss=91273</link><guid>http://newsroom.ucla.edu/portal/ucla/how-to-build-a-bigger-brain-91273.aspx</guid><description><![CDATA[<DIV>Push-ups, crunches, gyms, personal trainers — people have many strategies&nbsp;for building bigger muscles and stronger bones. But what can one do to build a bigger brain?</DIV>
<DIV>&nbsp;</DIV>
<DIV>Meditate.</DIV>
<DIV>&nbsp;</DIV>
<DIV>That's the finding from a group of researchers at UCLA who used high-resolution magnetic resonance imaging (MRI) to scan the brains of people who meditate. In a study&nbsp;published in&nbsp;the journal NeuroImage and currently available online (by subscription), the researchers report that certain regions&nbsp;in the&nbsp;brains of&nbsp;long-term meditators were larger than in a similar control group.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Specifically, meditators showed significantly larger volumes of the hippocampus and areas within the orbito-frontal cortex, the thalamus and the inferior temporal gyrus —&nbsp;all regions known for regulating emotions.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We know that people who consistently meditate have a singular ability to cultivate positive emotions, retain emotional stability and engage in mindful behavior," said Eileen Luders, lead author and a postdoctoral research fellow at the UCLA Laboratory of Neuro Imaging. "The observed differences in brain anatomy might give us a clue why meditators have these exceptional abilities."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Research has confirmed the beneficial aspects of meditation. In addition to having better focus and control over their emotions, many people who meditate regularly have reduced levels of stress and bolstered immune systems.&nbsp;But less&nbsp;is known about the link between meditation and brain structure.</DIV>
<DIV>&nbsp;&nbsp; </DIV>
<DIV>In the study, Luders and her colleagues examined 44 people —&nbsp;22 control subjects and 22 who had practiced various forms of meditation, including Zazen, Samatha and Vipassana, among others.&nbsp;The&nbsp;amount of time&nbsp;they had&nbsp;practiced ranged from&nbsp;five&nbsp;to 46 years,&nbsp;with an average of 24 years. </DIV>
<DIV>&nbsp;</DIV>
<DIV>More than half of all the meditators said that deep concentration was an essential part of their practice, and most meditated between 10 and 90 minutes every day.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers used a high-resolution, three-dimensional form of MRI and two different approaches to measure differences in brain structure. One approach automatically divides the brain into several regions of interest, allowing researchers to compare the size of certain brain structures. The other segments the brain into different tissue types, allowing researchers to compare the amount of gray matter within specific regions of the brain.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers&nbsp;found significantly larger cerebral measurements in meditators compared&nbsp;with controls, including larger volumes of the right hippocampus and increased gray matter in the right orbito-frontal cortex, the right thalamus and the left inferior temporal lobe. There were no regions where controls had significantly larger volumes or more gray matter than meditators.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Because these areas of the brain are closely linked to emotion, Luders said, "these might be the neuronal underpinnings that give meditators' the outstanding ability to regulate their emotions and allow for well-adjusted responses to whatever life throws their way."</DIV>
<DIV>&nbsp;</DIV>
<DIV>What's not known, she said, and will require further study, are what the specific correlates are on a microscopic level — that is, whether it's an increased number of neurons, the larger size of the neurons or a particular "wiring" pattern meditators may develop that other people don't.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Because this was not a longitudinal study —&nbsp;which would have&nbsp;tracked meditators from the time they began meditating onward — it's possible that the meditators already had more regional gray matter and volume in specific areas; that may have attracted them to meditation in the first place, Luders said. </DIV>
<DIV>&nbsp;</DIV>
<DIV>However, she also noted that numerous previous studies have pointed to the brain's remarkable plasticity and how environmental enrichment has been shown to change brain structure.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Other authors of the study included Arthur Toga, director of the UCLA Laboratory of Neuro Imaging; Natasha Lepore of UCLA; and Christian Gaser of the University of Jena in Germany. Funding for the study was provided by the National Institutes of Health. The authors report no conflicts of interest.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.loni.ucla.edu/" target=_blank>The&nbsp;UCLA&nbsp;Laboratory of Neuro Imaging</A>,</STRONG> which seeks to improve understanding of the brain in health and disease, is a leader in the development of advanced computational algorithms and scientific approaches for the comprehensive and quantitative mapping of brain structure and function.&nbsp;The laboratory&nbsp;is part of the <A href="http://www.neurology.ucla.edu/" target=_blank>UCLA Department of Neurology</A>, which encompasses more than a dozen research, clinical and teaching programs. The department has ranked No. 1 among its peers nationwide in National Institutes of Health funding for the last seven years (2002–08).</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=151632" height="1" width="1" />]]></description><pubDate>Tue, 12 May 2009 16:20:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>UCLA scientists identify how key protein keeps chronic infection in check</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-identify-how-key-91091.aspx?link_page_rss=91091</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-identify-how-key-91091.aspx</guid><description><![CDATA[<DIV>Why is the immune system able to fight off some viruses but not others, leading to chronic, life-threatening infections like HIV and hepatitis C?</DIV>
<DIV>&nbsp;</DIV>
<DIV>A new UCLA AIDS Institute study suggests the answer lies in a protein called interleukin-21 (IL-21), a powerful molecule released by immune cells during chronic infection. Published May 7 in the online edition of Science, the finding could explain how the immune system limits viral replication, restricting&nbsp;a virus's&nbsp;spread through the body.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers looked at two types of T-cells&nbsp;— CD4 T-cells and CD8 T-cells&nbsp;— which are immune cells that play an important role in the body's response to infection. The CD4 T-cells help the immune system by producing IL-21 during chronic infection, bolstering the CD8 T-cells' ability to fight off the virus.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The CD4 cells are the regulators — the generals, if you will,"&nbsp;said principal investigator David Brooks, assistant professor of<B> </B>microbiology, immunology and molecular genetics at the David Geffen School of Medicine at UCLA. "The CD8 cells go out and kill the invaders; they're like the privates in the field."</DIV>
<DIV>&nbsp;</DIV>
<DIV>To shed light on how CD4 T-cells help their CD8 counterparts clear viruses, the researchers infected mice with one of two strains of a virus. They knew that the first strain would generate a short-term infection and the second a chronic infection.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The scientists tested each strain on two groups of mice. One group was normal and the other was bred without IL-21 receptors.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In the normal mice, the first strain elicited a strong T-cell response that completely eliminated the virus in 10 days. The second strain caused a chronic infection that exhausted the T-cells, hampering their ability to fight the virus. The UCLA team detected high levels of IL-21 in these mice, suggesting that the protein plays a crucial role in sustaining the T-cells' ability to mount an immune response during long-lasting infection.</DIV>
<DIV>&nbsp;</DIV>
<DIV>When the scientists infected the mice that lacked IL-21 receptors with the chronic infection strain, something curious happened. The majority of virus-fighting CD8 T-cells disappeared, preventing the immune system from containing the spread of the virus.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"IL-21 fuels CD8 T-cells' ability to function," Brooks said. "These immune cells are running a long-distance race to contain the virus before it spreads. If they don't get fed, they collapse on the track."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Without IL-21, the CD8 T-cells dwindled, even when the CD4 T-cells produced a robust response. The result indicates that the T-cells rely on IL-21 to resolve persistent infection.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"After the immune system loses CD8 T-cells, it's unable to clear the virus," Brooks said. "This tells us that IL-21 is a critical player in the body's fight against chronic infection."<BR><BR>The study was funded by the UCLA Center for AIDS Research, the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA, and the National Institutes of Health. Brooks' co-authors included Heidi Elsaesser of UCLA and Karsten Sauer of the Scripps Research Institute. </DIV>
<DIV>&nbsp;</DIV>
<DIV><B><A href="http://www.uclaaidsinstitute.org/" target=_blank>The UCLA AIDS Institute</A></B>, established in 1992, is a multidisciplinary think tank drawing on the skills of top-flight researchers in the worldwide fight against HIV and AIDS, the first cases of which were reported in 1981 by UCLA physicians. Institute members include researchers in virology and immunology, genetics, cancer, neurology, ophthalmology, epidemiology, social science, public health, nursing and disease prevention. Their findings have led to advances in treating HIV, as well as other diseases, such as hepatitis B and C, influenza and cancer.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu" target=_self>UCLA Newsroom</A>. </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=151354" height="1" width="1" />]]></description><pubDate>Thu, 07 May 2009 23:20:00 GMT</pubDate></item><item><author>Jennifer Marcus</author><title>Startup uses new incubator space in CNSI to commercialize UCLA technology</title><link>http://newsroom.ucla.edu/portal/ucla/matrix-sensors-inc-commercializing-90256.aspx?link_page_rss=90256</link><guid>http://newsroom.ucla.edu/portal/ucla/matrix-sensors-inc-commercializing-90256.aspx</guid><description><![CDATA[<DIV>UCLA has opened its new technology incubation space within the California NanoSystems Institute to Matrix Sensors Inc., a startup company in the process of developing multichannel gas and biological sensor systems based on technology developed jointly by UCLA and Stanford University researchers.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The technology holds promise for the highly sensitive and accurate detection of harmful gases, which could have practical applications in both public and industrial settings.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Matrix Sensors is a seed-stage company founded in March 2006 by UCLA chemistry and biochemistry professor James Gimzewski and Stanford electrical engineering professors Butrus (Pierre) T. Khuri-Yakub and Calvin F. Quate, the key researchers and inventors in the area of developing CMUT (capacitive micromachined ultrasonic transducer) technology for chemical and biological sensors.<BR><BR>As part of this arrangement, Matrix Sensors has obtained an exclusive license for this technology that will provide the University of California with an equity position in the company. Matrix has rented lab space in the incubator at the CNSI and has access to core lab facilities to pursue research and development work.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The company proposes to use CMUT technology for gas and biological analytes. The goal of the technology is to develop products with high analyte resolution, accuracy and stability suitable for commercial applications, such as monitoring the release of gases in large public settings.<BR><BR>Atomic-force microscope instrumentation will be used to characterize sensor microchips to do functionalization work. This will lay the foundation to test, in careful and controlled ways, how well the chemical layers can be applied. The initial goals are to make microchip devices that are chemically sensitive and to characterize the nature of the chemical sensitivity.<BR><BR></DIV>
<DIV>"The CNSI is committed to accelerating the transfer of new technologies from the laboratory to the clinical and commercial marketplace," said Leonard H. Rome, interim director of the CNSI and senior associate dean of research at the David Geffen School of Medicine at UCLA. "Matrix can serve as a potential model for how UCLA may support startups with unique access to faculty and lab facilities to nurture early-stage R&amp;D. This directly flows from the institute's mission to facilitate collaborations with private industry for the rapid commercialization of new innovations."<BR><BR>"At this stage in the company's development, we can't possibly afford to set up sufficient lab space on our own," said Mike Cable, CEO of Matrix Sensors. "Having access to core lab facilities, particularly the Nano and Pico Characterization Lab, with state-of-the-art atomic-force microscopes, will be essential to our ability to take the R&amp;D to the next level."<BR><BR>"The versatility of these microchip sensors is very encouraging in terms of practical applications," Gimzewski said. "We think the sensors can be placed in portable handheld devices such as cell phones, which broadens the accessibility of instant analysis."</DIV>
<DIV>&nbsp;</DIV>
<DIV><B><A href="http://www.cnsi.ucla.edu/">The California NanoSystems Institute</A></B> (CNSI) is an integrated research center operating jointly at UCLA and UC Santa Barbara whose mission is to foster interdisciplinary collaborations for discoveries in nanosystems and nanotechnology; train the next generation of scientists, educators and technology leaders; and facilitate partnerships with industry, fueling economic development and the social well-being of California, the United States and the world. The CNSI was established in 2000 with $100 million from the state of California and an additional $250 million in federal research grants and industry funding. At the institute, scientists in the areas of biology, chemistry, biochemistry, physics, mathematics, computational science and engineering are measuring, modifying and manipulating the building blocks of our world — atoms and molecules. These scientists benefit from an integrated laboratory culture enabling them to conduct dynamic research at the nanoscale, leading to significant breakthroughs in the areas of health, energy, the environment and information technology.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=151296" height="1" width="1" />]]></description><pubDate>Thu, 07 May 2009 22:00:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>UCLA scientists reveal how deadly pediatric disorder develops in brain</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-reveal-how-deadly-90544.aspx?link_page_rss=90544</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-reveal-how-deadly-90544.aspx</guid><description><![CDATA[<DIV>A deadly brain disorder in toddlers may find its first treatment in drugs for Alzheimer's disease.</DIV>
<DIV>&nbsp;</DIV>
<DIV>UCLA scientists have discovered how a form of the rare genetic disease known as&nbsp;Sanfilippo syndrome develops in the young brain, causing severe mental retardation and death as early as age 14. Published this week&nbsp;in the early online edition of Proceedings of the National Academy of Sciences, the findings suggest that new Alzheimer's drugs may provide therapy for the currently untreatable metabolic disorder.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Four different enzyme deficiencies cause Sanfilippo syndrome, leading to the disorder's classification as type A, B, C or D. The UCLA team studied type B, the second most common form.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We knew that Sanfilippo syndrome type B results from a mutation of the gene that produces the enzyme needed to break down sugar molecule chains in the body,"&nbsp;said Elizabeth Neufeld, a professor of biological chemistry at the David Geffen School of Medicine at UCLA. "We studied the disease in mice bred to possess the same gene defect seen in human patients."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Neufeld's team found that mice with the defective gene produce higher amounts of two proteins called lysozyme and P-tau. They tracked the proteins to neurons in the medial entorhinal cortex&nbsp;— an important memory center in the brain. One of the first areas to be affected by Alzheimer’s disease, the region also has been implicated in other abnormalities in Sanfilippo syndrome.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Earlier research had linked high levels of lysozyme to the production of P-tau, a misshapen protein that helps form the strands that clump into tangles in the brain. These tangles impair neuron function and are a hallmark of Alzheimer's and other degenerative brain diseases.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This is really exciting," said co-author Stanislav Karsten, a UCLA assistant professor of neurology and of obstetrics and gynecology. "If we can replicate our discovery of P-tau in the brains of human patients, it may be possible to treat Sanfilippo syndrome with new drugs created for Alzheimer's disease. We believe our finding will accelerate the development of an effective therapy for this heartbreaking disorder."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Many scientists have searched for P-tau in the brains of Sanfilippo syndrome patients and in animal models. The UCLA team was the first to uncover it.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We were fortunate to find the P-tau, because it appears in only a very small part of the brain," said lead author Kazuhiro Ohmi, a UCLA assistant researcher in biological chemistry.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Sanfilippo syndrome falls under MPS, a family of disorders involving mucopolysaccharides, which are long chains of sugar molecules used to build connective tissue. After the body finishes using these sugars, it breaks them down with enzymes and disposes of them.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Children with Sanfilippo syndrome lack the enzyme to digest the molecules, and they store them instead, leading to misshapen cells and enlarged organs. While infants rarely show signs of the disorder, symptoms worsen as&nbsp;children grow and their cells suffer more damage.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Fewer than&nbsp;one in 75,000 children are born with Sanfilippo syndrome. Both parents must carry and pass on the defective gene in order for their child to be affected&nbsp;— a one-in-four chance. Unaffected children have a two-in-three chance of carrying the gene.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Neufeld's earlier research identified the enzyme deficiencies that cause MPS. Her findings led to tests that enabled physicians to accurately diagnose the syndromes and counsel families. She is a consultant for Zacharon Pharmaceuticals, a biotechnology firm in San Diego.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study's co-authors included Lili Kudo and Sergey Ryazantsev, both of UCLA. The research was funded by the National Institute of Neurological Disorders and Stroke, the Children's Medical Research Foundation, and the Alzheimer's Association.</DIV>
<DIV>&nbsp;</DIV>
<DIV>To learn more about families living with Sanfilippo syndrome, visit&nbsp;the National MPS Society website&nbsp;at <A href="http://www.mpssociety.org/">www.mpssociety.org</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=150990" height="1" width="1" />]]></description><pubDate>Wed, 06 May 2009 21:55:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Study finds link between hot flashes and lower bone density in women</title><link>http://newsroom.ucla.edu/portal/ucla/study-finds-link-between-hot-flashes-90501.aspx?link_page_rss=90501</link><guid>http://newsroom.ucla.edu/portal/ucla/study-finds-link-between-hot-flashes-90501.aspx</guid><description><![CDATA[<H3><STRONG></STRONG></H3>
<DIV><B></B></DIV>
<DIV><B></B></DIV>
<DIV><B>FINDINGS: </B></DIV>
<DIV>UCLA researchers and colleagues analyzed data for 2,213 women between the ages of&nbsp;42&nbsp;and 52 who participated in the bone sub-study of the Study of Women's Health Across the Nation to determine whether women with vasomotor symptoms (VMS) — which include hot flashes and night sweats — had lower bone mineral density. </DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers&nbsp;found that postmenopausal women with VMS had lower lumbar and total hip bone mineral density than those without VMS. Premenopausal women and early perimenopausal women who had VMS were found to have lower femoral neck bone mineral density than those without VMS.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>AUTHORS: </B></DIV>
<DIV>UCLA study co-authors Dr. Carolyn J. Crandall, associate clinical professor of general internal medicine and health services research; Gail A. Greendale, professor of medicine in geriatrics; and&nbsp;Yan Zheng, of the division of general internal medicine and health services research, are available for interviews.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>JOURNAL: </B></DIV>
<DIV>The research appeared in the March/April 2009 issue of the journal Menopause.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>FUNDING: </B></DIV>
<DIV>The National Institute on Aging, the U.S. Department of Health and Human Services' National Institutes of Health, the National Institute of Nursing Research, and the NIH Office of Research on Women's Health supported this study.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B></B></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=149064" height="1" width="1" />]]></description><pubDate>Fri, 01 May 2009 16:40:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Popular diabetes treatment could trigger pancreatitis, pancreatic cancer</title><link>http://newsroom.ucla.edu/portal/ucla/two-popular-diabetes-drugs-could-89771.aspx?link_page_rss=89771</link><guid>http://newsroom.ucla.edu/portal/ucla/two-popular-diabetes-drugs-could-89771.aspx</guid><description><![CDATA[<DIV><SPAN style="FONT-SIZE: 8pt">
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">A drug&nbsp;widely used to treat&nbsp;Type 2 diabetes may have unintended effects on the pancreas that could lead to a form of low-grade pancreatitis in some patients and a greater&nbsp;risk of pancreatic cancer in long-term users, UCLA researchers have found.</SPAN><SPAN style="FONT-SIZE: 8pt"><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;<o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">In a study published in the online edition of the journal Diabetes, researchers from the <A href="http://www.lhirc.med.ucla.edu/" target=_blank>Larry L. Hillblom Islet Research Center at UCLA</A> found that sitagliptin, sold in pill form as Januvia, caused abnormalities in the pancreas that are recognized as risk factors for pancreatitis and, with time, pancreatic cancer in humans. Januvia is marketed by Merck &amp; Co. Inc. Sitagliptin is a member of a new class of drugs&nbsp;that enhance the actions of the gut hormone known as&nbsp;glucagon-like peptide 1 (GLP-1), which&nbsp;has been shown to be effective in lowering blood sugar in people with Type 2 diabetes.</SPAN><SPAN style="FONT-SIZE: 8pt"><o:p></o:p></SPAN> The study is available at <A href="http://diabetes.diabetesjournals.org/cgi/content/abstract/db09-0058v1">http://diabetes.diabetesjournals.org/cgi/content/abstract/db09-0058v1</A>. </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;<o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">"Type 2 diabetes is a lifelong disease — people often take the same drugs for many years, so any adverse effect that could over time increase the risk for pancreatic cancer would be a concern," said Dr. Peter Butler, director of the Hillblom Center and the study's lead investigator. "A concern here is that the unwanted effects of this drug on the pancreas would likely not be detected in humans unless the pancreas was removed and examined."</SPAN><SPAN style="FONT-SIZE: 8pt"><o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;<o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">An observed connection between Byetta, a drug used to treat Type 2 diabetes that is related to Januvia in its intended actions, and pancreatitis has already been reported, prompting a&nbsp;Food and Drug Administration&nbsp;warning. Amylin Corp., which markets Byetta, has suggested that since there is no known mechanism linking the cases of pancreatitis with Byetta, the association might be chance. The UCLA study suggests that there may indeed be a link between drugs that enhance the actions of GLP-1 and pancreatitis —&nbsp;by increasing the rate of formation&nbsp;of cells that line&nbsp;the&nbsp;pancreatic ducts.</SPAN><SPAN style="FONT-SIZE: 8pt"><o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;<o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">In the study, researchers used human&nbsp;IAPP transgenic (HIP) rats to test both sitagliptin and metformin; metformin, a member&nbsp;of an&nbsp;older, different class of diabetes drugs in use since the 1950s, has recently been found to have anti-tumor properties. The researchers sought to determine how the drugs, both singly and in combination, affected islet disease progression in the pancreas — particularly how they&nbsp;affected beta cells in the pancreas's Islets of Langerhans. Beta cells are responsible for releasing insulin in people with normal metabolism, but they don't produce insulin in sufficient amounts in diabetes patients. HIP rats approximate both the islets and metabolism of people with Type 2 diabetes. The drugs were tested in 40 rats for 12 weeks.</SPAN><SPAN style="FONT-SIZE: 8pt"><o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;<o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">The researchers found that the two drugs in combination had a synergistic effect that helped preserve beta cells, improved their function and enhanced insulin sensitivity in the test rats. With the sitagliptin alone, however, the rats had&nbsp;abnormally high rates of cell production in their pancreatic ducts; a few developed an abnormality&nbsp;known as&nbsp;ductal metaplasia, and one developed pancreatitis.</SPAN><SPAN style="FONT-SIZE: 8pt"><o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;<o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">But the metformin, trade name Glucophage, seems to counteract sitagliptin's adverse effect. </SPAN><SPAN style="FONT-SIZE: 8pt"><o:p></o:p></SPAN></SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;<o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">"The apparent protection against the unwanted actions of sitagliptin in the exocrine pancreas are intriguing and may offer a potential way of using the GLP-1 class of drugs safely," <?xml:namespace prefix = st1 ns = "urn:schemas-microsoft-com:office:smarttags" /><st1:City w:st="on"><st1:place w:st="on">Butler</st1:place></st1:City> said. "The protective effect may have been either by the actions of metformin to decrease blood glucose values or its recently appreciated properties as a tumor suppressive agent."</SPAN><SPAN style="FONT-SIZE: 8pt"><o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;<o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><st1:City w:st="on"><st1:place w:st="on"><SPAN style="FONT-SIZE: 8pt">Butler</SPAN></st1:place></st1:City><SPAN style="FONT-SIZE: 8pt"> noted that the present study was undertaken in rats and that it is possible the adverse effects observed would not occur in humans. </SPAN><SPAN style="FONT-SIZE: 8pt"><o:p></o:p></SPAN></SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;<o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">"Given these findings, it is probably sensible to use the GLP-1 class of drugs only with metformin until other data is forthcoming,"&nbsp;he said.</SPAN><SPAN style="FONT-SIZE: 8pt"><o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;<o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">The National Institutes of Health, the Larry Hillblom Foundation and the Merck Research Foundation funded this study.</SPAN><SPAN style="FONT-SIZE: 8pt"><o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;<o:p></o:p></SPAN> </SPAN>
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">In addition to <st1:City w:st="on">Butler</st1:City>, researchers included Aleksey V. Matveyenko, Heather I. Cox, Artemis Moshtaghian, Tatyana Gurlo, Ryan Galasso and Alexandra E. Butler, all&nbsp;of the <st1:place w:st="on"><st1:PlaceName w:st="on">Hillblom</st1:PlaceName> <st1:PlaceType w:st="on">Center</st1:PlaceType></st1:place>, and Sarah Dry of the department of pathology and laboratory medicine at the David Geffen School of Medicine at UCLA.</SPAN><SPAN style="FONT-SIZE: 8pt"><o:p></o:p></SPAN>&nbsp;</SPAN><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN> 
<P class=MsoNormal style="MARGIN: 0in 0in 0pt"><SPAN style="FONT-SIZE: 8pt"><STRONG><SPAN style="FONT-SIZE: 8pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><A href="http://www.lhirc.med.ucla.edu/" target=_blank><SPAN style="FONT-SIZE: 8pt">The Larry L. Hillblom Islet Research Center at UCLA</SPAN></A></SPAN></STRONG><SPAN style="FONT-SIZE: 8pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'">,&nbsp;established in 2004, is the first center dedicated to the study of the Islets of Langerhans, which include the insulin-producing cells in the pancreas. An understanding of the causes of islet cell destruction is key to finding a cure for diabetes. The center's faculty members, recruited from around the world, provide leadership in the worldwide fight against the disease. The center is&nbsp;funded by a&nbsp;grant from the Larry Hillblom Foundation, which supports medical research in the state of California.</SPAN></SPAN></SPAN></P></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=148758" height="1" width="1" />]]></description><pubDate>Thu, 30 Apr 2009 18:35:49 GMT</pubDate></item><item><author>Jennifer Marcus</author><title>Researchers design unique method to induce immunity to certain STDs</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-researchers-design-a-unique-90255.aspx?link_page_rss=90255</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-researchers-design-a-unique-90255.aspx</guid><description><![CDATA[<DIV>Chlamydia trachomatis is the most common bacterial agent of sexually transmitted disease, accounting for more than a million reported infections in the United States each year.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Researchers at the California NanoSystems Institute (CNSI) at UCLA and the David Geffen School of Medicine at UCLA have now designed a unique method for inducing immunity to the infection. The findings could accelerate progress toward the development of a vaccine against Chlamydia trachomatis infections, which can lead to reproductive dysfunction and profound local inflammation requiring medical attention.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Their study, which describes the first use of a novel vaccine platform&nbsp;that utilizes&nbsp;an engineered nanoparticle delivery system, appears in the April 30 edition of the peer-reviewed online journal PLoS ONE, published by the Public Library of Science, and is available at <A href="http://dx.plos.org/10.1371/journal.pone.0005409">http://dx.plos.org/10.1371/journal.pone.0005409</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The research team, a partnership between UCLA immunologists and nanotechnologists, is led by Kathleen Kelly, an associate professor of pathology and laboratory medicine and a CNSI member, and Leonard H. Rome, interim director of the CNSI and a professor of biological chemistry. The team also includes Cheryl I. Champion, Valerie A. Kickhoefer, Guangchao Liu, Raymond J. Moniz, Amanda S. Freed, Liisa L. Bergmann, Dana Vaccari, Sujna Raval-Fernandes and Ann M. Chan.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers were able to uncover a surprising connection between vault nanoparticles and mucosal immunity. Vaults are barrel-shaped nanoscale capsules found in the cytoplasm of all mammalian cells that can be engineered to serve as potential therapeutic delivery devices.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The primary goal of vaccines is to generate robust cell-mediated immune responses at mucosal surfaces while reducing overall inflammation caused by infection," Kelly said. "We found that vault nanoparticles containing immunogenic proteins can act as 'smart adjuvants' for inducing protective immunity at mucosal surfaces while avoiding destructive inflammation."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Adjuvants are molecular triggers that initiate vaccine responses.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Mucosal immune responses provide superior protection against disease, but there are currently no adjuvants approved by the Food and Drug Administration that are capable of stimulating cell-mediated immune responses within mucosal tissues. Mucosal surfaces are hostile environments, and immunogenic proteins require added protection for delivery to cells in order to induce immunity.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The team produced recombinant vaults through a process that involved the molecular engineering of these naturally occurring cellular structures to test the concept that vaults can have a broad nanosystems application as malleable nanocapsules.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Our research team wanted to find out if recombinant vaults could provide such protection by encapsulating an antigen and preserving its functional characteristics, even within the cells," Kelly said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The internal cavity of the recombinant vault nanoparticle is large enough to hold multiple immunogenic proteins, and because vaults are the size of small microbes, a vault particle containing such proteins can be easily absorbed by the targeted cells.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Vaults are being studied for use in the delivery of a range of potential therapeutics, including synthetic and natural compounds, nucleic acids, and proteins. Recombinant vaults containing proteins are easily produced, making vaults a viable vaccine delivery platform.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Adjuvants provide the necessary assistance to vaccine preparations for promoting immunity or protection from infection by combining the vault with a part of the Chlamydia organism," Kelly said. "We were able to design a vaccine that prevented Chlamydia infection better than other designs."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The research team found that when they immunized female mice with recombinant vaults containing a component of Chlamydia and then exposed the mice to a vaginal challenge with live Chlamydia, their reproductive tracts were protected from severe bacterial infection.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The results suggest that vaults are superior adjuvants for immunization against infections largely limited to mucosal tissues.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We are encouraged that our findings could accelerate progress toward developing a vaccine to guard against this infection," Kelly said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The research was supported by the UCLA AIDS Institute and the National Institutes of Health.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.cnsi.ucla.edu/" target=_blank>The California NanoSystems Institute</A> </STRONG>(CNSI) is an integrated research center operating jointly at UCLA and UC Santa Barbara whose mission is to foster interdisciplinary collaborations for discoveries in nanosystems and nanotechnology; train the next generation of scientists, educators and technology leaders; and facilitate partnerships with industry, fueling economic development and the social well-being of California, the United States and the world. The CNSI was established in 2000 with $100 million from the state of California and an additional $250 million in federal research grants and industry funding. At the institute, scientists in the areas of biology, chemistry, biochemistry, physics, mathematics, computational science and engineering are measuring, modifying and manipulating the building blocks of our world —&nbsp;atoms and molecules. These scientists benefit from an integrated laboratory culture enabling them to conduct dynamic research at the nanoscale, leading to significant breakthroughs in the areas of health, energy, the environment and information technology.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=148527" height="1" width="1" />]]></description><pubDate>Thu, 30 Apr 2009 00:00:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>World's largest DNA scan for autism uncovers new gene variant for disorder</title><link>http://newsroom.ucla.edu/portal/ucla/world-s-largest-dna-scan-uncovers-89292.aspx?link_page_rss=89292</link><guid>http://newsroom.ucla.edu/portal/ucla/world-s-largest-dna-scan-uncovers-89292.aspx</guid><description><![CDATA[<DIV>UCLA scientists, in partnership with 30 research institutions across the country, have identified a new gene&nbsp;variant that is highly common in autistic children. And when researchers scrutinized the activity of the gene, known as CDH10, in the fetal brain, they discovered that it is most active in key regions that support language, speech and interpreting social behavior.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Published April 28 in the advance online edition of the journal Nature, the two findings suggest that CDH10 plays a critical role in shaping the developing brain and may contribute to a prenatal risk of autism.</DIV>
<DIV>&nbsp;</DIV>
<DIV>A variant is a gene that has undergone subtle changes from the normal DNA yet is shared by a significant portion of the population.</DIV>
<DIV><BR>"While this gene variant is common in the general population, we discovered that it occurs about 20 percent more often in children with autism," said study author Dr. Daniel Geschwind, director of the UCLA Center for Autism Treatment and Research. "A major change like this in the genetic code is too common to be a simple mutation — it is a risk factor in the origin of the disease."</DIV>
<DIV><BR>Using the largest population sample to date, the scientists systematically scanned the DNA of 3,100 individuals from 780 families nationwide. Each family had at least two autistic children.<BR><BR>The scan connected autism to a specific region of chromosome 5, which previous studies at UCLA and collaborating institutions had pinpointed as a hub for genetic variations linked to higher autism risk.<BR><BR>To verify the findings, Dr. Hakon Hakonarson at the Children's Hospital of&nbsp;Philadelphia led the team in conducting a second scan on the DNA of 1,200 individuals from families affected by autism, as well as nearly 6,500 healthy controls. All participants shared European ancestry.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The scientists evaluated the relationship of more than half a million gene variants to autism and consistently discovered six changes that occurred more frequently in autistic children than in the control group. These variants sat on chromosome 5 between two genes, CDH9 and CDH10.</DIV>
<DIV><BR>In the second half of the study, the UCLA team looked at the two genes' presence in the developing human brain. While CDH9's presence appeared minimal, the scientists discovered that CDH10 was most active in the fetal brain's frontal cortex, a region critical to language, social behavior and complex thought processes such as judgment.<BR><BR>"This is a landmark finding," Geschwind said. "It's no coincidence that a gene linked to autism has a higher concentration in key brain regions that regulate speech and the ability to interpret social interaction. Our research suggests that CDH10 is switched on at a very early stage and plays an important role in regulating the developing brain. This prenatal activity somehow makes the infant more susceptible to autism."<BR><BR>By influencing the development of important brain structures, CDH10 provides a tangible link between genes, brain circuitry and a child's future behavior, Geschwind noted. The discovery also opens up a number of intriguing next steps for research, including the possibility of an imaging study to explore whether the gene behaves differently in the autistic brain.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The DNA samples and clinical data were provided by families who donated blood to the Los Angeles–based Autism Genetic Resource Exchange (AGRE), a program created and funded by Cure Autism Now, which merged with Autism Speaks in 2007.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"When parents like me first formed AGRE, this was our dream, that talented scientists would use our gene bank to collaborate and bring us closer to understanding autism," said Jon Shestack, co-founder of Cure Autism Now and a board member of Autism Speaks. "AGRE has played an important role in almost every major autism genetics paper in the past five years."</DIV>
<DIV><BR>Autism is a complex brain disorder that strikes in early childhood. The condition disrupts a child's ability to communicate and develop social relationships and is often accompanied by acute behavioral challenges. The Centers for Disease Control and Prevention report that one in 150 American children is diagnosed with an autism spectrum disorder; the disorder affects four times as many boys as girls. The diagnosis of autism has expanded tenfold in the last decade.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The UCLA portion of the study was supported primarily with funding from the National Institute of Mental Health. Geschwind's UCLA colleagues included Brett Abrahams, Rita Cantor, Hongmei Dong, Edward Herman, Ted Hutman, Ana Alvarez Retuerto, Marian Sigman and Lisa Sonnenblick.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Additional co-authors included scientists from the Children's Hospital of Philadelphia, USC, Autism Speaks, the University of Pennsylvania, the University of Miami, Mount Sinai School of Medicine, the University of Washington, the University of North Carolina, UC Davis, Yale University, the University of Illinois, the University of Utah, Indiana University, Vanderbilt University and the University of Pittsburgh.</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.autism.ucla.edu/"><STRONG>The UCLA Center for Autism Research and Treatment</STRONG></A> provides diagnosis, family counseling and treatment for patients with autism. UCLA is one of eight centers in the National Institutes of Health–funded Studies to Advance Autism Research and Treatment network and one of 10 original Collaborative Programs for Excellence in Autism.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=147238" height="1" width="1" />]]></description><pubDate>Tue, 28 Apr 2009 17:35:00 GMT</pubDate></item><item><title>Swine flu questions and answers for the UCLA community</title><link>http://newsroom.ucla.edu/portal/ucla/swine-flu-questions-and-answers-90294.aspx?link_page_rss=90294</link><guid>http://newsroom.ucla.edu/portal/ucla/swine-flu-questions-and-answers-90294.aspx</guid><description><![CDATA[<DIV>Dr. Jo Ann Dawson, director&nbsp;of UCLA's Arthur Ashe Student Health and Wellness Center, answered questions about the swine flu outbreak that triggered the declaration of a U.S. public health emergency:</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Q:</B> What are the symptoms of the swine flu?</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>A:</B> According to the U.S. Centers for Disease Control and Prevention (CDC), symptoms include fever, cough, sore throat, body aches, headache, chills and fatigue. Some people have reported diarrhea and vomiting.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Q: </B>Have there been any cases of this flu at UCLA?</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>A.</B> None have been reported.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Q: </B>I got a flu shot last fall – will that protect me now? Should I get a flu shot if I haven’t had one already?</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>A:</B> <SPAN style="FONT-SIZE: 8pt; COLOR: #333333; FONT-FAMILY: Verdana; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'">The swine flu is a different strain of influenza. There currently is no vaccine for it. However, you may still consider a flu shot for the seasonal flu.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt; COLOR: #333333; FONT-FAMILY: Verdana; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt; COLOR: #333333; FONT-FAMILY: Verdana; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman'"></SPAN><B>Q: </B>Are there effective treatments for this flu?</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>A:</B> Yes. Please see CDC website for information: <A href="http://www.cdc.gov/swineflu/swineflu_you.htm">http://www.cdc.gov/swineflu/swineflu_you.htm</A>. </DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Q: </B>How likely is it that I might contract this flu?</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>A:</B> It is unlikely, but the situation is evolving and normal precautions should be taken.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Q: </B>Should I be wearing a mask?</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>A:</B> There are no recommendations at present for that.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Q: </B>What should I do if I notice someone else with flu symptoms?</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>A:</STRONG> Stay away from them. Practice good respiratory hygiene. Encourage the person to go to bed and use symptomatic treatments.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Q: </B>What should I do if I feel ill myself?</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>A: </B>If you are a student, you should contact the <A href="http://www.studenthealth.ucla.edu/">Arthur Ashe Student Health and Wellness Center</A> or (310) 825-4073. Walk-in advice and information is available during regular business hours. When the center is closed, information is available from Nurseline at (866) 704-9660. Faculty and staff should consult their physicians.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Q: </B>What can I do to avoid the swine flu?</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>A:</B> The CDC recommends that you:</DIV>
<DIV>&nbsp;</DIV>
<DIV>· Cover your nose and mouth with a tissue when you cough or sneeze. Throw the tissue in the trash after you use it. <BR><BR>· Wash your hands often with soap and water, especially after you cough or sneeze. Alcohol-based hands cleaners are also effective. <BR><BR>· Avoid touching your eyes, nose or mouth. Germs spread that way. <BR><BR>· Try to avoid close contact with sick people. Influenza is thought to spread mainly person-to-person through coughing or sneezing of infected people. <BR><BR>· If you get sick, CDC recommends that you stay home from work or school and limit contact with others to keep from infecting them. <BR><BR><B>Q:</B> Where can I go for the latest information about this flu?</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>A:</B> Here are some resources, all of which are updating frequently.</DIV>
<DIV>&nbsp;</DIV>
<DIV>CDC: <A href="http://www.cdc.gov/swineflu" target=_blank>www.cdc.gov/swineflu</A>.</DIV>
<DIV>World Health Organization: <A href="http://www.who.int/csr/disease/swineflu/en/index.html" target=_blank>www.who.int/csr/disease/swineflu/en/index.html</A>.<BR>Los Angeles County Health Department: <A href="http://www.lapublichealth.org/" target=_blank>http://www.lapublichealth.org/.</A></DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Q:</B> Is UCLA going to be closed?</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>A:</B> Based on the current information, there is no recommendation to do that.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Updated information from UCLA on the swine flu outbreak is available at <A href="http://www.newsroom.ucla.edu/swineflu" target=_blank>http://www.newsroom.ucla.edu/swineflu</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=146780" height="1" width="1" />]]></description><pubDate>Mon, 27 Apr 2009 22:34:03 GMT</pubDate></item><item><author>Amy Albin</author><title>Mental health problems more common in kids who feel racial discrimination</title><link>http://newsroom.ucla.edu/portal/ucla/children-who-feel-racial-discrimination-89333.aspx?link_page_rss=89333</link><guid>http://newsroom.ucla.edu/portal/ucla/children-who-feel-racial-discrimination-89333.aspx</guid><description><![CDATA[<DIV>A new multicenter study involving UCLA and the RAND Corp. has found that perceived racial or ethnic discrimination is&nbsp;not an uncommon&nbsp;experience among fifth-grade students and that it may have a negative effect on their mental health.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Study results show that 15 percent of children surveyed reported experiencing what they perceived as discrimination and that the vast majority of these encounters occurred at school. The study also&nbsp;found that children who reported feeling discrimination were more likely to have symptoms of one or more of four different mental health disorders: depression, attention-deficit hyperactivity disorder, oppositional defiant disorder and conduct disorder.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study will be published in the May issue of the American Journal of Public Health and is currently available online by subscription.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Racial and ethnic discrimination and their effect on mental health have been studied in adults and adolescents, but less is known about the effects of perceived discrimination on children's mental health.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"It was surprising to see positive associations between perceived racial and ethnic discrimination in the children and symptoms of all four examined mental health conditions," said lead author Dr. Tumaini R. Coker, clinical instructor of pediatrics at Mattel Children's Hospital UCLA and an associate natural scientist at RAND. "Parents, clinicians and teachers should be aware that children may experience racial&nbsp;and ethnic discrimination in and out of school and that there may be detrimental effects on their mental health."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Researchers analyzed data from a 2004–06 study of 5,147 fifth-graders and their parents from public schools in Los Angeles, Houston and Birmingham, Ala.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study found that a greater percentage of&nbsp;African American children&nbsp;(20 percent), Hispanic children&nbsp;(15 percent) and children identified as "other" (15 percent) reported perceived racial or ethnic discrimination than white children&nbsp;(7 percent). </DIV>
<DIV>&nbsp;</DIV>
<DIV>The strongest and most consistent association of discrimination with mental health symptoms involved symptoms of depression in African American, Hispanic and "other" children reporting discrimination. This association was&nbsp;not significant for whites.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Other findings included:</DIV>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>Among Hispanic children, those who reported&nbsp;perceived discrimination were more likely to have symptoms of each of the four mental health conditions. </LI>
<LI>Among&nbsp;African American&nbsp;children, those who reported&nbsp;perceived discrimination were more likely to have symptoms of depression and conduct disorder. </LI>
<LI>Among white children, those who reported&nbsp;perceived discrimination were more likely to have symptoms of&nbsp;oppositional defiant disorder&nbsp;and conduct disorder. </LI></UL>
<DIV>&nbsp;</DIV>
<DIV>"It is concerning that children this young are already reporting that they have faced racial or ethnic discrimination," said senior author Dr. Mark A. Schuster, William Berenberg Professor of Pediatrics at Children's Hospital Boston and Harvard Medical School. "We need to examine what they are experiencing and how to address this issue."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The next stages of research will examine if racial and ethnic discrimination precede the symptoms of mental health conditions and also will&nbsp;look at the mechanisms by which discrimination might lead to poor mental health outcomes and how these mechanisms might differ by race and mental health condition.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Many parents have discussions about school with their child's health care provider during regular check-ups," Coker said. "Because most children in our study with perceived racial&nbsp;or ethnic discrimination reported that it occurred at school, clinicians could address the topic as part of these school-related discussions."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Additional&nbsp;sites involved in the study included the University of Alabama at Birmingham and the&nbsp;University of Texas, Houston. The research was supported by the Centers for Disease Control and Prevention. The authors have no financial ties to disclose.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to Coker, study authors included Marc N. Elliott, David E. Kanouse, Jo Anne Grunbaum, David C. Schwebel, Janice Gilliland, Susan R. Tortolero, Melissa F. Peskin and Mark A. Schuster.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=146266" height="1" width="1" />]]></description><pubDate>Mon, 27 Apr 2009 16:45:00 GMT</pubDate></item><item><author>Roxanne Moster</author><title>UCLA ranks 11th among U.S. medical schools in annual survey</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-ranks-in-top-20-among-u-s-89487.aspx?link_page_rss=89487</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-ranks-in-top-20-among-u-s-89487.aspx</guid><description><![CDATA[<DIV>The David Geffen School of Medicine at UCLA ranks 11th among the nation's research-based medical schools and 10th among primary care medical school programs, according to U.S. News & World Report's annual survey of the best graduate schools in the United States.</DIV>
<DIV> </DIV>
<DIV>The 2010 edition of "America's Best Graduate Schools" — slated to hit newsstands April 28 and currently available online at <A href="http://www.usnews.com/grad" target=_blank>www.usnews.com/grad</A> <SPAN style="COLOR: #333333">— </SPAN>is the most comprehensive listing of its kind, with more than 1,500 graduate school programs nationwide.</DIV>
<DIV> </DIV>
<DIV>In addition to its overall ranking, the Geffen School of Medicine also received high marks in a number of specialty training programs, ranking third in geriatrics, sixth in AIDS, eighth in drug and alcohol abuse programs, and ninth in women's health.</DIV>
<DIV> </DIV>
<DIV>"We are thrilled to be recognized for the superb job that the David Geffen School of Medicine does in conducting leading-edge research programs and, at the same time, training high-quality primary care physicians," said Dr. Gerald S. Levey, UCLA vice chancellor for medical sciences and dean of the Geffen School of Medicine. "This is a wonderful tribute to our outstanding physicians, scientists, staff and students, as well as our affiliated hospitals and community partners who help train our stellar graduates."</DIV>
<DIV> </DIV>
<DIV>U.S. News & World Report ranked medical schools based on two types of data: peer experts' opinions about program quality and statistical indicators that measure the quality of a school's faculty, research and students. The statistical indicators included both the qualities that students and faculty bring to the educational experience and graduates' achievements linked to their degrees. </DIV>
<DIV> </DIV>
<DIV>Among the criteria were students' average undergraduate grade-point average and average medical college admission test score, as well as the school's acceptance rate, total enrollment, faculty-to-student ratio, total National Institutes of Health research funding and average funding per faculty member, and the percentage of graduates entering primary care residencies in the fields of family practice, pediatrics and internal medicine. </DIV>
<DIV> </DIV>
<DIV>The specialty training program rankings were based solely on peer ratings by medical school deans and senior faculty.</DIV>
<DIV> </DIV>
<DIV>Founded in 1951, the David Geffen School of Medicine at UCLA is the youngest medical school to be ranked among the top 11 in the nation. The school has more than<B> </B>2,000 full-time faculty members, including recipients of the Nobel Prize, the Pulitzer Prize and the National Medal of Science.</DIV>
<DIV> </DIV>
<DIV>Nearly 5,800 candidates apply each year for one of 121 available spaces in the first-year class. Total enrollment numbers some 750 students and approximately 400 Ph.D. candidates. More than 1,400 residents and fellows pursue advanced training at UCLA and its affiliated hospitals.</DIV>
<DIV> </DIV>
<DIV><A href="http://dgsom.healthsciences.ucla.edu/about/" target=_blank><STRONG>The David Geffen School of Medicine</STRONG></A> is affiliated with the Ronald Reagan UCLA Medical Center, ranked the best hospital in the western United States for 19 consecutive years and No. 3 among the nation's hospitals by U.S. News & World Report. The I.M. Pei-designed medical center features 520 spacious private rooms for patients and the most advanced medical technology in the world. </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=145582" height="1" width="1" />]]></description><pubDate>Fri, 24 Apr 2009 04:01:15 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Pesticide exposure found to increase risk of Parkinson's disease</title><link>http://newsroom.ucla.edu/portal/ucla/pesticide-exposure-found-to-increase-89084.aspx?link_page_rss=89084</link><guid>http://newsroom.ucla.edu/portal/ucla/pesticide-exposure-found-to-increase-89084.aspx</guid><description><![CDATA[<DIV>The fertile soil of California's Central Valley has long made it famous as one of the nation's prime crop-growing regions. But it's not just the soil that allows for such productivity. Crops like potatoes, dry beans and tomatoes have long been protected from bugs and weeds by the fungicide maneb and the herbicide paraquat.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Scientists know that in animal models and cell cultures, such pesticides trigger a neurodegenerative process that leads to Parkinson's disease. Now,&nbsp;researchers at UCLA provide the first evidence for a similar process in humans.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In a new epidemiological study of Central Valley residents who have been diagnosed with Parkinson's disease,&nbsp;researchers found that years of exposure to the combination of these two pesticides increased the risk of Parkinson's by 75 percent. Further, for people 60 years old&nbsp;or younger diagnosed with Parkinson's, earlier exposure had increased their risk&nbsp;for the disease by as much as four- to six-fold.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Reporting in the April 15 issue of the American Journal of Epidemiology, Beate Ritz, professor of epidemiology at the UCLA School of Public Health, and Sadie Costello, a former doctoral student at UCLA who is now at the University of California, Berkeley, found that Central Valley residents who lived within 500 meters of fields sprayed between 1974 and 1999 had a 75-percent increased risk&nbsp;for Parkinson's.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition, people who were diagnosed with Parkinson's at age 60 or younger were found to have been at much higher risk because they had been exposed to maneb, paraquat or both in combination between 1974 and 1989, years when they would have been children, teens or young adults.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The&nbsp;researchers enrolled 368 longtime residents diagnosed with&nbsp;Parkinson's and 341 others as a control group.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Parkinson's disease is a degenerative disorder of the central nervous system that often impairs motor skills, speech and other functions. It has been reported to occur at high rates among farmers and in rural populations, contributing to the hypothesis that agricultural pesticides may be partially responsible.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Until now, however, data on human exposure has been unavailable, largely because it has&nbsp;been too hard to measure an individual's environmental exposure to any specific pesticide.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Because pesticides applied from the air or ground may drift from their intended treatment sites — with measurable concentrations subsequently detected in the air, in plants and in animals up to several hundred meters from application sites —&nbsp;accurate methods of estimating environmental exposures in rural communities have long been sorely needed," said Ritz, the study's senior author and vice chair of the School of Public Health's epidemiology department.</DIV>
<DIV>&nbsp;</DIV>
<DIV>So Ritz, Costello and colleague Myles Cockburn from the University of Southern California, developed a geographic information system–based tool that estimated human exposure&nbsp;to pesticides applied to&nbsp;agricultural crops. This GIS&nbsp;tool combined land-use maps and pesticide-use reporting data from the state of California. Each&nbsp;pesticide-use&nbsp;record includes the name of the pesticide's active ingredient, the amount applied, the crop,&nbsp;the acreage of the field, the application method and the date of application.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Research subjects were recruited between 1998 to 2007; telephone interviews were conducted to obtain their demographic and exposure information. Detailed residential history forms were mailed to subjects in advance of their interviews and were reviewed in person or over the phone. The researchers recorded and added lifetime residential histories and estimated ambient exposures into the system for all historical addresses at which participants had resided between 1974 and 1999, the period covered by the&nbsp;pesticide-use&nbsp;data.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The results confirmed two previous observations from animal studies," Ritz said. "One, that exposure to multiple chemicals may increase the effect of each chemical. That's important, since humans are often exposed to more than one pesticide in the environment. And second, that the timing of exposure is also important." </DIV>
<DIV>&nbsp;</DIV>
<DIV>Ritz noted that this is the first epidemiological study to provide strong evidence that maneb and paraquat act synergistically to become neurotoxic and strongly increase the risk of Parkinson's disease in humans.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Of particular concern, Ritz&nbsp;said, and consistent with other theories regarding the progression of Parkinson's pathology, is that the data "suggests that the critical window of exposure to toxicants may have occurred years before the onset of motor symptoms when a diagnosis of Parkinson's is made."</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to Ritz and first author Costello, study authors included Jeff Bronstein, UCLA professor of neurology, and Xinbo Zhang of USC. The authors declare no conflicts of interest. </DIV>
<DIV>&nbsp;</DIV>
<DIV>The research was supported by the National Institute of Environmental Health Science, the National Institute of Neurological Disorders and Stroke, and the Department of Defense Prostate Cancer Research Program. In addition, initial pilot funding was provided by the American Parkinson Disease Association.</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.ph.ucla.edu/" target=_blank><STRONG>The UCLA School of Public Health</STRONG></A>&nbsp;is dedicated to enhancing the public's health by conducting innovative research, training future leaders and health professionals, translating research into policy and practice, and serving local, national and international communities. </DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/" target=_self>UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=143685" height="1" width="1" />]]></description><pubDate>Mon, 20 Apr 2009 07:00:00 GMT</pubDate></item><item><author>Sarah Anderson</author><title>Jonathan Fielding, public health leader, awarded prestigious UCLA Medal</title><link>http://newsroom.ucla.edu/portal/ucla/dr-jonathan-fielding-awarded-prestigious-88659.aspx?link_page_rss=88659</link><guid>http://newsroom.ucla.edu/portal/ucla/dr-jonathan-fielding-awarded-prestigious-88659.aspx</guid><description><![CDATA[<DIV><B></B></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">The UCLA Medal, the university's highest honor,&nbsp;has been awarded&nbsp;to Dr. Jonathan Fielding, the director&nbsp;of the Los Angeles County Department of Public Health,&nbsp;a county health officer&nbsp;and a professor at the UCLA School of Public Health, for his work as an innovator, leader and public health visionary.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">The award was bestowed on Fielding&nbsp;April 16 at the 35th annual Lester Breslow Distinguished Lecture and Dinner, held at the Luxe Hotel in Brentwood, Calif.,&nbsp;where&nbsp;Fielding was the keynote speaker. Organized by the UCLA School of Public Health and UCLA Public Health Alumni Association, the lecture provides a forum for public health leaders to address critical public health issues of our time.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Fielding is responsible for providing public health services to more than 10 million people, including residents of the eighth largest city in the world, and is credited with implementing the letter grading system in Los Angeles County restaurants, which&nbsp;has reduced restaurant-related food-borne illness outbreaks and hospitalizations by up to 20 percent. He is the chairman of two major national health committees, Healthy People 2020 and the&nbsp;Task Force on&nbsp;Community Preventive Services.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"Dr. Fielding's professional excellence and unwavering dedication to our city and to the next generation of public health leaders is exemplary of the contributions to society that we strive for our students to make with their UCLA degree," said UCLA Chancellor Gene Block.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Fielding joins heads of state; renowned scientists, artists and scholars; peacemakers; social reformers; and visionaries in the realm of commercial enterprise in receiving UCLA's highest honor. Past recipients of the UCLA Medal include former Presidents Bill Clinton and Jimmy Carter; former&nbsp;Israeli Prime Minister&nbsp;Shimon Peres; actors Laurence Oliver, Carol Burnett and Anthony Hopkins; writers Carlos Fuentes and Mario Vargas Llosa; architect Frank Gehry; and former Los Angeles Mayor Tom Bradley.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV>Named for one of the most distinguished members of the UCLA family, Dr. Lester Breslow, dean emeritus of the UCLA School of Public Health, the the lecture event also recognized three alumni who have shown their dedication to public health through their outstanding accomplishments. Rod Lew, who received an M.P.H. in community health sciences in 1988,&nbsp;was honored with&nbsp;the Breslow Lifetime Achievement Award. Manal J. Aboelata, who earned an M.P.H. in epidemiology in 2001, and Nicole Monastersky Maderas, who earned an M.P.H. in community health sciences in 2003,&nbsp;received the Young Alumnae Achievement Award. Selected by a blue-ribbon panel, all three were inducted into the UCLA School of Public Health Alumni Hall of Fame.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In recognition of Breslow's legacy as a leader in the field of public health, the school also announced the creation of the Lester Breslow Student Fellowship. Breslow's career has spanned more than 60 years, and his ongoing research on chronic disease prevention and health behavior intervention continues to yield insights in this new era of health promotion and wellness. The new&nbsp;fellowship will support students who follow in Breslow's footsteps and represent the future of public health leadership.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We know that public health interventions work not only to improve health but also to reduce health care costs," said Dr. Linda Rosenstock, dean of the UCLA School of Public Health. "We also know the demand for trained public health professionals will increase in the coming years, so it is imperative that our students are given the resources they need to prepare for the public health challenges that lie ahead. The creation of the Breslow Fellowship will ensure that our students will continue Dr. Breslow's legacy of improving the lives of millions of people across the world through education, research and service."</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.ph.ucla.edu/">The UCLA School of Public Health</A></STRONG>&nbsp;is dedicated to enhancing the public's health by conducting innovative research, training future leaders and health professionals, translating research into policy and practice, and serving local, national and international communities.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>UCLA</STRONG> is California's largest university, with an enrollment of nearly 38,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 323 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize. </DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=142484" height="1" width="1" />]]></description><pubDate>Fri, 17 Apr 2009 07:00:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>UCLA scientists will work with community partners to improve treatment of disadvantaged minority patients for stroke, heart disease</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-will-work-with-88635.aspx?link_page_rss=88635</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-will-work-with-88635.aspx</guid><description><![CDATA[<DIV>UCLA has been awarded a four-year, $3.89 million grant from the American Heart Association to establish a new research center focused on improving the health of disadvantaged minority patients at risk for stroke and heart attack. </DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to training future scientists, the center will collaborate with community partners on two studies exploring how to prevent stroke survivors from suffering a second stroke.&nbsp;Stroke is&nbsp;the nation's leading cause of disability and third leading cause of death. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Principal investigator Dr. Barbara Vickrey and co-director Dr. Jeffrey Saver, professors of neurology at the David Geffen School of Medicine at UCLA, will lead the center with a team of faculty from the Geffen School and the UCLA School of Public Health. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"For patients who survive a stroke, the risk of suffering a second, more devastating stroke within a year is extremely high," Vickrey said. "While effective preventive treatments exist, these therapies are often not provided or continued long enough because the medical system is fragmented and difficult to navigate, especially for poor people without health insurance." </DIV>
<DIV>&nbsp;</DIV>
<DIV>Dr. William Cunningham, UCLA professor of medicine and health services, will lead a study exploring a new model&nbsp;of care in which county hospitals partner with local community organizations. The model also uses nurse-practitioners to monitor and manage patients' stroke risk factors over time, organize group clinics, and empower patients to manage their risk factors. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Dr. Arleen Brown, UCLA associate professor of medicine, will lead a second study examining how neighborhoods&nbsp;influence&nbsp;people's risk for stroke and stroke-related disability or death. Examples include whether a neighborhood offers safe places to walk and resources such as grocery stores and health clinics. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"We hope to team with local community partners to develop neighborhood interventions that reduce stroke risk factors and improve treatment results," Brown said. </DIV>
<DIV>&nbsp;</DIV>
<DIV>To benefit communities nationwide, the UCLA center will share its findings with new centers at Duke University, Saint Luke's Mid America Heart Institute in Missouri and Stanford University–Kaiser Permanente. </DIV>
<DIV>&nbsp;</DIV>
<DIV>The American Heart Association's Pharmaceutical Roundtable, a coalition of 10 pharmaceutical companies, funded the four centers. Additional support was provided by a gift from AHA national board member David Spina and his wife, Stevie Spina, of Wayland, Mass. </DIV>
<DIV>&nbsp;</DIV>
<DIV>For more information about the UCLA center or fellowship opportunities, please contact center administrator Eliza Aceves at 310-206-7671 or <A href="mailto:eaceves@ucla.edu">eaceves@ucla.edu</A>. </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>UCLA </STRONG>is California's largest university, with an enrollment of nearly 38,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 323 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize. </DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=142221" height="1" width="1" />]]></description><pubDate>Thu, 16 Apr 2009 07:00:00 GMT</pubDate></item><item><author>Stuart Wolpert</author><title>New drug shows promise in treating drug-resistant prostate cancer</title><link>http://newsroom.ucla.edu/portal/ucla/new-medications-show-promise-in-88087.aspx?link_page_rss=88087</link><guid>http://newsroom.ucla.edu/portal/ucla/new-medications-show-promise-in-88087.aspx</guid><description><![CDATA[<DIV>A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Chemists and biologists at UCLA and colleagues at several other institutions, including Memorial Sloan-Kettering Cancer Center, have created a new drug to treat a particularly lethal form of the disease, known as castration-resistant prostate cancer, or CRPC. Also referred to as hormone-refractory prostate cancer, CRPC is resistant to further treatment by anti-hormone drugs such as Casodex and Eulexin.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In an article published April 9 in the advanced online edition of the journal Science, the scientists describe the development and testing of two novel compounds, MDV3100 and RD162, which block the androgen receptor (AR) in CRPC cells, and report results from clinical trials in which MDV3100 was found to lower prostate-specific antigen (PSA) levels — a marker for tumor growth — in men with CRPC.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The new, small organic molecule MDV3100<B> </B>was "designed as a very strong antagonist of the androgen receptor to stop the growth of any prostate cancer that requires the AR for propagation, which includes most forms of prostate cancer," said Michael Jung, UCLA professor of chemistry and biochemistry and a researcher&nbsp;at UCLA's <A href="http://www.cancer.ucla.edu/">Jonsson Comprehensive Cancer Center</A>, whose research group synthesized both MDV3100 and RD162.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The biology research was carried out in the UCLA departments of medicine, urology and pharmacology by Charles Sawyers and his research group; Sawyers has since moved to Memorial Sloan-Kettering Cancer Center<B> </B>in New York,<B> </B>where he serves as chair of the human oncology and pathogenesis program. The UCLA patents for both compounds were licensed by the pharmaceutical company Medivation Inc., which chose to test MDV3100 in clinical trials.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The drug has successfully completed Phase 1 and Phase 2 clinical trials, and the Food and Drug Administration has agreed to allow Medivation to begin what Jung described as "the pivotal Phase 3 clinical trials."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The results of clinical studies with MDV3100 were described at the 2009 ASCO Genitourinary Cancer Symposium in February by the trials' principal investigator, Dr. Howard Scher of Memorial Sloan-Kettering Cancer Center. In general, the drug, at 240 mg once a day, was very effective at lowering PSA levels and also in reducing the number of circulating tumor cells, without any significant toxicity.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"I think it is quite likely that the exciting results seen in the smaller population will also be evident in the larger Phase 3 trial and that the drug could be approved for use in the next few years," said Jung,&nbsp;who is also a&nbsp;member of the California NanoSystems Institute (<A href="http://www.cnsi.ucla.edu/">CNSI</A>) at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Of 30 men with anti-androgen–resistant prostate cancer who received low doses of MDV3100 in the multisite Phase 1/2 trial designed to evaluate safety, 22 showed a sustained decline in PSA levels, an indication that their cancer was responding favorably to the drug. This trial is still underway, and results from a total of 140 patients receiving higher doses of the drug will be reported within the next year, Sawyer said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Phase 3 clinical trial will evaluate the drug's effect on survival in a large group of patients with metastatic prostate cancer.</DIV>
<DIV>&nbsp;</DIV>
<DIV>MDV3100 and RD162 are second-generation anti-androgen therapies that prevent male hormones from stimulating the growth of prostate cancer cells. These new compounds appear to work well even in prostate cells that have a heightened sensitivity to hormones; that heightened sensitivity makes prostate cancer cells resistant to existing anti-androgen therapies.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Approximately 186,000 new cases of prostate cancer are diagnosed each year in the United States. The male hormones testosterone and dihydrotestosterone, which are also known as androgens, spur the growth of prostate cells, and drugs that block the receptors for these hormones are the most common treatment for the disease in its advanced, metastatic stage. Anti-androgen drugs, such as bicalutamide (Casodex), suppress the growth of cancer cells temporarily, but in most patients, the cancer ultimately develops resistance to drugs. Approximately 29,000 men in the United States die each year from the disease.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Prostate cancer becomes resistant to anti-androgen drugs when cancer cells begin to increase production of the androgen receptor, Sawyers said. When the level of androgen receptors on the cells' surface reaches a certain level, the drugs that originally suppressed the cancer actually begin to stimulate cancer growth.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Because of this backlash effect, many scientists have questioned whether blocking the androgen receptor is a wise course of action. Sawyers and his colleagues, however, believe that blocking the receptor is critical to successful treatment. They set out to design a new generation of drugs that can block the androgen receptor without unwanted side effects, even when levels of the receptor are high.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Researchers in Jung's and Sawyers' laboratories based their designs on a drug that tightly attaches to the site on the androgen receptor that binds with testosterone. If that site is blocked, the hormone cannot bind to prostate cells and tell the receptor to stimulate growth. Using this initial drug as a chemical scaffold, the researchers synthesized nearly 200 slightly different versions of the drug. They tested each one in the laboratory on prostate cancer cells that had been engineered to produce high levels of androgen receptor.</DIV>
<DIV>&nbsp;</DIV>
<DIV>This screening yielded MDV3100 and RD162, molecules which tightly bind to the androgen receptor and do not show the cancer-stimulating effect of bicalutamide and other current anti-androgen drugs. The molecules were good candidates for drugs, because they are readily absorbed into the blood when taken orally and they persist in the bloodstream. The researchers tested the new drugs' effectiveness in mice with tumors derived from drug-resistant prostate cancer cells.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"To our delight, we found that these compounds caused very dramatic shrinkage of tumors in the mice," Sawyers said. "While treating these animals with bicalutamide produced a modest effect on their tumors, the new drugs caused the tumors to shrink dramatically, and in some animals almost completely."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Sawyers said the new drugs bind tightly enough to the natural hormone-binding site on androgen receptors to prevent most of them from functioning, even in cells with many androgen receptors.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The promising laboratory studies led Medivation to license the drugs for commercial development.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Medivation has received permission from the FDA for a large Phase 3 clinical trial of MDV3100 on about 1,200 patients with anti-androgen-resistant disease. This study will assess MDV3100's effect on cancer survival and will take several years.</DIV>
<DIV>&nbsp;</DIV>
<DIV>While the preliminary results are promising, Sawyers said his laboratory will continue to seek further improvements in drug therapy for prostate cancer.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"There were some men in the initial trial in which the drug didn't work at all, and we want to find out why," he said. "It may be because the drug is not potent enough to overcome resistance due to androgen receptor over-expression. Or it may be that the cancers in these men are not driven by the androgen receptor anymore. Also, there were men who initially received benefit from the drug but then relapsed, and their PSA levels came back up. We want to understand the mechanism of that relapse and to try to develop drugs that prevent that renewed resistance."</DIV>
<DIV>&nbsp;</DIV>
<DIV>For years, no treatment was available for CRPC; recently paclitaxel — a strongly cytotoxic drug&nbsp;— was approved.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to Sawyers' and Jung's teams, researchers from the Oregon Health and Science University, the<B> </B>University of Washington and Medivation contributed to the research.</DIV>
<DIV>&nbsp;</DIV>
<DIV>This research was supported by the National Institutes of Health, the Department of Defense, the Prostate Cancer Foundation and Medivation and was conducted through the Prostate Cancer Clinical Trials Consortium.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more information about Jung, visit <A href="http://www.chem.ucla.edu/~jung/home.html">www.chem.ucla.edu/~jung/home.html</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>UCLA </B>is California's largest university, with an enrollment of nearly 38,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 323 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=139900" height="1" width="1" />]]></description><pubDate>Thu, 09 Apr 2009 07:00:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Teaching autistic teens to make friends</title><link>http://newsroom.ucla.edu/portal/ucla/teaching-autistic-teens-to-make-87162.aspx?link_page_rss=87162</link><guid>http://newsroom.ucla.edu/portal/ucla/teaching-autistic-teens-to-make-87162.aspx</guid><description><![CDATA[<DIV><SPAN style="FONT-SIZE: 8pt">During the first week of class, the teens' eyes were downcast, their responses were mumbled and&nbsp;eye contact was almost nonexistent. By Week 12, though, these same kids were talkative, responsive and&nbsp;engaged.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">That's the result of a special class designed at UCLA to help teens with autism spectrum disorders (ASD) learn to interact appropriately with their peers. ASD includes a range of pervasive developmental disorders&nbsp;characterized by&nbsp;problems with communication and socialization; it's estimated that one in 150 children born in the United States has some form of ASD. </SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">In a study appearing in the April edition of the Journal of Autism and Developmental Disorders, UCLA clinical instructor of psychiatry Elizabeth Laugeson and colleagues report that in comparison with a control group, the treatment group taking the class significantly improved their overall social skills and interactions with their peers.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"Although, typically, developing teens often learn basic social rules through observation of peer behavior and specific instruction from parents," Laugeson said, "adolescents with autism spectrum disorders often require further instruction.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"It's hard enough to be a teenager," she said, "but it's harder still for adolescents with autism because they typically lack the ability to pick up on all the social cues most of us take for granted&nbsp;— things like body language, hand gestures and facial expressions, along with speech inflections like warmth, sarcasm or hostility.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"Lack of these basic social skills may lead to rejection, isolation or bullying from their peers.&nbsp;And sadly, that isolation can carry into their adult life."</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Laugeson and her colleagues developed the class, called PEERS (Program for the Education and Enrichment of Relational Skills), to give high-functioning teens with ASD a set of specific social skills. </SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"How do you have a successful get-together with someone? How do you go up to a group of teens and join their conversation? What do you say as a comeback when someone teases you? Without these core social skills, it becomes very difficult for teenagers to make and keep friends," Laugeson said.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">In the study, 33 teens with ASD —&nbsp;28 males and five females — attended the PEERS classes. All the participants had a previous diagnosis of high-functioning autism, Asperger's Disorder or Pervasive Developmental Disorder–Not Otherwise Specified (PDD-NOS). The teens met once a week for 12 weeks; each session lasted 90 minutes. Instruction was conducted in a small-group format, with&nbsp;seven to 10 teens, using established strategies for teaching social skills to adolescents with ASD.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Parents were also required to attend separate, concurrent sessions where they were provided direct instruction and guidance to support their child's development. </SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"Parental involvement was mandatory and important," said Laugeson, who is also associate director&nbsp;of the UCLA Parenting and Children's Friendship Program and director of the Help Group–UCLA Autism Research Alliance. "Other research has shown us that parent involvement can have significant positive effects upon children's friendships, both in terms of direct instruction and supervision, as well as&nbsp;supporting a child's development of an appropriate peer network."</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">The class focused on teaching rules of social etiquette to the teens, while their parents were given information about how to supervise the implementation of these newly learned skills. These included: how to comfortably join and exit a group of peers; how to pick the right peer group (such as jocks, nerds or gamers); learning good sportsmanship; learning good host behavior during get-togethers; changing bad reputations by changing one's&nbsp;"look" and owning up to a previously bad reputation; and handling teasing, bullying and arguments. </SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Each class included brief didactic instruction, role-playing exercises in which appropriate social skills were modeled, behavioral rehearsal for teens to practice newly learned skills, coaching with performance feedback, and weekly "homework" assignments supervised by parents, such as inviting a friend over to the home for a get-together.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"The class is very structured, and the skills are broken into small steps that give the teens specific actions they can take in response to a social situation," Laugeson said. "This method of instruction is very appealing to teens with autism because they tend to think concretely and often learn by rote. So if they are teased, for example, we teach them to give a short comeback — like saying 'whatever' or 'so what?' They learn not to take the bait."</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Results of testing show that teens who have been through the PEERS program were having&nbsp;more peer interactions with their friends outside of school, and parents reported significant improvement in overall social skills, as measured by a standardized test of social functioning. </SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Results were encouraging, as improvement was demonstrated on a number of outcome measures. Teens in the treatment group demonstrated improved knowledge of rules of social etiquette relevant to making and keeping friends. They and their parents also reported a significant increase in the frequency of hosted get-togethers and a significantly better quality of friendships at the end of treatment, in comparison&nbsp;with the control group.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"For me, the most important outcome of this research is that we're able to have a direct impact on the quality of lives&nbsp;for teenagers with ASD," Laugeson said. "Helping them to develop meaningful relationships and feel more comfortable within their social world&nbsp;— these are essential ingredients to living a happy life, and what could be more important than that?"</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">The classes are continuing and currently enrolling. For more information,&nbsp;visit </SPAN><A href="http://www.semel.ucla.edu/socialskills/"><SPAN style="FONT-SIZE: 8pt"><A href="http://www.semel.ucla.edu/socialskills/">www.semel.ucla.edu/socialskills/</SPAN><SPAN style="FONT-SIZE: 8pt"></A> or call the UCLA Parenting and Children's Friendship Program at 310-825-0142.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Other authors of the study were Dr. Fred Frankel, Dr. Catherine Mogil and Ashley Dillon, all of UCLA. </SPAN><SPAN style="FONT-SIZE: 8pt">Funding was provided by the National Institutes of Health and the National Institute of Mental Health. The study was also supported by a generous donation from the Nathan and Lilly Shapell Foundation, as well as&nbsp;the Friends of the Semel Institute. The authors report no conflict of interest. </SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt"><STRONG>The Program for the Education and Enrichment of Relational Skills</STRONG> (PEERS)&nbsp;is part of the UCLA Semel Institute for Neuroscience and Human Behavior, an interdisciplinary research and education institute devoted to the understanding of complex human behavior, including the genetic, biological, behavioral and sociocultural underpinnings of normal behavior, and the causes and consequences of neuropsychiatric disorders.</SPAN></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=138678" height="1" width="1" />]]></description><pubDate>Tue, 07 Apr 2009 07:00:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>UCLA scientists identify gene linked to deadly disorder in newborns</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-identify-gene-86795.aspx?link_page_rss=86795</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-identify-gene-86795.aspx</guid><description><![CDATA[<DIV><SPAN style="FONT-SIZE: 8pt">After 12 years of searching, UCLA scientists have tracked down the first known gene mutation responsible for short rib polydactyly syndrome, a rare disorder that kills newborn babies.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Published in the April 1 online&nbsp;edition of the American Journal of Human Genetics, their findings will allow for earlier testing of embryos at risk for the disease.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Many things go awry in short rib polydactyly syndrome. The fetus develops extra fingers and toes and its skeleton doesn't grow, resulting in stunted ribs that prevent the lungs from maturing in the womb. Unable to breathe on its own, the child dies shortly after birth.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Parents currently must wait until the second trimester of pregnancy for a diagnosis&nbsp;— a long time to wait for potentially agonizing news about one's unborn child.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"Now that we've identified the genetic basis of the disease, families will be able to obtain a prenatal diagnosis within about 12 weeks,"&nbsp;said Dr. Deborah Krakow, associate professor of orthopedic surgery and human genetics at the David Geffen School of Medicine at UCLA. "Parents will also be able to screen embryos conceived in vitro to help select those free of the genetic mutation before uterine implantation."</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Roughly one in 300 people is a carrier of the&nbsp;gene mutation responsible&nbsp;for the syndrome. Both parents must carry the mutated gene in order for their child to inherit the disease.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">In the hope of finding a common genetic link to the disease, the UCLA team studied DNA samples from three families whose children died of short rib polydactyly syndrome. Dr. Stan Nelson, UCLA professor of human genetics, and his laboratory employed powerful genomic technology to rapidly test hundreds of thousands of gene variations in each fetus.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"It took scientists 10 years to map the human genome," Nelson said. "New technology enables us to search a child's entire genome in two weeks without testing the parents or other family members. It's a highly efficient way to quickly sample DNA and identify shared gene variations among people."</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">In the UCLA study, the research team identified a DNA sequence shared by three&nbsp;siblings who died of the disease. Like a signpost, it directed the scientists to a chromosomal location they suspected of housing the disease-causing gene.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"Each of us inherits different chromosomes from our mothers and fathers," Nelson said. "If the child's genome contains the same DNA from both parents, we know that the mother and father are related in some way. They share a piece of ancestral DNA&nbsp;— a common red flag for people known to have or carry a genetic disease."</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">After narrowing her search to three identical regions on the genome, Krakow zeroed in on one as the likely culprit. Her hunch proved correct. Not only did she identify the mutation in the initial family that lost three children, but she confirmed its presence in two other families whose infants also died of the disease.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Krakow and Nelson's next step will be to seek out other genes that contribute to short rib polydactyly syndrome and uncover how these factors interact to cause the disorder.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">"One of the reasons this disease is hard to crack is that it is caused by multiple genes, not just one," Krakow said. "We are searching for other gene variants in other families affected by the syndrome."</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">The DNA-scanning techniques developed by Nelson and his colleagues can be used to identify any hereditary disease-causing gene. The findings will enhance doctors' abilities to determine individual genes' specific roles and provide a more complete picture&nbsp;of healthy and abnormal human development.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Roughly 3 percent of all infants are born with birth defects. Some 5 percent of these children suffer from genetic defects affecting the skeleton, and in&nbsp;this group, about 5 percent are short rib polydactyly syndrome patients.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">The National Institute of Child Health and Human Development funded the study. </SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">Co-authors included Amy Merrill, Barry Merriman, Clare Farrington-Rock, Natalia Camacho, Eiman Sebald, Vicente Funari, Matthew Schibler, Marc Firestein, Zachary Cohen, Maryann Priore, Alicia Thompson, David Rimoin and Daniel Cohn, all affiliated with UCLA and Cedars-Sinai Medical Center.</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt">&nbsp;</SPAN></DIV>
<DIV><SPAN style="FONT-SIZE: 8pt"><SPAN style="FONT-SIZE: 8pt">For more news, visit the </SPAN><A href="http://www.newsroom.ucla.edu/"><SPAN style="FONT-SIZE: 8pt">UCLA Newsroom</SPAN></A><SPAN style="FONT-SIZE: 8pt">.</SPAN></SPAN></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=136412" height="1" width="1" />]]></description><pubDate>Wed, 01 Apr 2009 07:00:00 GMT</pubDate></item><item><author>Kim Irwin</author><title>UCLA acquires new tool that delivers higher doses of radiation in less time</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-acquires-new-tool-that-delivers-86692.aspx?link_page_rss=86692</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-acquires-new-tool-that-delivers-86692.aspx</guid><description><![CDATA[<DIV>UCLA has added a new tool to its cancer-fighting arsenal, a state-of-the-art, image-guided device that provides more accurate, concentrated doses of radiation, allowing patients to be treated in fewer visits with fewer side effects.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The UCLA Department of Radiation Oncology is the first center in the Los Angeles area to install the Novalis Tx, a noninvasive stereotactic radiosurgery machine that includes three imaging modalities. The modalities track the location of tumors during respiration and other movement and allow physicians to pinpoint the tumor and position the patient so that radiation is delivered with the highest precision to the cancerous tissue while protecting the healthy surrounding tissues.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Novalis Tx has an advanced system that continuously shapes the radiation beam to mirror the tumor's size and dimensions as&nbsp;the machine rotates around the patient, delivering treatment from different angles. In addition, the platform holding the patient moves not only side to side and up and down but also rotates around a vertical axis.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Physicians using the machine have likened it to a high-performance sports car with all the bells and whistles that make such a vehicle desirable.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This Novalis Tx is like having a really nice BMW. With it, you get all the basic features of stereotactic radiosurgery, but you also get all these amazing high-tech accessories," said Dr. Percy Lee, assistant professor of radiation oncology at UCLA and director of the stereotactic body radiation therapy (SBRT) program, which will employ the Novalis Tx to treat localized tumors. "This machine has state-of-the-art features like the multiple imaging modalities to cover every clinical circumstance and make it more precise and accurate."</DIV>
<DIV>&nbsp;</DIV>
<DIV>In some cases, the Novalis Tx can reduce&nbsp;the period of&nbsp;radiation needed from six weeks of daily treatments to just three to five days because of the high doses that can be delivered using the SBRT approach, Lee said. This results in less radiation to the neighboring normal tissues,&nbsp;greatly reducing&nbsp;side effects while also improving tumor control rates.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The device will be used to treat cancers of the brain, spine, lung, liver, pancreas, prostate and kidney. Because the radiation is so precisely aimed, the Novalis Tx also will allow patients&nbsp;who may have inoperable, untreatable tumors to receive therapy they might not otherwise have been given.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The technology's precision also will enable UCLA physicians to employ the Novalis Tx to address a number of medical conditions unrelated to cancer. For example, the beam can be directed to pinpoint nerves responsible for causing the severe facial pain and muscle spasms&nbsp;associated with&nbsp;trigeminal neuralgia. It also can target arteriovenous malformations, or AVMs, abnormal tangles of blood vessels that prevent oxygenated blood from reaching and nourishing tissue. Depending on their location in the body, some AVMs are otherwise inoperable.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Michael Selch, a UCLA professor of radiation oncology, said the Novalis Tx offered several advantages over current technology, but what caught UCLA's attention was an upgrade to the multileaf collimator, the mechanism that controls the continuous shaping of the radiation beam as it enters the patient from different angles.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"It allows us to shape the dose and target tumors very precisely to protect normal tissues," said Selch, a specialist in central nervous system radiation oncology. "It helps us to be more efficient, accurate and rapid in targeting stereotactic body radiation therapy to tissues such as the lung and liver, where movement with respiration is a problem. Novalis Tx will open up new avenues of radiosurgery for us, allowing us to treat even difficult-to-plan tumors with unusual shapes."</DIV>
<DIV>&nbsp;</DIV>
<DIV>In late 2008, Beverly Namnoun, 63, of Long Beach, Calif.,&nbsp;suffered a recurrence of lung cancer first diagnosed in 2007. Although her tumor was still small&nbsp;— a good sign&nbsp;— because of its location near her airway, esophagus and spinal cord, she would not otherwise have been a candidate for radiation. But she recently underwent her first treatment with the Novalis Tx, which delivered the dose without harming her nearby tissues.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"UCLA is known for being on the leading edge of technology. That's why I wanted to be treated there. I think it's exciting to be getting this new technology," Namnoun said after her first treatment. "It was quick, and I didn’t feel a thing."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Lee, who is Namnoun's radiation oncologist, said her tumor presented challenges, but with the advanced technology available now, he believes she has a good prognosis.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"With its advanced accuracy, Novalis Tx will improve our therapeutic ratio between controlling the cancer and minimizing side effects," said Lee, who also is a researcher with UCLA's Jonsson Comprehensive Cancer Center. "It also will provide us with daily verifications that we're keeping our radiation beam to the intended tumor target. This is especially important because Beverly also has scleroderma, a systemic disease that may possibly predispose her to more normal tissue radiation side effects."</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to the advanced technology of the Novalis Tx, UCLA's radiation oncology department employs a multidisciplinary care approach to ensure that patients get the best treatment. Using computers and specialized software, physicists create an individual treatment plan for each patient based on their tumor's size and shape. Technicians, nurses and radiation oncologists work together to treat the patient.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"It's like that fancy car," Lee said. "If you don't have a good driver, all the bells and whistles don't matter. It's just a machine that's fancy. At UCLA, we have the top experts from all the disciplines driving this machine. Our patients are in excellent hands."</DIV>
<DIV>&nbsp;</DIV>
<DIV>UCLA has led the charge in the use of Novalis technology. In 1998, the radiation oncology department installed the first Novalis machine in the world. Initially, it was used only to treat brain tumors but later expanded to other cancers in the body. In all, more than 4,000 cancer patients have been treated using the original machine.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We have an incredible amount of experience using this type of machine," said Dr. Michael Steinberg, chair of the radiation oncology department and a Jonsson Cancer Center scientist. "That will aid us in treating the most difficult cases."</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=135949" height="1" width="1" />]]></description><pubDate>Tue, 31 Mar 2009 07:00:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Study details strategy for boosting ranks of black HIV/AIDS researchers</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-details-a-strategy-for-boosting-86750.aspx?link_page_rss=86750</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-details-a-strategy-for-boosting-86750.aspx</guid><description><![CDATA[<DIV>African Americans, who make up 13 percent of the U.S. population,&nbsp;are disproportionately affected by AIDS,&nbsp;accounting for&nbsp;nearly 49 percent of newly diagnosed HIV/AIDS cases nationwide. About 500,000 African Americans are now living with HIV/AIDS.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Yet there are very few African American HIV/AIDS researchers, due to historical, social and other factors that prevent them from training in the biomedical, behavioral and social aspects of HIV/AIDS research.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In response to the shortage, researchers from the UCLA Center for Culture, Trauma and Mental Health Disparities and the UCLA AIDS Institute&nbsp;have developed&nbsp;a series of recommendations that could reverse the trend and lead more African American researchers into the field. The recommendations are outlined in an article published in a supplement to the April issue of&nbsp;the American Journal of Public Health (available online at <A href="http://www.ajph.org/cgi/content/full/99/S1/S48">www.ajph.org/cgi/content/full/99/S1/S48</A>).</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The most effective behavior-change policies allow for individuals to be part of the solution and not the problem," said lead author Dr. Gail Wyatt, professor of psychiatry and biobehavioral sciences at the Semel Institute for Neuroscience and Human Behavior at UCLA. "We need African American experts who are at the forefront of HIV/AIDS prevention."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers have identified four institutional factors, as well as two individual factors, that limit the number of African Americans pursuing HIV/AIDS research.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Institutional factors include limitation of early career decisions and&nbsp;a lack of exposure to research, research socialization and mentoring. For example, African American college students often don't receive research training early in their careers, so they may not be experienced in pulling together a team of strong research collaborators. In addition, some department chairs may think it is&nbsp;"too late" for doctoral graduates to move into a research career, and there are few senior African Americans to mentor and encourage a new generation of&nbsp;African American&nbsp;HIV/AIDS investigators.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Compounding this situation are individual factors. Given the scarcity of role models, African American students may have negative perceptions about their own competence as HIV/AIDS investigators, and there is limited support for culturally congruent research.</DIV>
<DIV>&nbsp;</DIV>
<DIV>To boost the ranks of African American HIV/AIDS researchers, the study authors make the following seven recommendations to universities and other institutions of higher learning, and private and government funders of research and training:</DIV>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>Fund research that encourages partnerships with historically African American and minority-serving institutions, such as the National Medical Association and the Association of Black Psychologists, so that clinically trained professionals can participate in and learn more about HIV/AIDS research.</LI></UL>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>Provide for retraining of established researchers who wish to shift their focus to HIV/AIDS.</LI></UL>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>Continue to offer loan-repayment programs for graduate education.</LI></UL>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>Incorporate mentorships into graduate and professional training programs.</LI></UL>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>Encourage universities and training programs to recognize mentors whose students pursue HIV/AIDS research, and establish awards that recognize the work of African American investigators in the field.</LI></UL>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>Develop and use culturally congruent theories and measures in HIV/AIDS research.</LI></UL>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>Require training in cultural competence for federal staff, reviewers and mentors.</LI></UL>
<DIV>&nbsp;</DIV>
<DIV>"HIV/AIDS research conducted by highly trained African Americans should be the norm and not the exception," the authors conclude. "Such researchers add an important voice and level of expertise to HIV prevention that can only be enhanced by implementing programs to increase the representation of African American investigators in NIH-funded research. A concerted effort to remove barriers to funding and career trajectories to ensure that HIV/AIDS research addresses the most affected populations is needed."</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to Wyatt, study authors included&nbsp;John K. Williams, Tina Henderson and LeKeisha Sumner, all of&nbsp;the UCLA Department of Psychiatry and Biobehavioral Sciences.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The National Institute of Mental Health (NIMH)&nbsp;and the UCLA AIDS Institute funded this study.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>The UCLA Center for Culture, Trauma and Mental Health Disparities </STRONG>is a unique new interdisciplinary, center funded by the NIMH&nbsp;that promotes research into the behavioral, biological, psychological and social factors associated with trauma among ethnic minorities. The Center faculty aim to understand how depression, post-traumatic stress disorder, and other mental health outcomes affect men and women who may not seek or receive effective care. This understanding would help healthcare professionals create new strategies to reduce mental health disparities among these groups.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.uclaaidsinstitute.org/">The UCLA AIDS Institute</A></STRONG>, established in 1992, is a multidisciplinary think tank drawing on the skills of top-flight researchers in the worldwide fight against HIV and AIDS, the first cases of which were reported in 1981 by UCLA physicians. Institute members include researchers in virology and immunology, genetics, cancer, neurology, ophthalmology, epidemiology, social science, public health, nursing, and disease prevention. Their findings have led to advances in treating HIV, as well as other diseases, such as hepatitis B and C, influenza and cancer.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=135939" height="1" width="1" />]]></description><pubDate>Tue, 31 Mar 2009 07:00:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Bad news for insomniacs: 'hunger hormones' affected by poor sleep</title><link>http://newsroom.ucla.edu/portal/ucla/hunger-hormones-impacted-by-poor-86428.aspx?link_page_rss=86428</link><guid>http://newsroom.ucla.edu/portal/ucla/hunger-hormones-impacted-by-poor-86428.aspx</guid><description><![CDATA[<DIV>Insomnia has long been associated with poor health, including weight gain and even obesity. Now researchers at UCLA have found out why. </DIV>
<DIV>&nbsp;</DIV>
<DIV>In a study to be published in the May issue of the journal Psychoneuroendocrinology and currently available <A href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6TBX-4V34RPP-1&amp;_user=4423&amp;_coverDate=05%2F31%2F2009&amp;_rdoc=8&amp;_fmt=high&amp;_orig=browse&amp;_srch=doc-info(%23toc%235154%232009%23999659995%23995090%23FLA%23display%23Volume)&amp;_cdi=5154&amp;_sort=d&amp;_docanchor=&amp;_ct=22&amp;_acct=C000059605&amp;_version=1&amp;_urlVersion=0&amp;_userid=4423&amp;md5=75add73d01fc90233af4660fe5143b4f">online by subscription</A>, Sarosh Motivala, an assistant professor of psychiatry&nbsp;at the Semel Institute for Neuroscience and Human Behavior at UCLA, and colleagues looked at two hormones that are primarily responsible for regulating the body's energy balance, telling&nbsp;the body&nbsp;when&nbsp;it is&nbsp;hungry and when&nbsp;it is&nbsp;full. The study found that chronic insomnia disrupts one of these two hormones.</DIV>
<DIV>&nbsp;</DIV>
<DIV>To date, no study&nbsp;has evaluated nocturnal levels of the two hormones, ghrelin and leptin, in primary insomnia patients. Ghrelin, a peptide secreted by the stomach, stimulates appetite and increases before meals. Leptin, which&nbsp;affects body weight and&nbsp;is secreted primarily by fat cells, signals the hypothalamus regarding the degree of fat storage in the body; decreased leptin tells the body there is a calorie shortage and promotes hunger, while increased levels promote energy expenditure.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In the study, researchers compared healthy sleepers with those suffering from chronic insomnia and measured the levels of the two hormones at various times throughout the night. They found that while leptin levels averaged out over the night to be roughly the same between the two groups, levels of ghrelin were 30 percent lower in insomnia sufferers.</DIV>
<DIV>&nbsp;</DIV>
<DIV>On the face of it, a decreased level of ghrelin would seem to inhibit weight gain; it is an increase in ghrelin, after all, that stimulates appetite. But Motivala compared his findings with other, earlier studies on sleep deprivation and speculates that a switch may occur during the day: Sleep loss leads to increased ghrelin and decreased leptin, a "double whammy" that stimulates appetite. Motivala is currently working on a study to examine this switch.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The current study shows that insomnia patients have a dysregulation in energy balance that could explain why these patients gain weight over time," said Motivala, who is also a member of the Cousins Center for Psychoneuroimmunology at UCLA. "This is an exciting finding because it highlights how diverse behaviors like sleep and eating are connected. We are just beginning to explore the possible consequences of these connections, but it is another example of the importance of a good night's sleep for the body."</DIV>
<DIV>&nbsp;</DIV>
<DIV>For the&nbsp;study, 38 male participants were divided into two groups —&nbsp;14 insomnia sufferers and 24 healthy subjects. Both groups had similar ages and body weight. Both groups underwent polysomnography sleep studies that monitor brain waves. Circulating levels of ghrelin and leptin were measured at 11 p.m., 2 a.m. and 6&nbsp;a.m. Ghrelin levels across the night were significantly lower in insomnia patients, while leptin were not significantly different between the two groups.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.cousinspni.org/">The UCLA Cousins Center for Psychoneuroimmunology</A></STRONG> encompasses an interdisciplinary network of scientists working to advance the understanding of psychoneuroimmunology by linking basic and clinical research programs and by translating findings into clinical practice. The center is affiliated with the Semel Institute for Neuroscience and Human Behavior and the David Geffen School of Medicine at UCLA.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=133566" height="1" width="1" />]]></description><pubDate>Wed, 25 Mar 2009 07:00:00 GMT</pubDate></item><item><author>Roxanne Moster</author><title>UCLA's medical center makes list of top hospitals in AARP magazine</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-medical-center-makes-aarp-86548.aspx?link_page_rss=86548</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-medical-center-makes-aarp-86548.aspx</guid><description><![CDATA[<DIV>Ronald Reagan UCLA Medical Center has been selected as one of the&nbsp;country's&nbsp;leading hospitals, and one of the most highly recommended&nbsp;in a number of medical specialties, in a major survey of&nbsp;physicians across the nation. The results of the survey&nbsp;appear in the May–June issue of AARP The Magazine.</DIV>
<DIV>&nbsp;</DIV>
<DIV>To coincide with the release of the issue, the magazine —&nbsp;which has the world's largest circulation, with more than 34 million readers —&nbsp;today debuted on its website&nbsp;an <A href="http://www.aarpmagazine.org/health/right_hospital_for_you.html">interactive map</A> listing the survey's&nbsp;125 top-ranked hospitals&nbsp;in the U.S., including UCLA,&nbsp;by geographic region. The list is based on&nbsp;a survey&nbsp;conducted by <A href="http://www.checkbook.org/">Consumers' Checkbook</A>, a nonprofit research organization.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This is a wonderful tribute to our entire health care team as we celebrate the recent opening of our new Ronald Reagan UCLA Medical Center," said Dr. David Feinberg, chief executive officer and associate vice chancellor of the UCLA Hospital System. "We are grateful to our medical staff, who go the extra mile every day to save lives and deliver compassionate care to patients in our community and from around the world."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Consumers' Checkbook surveyed doctors across the&nbsp;U.S. and collected&nbsp;140,000 ratings of hospitals in these doctors'&nbsp;local communities. The doctors were also&nbsp;asked whether they would recommend that patients seek care at hospitals in other communities for certain extremely difficult cases involving&nbsp;heart conditions, cancer and other ailments — and if so, which hospitals they would recommend.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Ronald Reagan UCLA Medical Center, in addition to making the top 125 list, was ranked among the&nbsp;most recommended hospitals for neurosurgery, mystery diagnoses and eye care, through UCLA's Jules Stein Eye<B> </B>Institute,&nbsp;for extremely difficult cases.</DIV>
<DIV>&nbsp;</DIV>
<DIV>This survey was conducted as part of the research for Consumers' Checkbook's new book "Consumers' Guide to Hospitals," which uses volumes of government safety statistics and data on death and complication rates, along with survey results, to compare and rank hospitals in the country's 53 largest metro areas. </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.uclahealth.org./">The UCLA Health System</A></STRONG> has been a leader in patient care, medical research and teaching for more than 50 years. Today, our physicians provide an array of cutting-edge and research-based primary and specialty services in four hospitals on two campuses, and in numerous outpatient clinic locations. Composed of the UCLA Hospital System and the UCLA Medical Group and its affiliates, the UCLA Health System has provided the best in health care and the most advanced treatment options to the people of Southern California, the U.S. and around the globe. UCLA's preeminence in health care — a strength that comes from the union of research, teaching and excellence in patient care — continues to be recognized nationally and internationally. The clinical programs of Ronald Reagan UCLA Medical Center, Santa Monica–UCLA Medical Center and Orthopaedic Hospital, the Resnick Neuropsychiatric Hospital at UCLA, and Mattel Children's Hospital UCLA comprise a system of hospital care that has been ranked among the best in the nation. UCLA physicians and hospitals continue to be world leaders in the full range of care, from maintaining the health of families to the diagnosis and treatment of complex illnesses. </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=133322" height="1" width="1" />]]></description><pubDate>Tue, 24 Mar 2009 07:00:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Study quantifies racial disparities in cancer mortality rates between blacks and whites</title><link>http://newsroom.ucla.edu/portal/ucla/study-quantifies-racial-disparities-85088.aspx?link_page_rss=85088</link><guid>http://newsroom.ucla.edu/portal/ucla/study-quantifies-racial-disparities-85088.aspx</guid><description><![CDATA[<DIV>African Americans&nbsp;have a shorter life expectancy&nbsp;than whites, and cancer plays a major role in this disparity.&nbsp;African Americans&nbsp;are more prone to get cancer; they tend to present at a later, deadlier stage; and they have poorer survival rates after diagnosis.</DIV>
<DIV>&nbsp;</DIV>
<DIV>But to what extent are each of these three factors responsible for the disparity in cancer mortality? A new UCLA study, published in Journal of General Internal Medicine Feb. 18, answers that question, finding that for most types of cancer, the disparity in mortality is almost entirely&nbsp;due to the fact that African Americans&nbsp;are more likely to get cancer in the first place. Their stage at presentation and survival after diagnosis play a much smaller role.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Overall, African American men live 1.47 fewer years than white men, and&nbsp;African American&nbsp;women 0.91 fewer years than white women, due to all cancers combined. The results spotlight the need for greater prevention efforts aimed at African Americans.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study is available online at <A href="http://www.springerlink.com/content/u3u072071t08xl1u/fulltext.html">www.springerlink.com/content/u3u072071t08xl1u/fulltext.html</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV>This is the first time that researchers have quantified the role that disparities in cancer incidence, stage at diagnosis and survival after cancer plays in African Americans' shorter life expectancy, according to lead author Dr. Mitchell D. Wong, associate professor of medicine in the division of general internal medicine and health services research at the David Geffen School of Medicine at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Putting a number on it is very informative, because when you look at the figures, you see that the reason their mortality is worse is almost entirely due to the fact that blacks are more likely to get cancer," Wong said. "This highlights the importance of prevention — it's where most of the efforts should be."</DIV>
<DIV>&nbsp;</DIV>
<DIV>A notable exception to this pattern was breast cancer. While white women are <I>more</I> likely to get breast cancer than African American women, the disparities between whites and blacks in stage at presentation and survival after diagnosis for breast cancer had a large impact on the racial gap in life expectancy. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"This argues for much more research and efforts to close the gap in breast cancer screening and treatment," Wong said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers analyzed data from the Surveillance and Epidemiology End Result (SEER) cancer registry and the National Health Interview Survey (NHIS). Together, the data sets covered about 2.7 million white and 291,000 African American cancer patients from 12 geographic regions in the United States: San Francisco/Oakland, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle (Puget Sound), Utah, Atlanta, Alaska, San Jose/Monterey and Los Angeles.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Among the other findings:</DIV>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>Cancer incidence, stage at diagnosis and post-diagnosis survival accounted for 1.12, 0.17 and 0.21 years, respectively, in the life-expectancy disparity among men.</LI></UL>
<UL>
<LI>Among women, those categories accounted for 0.41, 0.26 and 0.31 years, respectively.</LI></UL>
<UL>
<LI>The difference in incidence of cancer had a greater impact on the racial gap in cancer mortality than did the stage at which the cancer was diagnosed.</LI></UL>
<UL>
<LI>The differences in post-diagnosis survival were significant with only two types of cancer: breast (0.14 years) and prostate (0.05 years).</LI></UL>
<DIV>&nbsp;</DIV>
<DIV>"Continuing to improve cancer treatment and screening is undoubtedly important to improving life expectancy and quality of life for all adults, yet substantial disparities in cancer mortality will persist unless we can find ways to address the enormous impact of racial differences in cancer incidence," the researchers concluded.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to Wong, study authors included Susan L. Ettner and Martin F. Shapiro of the David Geffen School of Medicine at UCLA, and John Boscardin of the division of geriatrics at the San Francisco Veterans Administration Medical Center.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The National Institute on Aging, the National Center on Minority Health and Health Disparities, a Pfizer Scholars Grant in Clinical Epidemiology, and a Doris Duke Charitable Foundation Clinical Scientist Development Award funded this study.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B></B></DIV>
<DIV><B><A href="http://gim.med.ucla.edu/index.php">The General Internal Medicine and Health Services Research Division</A></B> in the department of medicine at the David Geffen School of Medicine at UCLA provides a unique interactive environment for collaborative efforts between health services researchers and clinical experts with experience in evidence-based work. The division's 100-plus clinicians and researchers are engaged in a wide variety of projects that examine issues related to access to care, quality of care, health measurement, physician education, clinical ethics and doctor-patient communication. Researchers in the division have close working relationships with economists, statisticians, social scientists and other specialists throughout UCLA and frequently collaborate with their counterparts at the RAND Corp. and the Charles Drew University of Medicine and Science. </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=131420" height="1" width="1" />]]></description><pubDate>Thu, 19 Mar 2009 07:00:00 GMT</pubDate></item><item><author>Amy Albin</author><title>Actress Dakota Fanning to host annual 5K to benefit Mattel Children's Hospital</title><link>http://newsroom.ucla.edu/portal/ucla/actress-dakota-fanning-joins-ucla-85120.aspx?link_page_rss=85120</link><guid>http://newsroom.ucla.edu/portal/ucla/actress-dakota-fanning-joins-ucla-85120.aspx</guid><description><![CDATA[<DIV><B>WHAT:</B> </DIV>
<DIV>Actress Dakota Fanning, star of "Coraline" and "The Cat in the Hat,"&nbsp;will host the 10th Annual UCLA 5K Run/Walk to benefit the Child Life/Child Development program at UCLA's Mattel Children’s Hospital. In addition to the 5-kilometer&nbsp;run/walk through the UCLA campus,&nbsp;the student-organized event will feature live&nbsp;entertainment, a silent auction, exciting prizes and activities for kids, including a bounce-ball station and face painting.</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>WHEN:</B> </DIV>
<DIV>Sunday, April 5</DIV>
<UL>
<LI>6 a.m: registration begins 
<LI>7 a.m.: opening ceremonies 
<LI>7:30 a.m.: 5K run/walk begins 
<LI>10 a.m.: closing ceremonies</LI></UL>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>WHERE:</B> </DIV>
<DIV>Wilson Plaza, 308 Westwood Plaza, UCLA campus</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>PHOTO | INTERVIEW OPPORTUNITIES:</B></DIV>
<UL>
<LI>
<DIV>Actress Dakota Fanning </DIV></LI>
<LI>
<DIV>UCLA student organizers </DIV></LI>
<LI>
<DIV>UCLA Child Life/Child Development staff </DIV></LI>
<LI>
<DIV>Hundreds of participants, including students and medical staff </DIV></LI>
<LI>
<DIV>Radio statio JackFM (93.1 FM)</DIV></LI></UL>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>INFORMATION:</B> </DIV>
<DIV>For more information or to register&nbsp;to participate in&nbsp;the 5K event, please visit <A href="http://www.runwalk.ucla.edu/">www.runwalk.ucla.edu</A>. </DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>BACKGROUND:</B></DIV>
<DIV>Proceeds will directly benefit the internationally renowned Child Life/Child Development Program at Mattel Children's Hospital UCLA. Established in 1968, the program was one of the first of its kind in the country and continues to be a model for other medical centers. The Child Life program addresses the unique needs of pediatric patients — especially the critically and chronically ill — by offering play therapy, expert consultations and genuine support for the patients and their families.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>CONTACT: </B></DIV>
<DIV>Michelle Barton, Run/Walk at UCLA public relations, 818-292-6888 (cell)</DIV>
<DIV>&nbsp;</DIV>
<DIV>
<DIV><B>PARKING: </B></DIV>
<DIV>Media should call contact to arrange parking.&nbsp;</DIV></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=130678" height="1" width="1" />]]></description><pubDate>Wed, 18 Mar 2009 07:00:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Unique nerve-stimulation device proves effective against epilepsy</title><link>http://newsroom.ucla.edu/portal/ucla/unique-nerve-stimulation-device-85136.aspx?link_page_rss=85136</link><guid>http://newsroom.ucla.edu/portal/ucla/unique-nerve-stimulation-device-85136.aspx</guid><description><![CDATA[<DIV>Epilepsy is a common medical condition characterized by convulsions and short periods of confusion. It affects&nbsp;more than&nbsp;50 million people worldwide. But intractable epilepsy, which affects more than 1 million Americans and is often&nbsp;resistant to drug treatment and surgery, is arguably worse.</DIV>
<DIV>&nbsp;</DIV>
<DIV>But in a just completed clinical trial, a unique nerve-stimulation treatment for intractable epilepsy reduced the number of seizures by more than&nbsp;50 percent. In the March edition of the journal Neurology, UCLA neurology professor Christopher M. DeGiorgio and colleagues report the results of&nbsp;the long-term pilot trial, which&nbsp;demonstrated the effectiveness of&nbsp;the new treatment, called trigeminal nerve stimulation (TNS).</DIV>
<DIV>&nbsp;</DIV>
<DIV>The results, though preliminary, are very encouraging, DeGiorgio said. Those participating in the trial for three months saw a 66 percent reduction in the number of seizures, those participating for six months saw a 56 percent reduction and those who completed one year saw a 59 percent reduction in seizures. One of the subjects who participated for a full year had a 90-percent reduction in seizures.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The trigeminal nerve extends into the brain from the face and forehead and is known to play a role in seizure inhibition. The stimulator, about the size of a large cell phone, attaches to a belt or can slip into a pocket. Two wires from the stimulator are passed under the clothing and connected to electrodes attached to the forehead by adhesive. The electrodes, which can&nbsp;be covered by a cap or scarf, transmit an electrical current to the nerve.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"People with intractable epilepsy who have continuing seizures are often drug-resistant," DeGiorgio&nbsp;said. "In addition, anti-seizure drugs can have significant side effects on thinking and alertness." </DIV>
<DIV>&nbsp;</DIV>
<DIV>Epilepsy brain surgery can be very effective, he said, but some patients are not ideal candidates because there is no&nbsp;single focal point in the brain for their seizures.</DIV>
<DIV>&nbsp;</DIV>
<DIV>A larger clinical trial to further test for safety and effectiveness is now underway. The investigators hope that eventually a device can be permanently implanted above the eyebrow that would stimulate the trigeminal nerve and replace the external device. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"TNS is a promising alternative mode of neurostimulation because the trigeminal nerve can be stimulated in minimally invasive fashion," DeGiorgio&nbsp;said. "The major branches of the trigeminal nerve in the face are located close to the surface of the skull; that allows physicians to assess response prior to permanent implantation of a future device.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"For all of these reasons, we need to find non-drug and non-surgical alternatives,"&nbsp;he said. "The results of our study are very encouraging and support further investigation into the safety and efficacy of TNS.”</DIV>
<DIV>&nbsp;</DIV>
<DIV>DeGiorgio and his colleagues are currently recruiting 50 patients, age 18 and older, with intractable epilepsy for the next phase of the clinical trial, which will stimulate the ophthalmic branch of the trigeminal nerve and will compare the use of a higher level of stimulation to the trigeminal&nbsp;with a lower-level frequency. For more information on this trial, call Diana Murray at 818-364-3104.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Funding for the research was provided by Advanced Bionics and Boston Scientific and by grants from James Peters and&nbsp;the Salter, Brill, Jacoby, Lagermeier, Lester and Johnson families. The Epilepsy Research Foundation–Therapy Development Program and Boston Scientific fund the new study. DeGiorgio has received grant support from Advanced Bionics and Boston Scientific; co-author Todd Whitehurst is an employee of Boston Scientific.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://neurology.medsch.ucla.edu/">The UCLA Department of Neurology</A></STRONG> encompasses more than a dozen research, clinical and teaching programs.&nbsp;These programs&nbsp;cover brain mapping and neuroimaging, movement disorders, Alzheimer's disease, multiple sclerosis, neurogenetics, nerve and muscle disorders, epilepsy, neuro-oncology, neurotology, neuropsychology, headaches and migraines, neurorehabilitation, and neurovascular disorders. The department has ranked No. 1 among its peers nationwide in National Institutes of Health funding for the last seven years, 2002–08.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=130681" height="1" width="1" />]]></description><pubDate>Wed, 18 Mar 2009 07:00:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>UCLA medical students brace for news at residency 'Match Day'</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-match-day-85173.aspx?link_page_rss=85173</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-match-day-85173.aspx</guid><description><![CDATA[<DIV><B>WHAT:</B> </DIV>
<DIV>Match Day is the fun, frenzied day when medical students nationwide learn which hospital has&nbsp;accepted them for residency&nbsp;— advanced training in their chosen specialty. At UCLA, the ceremony climaxes in a mad scramble for the envelopes, with&nbsp;150 aspiring doctors tearing them open with their families and friends. Many videotape themselves and let distant loved ones listen in&nbsp;on cell phones during this emotional rollercoaster of an event.</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>WHEN:</B> </DIV>
<DIV>Thursday, March 19</DIV>
<UL>
<LI>8 a.m.: Students and families arrive for check-in and breakfast. 
<LI>8:45 a.m.: Welcome by Dr. Neil Parker, senior associate dean of student affairs at the David Geffen School of Medicine at UCLA. 
<LI>9 a.m.: Students at UCLA (and across the country) open their envelopes.</LI></UL>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>WHERE:</B> </DIV>
<DIV>Covel Commons, third-floor Grand Ballroom, 330 De Neve Dr., on the UCLA campus</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>STORY OPPORTUNITIES:</B></DIV>
<DIV>The following&nbsp;students and others are available for interviews:</DIV>
<BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px">
<DIV><STRONG>Carolina Maria Covarrubias</STRONG>,<STRONG> </STRONG>27 (Santa Ana, Calif.)</DIV>
<DIV>The second-eldest of eight daughters, Covarrubias considered a career in pediatrics. But her Spanish fluency helped her find her niche in medical school, as Hispanic patients confided how depression and anxiety were undermining their physical health. By pursuing a residency in psychiatry, Covarrubias aims to address mental health disparities in the Latino community.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Barkha Gurbani</B>, 26 (Orange, Calif.)</DIV>
<DIV>Prior to entering medical school,&nbsp;Gurbani worked as a Fulbright scholar with HIV/AIDS widows in her parents' native India. She has chosen to follow her father into orthopedic surgery&nbsp;— a rare field for female physicians. Engaged to be married next year, she is anxious to discover whether she and her fiancé have matched for the same teaching hospital.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>Esther Oh</STRONG>, 25 (Cerritos, Calif.)</DIV>
<DIV>Despite what she says is some Asians' lack of respect for the field of psychiatry — including her chagrined Korean parents —&nbsp;Oh is adamant about the need for child psychiatrists who can speak the same language as&nbsp;their patients. She looks forward to training in psychiatry in order to destigmatize mental disorders as treatable medical problems.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>Cherie Cross</STRONG>,<STRONG> </STRONG>24 (Culver City, Calif.)</DIV>
<DIV>Cross earned two national scholarships for her academic career, was chosen for the medical honor society Alpha Omega Alpha and is a regional leader of the oldest and largest U.S. organization for African American medical students. She is eager to learn where she will launch her obstetrics and gynecology&nbsp;residency&nbsp;— as is her boyfriend, Carl, who will move with her to a new city.</DIV></BLOCKQUOTE>
<DIV><B>MEDIA CONTACT: </B></DIV>
<DIV>Elaine Schmidt, UCLA Health Sciences Media Relations</DIV>
<DIV>310-794-2272 (office) |&nbsp;310-597-5767 (cell) | <A href="mailto:eschmidt@mednet.ucla.edu">eschmidt@mednet.ucla.edu</A></DIV>
<DIV>&nbsp;</DIV>
<DIV>
<DIV><STRONG>PARKING: </STRONG></DIV>
<DIV>
<DIV>Oversized media trucks may park south of&nbsp;Covel Commons, at the meters on Charles Young Dr. West. Please R.S.V.P. by 4 p.m. on Wednesday, March 18, to reserve complimentary parking permits for passenger vehicles.</DIV></DIV></DIV>
<DIV>&nbsp;</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=130724" height="1" width="1" />]]></description><pubDate>Wed, 18 Mar 2009 07:00:00 GMT</pubDate></item><item><author>Office of Media Relations</author><title>UCLA faculty experts advisory: Actress Natasha Richardson's brain injury</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-faculty-experts-advisory-85230.aspx?link_page_rss=85230</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-faculty-experts-advisory-85230.aspx</guid><description><![CDATA[<DIV>Actress Natasha Richardson has suffered a potentially fatal brain injury following a skiing accident. UCLA has experts on traumatic brain injury and brain death.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>Dr. Neil Martin</STRONG>, chief of the UCLA Department of Neurosurgery and co-director of the UCLA Stroke Center, is an expert on cerebral blood flow and brain metabolism following brain injury. He is recognized as one of the top specialists in the area of surgical treatment of cerebrovascular disease. </DIV>
<DIV>[<A href="http://www.uclahealth.org/body.cfm?xyzpdqabc=0&amp;id=479&amp;action=detail&amp;ref=10004">Full bio</A>] </DIV>
<DIV>Media contact: </DIV>
<DIV>Mark Wheeler | 310-794-2265 | <A href="mailto:mwheeler@mednet.ucla.edu">mwheeler@mednet.ucla.edu</A> </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>Dr. Paul Vespa</STRONG>,<STRONG> </STRONG>professor of neurosurgery and neurology and director of the UCLA Neurosurgical Intensive Care Unit, is an authority on the determination of brain death, the pathophysiology of acute brain injury and&nbsp;the design of&nbsp;critical-care treatments to preserve brain function post-trauma. </DIV>
<DIV>[<A href="http://www.uclahealth.org/body.cfm?xyzpdqabc=0&amp;id=479&amp;action=detail&amp;ref=14076">Full bio</A>] </DIV>
<DIV>Media contact: </DIV>
<DIV>Mark Wheeler | 310-794-2265 | <A href="mailto:mwheeler@mednet.ucla.edu">mwheeler@mednet.ucla.edu</A> </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>Dr. Christopher Giza</STRONG>, associate professor of neurosurgery and neurology and a member of the UCLA Brain Injury Research Center, is an expert in developmental brain injury and its pathophysiology. His ongoing studies examine impaired neurotransmission, altered developmental plasticity, acute alterations in metabolism, morphological injury, vulnerability to secondary insults and behavioral impairments. </DIV>
<DIV>[<A href="http://www.uclahealth.org/body.cfm?xyzpdqabc=0&amp;id=479&amp;action=detail&amp;ref=12931">Full bio</A>] </DIV>
<DIV>Media contact: </DIV>
<DIV>Mark Wheeler | 310-794-2265 | <A href="mailto:mwheeler@mednet.ucla.edu">mwheeler@mednet.ucla.edu</A> </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=130727" height="1" width="1" />]]></description><pubDate>Wed, 18 Mar 2009 07:00:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Study gives more proof that intelligence is largely inherited</title><link>http://newsroom.ucla.edu/portal/ucla/more-proof-that-intelligence-is-85134.aspx?link_page_rss=85134</link><guid>http://newsroom.ucla.edu/portal/ucla/more-proof-that-intelligence-is-85134.aspx</guid><description><![CDATA[<DIV>They say a picture tells a thousand stories, but can it also tell how smart you are? Actually, say UCLA researchers, it can. </DIV>
<DIV>&nbsp;</DIV>
<DIV>In a study published in the Journal of Neuroscience Feb. 18, UCLA neurology professor Paul Thompson and colleagues used a new type of brain-imaging scanner to show that intelligence is strongly influenced by the quality of the brain's axons, or wiring that sends signals throughout the brain. The faster the signaling, the faster the brain processes information. And since the integrity of the brain's wiring is influenced by genes, the genes we inherit play a far greater role in intelligence than was previously thought.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Genes appear to influence intelligence by determining how well nerve axons are encased in myelin — the fatty sheath of "insulation" that coats our axons and allows for fast signaling bursts in our brains. The thicker the myelin, the faster the nerve impulses.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Thompson and his colleagues scanned the brains of 23 sets of identical twins and 23 sets of fraternal twins. Since identical twins share the same genes while fraternal twins share about half their genes, the researchers were able to compare each group to show that myelin integrity was determined genetically in many parts of the brain that are key for intelligence. These include the parietal lobes, which are responsible for spatial reasoning, visual processing and logic, and the corpus callosum, which pulls together information from both sides of the body.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers used a faster version of a type of scanner called a HARDI (high-angular resolution diffusion imaging) — think of an MRI machine on steroids — that takes scans of the brain at a much higher resolution than a standard MRI. While an MRI scan shows the volume of different tissues in the brain by measuring the amount of water present, HARDI tracks how water diffuses through the brain's white matter —&nbsp;a way to measure the quality of its myelin.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"HARDI measures water diffusion," said Thompson, who is also a member of the UCLA Laboratory of Neuro-Imaging. "If the water diffuses rapidly in a specific direction, it tells us that the brain has very fast connections. If it diffuses more broadly, that's an indication of slower signaling, and lower intelligence."</DIV>
<DIV>&nbsp;</DIV>
<DIV>"So it gives us a picture of one's mental speed," he said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Because the myelination of brain circuits follows an inverted U-shaped trajectory, peaking in middle age and&nbsp;then slowly beginning to decline, Thompson believes identifying the genes that promote high-integrity myelin is critical&nbsp;to forestalling brain diseases like multiple sclerosis and autism, which have been linked to the breakdown of myelin.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The whole point of this research," Thompson said, "is to give us insight into brain diseases." </DIV>
<DIV>&nbsp;</DIV>
<DIV>He said his team has already narrowed down the number of gene candidates that may influence myelin growth.</DIV>
<DIV>&nbsp;</DIV>
<DIV>And could this someday lead to a therapy that could make us smarter, enhancing our intelligence? </DIV>
<DIV>&nbsp;</DIV>
<DIV>"It's a long way off but within the realm of the possible," Thompson said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Graphics from the study can be found at <A href="http://www.loni.ucla.edu/~thompson/HARDI/PDF/hardi3.jpg">www.loni.ucla.edu/~thompson/HARDI/PDF/hardi3.jpg</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://neurology.medsch.ucla.edu/">The UCLA Department of Neurology</A></STRONG> encompasses more than a dozen research, clinical and teaching programs. These programs cover brain mapping and neuroimaging, movement disorders, Alzheimer's disease, multiple sclerosis, neurogenetics, nerve and muscle disorders, epilepsy, neuro-oncology, neurotology, neuropsychology, headaches and migraines, neurorehabilitation, and neurovascular disorders. The department has ranked No. 1 among its peers nationwide in National Institutes of Health funding for the last seven years, 2002–08.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=130415" height="1" width="1" />]]></description><pubDate>Tue, 17 Mar 2009 07:00:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Teenage stress has implications for adult health</title><link>http://newsroom.ucla.edu/portal/ucla/teen-angst-has-implications-for-84277.aspx?link_page_rss=84277</link><guid>http://newsroom.ucla.edu/portal/ucla/teen-angst-has-implications-for-84277.aspx</guid><description><![CDATA[<DIV>Most of us remember our teenage years with a mix of fondness and relief. Fondness for the good memories, and relief that all that teenage stress, angst and drama&nbsp;— first love, gossip, SATs, fights with parents — is behind us.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Or is it? It turns out, say UCLA researchers, that even stressful times from the teenage years exact a physical toll that could have implications for health during adulthood.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Andrew J. Fuligni, a professor of psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA, and colleagues report that in a study of otherwise healthy, normal teens who self-reported various negative interpersonal interactions, researchers found that a greater frequency of such stress was associated with higher levels of an inflammatory marker called C-reactive protein, or CRP. CRP has been identified as an indicator for the later development of cardiovascular disease (CVD).</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study will appear in an upcoming issue of the journal Psychosomatic Medicine and is currently available&nbsp;online&nbsp;(subscription only). </DIV>
<DIV>&nbsp;</DIV>
<DIV>"Although most research on stress and inflammation has focused upon adulthood, these results show that such links can occur as early as the teenage years, even among a healthy sample of young men and women," Fuligni said. "That suggests that alterations in the biological substrates that initiate CVD begin before adulthood."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Those everyday kinds of stressors, such as a fight with a parent or peer, are among the most frequent and powerful predictors of psychological distress among individuals, he said. That led the researchers to wonder: If stress could have a powerful psychological influence, could it have a physiological influence as well? </DIV>
<DIV>&nbsp;</DIV>
<DIV>The study looked at a total of 69 adolescents, average age 17, from Latin American and European backgrounds, who completed a daily diary checklist each night for 14 days. In it, they reported any experiences of negative interpersonal interaction with family, peers or&nbsp;school personnel&nbsp;— for example, conflicts with family and friends, peer harassment or any kind of punishment by parents or teachers. Blood samples were obtained an average of eight months later and assayed for circulating levels of the CRP protein; the research protocol took into account such&nbsp;factors as socioeconomic status, major stressful life events&nbsp;and being overly sensitive to rejection or daily psychological distress.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers found that daily interpersonal stress experienced during the high school years was associated with elevated levels of inflammation, as measured by higher levels of CRP, even among normal, healthy teens. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"Our findings are consistent with the emerging body of evidence that points to the link between stress and increased inflammation, which places individuals at risk for the later development of cardiovascular disease," said Fuligni, who is also a member of the UCLA Cousins Center for Psychoneuroimmunology and the UCLA Center for Culture and Health.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The results are also interesting because they suggest that the association of interpersonal stress with inflammation exists regardless of individual teens'&nbsp;psychological appraisal of stressful experiences&nbsp;or any tendency to be particularly sensitive to social rejection, he said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Fuligni suggests the results of this research show the importance of focusing on actual daily stressful experiences when examining the implications of psychological and social factors for the development of risk for CVD during the teenage years. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"Although the frequency of some of these experiences may be low, they could have a significant impact upon long-term physical health during adulthood," Fulgini said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Other authors included Julienne Bower, Steve W. Cole, senior author Michael R. Irwin and&nbsp;Eva H. Telzer, all of UCLA, and Lisa Kiang, of&nbsp;Wake Forest University. The authors report no conflicts of interest. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Support for this project was provided by the Russell Sage Foundation and the UCLA Cousins Center, and by the UCLA Older Americans Independence Center Inflammatory Biology Core.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.cousinspni.org/">The Cousins Center for Psychoneuroimmunology at UCLA</A></STRONG>&nbsp;encompasses an interdisciplinary network of scientists working to advance the understanding of psychoneuroimmunology by linking basic and clinical research programs and by translating findings into clinical practice. The center is affiliated with the Semel Institute for Neuroscience and Human Behavior and the David Geffen School of Medicine at UCLA. The Semel Institute is an interdisciplinary research and education institute devoted to the understanding of complex human behavior, including the genetic, biological, behavioral and sociocultural underpinnings of normal behavior, and the causes and consequences of neuropsychiatric disorders.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=128819" height="1" width="1" />]]></description><pubDate>Tue, 10 Mar 2009 07:00:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>Father and son authors discuss personal journeys through addiction and back</title><link>http://newsroom.ucla.edu/portal/ucla/father-and-son-authors-will-describe-84341.aspx?link_page_rss=84341</link><guid>http://newsroom.ucla.edu/portal/ucla/father-and-son-authors-will-describe-84341.aspx</guid><description><![CDATA[<DIV><B>WHAT:</B></DIV>
<DIV>Father and son authors David and Nic Sheff will talk about their respective memoirs. David's "Beautiful Boy," a powerful book about his son's descent into drug addiction, and Nic's "Tweak," a compelling chronicle of growing up on methamphetamines and struggles with recovery, offer hope to families fighting the same battles. The Friends of the Semel Institute for Neuroscience and Human Behavior at UCLA is sponsoring the event. Refreshments will be served.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>WHO:</STRONG></DIV>
<DIV>Event speakers: </DIV>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>Nic Sheff is a recovering drug addict and alcoholic in his mid-20s. "Tweak," a New York Times bestseller, is&nbsp;his first book. His writing has been published in Newsweek, Nerve and the San Francisco Chronicle.</LI></UL>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>David Sheff is a renowned journalist and magazine editor.&nbsp;"Beautiful Boy,"&nbsp;a New York Times bestseller, grew out of his 2005 New York Times Magazine piece "My Addicted Son," which received the American Psychological Association's award for outstanding contribution to advancing the understanding of addicition.&nbsp;</LI></UL>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>The authors will be joined by three Semel Institute faculty members who are leading experts in the field of drug addiction and recovery: brain researcher Edythe London, psychologist Steven Shoptaw and substance-abuse programs director Richard Rawson.</LI></UL>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>WHEN:</B></DIV>
<DIV>6–9 p.m., Wednesday, March 18</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>WHERE:</B></DIV>
<DIV>De Neve Auditorium, 351 Charles E. Young Drive West, on the UCLA campus</DIV>
<DIV><B></B></DIV>
<DIV>&nbsp;</DIV>
<DIV><B>COST:</B></DIV>
<DIV>Admission is free. Parking is available for $9 in Lot 7.</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>R.S.V.P.:</B></DIV>
<DIV>Please R.S.V.P. to Vicky Goodman at 310-825-8871 or <A href="mailto:vickyg@friendsofnpi.org">vickyg@friendsofnpi.org</A>.</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>MEDIA CONTACT:</B></DIV>
<DIV>Elaine Schmidt, UCLA Health Sciences Media Relations, 310-794-2272, <A href="mailto:eschmidt@mednet.ucla.edu">eschmidt@mednet.ucla.edu</A></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=127437" height="1" width="1" />]]></description><pubDate>Thu, 05 Mar 2009 08:00:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Most states' laws consistent with CDC's opt-out HIV testing guidelines</title><link>http://newsroom.ucla.edu/portal/ucla/most-states-laws-are-consistent-83883.aspx?link_page_rss=83883</link><guid>http://newsroom.ucla.edu/portal/ucla/most-states-laws-are-consistent-83883.aspx</guid><description><![CDATA[<DIV>In 2006, the Centers for Disease Control and Prevention released new guidelines recommending that every patient between the ages of 13 and 64 be offered an HIV test on an opt-out basis in all health care settings, without the requirements of written consent or prevention counseling. <BR><BR>The CDC's recommendations sparked significant debate about whether existing state laws would conflict with the guidelines and impede their widespread implementation and raised questions about threats to patient autonomy.</DIV>
<DIV> </DIV>
<DIV>But a new UCLA study published in the Feb. 17 issue of the <A href="http://www.annals.org/cgi/content/full/150/4/263">Annals of Internal Medicine</A> has found that the majority of states have laws that do not interfere with implementation of the guidelines, and that contrary to what some have argued, the guidelines include protections for the patient. </DIV>
<DIV> </DIV>
<DIV>According to the CDC recommendations, health care providers offering HIV tests are required to provide patients information about the test, ask if patients have any questions and inform them that they have the right to decline — or opt out of — the test.</DIV>
<DIV> </DIV>
<DIV>"Patient advocates have voiced opposition to opt-out screening for HIV because of legitimate concerns that it would not ensure that patients feel they actually have the choice to accept or decline testing," said Dr. Anish P. Mahajan, lead author of the study and a Robert Wood Johnson Foundation Clinical Scholar in the division of general internal medicine and health services research at the David Geffen School of Medicine at UCLA.</DIV>
<DIV> </DIV>
<DIV>"We found that the CDC guidelines' definition of 'opt-out' <EM>does</EM> require specific protection of patient autonomy, which in many cases is not required by state laws," he said. "Beyond simply complying with state laws, providers, consumer groups and other stakeholders should ensure that these protections are adhered to."</DIV>
<DIV> </DIV>
<DIV>Timely HIV testing continues to be a major public health challenge in the United States. Of the 1 million people infected with HIV nationwide, 300,000 are unaware of their status and unknowingly infect others, accounting for the majority of new HIV infections, according to the CDC. For this reason, the CDC issued the new guidelines for opt-out HIV screenings. Despite the revised guidelines, however, low HIV screening rates persist.</DIV>
<DIV> </DIV>
<DIV>State law on HIV testing also has been widely assumed to be a barrier to implementing the recommendations. The researchers performed a state-by-state review of all statutes pertaining to HIV testing and systematically assessed the consistency of these laws with the new recommendations.</DIV>
<DIV> </DIV>
<DIV>Major findings of their analysis include: </DIV>
<DIV style="FONT-SIZE: 3px"> </DIV>
<UL>
<LI>
<DIV>34 states and the District of Columbia have laws that are consistent with or neutral toward the recommendations. </DIV>
<LI>
<DIV>In the two years since the release of the recommendations, nine states have passed new laws to move from inconsistent to consistent with the guidelines.</DIV>
<LI>
<DIV>16 states still have laws that are barriers to the CDC recommendations.</DIV></LI></UL>
<DIV> </DIV>
<DIV>"Opt-out screening could still result in unintended consequences, such as patients avoiding the doctor because they do not want to be asked about HIV testing," said Mahajan, who is currently looking at how opt-out HIV screening compares with the more traditional opt-in HIV screening in a collaborative project among UCLA, Los Angeles County and safety-net clinics in South Los Angeles. Results of this research are expected later this year.</DIV>
<DIV> </DIV>
<DIV>Study co-authors are Martin F. Shapiro and William E. Cunningham of the David Geffen School of Medicine at UCLA, Lara Stemple of the UCLA School of Law, and Jan. B. King of the Los Angeles County Department of Public Health. Cunningham is also associated with the UCLA School of Public Health.</DIV>
<DIV> </DIV>
<DIV>The Robert Wood Johnson Clinical Scholars Program and grants from the National Institutes of Health to the Charles Drew/UCLA Project EXPORT and to the UCLA/Drew Resource Centers for Minority Aging Research/Center for Health Improvement of Minority Elderly funded this study.</DIV>
<DIV><STRONG></STRONG> </DIV>
<DIV><STRONG><A href="http://rwjcsp.unc.edu/">The Robert Wood Johnson Clinical Scholars Program</A> </STRONG>has for more than three decades fostered the development of physicians who are leading the transformation of health care in the United States through positions in academic medicine, public health and other leadership roles. Through the program, future leaders learn to conduct innovative research and work with communities, organizations, practitioners and policymakers on issues important to the health and well-being of all Americans. </DIV>
<DIV> </DIV>
<DIV><B><A href="http://gim.med.ucla.edu/index.php">The Division of General Internal Medicine and Health Services Research</A></B> within the department of medicine at the David Geffen School of Medicine at UCLA provides a unique interactive environment for collaborative efforts between health services researchers and clinical experts with experience in evidence-based work. The division's 100-plus clinicians and researchers are engaged in a wide variety of projects that examine issues related to access to care, quality of care, health measurement, physician education, clinical ethics and doctor-patient communication. Researchers in the division have close working relationships with economists, statisticians, social scientists and other specialists throughout UCLA and frequently collaborate with their counterparts at the RAND Corp. and the Charles Drew University of Medicine and Science. </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=127494" height="1" width="1" />]]></description><pubDate>Thu, 05 Mar 2009 08:00:00 GMT</pubDate></item><item><author>Kim Irwin</author><title>UCLA launches new Institute of Urologic Oncology</title><link>http://newsroom.ucla.edu/portal/ucla/urologic-oncology-institute-launched-83634.aspx?link_page_rss=83634</link><guid>http://newsroom.ucla.edu/portal/ucla/urologic-oncology-institute-launched-83634.aspx</guid><description><![CDATA[<DIV>UCLA has launched a first-of-its-kind, patient-centered institute dedicated to developing leading-edge therapies for the treatment of kidney, bladder, testicular and prostate cancers.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Institute of Urologic Oncology at UCLA challenges the traditional model of academic departments operating independently of each other, bringing a multidisciplinary team of scientists and physicians together as part of one cohesive organization. Their goal is to expedite the development of new therapies for patients with genitourinary cancers.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The disciplines represented at the institute include urologic oncology, medical oncology, diagnostic and interventional radiology, pathology, nursing, basic sciences and clinical trials. The new institute will allow experts from these areas to collaborate more efficiently and effectively, bringing to patients the most promising advances in medical and surgical treatments, including targeted therapies, chemotherapy, immunotherapy, radiation therapy, and minimally invasive and ablative surgery.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This is a one-stop shop for patients. All the experts will be involved in their care, all working together," said the institute's new director, Dr. Arie Belldegrun, a professor of urology and a researcher at UCLA's Jonsson Comprehensive Cancer Center. "Our goal is to bring all our resources to the patient, rather than the patient going from office to office to see everyone they need to see."</DIV>
<DIV>&nbsp;</DIV>
<DIV>This multidisciplinary, translational approach to care and targeted therapies was pioneered at UCLA. The molecularly targeted drugs Herceptin, for breast cancer, and Gleevec, for chronic myeloid leukemia, among others, were developed based on research conducted in Jonsson Cancer Center laboratories. Such leading-edge work will be done within the institute to develop new, more effective and less toxic therapies for urologic cancers.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Dr. Dennis Slamon, director of clinical and translational research at the Jonsson Cancer Center, called the institute's research and clinical model "outstanding."</DIV>
<DIV>&nbsp;</DIV>
<DIV>"It's an excellent idea to bring people together from different disciplines that overlap around a disease," said Slamon, whose laboratory and clinical research led to the development of Herceptin. "It creates a synergy that allows us to do things more quickly and efficiently."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Dr. Jean DeKernion, chairman of the UCLA Department of Urology, agrees.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"With this approach, we'll be able to get leading-edge therapies to the patient faster, taking them out of the lab and into practice in much less time," he said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Patients also will benefit from the institute's top diagnostic tools, expertise in robotic and minimally invasive surgery, and the combined experience of the experts, who often treat the most complicated urologic cancer cases. In addition, a joint, multidisciplinary board representing all genitourinary specialties will meet at the institute to discuss complicated and challenging tumor cases referred to UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This unique institute, blending both academic and clinical pursuits, will offer the patient the latest treatments as well as allow researchers and clinicians the opportunity to collaborate in moving cancer therapies forward," said Dr. Gerald Levey, vice chancellor of UCLA Medical Sciences and dean of the David Geffen School of Medicine at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>An <A href="http://www.newsroom.ucla.edu/portal/ucla/symposium-celebrates-new-institute-82409.aspx">educational symposium</A> will be held at UCLA on March 3 to celebrate the launch of the institute. The symposium will feature top oncologists and researchers discussing translational research, advances in personalized medicine for prostate cancer, targeted treatments for kidney cancer and the latest in therapies for bladder cancer. Slamon will discuss the lessons learned from the development of Herceptin and how they may apply to prostate cancers. Keynote speakers include Michael Milken, chairman of the Milken Institute, and Dr. Andrew C. von Eschenbach, former director of the National Cancer Institute and a former commissioner for the U.S. Food and Drug Administration.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The institute will be housed in temporary space until a permanent, state-of-the-art facility can be built.</DIV>
<DIV>&nbsp;</DIV>
<DIV>About 390,000 Americans were diagnosed with kidney, bladder, testicular and prostate cancer last year, resulting in approximately 56,000 deaths. The institute's goal is to dramatically lower the death rates for urologic cancers.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Our mission is to offer patients outstanding, individualized surgical and medical care and access to leading-edge experimental therapies with the overall goal to cure urologic cancers," Belldegrun said.</DIV>
<DIV>&nbsp;</DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>. <img src="http://newsroom.ucla.edu/rss.ashx?id=126105" height="1" width="1" />]]></description><pubDate>Tue, 03 Mar 2009 14:00:00 GMT</pubDate></item><item><author>Rachel Champeau</author><title>Broccoli may help protect against respiratory conditions like asthma</title><link>http://newsroom.ucla.edu/portal/ucla/broccoli-may-help-protect-against-81667.aspx?link_page_rss=81667</link><guid>http://newsroom.ucla.edu/portal/ucla/broccoli-may-help-protect-against-81667.aspx</guid><description><![CDATA[<DIV>Here's another reason to eat your broccoli: UCLA researchers report that a naturally occurring compound found in broccoli and other cruciferous vegetables may help protect against respiratory inflammation that causes conditions like asthma, allergic rhinitis and chronic obstructive pulmonary disease.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Published in the March edition of the journal Clinical Immunology, the research shows that sulforaphane, a chemical in broccoli, triggers an increase of antioxidant enzymes in the human airway that offers protection against the onslaught of free radicals that we breathe in every day in polluted air, pollen, diesel exhaust and tobacco smoke. A supercharged form of oxygen, free radicals can cause oxidative tissue damage, which leads to inflammation and respiratory conditions like asthma.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This is one of the first studies showing that broccoli sprouts&nbsp;— a readily available food source&nbsp;— offered potent biologic effects in stimulating an antioxidant response in humans," said Dr. Marc Riedl, the study's principal investigator and an assistant professor of clinical immunology and allergy at the David Geffen School of Medicine at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We found a two- to three-fold increase in antioxidant enzymes in the nasal airway cells of study participants who had eaten a preparation of broccoli sprouts," Riedl said. "This strategy may offer protection against inflammatory processes and could lead to potential treatments for a variety of respiratory conditions."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The UCLA team worked with 65 volunteers who were given varying oral doses of either broccoli or alfalfa sprout preparations for three days. Broccoli sprouts are the richest natural source of sulforaphane; the alfalfa sprouts, which do not contain the compound, served as a placebo.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Rinses of nasal passages were collected at the beginning and end of the study to assess the gene expression of antioxidant enzymes in cells of the upper airways. Researchers found significant increases of antioxidant enzymes at broccoli sprout doses of 100 grams and higher, compared with the placebo group.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The maximum broccoli sprout dosage of 200 grams generated a 101-percent increase of an antioxidant enzyme called GSTP1 and a 199-percent increase of another key enzyme called NQO1.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"A major advantage of sulforaphane is that it appears to increase a broad array of antioxidant enzymes, which may help the compound's effectiveness in blocking the harmful effects of air pollution," Riedl said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>According to the authors, no serious side effects occurred in study participants receiving broccoli sprouts, demonstrating that this may be an effective, safe antioxidant strategy to help reduce the inflammatory impact of free radicals.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Riedl notes that more research needs to be done to examine the benefits of sulforaphane for specific respiratory conditions. It is too early to recommend a particular dosage.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Riedl recommends including broccoli and other cruciferous vegetables as part of a healthy diet.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study was supported by the National Institutes of Health, the National Institute of Environmental Health Sciences and the U.S. Environmental Protection Agency.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Other study authors include Dr. Andrew Saxon of the Hart and Louis Lyon Laboratory, division of clinical immunology and allergy in the department of medicine at the David Geffen School of Medicine at UCLA, and Dr. David Diaz-Sanchez of the human studies division of the U.S. Environmental Protection Agency.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=125652" height="1" width="1" />]]></description><pubDate>Mon, 02 Mar 2009 08:00:00 GMT</pubDate></item><item><author>Rachel Champeau</author><title>Symposium celebrates new Institute of Urologic Oncology at UCLA</title><link>http://newsroom.ucla.edu/portal/ucla/symposium-celebrates-new-institute-82409.aspx?link_page_rss=82409</link><guid>http://newsroom.ucla.edu/portal/ucla/symposium-celebrates-new-institute-82409.aspx</guid><description><![CDATA[<B>
<DIV>WHAT:</DIV>
<DIV></B></DIV>This educational symposium celebrates the March 3 launch of the Institute of Urologic Oncology at UCLA — a new academic and clinical institute designed to bring together scientists and physicians dedicated to developing cutting-edge cancer therapies. The multidisciplinary team will help move treatments from the lab to the bedside quicker, offering patients the latest in personalized treatments for prostate, bladder, kidney and testicular cancers. <BR><BR>Advances in imaging, minimally invasive surgery and molecularly targeted drug therapies have led to more individualized treatments based on a patient's unique tumor biology, biochemistry and molecular signature. This one-day conference on personalized cancer therapies will feature speakers from leading cancer institutions across the country who will discuss the latest discoveries and trends in tailored cancer treatments. 
<DIV> </DIV>
<DIV><STRONG>WHO:</STRONG></DIV>
<DIV><STRONG></STRONG>Symposium participants will include:</DIV>
<BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px">
<DIV><STRONG>Dr. Arie Belldegrun</STRONG></DIV>
<DIV>Belldegrun, director of the Institute of Urologic Oncology at UCLA, will deliver the welcome address. (9 a.m.)</DIV>
<DIV> </DIV>
<DIV><B>Dr. Jean B. DeKernion</B></DIV>
<DIV>Professor and chair of the UCLA Department of Urology</DIV>
<DIV> </DIV>
<DIV><B>Judith C. Gasson</B></DIV>
<DIV>Director of UCLA's Jonsson Comprehensive Cancer Center</DIV>
<DIV> </DIV>
<DIV><B>Dr.</B> <STRONG>Gerald S. Levey</STRONG></DIV>
<DIV>Vice chancellor for medical sciences and dean of the David Geffen School of Medicine at UCLA </DIV>
<DIV> </DIV>
<DIV><STRONG>Michael Milken</STRONG></DIV>
<DIV>Milken, chairman of the Milken Institute, will survey the current state of medical research within the broader social and political environment in his keynote address. (10 a.m.) </DIV>
<DIV> </DIV>
<DIV><STRONG>Dr. Andrew C. von Eschenbach</STRONG></DIV>
<DIV>Former Food and Drug Administration commissioner and former director of the National Cancer Institute, will present his keynote address, "Government Programs for Cancer Prevention and Cure: Present and Future Progress." (10:30 a.m.)</DIV>
<DIV> </DIV>
<DIV><B>Dr. Dennis J. Slamon</B></DIV>
<DIV>Slamon, professor and chief of the UCLA Division of Hematology and Oncology, whose laboratory and clinical research led to the development of the molecularly targeted breast cancer drug Herceptin, will discuss his work and the challenges of pursuing targeted therapies. (12:45 p.m.)</DIV>
<DIV> </DIV>
<DIV><STRONG>Dr. Philip Kantoff </STRONG></DIV>
<DIV>Kantoff, director of the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and chief of the division of solid tumor oncology and professor of medicine at Harvard University School of Medicine, will discuss advances in personalized prostate cancer therapies.<STRONG> </STRONG>(1:15 p.m.)</DIV>
<DIV> </DIV>
<DIV><STRONG>Dr. W. Marston Linehan </STRONG></DIV>
<DIV>Linehan, branch chief of urologic oncology at the National Institutes of Health's National Cancer Center, will present the latest targeted treatments in kidney cancer.<STRONG> </STRONG>(1:45 p.m.) </DIV>
<DIV> </DIV>
<DIV><STRONG>Dr. Colin P. Dinney</STRONG></DIV>
<DIV>Dinney, professor and chair of the department of urology at the University Texas M.D. Anderson Cancer Center, will cover the newest bladder cancer therapies. (2:15 p.m.)</DIV></BLOCKQUOTE><B>
<DIV>WHEN:</B></DIV>
<DIV>9 a.m. to 3 p.m., Tuesday, March 3</DIV>
<DIV> </DIV>
<DIV><B>WHERE: </B></DIV>
<DIV>Dr. S. Jerome and Judith D. Tamkin Auditorium at Ronald Reagan UCLA Medical Center (B-Level),</DIV>
<DIV>757 Westwood Plaza (UCLA campus)</DIV>
<DIV> </DIV>
<DIV><B>MEDIA CONTACTS:</B></DIV>Rachel Champeau, UCLA Health Sciences Media Relations, 310-794-0777 
<DIV>Kim Irwin, UCLA's Jonsson Cancer Center, 310-206-2805</DIV>
<DIV> </DIV>
<DIV><STRONG>PARKING:</STRONG></DIV>
<DIV>Press should call media contacts to reserve parking. Parking will be available in Lot 8 after picking up a pass from the parking kiosk on Westwood Boulevard.<B></DIV></B><B></B></B></B> <img src="http://newsroom.ucla.edu/rss.ashx?id=125631" height="1" width="1" />]]></description><pubDate>Mon, 02 Mar 2009 08:00:00 GMT</pubDate></item><item><author>Gwendolyn Driscoll</author><title>California's single seniors can't make ends meet</title><link>http://newsroom.ucla.edu/portal/ucla/california-s-single-seniors-can-81264.aspx?link_page_rss=81264</link><guid>http://newsroom.ucla.edu/portal/ucla/california-s-single-seniors-can-81264.aspx</guid><description><![CDATA[<DIV>Nearly half a million elders living alone in California cannot make ends meet, lacking sufficient income to pay for a minimum level of housing, food, health care, transportation and other basic expenses, according to a new policy brief by the UCLA Center for Health Policy Research and the Insight Center for Community Economic Development.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The brief, "<A href="http://www.healthpolicy.ucla.edu/">Half-Million Older Californians Living Alone Unable to Make Ends Meet</A>," will be released today at a state legislative hearing on the growing economic plight of California's seniors jointly held by Assemblyman Jim Beall Jr. (D-San Jose), chairman of the Human Services Committee, and Assemblywoman Bonnie Lowenthal (D-Long Beach), chairwoman of the Aging and Long-Term Care Committee. The hearing will take place from 10 a.m. to noon at the State Capitol, Room 437. A press conference will precede the hearing, at 9:30 a.m. in the Governor's Press Room (1190)&nbsp;at the Capitol.</DIV>
<DIV>&nbsp;</DIV>
<DIV>More than 1 million seniors, both living alone and with family members, can't make ends meet, according to recent research. The center's policy brief looks at the most vulnerable group&nbsp;— seniors living alone&nbsp;— while the hearing features county-by-county data on all seniors.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The policy brief research is based on 2007 data, the last time comprehensive, statewide data was collected. But the numbers of affected seniors are likely to be even higher today as the current recession deepens, according to the brief's authors.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"As the economy wipes out retirement savings and destroys home equity, our parents and grandparents will find paying for a roof over their heads and affording basic necessities even more of a struggle," said Steven P. Wallace, Ph.D., associate director of the Center for Health Policy Research and lead author of the policy brief.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The brief includes county estimates of the percentage of economically vulnerable seniors. Those estimates show that elder economic insecurity is a problem in both more and less affluent counties: The two counties with the highest elder economic insecurity are Imperial and San Francisco.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The findings in the policy brief are based on the Elder Economic Security Standard Index (Elder Index) for California, a tool that measures the actual cost of basic necessities for older adults in each of California's 58 counties. The Elder Index is viewed by many as a more accurate measure of economic security than federal poverty level (FPL) guidelines, a standardized national estimate that does not take into account the cost of living in high-cost states such as California.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Policymakers, advocates, service providers and foundations are using the Elder Index to improve programs and policies for older adults across California.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This data provides an empirical way to demonstrate what those in the community witness daily: Increasingly, our elders cannot get by," said Susan E. Smith, director of Californians for Economic Security at the Insight Center and one of the co-authors of the policy brief. "We are using the information on the ground to promote the Elder Economic Dignity Act of 2009 this legislative season in Sacramento."<BR><BR>Among the findings:<BR></DIV>
<BLOCKQUOTE dir=ltr style="MARGIN-RIGHT: 0px">
<DIV><B>Most older renters can't make ends meet</B><BR>Older renters were more than twice as likely to be economically insecure as those who owned their homes and had paid off their mortgages (70.4 percent of older single renters were insecure, compared with 34.4 percent of homeowners without mortgages).</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Latino elders at risk</B> <BR>About three-fourths of Latino elders who lived alone, and almost half of those who lived with only a spouse, could not cover their basic costs of living.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>Women at risk<BR></B>Older women accounted for 72 percent of all older Californians who lived alone. Those women were more likely than older men to be unable to cover their basic needs (53.5 percent of women, compared with 44 percent of men).</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>The very old at risk<BR></B>A majority of all single elders aged 75 or older were economically insecure, regardless of ethnicity. More than 90 percent of female single renters aged 75 and older who were Latino or Asian had incomes below the Elder Index, as did two-thirds of all white single renters and 85 percent of all African American single renters aged 75 and older.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>FPL indicates only half of what is needed<BR></B>In 2007, the nationwide federal poverty level (FPL), used to determine eligibility for public assistance, was $10,210 for a single adult living alone. According to Elder Index calculations, however, the average minimum income needed by a single older Californian who rented was $21,011.</DIV></BLOCKQUOTE>
<DIV>Seniors could benefit most immediately from more affordable housing, the single biggest expense and one that often forces the elderly to make "untenable choices," according to Wallace.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"If there is little or no money left over once rent is paid, what do you chose in terms of other basic necessities? Do you fill a prescription or buy healthy food?" Wallace said. "Hundreds of thousands of seniors have to make these hard choices every day."<BR><BR></DIV>
<DIV>Wallace also urged that older Californians who live alone and are on Supplemental Security Income should receive full food stamps benefits, which would help reduce their food costs. Policymakers should also raise the eligibility levels for programs that pay elders' Medicare premiums, which would reduce the costs of health care, Wallace said.</DIV><BR>
<DIV><B><A href="http://www.insightcced.org/">The Insight Center for Community Economic Development</A></B> is a 40-year-old national research, legal and consulting organization dedicated to building economic health in vulnerable communities. <BR><BR><A href="http://www.healthpolicy.ucla.edu/"><STRONG>The UCLA Center for Health Policy Research</STRONG></A> is one of the nation's leading health policy research centers and the premier source of health-related information on Californians.<BR></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=122836" height="1" width="1" />]]></description><pubDate>Tue, 24 Feb 2009 17:00:00 GMT</pubDate></item><item><author>Roxanne Moster</author><title>Geffen School of Medicine gets $1M to endow chair in clinical pharmacology</title><link>http://newsroom.ucla.edu/portal/ucla/the-rosalinde-and-arthur-gilbert-81697.aspx?link_page_rss=81697</link><guid>http://newsroom.ucla.edu/portal/ucla/the-rosalinde-and-arthur-gilbert-81697.aspx</guid><description><![CDATA[<DIV><EM>(Editors: To view a video of Dr. Barbara Levey discussing the new chair in clinical pharmacology, visit <A href="http://streaming.uclahealth.org/blevey">http://streaming.uclahealth.org/blevey</A>.)</EM></DIV>
<DIV>&nbsp;</DIV>
<DIV>The Rosalinde and Arthur Gilbert Foundation has pledged $1 million to The UCLA Foundation to fund an endowed chair in clinical pharmacology at the David Geffen School of Medicine at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Clinical pharmacology bridges the gap between laboratory science and the practice of medicine. Its primary aims are to promote safe and effective pharmaceutical drug use in patients and to optimize the medical benefits and minimize the potential risks of prescription drugs in treating diseases that affect mankind. The clinical pharmacology program at UCLA&nbsp;studies issues related to drug interactions, the individual's response to drugs and how different ethnicities metabolize drugs.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Rosalinde and Arthur Gilbert Foundation Endowed Chair in Interdepartmental Clinical Pharmacology will be an administrative chair held by the director of UCLA's Interdepartmental Clinical Pharmacology Training Program, currently Dr. Barbara A. Levey. The chair's focus will be to catalyze the crucial work of UCLA's current program by augmenting research in this emerging discipline while reinforcing the importance of clinical pharmacology education at the Geffen School of Medicine, which is internationally recognized for excellence in the field.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The vision to establish this chair in a critical area of medicine by the Rosalinde and Arthur Gilbert Foundation will benefit the health of future patients worldwide," said Levey, who is also assistant vice chancellor for biomedical affairs at UCLA. "Our program is particularly well positioned to become the country's leading advanced, patient-oriented research training program that has an emphasis on appropriate medication dosages, with a particular focus on medication issues as they affect minority populations. We are grateful for this very generous gift."<BR><BR>Levey was the original organizer of the Interdepartmental Clinical Pharmacology Training Program, whose mission is to improve therapeutics and research through the rigorous training of medical students and fellows.&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>Levey is a past president of the American Society for Clinical Pharmacology and Therapeutics, a member of the American Board of Clinical Pharmacology, and a professor in the departments of medicine and molecular and medical pharmacology at the Geffen School of Medicine. She contributed a chapter to the textbook "Pharmacology and Therapeutics: Principles to Practice" (2009).</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Rosalinde and Arthur Gilbert Foundation was created to promote education, tolerance, social services and the arts. The Gilberts were passionate philanthropists, inveterate art collectors and astute businesspeople. Born and raised in England, the Gilberts immigrated to Los Angeles in 1949 and became successful real estate entrepreneurs. They committed their efforts to significant charitable endeavors locally and in the state of Israel while assembling one of the world's preeminent decorative arts collections. After Rosalinde's death in 1996 and Sir Arthur's in 2001, the remainder of their estate was donated to the foundation in order to continue the humanitarian and philanthropic efforts to which the Gilberts had been so devoted during their lifetimes.&nbsp;The foundation's directors, Richard Ziman and Martin H. Blank Jr., are longtime UCLA supporters and have continued the foundation's enduring commitment to the university.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We are pleased to provide UCLA and Dr. Barbara Levey with this opportunity to advance the field of clinical pharmacology and to train future experts in this area of medicine," Blank said. "With the discovery of so many new pharmaceutical drugs, it is vital for doctors to understand drug interactions to best care for their patients."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Endowed chairs and professorships continue to play an increasingly crucial role in the recruitment and retention of outstanding university faculty. Reserved for the most distinguished scholars and teachers, including the best junior faculty, endowed chairs provide vital funds for the support of the chair holder's research, teaching and service activities. Donors continue to provide thoughtful and generous support for endowed chairs with the knowledge that their gifts supply a solid foundation for the enrichment of university programs and the recognition of academic excellence.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more information about UCLA's Interdepartmental Clinical Pharmacology Training Program, visit <A href="http://149.142.238.229/k12/">http://149.142.238.229/k12/</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=123028" height="1" width="1" />]]></description><pubDate>Tue, 24 Feb 2009 08:00:00 GMT</pubDate></item><item><author>Amy Albin</author><title>Coffee may protect against stroke</title><link>http://newsroom.ucla.edu/portal/ucla/coffee-may-protect-against-stroke-81879.aspx?link_page_rss=81879</link><guid>http://newsroom.ucla.edu/portal/ucla/coffee-may-protect-against-stroke-81879.aspx</guid><description><![CDATA[<DIV><STRONG>UCLA RESEARCH ALERT</STRONG></DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>FINDINGS:</STRONG></DIV>
<DIV>Coffee use in the adult population is associated with a reduced prevalence of stroke, according to a UCLA analysis of national health survey data. The study found that the prevalence of stroke and several vascular risk factors decrease as the number of daily cups of coffee increases&nbsp;— despite the tendency among heavy coffee drinkers to smoke.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>IMPACT:</STRONG></DIV>
<DIV>Symptoms of transient ischemic attack or stroke&nbsp;are "far less common" in people reporting intake of more than six cups of coffee per day, said researchers, who advocate further studies to pursue the beneficial effects of coffee on stroke, including its potential blood-vessel protective properties.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>AUTHORS:</STRONG></DIV>
<DIV>Lead study author Dr. David Liebeskind, associate neurology director at the UCLA Stroke Center, is available for interviews. </DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>PRESENTATION:</STRONG></DIV>
<DIV>The research was presented Feb. 19 at the American Stroke Association's International Stroke Conference 2009.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>FUNDING:</STRONG></DIV>
<DIV>This study was supported by grants from the National Institutes of Health and the National Institute of Neurological Disorders and Stroke.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=120360" height="1" width="1" />]]></description><pubDate>Thu, 19 Feb 2009 20:45:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Green, black tea can reduce stroke risk</title><link>http://newsroom.ucla.edu/portal/ucla/green-and-black-tea-can-reduce-81962.aspx?link_page_rss=81962</link><guid>http://newsroom.ucla.edu/portal/ucla/green-and-black-tea-can-reduce-81962.aspx</guid><description><![CDATA[<DIV>Drinking at least three cups of green or black tea a day can significantly reduce the risk of stroke, a new UCLA study has found. And the more you drink, the better your odds of staving off a stroke.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study results, published in the online edition of Stroke: Journal of the American Heart Association, were presented Feb. 19 at the American Heart Association's annual International Stroke Conference in San Diego, Calif.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The UCLA researchers conducted an evidence-based review of all human observational studies on stroke and tea consumption&nbsp;found in the PubMed and Web of Science archives. They found nine studies describing 4,378 strokes among nearly 195,000 individuals, according to lead author Lenore Arab, a professor of medicine in the division of general internal medicine and health services research at the David Geffen School of Medicine at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"What we saw was that there was a consistency of effect of appreciable magnitude," said Arab, who is also a professor of biological chemistry. "By drinking three cups of tea a day, the risk of a stroke was reduced by 21 percent. It didn't matter if it was green or black tea."</DIV>
<DIV>&nbsp;</DIV>
<DIV>And extrapolating from the data, the effect&nbsp;appears to be&nbsp;linear, Arab said. For instance, if one drinks three cups a day, the risk falls by 21 percent; follow that with another three cups and the risk drops another 21 percent.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B></B></DIV>
<DIV>This effect was found in tea made from the plant Camellia sinensis, not from herbal teas.</DIV>
<DIV>&nbsp;</DIV>
<DIV>There are very few known ways to reduce the risk of stroke, Arab said.&nbsp;And developing medications for stroke victims is particularly challenging, given that the drug has to get to the stroke-damaged site quickly because damage occurs so fast. Arab said that by the time a stroke victim gets medical care, it's nearly too late to impede the damage.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"That's why these findings are so exciting," she said. "If we can find a way to prevent the stroke, or prevent the damage, that is simple and not toxic, that would be a great advance."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Though no one is certain which compounds in tea are responsible for this effect, researchers have speculated that the antioxidant epigallocatechin gallate (EGCG) or the amino acid theanine may be what helps. Antioxidants are believed to help prevent coronary artery disease.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"And we do know that theanine is nearly 100-percent absorbed," Arab said. "It gets across the blood-brain barrier and it looks a lot like a molecule that's very similar to glutamate, and glutamate release is associated with stroke.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"It could be that theanine and glutamate compete for the glutamate receptor in the brain," she added.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Although a randomized clinical trial is needed to confirm this effect, the findings suggest that drinking three cups of green or black tea&nbsp;a day could help prevent an ischemic stroke.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Study co-authors with Arab are Weiqing Liu, a senior statistician in the UCLA Department of Biomathematics, and David Elashoff, associate professor of medicine in the division of general internal medicine and health services search at the David Geffen School of Medicine at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Unilever Lipton Institute of Tea funded this study.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B></B></DIV><STRONG><A href="http://gim.med.ucla.edu/index.php">The General Internal Medicine and Health Services Research Divison</A></STRONG> in the department of medicine at the David Geffen School of Medicine at UCLA provides a unique interactive environment for collaborative efforts between health services researchers and clinical experts with experience in evidence-based work. The division's 100-plus clinicians and researchers are engaged in a wide variety of projects that examine issues related to access to care, quality of care, health measurement, physician education, clinical ethics and doctor-patient communication. Researchers in the division have close working relationships with economists, statisticians, social scientists and other specialists throughout UCLA and frequently collaborate with their counterparts at the RAND Corp. and the Charles Drew University of Medicine and Science. <img src="http://newsroom.ucla.edu/rss.ashx?id=119916" height="1" width="1" />]]></description><pubDate>Thu, 19 Feb 2009 16:30:00 GMT</pubDate></item><item><author>Amy Albin</author><title>Ischemic stroke patients: Take your vitamins, cut future risk</title><link>http://newsroom.ucla.edu/portal/ucla/ischemic-stroke-patients-take-81679.aspx?link_page_rss=81679</link><guid>http://newsroom.ucla.edu/portal/ucla/ischemic-stroke-patients-take-81679.aspx</guid><description><![CDATA[<DIV><STRONG>UCLA RESEARCH ALERT</STRONG></DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>FINDINGS:</STRONG></DIV>
<DIV>Taking recommended doses of B-complex vitamins to reduce levels of homocysteine, an amino acid that increases artery disease risk, may lower ischemic stroke patients' risk of recurring stroke and other future vascular events, according to a new UCLA study of data from the Vitamin Intervention for Stroke Prevention (VISP) trial. VISP subjects who adhered well to the treatment regimen over the trial period were less likely to experience primary outcome (stroke, heart attack, or death from stroke or heart attack) than poor adherers&nbsp;— 13.4 percent, compared with 20.3 percent. A similar result was observed for 50th percentile or above versus below 25th percentile total pill adherence.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>IMPACT:</STRONG></DIV>
<DIV>Promoting good adherence to vitamin therapy may be a viable approach to facilitating favorable outcomes after ischemic stroke.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>AUTHORS:</STRONG></DIV>
<DIV>Lead study author Dr. Bruce Ovbiagele, associate professor of neurology at the David Geffen School of Medicine at UCLA and director of the Olive View–UCLA stroke program, is available for interviews.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>PRESENTATION:</STRONG></DIV>
<DIV>The research was presented Feb. 18 at the American Stroke Association's International Stroke Conference 2009.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>FUNDING:</STRONG></DIV>
<DIV>The National Institutes of Health–National Institute of Neurologic Disorders and Stroke (NIH-NINDS) and the Resource Centers for Minority Aging Research at UCLA supported this study.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=119685" height="1" width="1" />]]></description><pubDate>Wed, 18 Feb 2009 20:45:00 GMT</pubDate></item><item><author>Amy Albin</author><title>Patients reaching hospital within 'golden hour' more likely to get stroke drug</title><link>http://newsroom.ucla.edu/portal/ucla/stroke-patients-who-reach-hospitals-81680.aspx?link_page_rss=81680</link><guid>http://newsroom.ucla.edu/portal/ucla/stroke-patients-who-reach-hospitals-81680.aspx</guid><description><![CDATA[<DIV>Patients who arrived at specific hospitals within an hour of experiencing stroke symptoms received a powerful clot-busting drug twice as often as those who arrived later in the approved time window for treatment, according to a new UCLA study presented&nbsp;today at the American Stroke Association's International Stroke Conference 2009.<BR><BR>Among the more than 100,000 patients treated at hospitals participating in the American Heart Association's Get With the Guidelines–Stroke (GWTG–Stroke) quality improvement program, 27.1 percent who arrived within the "golden hour"&nbsp;— the hour following the onset of symptoms&nbsp;— were treated with the clot-busting drug known as tissue plasminogen activator (tPA). Of those who arrived between one and three hours of symptom onset, 12.9 percent received the drug.<BR><BR>"The treatment rate among under-one-hour-arriving patients is good news for Get With the Guidelines hospitals," said lead author Dr. Jeffrey L. Saver, professor of neurology and director of the UCLA Stroke Center at Ronald Reagan UCLA Medical Center. "Prior studies have suggested that 25 to 30 percent of early-arriving patients are fully eligible for clot-busting drug treatment, and Get With the Guidelines–Stroke hospitals are delivering the therapy to virtually all these individuals."<BR><BR>The drug is the only approved acute stroke treatment for clot-related, or ischemic, stroke and has been shown to reduce stroke-related disability. However, it is only approved for use within three hours of symptom onset.<BR><BR>Recently, the European Cooperative Acute Stroke Study suggested that tPA was safe and effective up to 4.5 hours after symptom onset for some patients, but the current research reinforces the importance of quick action by patients and physicians.<BR><BR>"These findings support public education efforts to increase the proportion of patients arriving within the first 30 to 60 minutes after stroke onset," Saver said. "Little has been known about how frequently patients arrive at a hospital within the golden hour or how often hospitals meet the guidelines for beginning tPA infusion within 60 minutes after hospital arrival."<BR><BR>Researchers reviewed the records of 106,924 ischemic stroke patients treated during a four-plus-year period at 905 GWTG–Stroke hospitals.<BR><BR>The analysis found that:</DIV>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>28.3 percent of patients arrived within 60 minutes of symptom onset. 
<LI>31.7 percent arrived one to three hours after symptoms started. 
<LI>40.1 percent arrived more than three hours after symptoms started.</LI></UL><BR>"That more than one-quarter of ischemic stroke patients arrived within the golden hour is a very encouraging finding, because in stroke, time lost is brain lost," Saver said. "However, more than 70 percent arrived beyond the golden hour, when larger amounts of brain damage have occurred and our chance to reverse damage is much reduced. We have a great deal of additional work to do in educating the public and stroke center staffs. For every minute in which blood flow is not restored, nearly 2 million additional nerve cells die."<BR><BR>Researchers said golden-hour patients showed significantly more stroke deficits than later arrivals, suggesting that more intense symptoms propelled them to seek medical attention early.<BR><BR>But early and late arrivals were about the same age and were split almost evenly among men and women in each category. African Americans were less often early arrivals: Only 11.8 percent arrived within one hour, and 11.9 percent arrived within three hours.<BR><BR>Once at the hospital, however, the time-to-treatment for golden-hour patients averaged nearly 15 minutes longer than for patients who arrived one to three hours after symptom onset. Hospital-performance improvement activities are needed to shorten the arrival-to-treatment initiation time for patients who arrive within the golden hour, researchers said.<BR><BR>Before stroke treatment can begin, patients must undergo numerous tests, including a brain scan to ensure the stroke's cause is a blocked artery and not a hemorrhaging blood vessel.<BR><BR>"There are a huge number of reasons for waiting, but they are all trumped by the fact that the longer you wait, the more brain dies," Saver said. "We need to overcome the natural tendency to relax in the early-arriving patient and to think there is some extra time."<BR><BR>Additional co-authors included Dr. Lee Schwamm; Dr. Eric E. Smith; Adrian Hernandez, Ph.D.; Dai Wai Olson, Ph.D.; and Xin Zhao, Ph.D.<BR><BR>The American Heart Association funded the study.<BR><BR>UCLA holds intellectual property rights in the Merci Retriever. Saver has served as an unpaid investigator in the National Institutes of Health CLEAR and IMS 3 trials and as a scientific consultant to CoAxia, Talecris and Boehringer Ingelheim. He has received research catheters from Concentric Medical. Other individual author disclosures can be found in the study's abstract. 
<DIV><BR></DIV>
<DIV><STRONG>The UCLA Stroke Center</STRONG>, recognized as one of the world's leading centers for the management of cerebral vascular disease, treats simple and complex vascular disorders by incorporating recent developments in emergency medicine, stroke neurology, microneurosurgery, interventional neuroradiology, stereotactic radiology, neurointensive care, neuroanesthesiology and rehabilitation neurology. The program is unique in its ability to integrate clinical and research activities across multiple disciplines and leading departments. A center without walls, the UCLA Stroke Center was founded in 1994. For more information and links to information about stroke signs and prevention, visit <A href="http://www.stroke.ucla.edu/">www.stroke.ucla.edu</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=119574" height="1" width="1" />]]></description><pubDate>Wed, 18 Feb 2009 16:00:00 GMT</pubDate></item><item><author>Gwendolyn Driscoll</author><title>One in four California adolescent girls has had HPV vaccine</title><link>http://newsroom.ucla.edu/portal/ucla/one-in-four-california-adolescent-80338.aspx?link_page_rss=80338</link><guid>http://newsroom.ucla.edu/portal/ucla/one-in-four-california-adolescent-80338.aspx</guid><description><![CDATA[<div>Less than two years after the HPV vaccine was approved as a routine vaccination for girls aged 11 and older, one-quarter of California adolescent girls have started the series of shots that protect against human papillomavirus, which is strongly linked to cervical cancer.</div>
<div> </div>
<div>Additionally, a majority of teen girls, parents and young women in California say they would like to have the vaccine, according to a new policy brief released today by the <a href="http://www.healthpolicy.ucla.edu/">UCLA Center for Health Policy Research</a>.</div>
<div> </div>
<div>The brief, "<a href="http://www.healthpolicy.ucla.edu/">One in Four California Adolescent Girls Have Had Human Papillomavirus Vaccination</a>," represents the first data on HPV vaccine use and acceptability published for any state. As such, it is an early indicator of how a controversial vaccine — shunned by some groups over concerns about its efficacy and potential effect on sexual mores — is being accepted by the general public.</div>
<div> </div>
<div>Among teen girls in California aged 13 to 17, about 378,000 out of 1,468,000 (26 percent) reported receiving at least one dose of the vaccine. Among California females aged 18 to 26, about 262,000 out of 2,273,000 (12 percent) reported receiving at least one dose of the vaccine in 2007, and 4 percent had completed the vaccine series.</div>
<div> </div>
<div>Awareness and interest in the vaccine is high: 76 percent of teen girls aged 13 to 17 and 60 percent of young adult women aged 18 to 26 reported an interest in getting the HPV vaccine themselves, while 57 percent of parents of age-eligible girls reported an interest in getting the HPV vaccine for their daughters.</div>
<div> </div>
<div>The HPV vaccine Gardasil was licensed for use by the Food and Drug Administration in June 2006 and recommended for routine use by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices in March 2007. The California Health Interview Survey, administered by the Center for Health Policy Research, collected data on HPV vaccine acceptance from July 2007 through March 2008.</div>
<div> </div>
<div>"For so many teens and young women to be vaccinated or to suggest interest in vaccination in such a short time suggests very few barriers to acceptance," said David Grant, Ph.D., director of the California Health Interview Survey and lead author of the policy brief. "A majority of parents, teens and young women want the vaccine and perceive it to be important to their health."</div>
<div> </div>
<div>The HPV virus is associated with about 90 percent of genital warts and up to 70 percent of all cervical cancers. The vaccine is administered in a series of three injections over a six-month period and targets the four HPV types most commonly associated with genital warts and cervical cancer.</div>
<div> </div>
<div>Among those surveyed who had not yet had the HPV vaccine, not knowing enough about the vaccine was the main reason cited by young adult women age 18 to 26 (31 percent) and parents of age-eligible daughters (54 percent). Other frequently cited explanations included concerns about the vaccine's safety and questions about the vaccine's necessity.</div>
<div> </div>
<div>Researchers noted that the findings of the policy brief do not conclusively explore reasons for non-acceptance.</div>
<div> </div>
<div>"Further research is needed to understand why some are not getting the vaccine," said Nancy Breen, an economist with the Applied Research Program of the National Cancer Institute, which funded the research. "What we do know is that many girls and women are getting the vaccine. That's good news in the fight against cervical cancer."</div>
<div> </div>
<div><b><a href="http://www.cancer.gov/">The National Cancer Institute (NCI)</a></b> leads the National Cancer Program and National Institutes of Health effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, visit the NCI website (<a href="http://www.cancer.gov/">www.cancer.gov</a>) or call the NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).</div>
<div> </div>
<div><a href="http://www.chis.ucla.edu/"><strong>The California Health Interview Survey (CHIS) </strong></a>is the nation's largest state health survey and one of the largest health surveys in the United States.</div>
<div> </div>
<div><a href="http://www.healthpolicy.ucla.edu/"><strong>The UCLA Center for Health Policy Research</strong></a> is one of the nation's leading health policy research centers and the premier source of health-related information on Californians. </div>
<div> </div>
<div>For more news, visit the <a href="http://www.newsroom.ucla.edu/">UCLA Newsroom</a>.</div> <img src="http://newsroom.ucla.edu/rss.ashx?id=118733" height="1" width="1" />]]></description><pubDate>Tue, 17 Feb 2009 17:00:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Gene therapy shows promise as weapon against HIV</title><link>http://newsroom.ucla.edu/portal/ucla/gene-therapy-shows-promise-as-81694.aspx?link_page_rss=81694</link><guid>http://newsroom.ucla.edu/portal/ucla/gene-therapy-shows-promise-as-81694.aspx</guid><description><![CDATA[<DIV>A new UCLA AIDS Institute study has found that gene therapy can be developed as a safe and active technique to combat HIV.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Researchers involved in this first-of-its-kind study found that cell-delivered gene transfer has the potential to be a once-only treatment that reduces viral load, preserves the immune system and avoids lifelong antiretroviral therapy. The study appears in the current online edition of the journal Nature Medicine.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Though modest, the results do show some promise that gene therapy can be developed as a potentially effective treatment for HIV, said lead investigator Dr. Ronald Mitsuyasu, professor of medicine and director of the Center for Clinical AIDS Research and Education (CARE) at the David Geffen School of Medicine at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"It is the first randomized controlled study done with gene therapy in HIV," said Mitsuyasu, who is also an associate director of the UCLA AIDS Institute. "What we were able to demonstrate was that the patients who received the gene-modified cells had a somewhat better suppression of their HIV viral replication after discontinuing their highly active antiretroviral therapy (HAART) treatment, compared with the controls."</DIV>
<DIV>&nbsp;</DIV>
<DIV>This was the first randomized, double-blind, placebo-controlled gene-transfer clinical trial and involved 74 HIV-positive adults.</DIV>
<DIV>The patients received their own blood stem cells, either untreated or modified to carry a molecule called OZ1, which prevents viral replication by targeting a key HIV gene. OZ1 was safe, causing no adverse effects over the course of the 100-week trial.</DIV>
<DIV>&nbsp;</DIV>
<DIV>At the primary end-point, the difference in viral load between the OZ1 and placebo group at weeks seven and eight, after they had stopped HAART treatment, was not statistically significant. But other viral parameters did demonstrate better HIV suppression and improvement in the counts of CD4+ lymphocytes&nbsp;— the cell population that is depleted by HIV.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The technique still needs to be developed further and perfected, Mitsuyasu said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Part of the reason that we didn't see a larger effect is that the persistence of the anti-HIV gene in the patient's blood was not as long as we would have liked," he said. "We need to find better ways to get the genes into the patients and maintain them, which could include using different vectors to get the gene into the cells or conditioning the patients prior to gene transfer."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Still, the results indicate that gene therapy could eventually be a useful tool in the fight against AIDS, said study co-author Dr. Thomas C. Merigan, the George and Lucy Becker Professor of Medicine emeritus at the Stanford University School of Medicine. He agrees that more needs to be done to perfect it.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"But in the way we set up the trial with randomized placebo controls, we could dissect out that there was a positive effect in patients who had the gene successfully installed," Merigan said. "This could be a first step in developing a new method of controlling a chronic infectious disease."</DIV>
<DIV>&nbsp;</DIV>
<DIV>This study was funded by Johnson and Johnson Research Pty Limited. Grants from the National Institutes of Health also helped support part of the research.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to Mitsuyasu and Merigan, authors are Andrew Carr, Jerome A Zack, Mark A. Winters, Cassy Workman, Mark Bloch, Jacob Lalezari, Stephen Becker, Lorna Thornton, Bisher Akil, Homayoon Khanlou, Robert Finlayson, Robert McFarlane, Don E. Smith, Roger Garsia, David Ma, Matthew Law, John M. Murray, Christof von Kalle, Julie A. Ely, Sharon M. Patino, Alison E. Knop, Philip Wong, Alison V. Todd, Margaret Haughton, Caroline Fuery, Janet L. Macpherson, Geoff P. Symonds, Louise A. Evans, Susan M. Pond and David A. Cooper.</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.uclaaidsinstitute.org/"><STRONG>The UCLA AIDS Institute</STRONG></A>, established in 1992, is a multidisciplinary think tank drawing on the skills of top-flight researchers in the worldwide fight against HIV and AIDS, the first cases of which were reported in 1981 by UCLA physicians. Institute members include researchers in virology and immunology, genetics, cancer, neurology, ophthalmology, epidemiology, social sciences, public health, nursing and disease prevention. Their findings have led to advances in treating HIV, as well as other diseases, such as hepatitis B and C, influenza and cancer.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=119069" height="1" width="1" />]]></description><pubDate>Tue, 17 Feb 2009 08:00:00 GMT</pubDate></item><item><author>Gwendolyn Driscoll</author><title>New factor in teen obesity: parents</title><link>http://newsroom.ucla.edu/portal/ucla/new-factor-in-teen-obesity-parents-80252.aspx?link_page_rss=80252</link><guid>http://newsroom.ucla.edu/portal/ucla/new-factor-in-teen-obesity-parents-80252.aspx</guid><description><![CDATA[<DIV>There may be a reason teenagers eat more burgers and fries than fruits and vegetables: their parents.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In a new policy brief released today by the <A href="http://www.healthpolicy.ucla.edu/">UCLA Center for Health Policy Research</A>, researchers found that adolescents are more likely to eat at least five servings of fruits and vegetables a day if their parents do. Contrarily, teens whose parents eat fast food or drink soda are more likely to do the same.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Every day, more than 2 million California adolescents (62 percent) drink soda and 1.4 million (43 percent) eat fast food, but only 38 percent eat five or more servings of fruits and vegetables, according to the policy brief, "<A href="http://www.healthpolicy.ucla.edu/">Teen Dietary Habits Related to Those of Parents</A>." <BR><BR>The cause of the deficit of healthy foods in teen diets has been attributed in part to the high concentration of fast food restaurants in certain cities and neighborhoods and other environmental factors.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The new research is a reminder, however, that "good dietary habits start at home," according to center research scientist Susan H. Babey, a co-author of the policy brief. "If parents are eating poorly, chances are their kids are too."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Nearly one-third (30 percent) of California's teenagers are overweight or obese. Poor dietary habits, along with environmental and other factors, are strongly linked to obesity.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The policy brief, which was funded by a grant from the California Endowment,&nbsp;drew upon the responses of thousands of California teenagers queried by the center-administered California Health Interview Survey (CHIS), the nation's largest state health survey. Among the brief's findings:</DIV>
<DIV style="FONT-SIZE: 3px">&nbsp;</DIV>
<UL>
<LI>Teens whose parents drink soda every day are nearly 40 percent more likely to drink soda every day themselves than teens whose parents do not drink soda.</LI></UL>
<UL>
<LI>Teens whose parents eat five servings of fruits and vegetables daily are 16 percent more likely to do the same than teens whose parents do not<SPAN style="FONT-STYLE: italic">&nbsp;</SPAN>eat five servings a day.</LI></UL>
<UL>
<LI>Nearly half of adolescents (48 percent) whose parents drink soda every day eat fast food at least once a day, while only 39 percent of teens whose parents do <EM>not</EM> drink soda eat fast food at least once daily. </LI></UL>
<UL>
<LI>45 percent of teens&nbsp;whose parents do <EM>not</EM> eat five servings of fruits and vegetables daily eat fast food at least once a day, while only 39 percent of teens whose parents eat five servings a day eat fast food at least once daily.</LI></UL>
<UL></UL>
<DIV><BR>"The research shows us that one of the keys to solving the teen obesity crisis starts with parents, but we must also improve the abysmal food environments in many low-income communities," said Dr. Robert K. Ross, president and chief executive officer of the California Endowment. "While parents are the primary role models for their children and their behavior can positively&nbsp;— or negatively&nbsp;— influence their children's health, it is also essential that local officials representing low-income communities work to expand access to fruits, vegetables and other healthful foods."<BR><BR>Educating parents about unhealthy food choices, as well as how to plan and prepare healthier fare, would help in reducing teen obesity, according to the authors of the policy brief. They also recommend employment policies that promote a better work-life balance. Given a more flexible schedule, more families might have time to prepare food at home and engage more often in family meals&nbsp;— an activity that has been linked to healthier lifestyles.<BR><BR>Healthy "food environments," such as supermarkets, farmers markets and other retail food outlets that offer fruits and vegetables instead of fast food, are also important in helping parents and teens practice healthy behaviors, the brief's authors said.</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.calendow.org/"><STRONG>The California Endowment</STRONG></A>, a private, statewide health foundation, was established in 1996 to expand access to affordable, quality health care for underserved individuals and communities and to promote fundamental improvements in the health status of all Californians.</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.chis.ucla.edu/"><STRONG>The California Health Interview Survey (CHIS)</STRONG></A> is one of the largest health surveys in the United States. The CHIS is conducted by the UCLA Center for Health Policy Research in collaboration with the California Department of Public Health, the Department of Health Care Services and the Public Health Institute.</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.healthpolicy.ucla.edu/"><STRONG>The UCLA Center for Health Policy Research</STRONG></A> is one of the nation's leading health policy research centers and the premier source of health-related information on Californians. </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=115924" height="1" width="1" />]]></description><pubDate>Mon, 09 Feb 2009 17:00:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>UCLA scientists develop 'crystal ball' for personalized cancer treatment</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-develop-crystal-80033.aspx?link_page_rss=80033</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-develop-crystal-80033.aspx</guid><description><![CDATA[<DIV><EM>(Editors: PET scans revealing tumors glowing after absorbing probe are available upon request.)</EM></DIV>
<DIV>&nbsp;</DIV>
<DIV>For many cancer patients, chemotherapy can be worse than cancer itself. A patient may respond to one drug but not another, or the tumor may mutate and stop responding to the drug, resulting in months of wasted time, ineffective treatment and toxic side effects.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Now UCLA scientists have tested a non-invasive approach that may one day allow&nbsp;physicians to evaluate a tumor's response to a drug before prescribing therapy, enabling them to quickly pinpoint the most effective treatment and personalize it to&nbsp;a patient's unique biochemistry. </DIV>
<DIV>&nbsp;</DIV>
<DIV>The findings appear in the&nbsp;Feb. 2 advance online edition of&nbsp;Proceedings of the National Academy of Sciences.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"For the first time, we can watch a chemotherapy drug working inside the living body in real time," said Dr. Caius Radu, a researcher at&nbsp;UCLA's Crump Institute for Molecular Imaging and an assistant professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA. "We plan to test this method in healthy volunteers within the year to determine whether we can replicate our current results in humans."</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.newsroom.ucla.edu/portal/ucla/ucla-researchers-develop-new-pet-51536.aspx">In an earlier study</A>, Radu and his colleagues created a small probe by slightly altering the molecular structure of gemcitabine, one of the most commonly used chemotherapy drugs. They labeled the probe with a special tag that&nbsp;allowed them to watch its movement throughout the body during imaging.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In this study, the UCLA team injected the probe into mice that had developed leukemia and lymphoma tumors. After an hour, the researchers imaged the animals' bodies&nbsp;using positron emission tomography (PET), a non-invasive scan often used on cancer patients to identify whether a tumor has spread from its original site or returned after remission.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The PET scanner operates like a molecular camera, enabling us to watch biological processes in living animals and people," said Radu, who is also a member of&nbsp;UCLA's Jonsson Comprehensive Cancer Center. "Because we tag the probe with positron-emitting particles, the cells that absorb it glow brighter under the PET scan."</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The PET scan offers a preview for how the tumor will react to a specific therapy,"&nbsp;said first author Rachel Laing, a UCLA graduate researcher in molecular and medical pharmacology. "We believe that the tumor cells that absorb the probe will also take up the drug. If the cells do not absorb the probe, it suggests that the tumor might respond better to another medication."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The UCLA researchers plan to expand the scope of their research by examining whether the probe can predict cellular response to several other widely used chemotherapy drugs. Their goal is to determine whether the probe can provide a diagnostic test of clinical value.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The beauty of this approach is that it is completely non-invasive and without side effects," Radu said. "If we are successful in transporting this test to a clinical setting, patients will be able to go home immediately and resume their daily activities."</DIV>
<DIV>&nbsp;</DIV>
<DIV>If testing in healthy subjects proves safe and effective, UCLA researchers will begin recruiting volunteers for a larger clinical study of the probe in cancer patients.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study was funded by the Dana Foundation, the National Cancer Institute, the U.S. Department of Energy and the Howard Hughes Medical Institute. Radu and Laing's co-authors included Martin Walter, Dean Campbell, Harvey Herschman, Nagichettiar Satyamurthy, Michael Phelps, Johannes Czernin and Owen Witte, all of UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>
<DIV><B><A href="http://www.crump.ucla.edu/">The UCLA Crump Institute for Molecular Imaging</A></B> is a multidisciplinary collaborative of faculty, postdoctoral scholars and graduate students engaged in cutting-edge research in the fields of molecular diagnostics, microfluidics, systems biology and nanotechnology, with the aim of developing new technologies to observe, measure and understand biology in cells, tissues and living organisms through molecular imaging. The institute's ultimate goal is to provide the technology and science that will lead to a better understanding of the transition from health to disease at the molecular level and the development of new therapies to treat disease as part of a new era in molecular medicine.</DIV></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=112863" height="1" width="1" />]]></description><pubDate>Mon, 02 Feb 2009 22:00:00 GMT</pubDate></item><item><author>Sarah Anderson</author><title>Household chemicals may be linked to infertility</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-researchers-report-that-exposure-80017.aspx?link_page_rss=80017</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-researchers-report-that-exposure-80017.aspx</guid><description><![CDATA[<DIV>Researchers at the UCLA School of Public Health have found the first evidence that perfluorinated chemicals, or PFCs&nbsp;— chemicals that are widely used in everyday items such as food packaging, pesticides, clothing, upholstery, carpets and personal care products&nbsp;— may be associated with infertility in women.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Published online&nbsp;in Human&nbsp;Reproduction,&nbsp;Europe's leading reproductive medicine journal, the study found that women who had higher levels of perfluorooctanoate (PFOA) and perfluorooctane sulfonate (PFOS) in their blood took longer to become pregnant than women with lower levels.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The UCLA researchers used data from the Danish National Birth Cohort to assess whether levels of PFOS and PFOA in pregnant women's plasma were associated with a longer time to pregnancy. A total of 1,240 women were included in their analyses.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Blood samples were first taken between 4 and 14 weeks into the pregnancy so that concentrations of PFOS and PFOA could be measured. The researchers also interviewed the women at around the 12th week of pregnancy to find out whether the pregnancy was planned or not and how long it took them to become pregnant. Infertility was defined as a time to pregnancy of longer than 12 months or a situation in which infertility treatments&nbsp;were used&nbsp;to establish the pregnancy, and the results were adjusted for potential confounding factors such as age, lifestyle and socioeconomic status.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The level of PFOS in the women's plasma ranged from 6.4 nanograms per milliliter (ng/ml) to 106.7 ng/ml, and from less than 1 ng/ml to 41.5 ng/ml for PFOA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers divided the women's levels of PFOS/PFOA into four quartiles and found that, compared with women with the lowest levels of exposure, the likelihood of infertility increased by 70 to 134 percent for women in the higher three quartiles of PFOS exposure and by 60 to 154 percent for women in the higher three quartiles of PFOA exposure.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Perfluorooctanoate and perfluorooctane sulfonate were considered to be biologically inactive, but recently, animal studies have shown that these chemicals may have a variety of toxic effects on the liver, immune system and developmental and reproductive organs," said UCLA researcher Chunyuan Fei, the study's first author. "Very few human studies have been done, but one of our earlier studies showed that PFOA, although not PFOS, may impair the growth of babies in the womb, and another two epidemiological studies linked PFOA and PFOS to impaired fetal growth."</DIV>
<DIV>&nbsp;</DIV>
<DIV>"As far as we know, this is the first study to assess the associations between PFOA and PFOS levels in plasma with time to pregnancy in humans," said principal investigator Jørn Olsen, chair of the department of epidemiology at the UCLA School of Public Health. "We are waiting for further studies to replicate our findings in order to discover whether the chemicals should be added to the list of risk factors for infertility."</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to being found in household goods, PFCs, the class of chemicals to which PFOS and PFOA belong, are used in&nbsp;manufacturing processes&nbsp;involving industrial surfactants and emulsifiers. They persist in the environment and in the body for decades.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers believe that although they measured the PFOS/PFOA levels after pregnancy was established, these levels probably did not change significantly from the time before pregnancy. Men's sperm quality could also be affected by PFCs and might, therefore, contribute to the associations between PFC levels and time to pregnancy, since couples would tend to be sharing the same lifestyles and have similar exposures. However, the researchers did not have data on PFC levels in fathers. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"Studies on sperm quality and PFOA/PFOS are certainly warranted," Olsen said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers say the biological mechanisms by which exposure to PFOS and PFOA might reduce fertility are unknown, but PFCs may interfere with hormones that are involved in reproduction.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Our data showed that higher proportions of women reported irregular menstrual periods in the upper three quartiles of PFOA and PFOS, compared with the lowest, and so this could indicate a possible pathway," Fei said.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>The UCLA School of Public Health</STRONG> is dedicated to enhancing the public's health by conducting innovative research, training future leaders and health professionals, translating research into policy and practice, and serving local, national and international communities. For more information, see <A href="http://www.ph.ucla.edu/">www.ph.ucla.edu</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=112483" height="1" width="1" />]]></description><pubDate>Fri, 30 Jan 2009 08:00:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>From molecules to populations: Fighting the epidemics of obesity and diabetes</title><link>http://newsroom.ucla.edu/portal/ucla/from-molecules-to-populations-78506.aspx?link_page_rss=78506</link><guid>http://newsroom.ucla.edu/portal/ucla/from-molecules-to-populations-78506.aspx</guid><description><![CDATA[<DIV>Diabetes is exploding — it now afflicts some 200 million individuals worldwide and is fast becoming the No. 1 epidemic of our time. In the U.S. alone, more than 22 million people have diabetes, which is the leading cause of end-stage renal disease, preventable amputations and blindness.</DIV>
<DIV> </DIV>
<DIV>Now, thanks to a $2.5 million grant from the prestigious Burroughs Wellcome Fund, UCLA's next generation of scientists will be trained in multiple disciplines to fight diabetes through the newly established Burroughs Wellcome Fund Inter-school Training Program in Metabolic Disease (BWF-ITP-MD).</DIV>
<DIV> </DIV>
<DIV>The BWF-ITP-MD, a Ph.D. education and research training program devoted entirely to the understanding of metabolic diseases, will bring together researchers and educators from the UCLA School of Public Health, the David Geffen School of Medicine at UCLA, and other UCLA entities. </DIV>
<DIV> </DIV>
<DIV>"Our hope is to develop an integrative training and research framework where students can learn to assess the many seemingly distinct aspects of dietary, lifestyle and genetic factors that cause these prevalent phenotypes," said Dr. Simin Liu, program co-director and a professor of epidemiology and medicine. "Once trained, these scientists will be able to develop better insights and system strategies to curb this epidemic." </DIV>
<DIV> </DIV>
<DIV>In short, Liu said, the goal of the program is to "provide comprehensive, interdisciplinary education and research training in all facets, attacking such metabolic diseases across the board, from sick molecules to sick populations."</DIV>
<DIV> </DIV>
<DIV>The BWF-ITP-MD is the first-ever Ph.D. program to combine multiple disciplines in its approach to the study of metabolic diseases. </DIV>
<DIV> </DIV>
<DIV>"We live at a point in time when metabolic diseases are rising faster than we can keep up, even as breathtaking scientific discoveries are being made that are unprecedented in the history of biomedical sciences," said Dr. Thomas Drake, program co-director and a professor of pathology and laboratory medicine at the Geffen School of Medicine. "So the question many of us often ask is, how can we harness the major advances in biomedical sciences to bring out preventive and treatment measures to conquer what appears to be the public health nemesis of our time?"</DIV>
<DIV> </DIV>
<DIV>Unfortunately, Liu and Drake said, diabetes has a wide reach. For example, the incidence of major cardiovascular events has increased two- to four-fold due to diabetes, with women and minorities disproportionately bearing the largest burden. If this trend continues, they say, it is estimated that children who were born in the U.S. in 2000 will, on average, live shorter lives than their parents.</DIV>
<DIV> </DIV>
<DIV>"Talented young people who are well-trained in the concepts, strategies and advanced tools of both population and lab-based research remain a rarity, particularly in the field of metabolic diseases and disciplines of epidemiology and pathology," Drake said. "This program intends to fill that gap."</DIV>
<DIV> </DIV>
<DIV>Liu and Drake are leaders in translational research, pursuing multidisciplinary initiatives from the basic science of molecular mechanisms all the way to the genetic and nutritional epidemiology of metabolic diseases. The BWF-ITP-MD at UCLA is one of only three programs nationwide to be funded by the Burroughs Wellcome Fund (BWF), following a highly selective multistage process that was based on the quality, innovation, and logic of the proposed training program and its relevance to the goals of this award program, said Dr. John E. Burris, BWF president.</DIV>
<DIV> </DIV>
<DIV>UCLA demonstrated that kind of breadth with an existing program, which had already been set in motion by Liu. Three<B> </B>years ago, he established the Program on Genomics and Nutrition within the UCLA School of Public Health (<A href="http://nutrigen.ph.ucla.edu/">http://nutrigen.ph.ucla.edu</A>), which employs an integrative approach to training and research in the discipline of molecular epidemiology and the field of metabolic diseases.</DIV>
<DIV> </DIV>
<DIV>Specifically, the new training program's mission is to bring the best population and lab-based sciences to bear by assessing the impact of genes and their interactions with behavior, nutrition and the environment on health and diseases, and to critically and systematically evaluate the significance of genetic and dietary variations within populations, ultimately applying that knowledge to improving the public's health.</DIV>
<DIV> </DIV>
<DIV>"This new cross-disciplinary program represents the future of training in biomedical sciences," said Dr. Linda Rosenstock, dean of the UCLA School of Public Health. "We are excited about our role in training the next generation of scientists about the various genetic and environmental factors that cause obesity and diabetes, one of the most serious public health threats of our time." </DIV>
<DIV> </DIV>
<DIV>"I am delighted this innovative program is being implemented," said Dr. Gerald Levey, vice chancellor of UCLA Medical Sciences and dean of the Geffen School of Medicine. "Drs. Liu and Drake are respected leaders in translational science who care deeply about education and training a new generation of biomedical leaders capable of unifying the many technical and biological facets of modern biomedical science."</DIV>
<DIV> </DIV>
<DIV>The Burroughs Wellcome Fund is an independent, private foundation dedicated to advancing the medical sciences by supporting research and other scientific and educational activities. A majority of its grantmaking is made through competitive programs designed to support the career development of young scientists and to build capacity in undervalued research areas. For more information about the fund, contact communications officer Russ Campbell at 919-991-5119 or visit <A href="http://www.bwfund.org/">www.bwfund.org</A>.  </DIV>
<DIV> </DIV>
<DIV><STRONG>The UCLA School of Public Health</STRONG> is dedicated to enhancing the public's health by conducting innovative research, training future leaders and health professionals, translating research into policy and practice, and serving local, national and international communities. For more information, visit <A href="http://www.ph.ucla.edu/">www.ph.ucla.edu</A>.</DIV>
<DIV> </DIV>
<DIV><STRONG>The David Geffen School of Medicine at UCLA</STRONG>, an internationally recognized leader in research, medical education and patient care, is among the nation's elite medical schools, any of which are at least twice the Geffen School's age. The medical school today has more than 2,000 full-time faculty members, nearly 1,300 residents, more than 750 medical students and almost 400 Ph.D. candidates. For more information, visit <A href="http://dgsom.healthsciences.ucla.edu/">http://dgsom.healthsciences.ucla.edu</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=110645" height="1" width="1" />]]></description><pubDate>Wed, 28 Jan 2009 08:00:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Circumcision rates lower in states where Medicaid does not cover procedure</title><link>http://newsroom.ucla.edu/portal/ucla/male-circumcision-rates-lower-78871.aspx?link_page_rss=78871</link><guid>http://newsroom.ucla.edu/portal/ucla/male-circumcision-rates-lower-78871.aspx</guid><description><![CDATA[<DIV>Hospitals in&nbsp;states where Medicaid does not pay for routine male circumcision&nbsp;are only about half as likely to perform the procedure, and this&nbsp;disparity could lead to an increased risk&nbsp;of HIV infection among lower-income children later in life, according to a&nbsp;UCLA AIDS Institute study.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Researchers found that at hospitals in the 16 states&nbsp;where the procedure is not covered, circumcision rates&nbsp;were 24 percentage points lower than at hospitals&nbsp;in other states, with&nbsp;lower rates particularly prevalent among Hispanics. The mean male circumcision rate for all states was 55.9 percent.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study, published in the January issue of the American Journal of Public Health, is available online at <A href="http://www.ajph.org/cgi/content/full/99/1/138">www.ajph.org/cgi/content/full/99/1/138</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The findings are important because they document the effect of state Medicaid reimbursement policies on the medical services that are actually delivered, said the study's lead author, Arleen A. Leibowitz, a professor of public policy and a researcher&nbsp;with both the UCLA Center for HIV Identification, Prevention and Treatment Services and the UCLA AIDS Institute. These services include male circumcision, which has been shown to lead to substantial health benefits in later life.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Since children whose childbirth expenses are paid for by Medicaid are, by definition, lower income, the Medicaid policy in 16 states of not reimbursing for male circumcision is generating future disparities in health between children born to rich and poor families,"&nbsp;Leibowitz said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In 1999, the American Academy of Pediatrics (AAP)&nbsp;stated that the medical benefits of male circumcision were not enough for the group to recommend that the procedure be made routine at all hospitals. As a result, some states began withdrawing Medicaid coverage for circumcision.</DIV>
<DIV>&nbsp;</DIV>
<DIV>But recent clinical trials in South Africa, Kenya and Uganda have revealed that male circumcision can reduce a man's risk of becoming infected with HIV from a female partner by 55 to 76 percent. In June 2007, the AAP began reviewing its stance on the procedure.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The UCLA researchers relied on data from the 2004 Nationwide Inpatient Sample (NIS), collected as part of&nbsp;the Healthcare Cost and Utilization Project of the federal&nbsp;Agency for Healthcare Research and Quality. They studied information&nbsp;on about 417,000 routine discharges of newborn males from 683 U.S. hospitals.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to the overall lower circumcision rates, the researchers found that the more Hispanics a hospital served, the fewer circumcisions the hospital&nbsp;performed. For Hispanic parents, the circumcision decision was about more than simply cost, since male Hispanic infants were unlikely to receive the procedure even in states in which it was fully covered by Medicaid.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The 16 states without Medicaid coverage for male circumcision are California, Oregon, North Dakota, Mississippi, Nevada, Washington, Missouri, Arizona, North Carolina, Montana, Utah, Florida, Maine, Louisiana, Idaho and Minnesota.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study authors&nbsp;estimate that if all states' Medicaid plans paid for male circumcision, the national rates for the procedure would increase to 62.6 percent. If all states dropped the coverage, the rate would fall to about 38.5 percent.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"State Medicaid plans that attempt to reduce costs in the short run by not covering the cost of infant male circumcision may be generating higher health care costs for HIV/AIDS and other sexually transmitted infections in the future," Leibowitz said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Study co-authors&nbsp;were Katherine Desmond, M.S., and Thomas Belin, Ph.D, both with UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>A National Institute of Mental Health grant to UCLA's Center for HIV Identification, Prevention and Treatment Services funded the study.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.uclaaidsinstitute.org/">The UCLA AIDS Institute</A></STRONG>, established in 1992, is a multidisciplinary think tank drawing on the skills of top-flight researchers in the worldwide fight against HIV and AIDS, the first cases of which were reported in 1981 by UCLA physicians. Institute members include researchers in virology and immunology, genetics, cancer, neurology, ophthalmology, epidemiology, social sciences, public health, nursing and disease prevention. Their findings have led to advances in treating HIV, as well as other diseases, such as hepatitis B and C, influenza and cancer.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=109185" height="1" width="1" />]]></description><pubDate>Tue, 27 Jan 2009 08:00:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Moderate alcohol consumption may help seniors keep disabilities at bay</title><link>http://newsroom.ucla.edu/portal/ucla/moderate-alcohol-consumption-may-78427.aspx?link_page_rss=78427</link><guid>http://newsroom.ucla.edu/portal/ucla/moderate-alcohol-consumption-may-78427.aspx</guid><description><![CDATA[<DIV>It is well known that moderate drinking can have positive health benefits&nbsp;— for instance, a couple of glasses of red wine a day can be good for the heart. But if you're a senior in good health, light to moderate consumption of alcohol may also help prevent the development of physical disability.</DIV>
<DIV>&nbsp;</DIV>
<DIV>That's the conclusion of a new UCLA study, available in the <A href="http://aje.oxfordjournals.org/cgi/content/full/kwn294">American Journal of Epidemiology</A>, which found that light to moderate drinking among these seniors reduced their odds of developing physical problems that would prevent them from performing common tasks such as walking, dressing and grooming.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"If you start out in good health, alcohol consumption at light to moderate levels can be beneficial," said lead study author Dr. Arun Karlamangla, an associate professor of medicine in the division of geriatrics at the David Geffen School of Medicine at UCLA. "But if you don't start out healthy, alcohol will not give you a benefit."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers based their study on data from three waves of the National Health and Nutrition Examination Survey's Epidemiologic Follow-up Study (1982–84, 1987 and 1992). The sample, which included 4,276 people, split evenly between male and female, was about 92 percent white, with a mean age of 60.4 years.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Drinkers were classified as light to moderate if they consumed less than 15 drinks per week and less than five drinks per drinking day (less than four per day for women). Heavy drinkers were those who consumed 15 or more drinks per week or five or more per drinking day (four or more for women). Abstainers were those who drank fewer than 12 alcoholic beverages the previous year.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Having a physical disability means having trouble performing, or being unable to perform, routine tasks such as dressing and grooming, personal hygiene, arising, eating, walking, gripping, reaching, and doing daily errands and chores. Participants were asked if they experienced no difficulty, some difficulty, much difficulty or were unable to do these activities at all when alone and without the use of aids.</DIV>
<DIV>&nbsp;</DIV>
<DIV>At the start of the survey, 32 percent of men and 51 percent of women abstained from drinking, 51 percent of men and 45 percent of women were light to moderate drinkers, and 17 percent of men and 4 percent women were heavy drinkers.</DIV>
<DIV>&nbsp;</DIV>
<DIV>No one had any disabilities at the outset, but 7 percent died and 15 percent became disabled over five years.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers found that light to moderate drinkers in good health had a lower risk for developing new disabilities, compared with both abstainers and heavy drinkers.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In unadjusted analyses, light to moderate drinkers had a 17.7 percent chance of becoming disabled or dying in five years, compared with 26.7 percent for abstainers and 21.4 percent for heavy drinkers. Among survivors, the risk for new disability was 12.5 percent for light to moderate drinkers, compared with 20 percent for abstainers and 15.6 percent for heavy drinkers.</DIV>
<DIV>&nbsp;</DIV>
<DIV>However, after controlling for confounding variables such as age, smoking, exercise, heart attacks and strokes, the benefits of alcohol consumption were seen only in seniors who rated their health as good or better: There was a 3 to 8 percent reduction in the odds of developing disability with each additional drink per week in older men and women in good or better health who were not heavy drinkers, but there was no such benefit seen in those who rated their health as fair or poor.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Light to moderate alcohol consumption appears to have disability prevention benefits only in men and women in relatively good health," the researchers wrote. "It is possible that those who report poor health have progressed too far on the pathway to disability to accrue benefits from alcohol consumption and that alcohol consumption may even be deleterious for them."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Other study authors were Catherine A. Sarkisian, Deborah M. Kado, Howard Dedes, Diana H. Liao, Sungjin Kim, David B. Reuben, Gail A. Greendale and Alison A. Moore, all of the David Geffen School of Medicine. Sarkisian is also affiliated with the Geriatric Research Education and Clinical Center of the Veterans Affairs Greater Los Angeles Healthcare System.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study was supported by funding from the John A. Hartford Foundation/American Federation for Aging Research Medical Student Geriatrics Scholars Program; the National Institute on Alcohol Abuse and Alcoholism; and the Claude D. Pepper Older Americans Independence Center of the National Institute on Aging.</DIV><BR>
<DIV><B>UCLA</B> is California's largest university, with an enrollment of nearly 38,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 323 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=107361" height="1" width="1" />]]></description><pubDate>Thu, 15 Jan 2009 15:00:00 GMT</pubDate></item><item><author>Rachel Champeau</author><title>Most heart attack patients' cholesterol levels did not indicate cardiac risk</title><link>http://newsroom.ucla.edu/portal/ucla/majority-of-hospitalized-heart-75668.aspx?link_page_rss=75668</link><guid>http://newsroom.ucla.edu/portal/ucla/majority-of-hospitalized-heart-75668.aspx</guid><description><![CDATA[<DIV>A new national study has shown that nearly 75 percent of patients hospitalized for a heart attack had cholesterol levels that would indicate they were not at high risk for a cardiovascular event, based on current national cholesterol guidelines.</DIV>
<DIV> </DIV>
<DIV>Specifically, these patients had low-density lipoprotein (LDL) cholesterol levels that met current guidelines, and close to half had LDL levels classified in guidelines as optimal (less than 100 mg/dL).</DIV>
<DIV> </DIV>
<DIV>"Almost 75 percent of heart attack patients fell within recommended targets for LDL cholesterol, demonstrating that the current guidelines may not be low enough to cut heart attack risk in most who could benefit," said Dr. Gregg C. Fonarow, Eliot Corday Professor of Cardiovascular Medicine and Science at the David Geffen School of Medicine at UCLA and the study's principal investigator. </DIV>
<DIV> </DIV>
<DIV>While the risk of cardiovascular events increases substantially with LDL levels above 40–60 mg/dL, current national cholesterol guidelines consider LDL levels less than 100–130 mg/dL acceptable for many individuals. The guidelines are thus not effectively identifying the majority of individuals who will develop fatal and non-fatal cardiovascular events, according to the study's authors.</DIV>
<DIV> </DIV>
<DIV>Researchers also found that more than half of patients hospitalized for a heart attack had high-density lipoprotein (HDL) cholesterol levels characterized as poor by the national guidelines.</DIV>
<DIV> </DIV>
<DIV>Published in the January issue of the American Heart Journal, the study suggests that lowering guideline targets for LDL cholesterol for those at risk for cardiovascular disease, as well as developing better treatments to raise HDL cholesterol, may help reduce the number of patients hospitalized for heart attack in the future.</DIV>
<DIV> </DIV>
<DIV>"The study gives us new insight and intervention ideas to help reduce the number of heart attacks," said Fonarow, who is also director of the Ahmanson–UCLA Cardiomyopathy Center.</DIV>
<DIV> </DIV>
<DIV>"This is one of the first studies to address lipid levels in patients hospitalized for a heart attack at hospitals across the entire country."</DIV>
<DIV> </DIV>
<DIV>The research team used the national database sponsored by the American Heart Association's Get with the Guidelines program. The database includes information on patients hospitalized for cardiovascular disease at 541 hospitals across the country.</DIV>
<DIV> </DIV>
<DIV>Researchers analyzed data from 136,905 patients hospitalized for a heart attack nationwide between 2000 and 2006 whose lipid levels upon hospital admission were documented. This accounted for 59 percent of total hospital admissions for heart attack at participating hospitals during the study period.</DIV>
<DIV> </DIV>
<DIV>Among individuals without any prior cardiovascular disease or diabetes, 72.1 percent had admission LDL levels less than 130 mg/dL, which is the current LDL cholesterol target for this population. Thus, the vast majority of individuals having their first heart attack would not have been targeted for effective preventative treatments based on the criteria used in the current guidelines.</DIV>
<DIV> </DIV>
<DIV>The team also found that half of the patients with a history of heart disease had LDL cholesterol levels lower than 100 mg/dL, and 17.6 percent of patients had LDL levels below 70 mg/dL, which are guideline targets for LDL cholesterol in those at fair risk and at high risk for cardiovascular disease, respectively.</DIV>
<DIV> </DIV>
<DIV>The study also showed that HDL cholesterol, or "good cholesterol," levels have dropped in patients hospitalized for heart attack over the past few years, possibly due to increasing rates of obesity, insulin resistance and diabetes.</DIV>
<DIV> </DIV>
<DIV>Researchers found that 54.6 percent of patients had HDL levels below 40 mg/dL. Developing more effective treatments to boost HDL levels may help reduce the number of patients hospitalized for heart attacks, according to the authors.</DIV>
<DIV> </DIV>
<DIV>"We found that less than 2 percent of heart attack patients had both ideal LDL and HDL cholesterol levels, so there is room for improvement," said Fonarow.</DIV>
<DIV> </DIV>
<DIV>Fonarow said that only 59 percent of patients in the database had their lipid levels checked upon admission, which should be increased, since these early measurements can often help guide treatment decisions.</DIV>
<DIV> </DIV>
<DIV>He also noted that only 21 percent of patients in the study were taking lipid-lowering medications before admission, despite almost half having a prior history of cardiovascular events, which would prompt treatment.</DIV>
<DIV> </DIV>
<DIV>The national cholesterol guidelines are set by the National Cholesterol Education Program, part of the National Heart, Lung and Blood Institute of the National Institutes of Health.</DIV>
<DIV> </DIV>
<DIV>The study was sponsored by the Get with the Guidelines program, which is supported by the American Heart Association in part through an unrestricted education grant from the Merck Schering Plough Partnership.</DIV>
<DIV> </DIV>
<DIV>Fonarow has conducted research for GlaxoSmithKline and Pfizer and serves a consultant and has received honorarium from Abbott, AstraZeneca, GlaxoSmithKline, Merck, Pfizer and Schering Plough companies. He is also chair of the Get with the Guidelines steering committee.</DIV>
<DIV> </DIV>
<DIV>Other authors include: Dr. Amit Sachdeva, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA; Dr. Christopher P. Cannon, Brigham and Women's Hospital & Harvard Medical School, Boston, MA; Dr. Prakash C. Deedwania, Department of Cardiology, VA Medical Center/UCSF School of Medicine, San Francisco, CA; Dr. Kenneth A. LaBresh, Masspro, Waltham, MA; Dr. Sidney C. Smith, Jr., University of North Carolina School of Medicine, Chapel Hill, NC; David Dai, MS and Dr. Adrian Hernandez, Duke Clinical Research Institute, Durham, NC.</DIV>
<DIV> </DIV>
<DIV><STRONG>UCLA</STRONG> is California's largest university, with an enrollment of nearly 38,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 323 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize. </DIV>
<DIV> </DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=104732" height="1" width="1" />]]></description><pubDate>Mon, 12 Jan 2009 08:00:00 GMT</pubDate></item><item><author>Sandra Shagat</author><title>Dental School receives $1M pledge to endow chair honoring dean No-Hee Park</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-school-of-dentistry-receives-77138.aspx?link_page_rss=77138</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-school-of-dentistry-receives-77138.aspx</guid><description><![CDATA[<DIV>The Shapiro Family Charitable Foundation has made a $1 million pledge to the UCLA School of Dentistry&nbsp;for the establishment of the Dr. No-Hee Park Endowed Chair in Dentistry to honor the school's dean and foster excellence in research and scholarship in biomedical and dental science. </DIV>
<DIV>&nbsp;</DIV>
<DIV>The endowed professorship, which is intended to support the teaching and research activities of a distinguished faculty member at the dental school, will be held by the chair of the school's division of oral biology and medicine.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Park Chair is the latest gift to UCLA from Ralph and Shirley Shapiro, UCLA alumni with a long history of generous service and philanthropy to the campus, as well as to charitable organizations throughout Los Angeles and the United States. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"No-Hee Park has made significant advances in our understanding of cancer biology, and for&nbsp;10 years, he has provided exemplary service as dean of the UCLA School of Dentistry," said Ralph Shapiro. "My wife, Shirley, and I agree that the best way to honor his contributions is to support, in a lasting manner, the scholarship of another outstanding faculty member leading the field of dental medicine research."</DIV>
<DIV>&nbsp;</DIV>
<DIV>"I am deeply moved that Shirley and Ralph Shapiro have chosen to create this chair and to do so in my name," Park said. "The Shapiros are legendary UCLA leaders and philanthropists. This is the most significant honor of my career."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Shirley and Ralph Shapiro received bachelor's degrees from UCLA in 1959 and 1953, respectively, and Ralph earned a J.D. from the law school in 1958. Since obtaining their degrees, the Shapiros have been&nbsp;credited with more than $24 million in gifts to various UCLA initiatives, including scholarships for dental students. A prominent campus landmark, the Shirley and Ralph Shapiro Fountain at the top of Janss Steps, was named in recognition of the couple's longstanding commitment to the university. </DIV>
<DIV>&nbsp;</DIV>
<DIV>The Shapiros&nbsp;are very active participants in the campus community. Shirley serves on the boards of directors of Women &amp; Philanthropy and the Royce Center Circle and on the board of visitors of UCLA's School of the Arts and Architecture. Ralph, who is chairman of Avondale Investment Partners, is a longtime member of the board of directors of The&nbsp;UCLA Foundation and&nbsp;also serves on the board of advisors of the UCLA School of Law, the executive board&nbsp;of UCLA Medical Sciences and the advisory board of the California NanoSystems Institute at UCLA. In addition, he&nbsp;serves on the boards of directors of the United Cerebral Palsy Research and Education Foundation and the Spastic Children's Endowment Foundation and is a trustee of the Scripps Research Institute. </DIV>
<DIV>&nbsp;</DIV>
<DIV>The Shapiros have three children. Their son Peter William Shapiro currently serves as the president of the Shapiro Family Charitable Foundation.</DIV>
<DIV>&nbsp;</DIV>
<DIV>No-Hee Park holds the titles of dean and distinguished professor of dentistry at the UCLA School of Dentistry and the title of distinguished professor at the David Geffen School of Medicine at UCLA. Born in Korea, he received his D.D.S. degree from Seoul National University in 1968 and completed postgraduate training in periodontics in 1971. He earned a Ph.D. in pharmacology from the Medical College of Georgia in 1978, completed a postdoctoral fellowship at Harvard Medical School in 1980 and earned a D.M.D. degree from the Harvard School of Dental Medicine in 1982.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Park joined the faculty of the UCLA School of Dentistry in 1984 and has served as the director of the Dental Research Institute and as associate dean for research. Named dean of the school in 1998,&nbsp;he was appointed for a third term in 2006 and is the longest-serving dean in the dental school's history. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Under&nbsp;Park's leadership, the school has emerged as a research-intensive institution that currently ranks fifth among U.S. dental schools&nbsp;in funding&nbsp;by the National Institutes of Health. During the past&nbsp;10 years, Park eliminated a deficit, stabilized student clinic operations and increased the school's budget from $35 million in fiscal year 1998 to $65 million in fiscal year 2007.&nbsp;His successful fundraising efforts have yielded numerous renovations, six endowed chairs for the recruitment and retention of world-class faculty members, and more than $17 million in endowed funds. In fall 2008, Park's administration implemented a new D.D.S. curriculum designed to improve the integration of basic and clinical sciences and promote student leadership.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to serving in an administrative capacity, Park is a world-renowned scientist in the area of oral and head and neck cancer research and is credited with more than 150 publications in distinguished scientific journals. He has trained more than 100 research students, postdoctoral fellows and visiting faculty members during the past 25 years, many of whom are now faculty members of dental schools, medical schools and colleges of life sciences in the United States, Europe and Asia. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Park,&nbsp;the recipient of&nbsp;a Distinguished Scientist Award&nbsp;from the International Association for Dental Research, was named by&nbsp;Seoul National University as an alumnus&nbsp;of the year in 2007.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Dr. No-Hee Park Endowed Chair in Dentistry, the seventh endowed professorship for the dental school, is part of a 10-year campaign to increase the school's endowment by $30 million to ensure its continued financial stability and success.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>The UCLA School of Dentistry</B> is dedicated to improving the oral health of the people of California, the nation and the world through its teaching, research, patient care and public service initiatives. The school provides education and training programs that develop leaders in dental education, research, the profession and the community; conducts research programs that generate new knowledge, promote oral health and investigate the cause, prevention, diagnosis and treatment of oral disease; and delivers patient&#8209;centered oral health care to the community and state. For more information, visit <A href="http://www.dentistry.ucla.edu/">www.dentistry.ucla.edu</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>UCLA</B> is California's largest university, with an enrollment of nearly 38,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 323 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize. For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=102445" height="1" width="1" />]]></description><pubDate>Tue, 06 Jan 2009 17:30:00 GMT</pubDate></item><item><author>Rachel Champeau</author><title>Assessment technique lets scientists see brain aging before symptoms appear</title><link>http://newsroom.ucla.edu/portal/ucla/new-ucla-imaging-technique-coupled-75584.aspx?link_page_rss=75584</link><guid>http://newsroom.ucla.edu/portal/ucla/new-ucla-imaging-technique-coupled-75584.aspx</guid><description><![CDATA[<DIV>UCLA scientists have used innovative brain-scan technology developed at UCLA, along with patient-specific information&nbsp;on Alzheimer's disease risk,&nbsp;to help diagnose brain aging, often before symptoms appear. Published in the January issue of Archives of General Psychiatry, their study may offer a more accurate method&nbsp;for tracking brain aging. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Researchers used positron emission tomography (PET),&nbsp;which allows "a window into the brain" of living people and specifically reveals plaques and tangles, the hallmarks of neurodegeneration. The PET scans were&nbsp;complemented&nbsp;by information on patients' age and&nbsp;congnitive status and a genetic profile.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Combining key patient information with a brain scan may give us better predictive power in targeting those who may benefit from early interventions, as well as help test how well treatments are working," said study author Dr. Gary Small, who holds&nbsp;UCLA's Parlow-Solomon&nbsp;Chair on Aging and is a professor&nbsp;at the Semel Institute for Neuroscience and Human Behavior at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Scientists took PET brain scans&nbsp;of 76 non-demented volunteers&nbsp;after they had been intravenously injected with&nbsp;a new chemical marker called FDDNP, which binds to plaque and tangle deposits in the brain. Researchers were then able to pinpoint where these abnormal protein deposits were accumulating.</DIV>
<DIV>&nbsp;</DIV>
<DIV>They&nbsp;reported that older age correlated with higher concentrations of FDDNP in the medial and lateral temporal regions of the brain, areas involved with memory, where plaques and tangles usually collect. The average age of study volunteers was 67.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Thirty-four of the 76 volunteers carried the APOE-4 gene allele, which heightens the risk for developing Alzheimer's disease. This group demonstrated higher FDDNP levels in the frontal region of the brain, also involved in memory,&nbsp;than study participants without allele.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We found that for many volunteers, the imaging scans reflected subtle brain changes, which take place before symptoms manifest," said Small, who is also director of the&nbsp;UCLA Center on Aging.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Small noted that the brain will try&nbsp;to compensate for any problems, which is why cognitive symptoms may not become apparent until much later.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This type of scan offers an opportunity to see what is really going on in the brain," he said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Another subset of the volunteers had mild cognitive impairment (MCI), a condition that increases the risk of developing Alzheimer's disease. These 36 volunteers had higher measures of FDDNP in the medial temporal brain regions than&nbsp;normal volunteers. Those who had both MCI and the APOE-4 gene had higher<B> </B>concentrations of FDDNP in the medial temporal brain regions than volunteers&nbsp;who had&nbsp;MCI but not APOE-4.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We could see more advancing disease in those with mild cognitive impairment, who are already demonstrating some minimal symptoms," Small said. "Eventually, this imaging method, together with patient information like age, cognitive status and genetics, may help us better manage brain aging."</DIV>
<DIV>&nbsp;</DIV>
<DIV>According to Small, in the future, brain aging may be controlled similarly to high cholesterol or high blood pressure. Patients would receive a brain scan and perhaps a genetic test to predict their risk. Medications and other interventions&nbsp;could be prescribed, if necessary, to prevent or delay future neurodegeneration, allowing doctors to protect a healthy brain before extensive damage occurs. The brain scans may also prove helpful in tracking the effectiveness of treatments.</DIV>
<DIV>&nbsp;</DIV>
<DIV>PET, combined with the FDDNP probe, is the only imaging technology that offers a full profile of neurodegeneration that includes measures of <I>both</I> plaques and tangles&nbsp;— the physical evidence of Alzheimer's disease in the brain.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The fact that we can see tau tangles as well as amyloid plaques is critically important in early detection of brain aging, since the tangles are the first abnormal proteins that appear in the brain, long before dementia is clinically obvious to the physician," said Dr. Jorge R. Barrio, a study author and professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Such subtleties allow more insight into how the plaques and tangles spread and ultimately how Alzheimer's disease may develop.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Currently, the new FDDNP-PET scans are used in a research setting, but clinical trials are in development to bring the technology to wider patient use.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study was funded by both government and nonprofit agencies, including the National Institutes of Health, the U.S. Department of Energy, the Ahmanson Foundation, the Larry L. Hillblom Foundation and the Tamkin Foundation.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Additional UCLA authors include Prabha Siddarth, Ph.D.; Alison C. Burggren, Ph.D.; Linda M. Ercoli, Ph.D.; Karen J. Miller, Ph.D.; Dr. Helen Lavretsky; and Susan Y. Bookheimer, Ph.D, all&nbsp;from the UCLA Department of Psychiatry and Biobehavioral Sciences and the Semel Institute for Neuroscience and Human Behavior at UCLA; Vladimir Kepe, Ph.D.; S.C. Huang, Ph.D.; and Michael E. Phelps, Ph.D. from the UCLA Department of Molecular and Medical Pharmacology; and Paul M. Thompson, Ph.D., and Greg M. Cole, Ph.D., from the UCLA Department of Neurology.</DIV>
<DIV>&nbsp;</DIV>
<DIV><SPAN style="FONT-WEIGHT: bold">UCLA</SPAN> is California's largest university, with an enrollment of nearly 38,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 323 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize. </DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.<!--END PRINT--></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=102213" height="1" width="1" />]]></description><pubDate>Mon, 05 Jan 2009 21:00:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Vulnerability to post-traumatic stress disorder runs in families, study shows</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-researchers-report-that-vulnerability-76931.aspx?link_page_rss=76931</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-researchers-report-that-vulnerability-76931.aspx</guid><description><![CDATA[<DIV>Earthquakes have aftershocks — not just the geological kind but the mental kind as well. Just like veterans of war, earthquake survivors can experience post-traumatic stress disorder, depression and anxiety.</DIV>
<DIV> </DIV>
<DIV>In 1988, a massive earthquake in Armenia killed 17,000 people and destroyed nearly half the town of Gumri. Now, in the first multigenerational study of its kind, UCLA researchers studying survivors of that catastrophe have discovered that vulnerability to PTSD, anxiety and depression runs in families.</DIV>
<DIV> </DIV>
<DIV>Armen Goenjian, a research psychiatrist in the UCLA Department of Psychiatry and Biobehavioral Sciences, and colleagues studied 200 participants from 12 multigenerational families exposed to the earthquake. Participants suffered from varying degrees of the disorders. The researchers found that 41 percent of the variation of PTSD symptoms was due to genetic factors and that 61 percent of the variation of depressive symptoms and 66 percent of anxiety symptoms were attributable to genetics. Further, they found that a large proportion of the genetic liabilities for the disorders were shared.</DIV>
<DIV> </DIV>
<DIV>The research appears in the December issue of the journal Psychiatric Genetics.</DIV>
<DIV> </DIV>
<DIV>"This was a study of multigenerational family members — parents and offspring, grandparents and grandchildren, siblings, and so on — and we found that the genetic makeup of some of these individuals renders them more vulnerable to develop PTSD, anxiety and depressive symptoms," said Goenjian, a member of the UCLA–Duke University National Center for Child Traumatic Stress and lead author of the study.</DIV>
<DIV> </DIV>
<DIV>In addition, Goenjian noted, the study suggests that a large percentage of genes are shared between the disorders. <BR><BR>"That tracks with clinical experience," he said. "For example, in clinical practice, the therapist will often discover that patients who come in for treatment of depression have coexisting anxiety. Our findings show that a substantial portion of the coexistence can be explained on the basis of shared genes and not just environmental factors such as upbringing."</DIV>
<DIV> </DIV>
<DIV>The researchers used statistical methods to assess heritabilities. One method was used to determine the genetic component of a disorder such as PTSD. Then, a separate analysis was used to see if different phenotypes shared genes. The results showed that a significant amount of genes are shared between PTSD and depression, PTSD and anxiety, and finally depression and anxiety.</DIV>
<DIV> </DIV>
<DIV>Until now, Goenjian said, the only studies that have suggested such a heritability of PTSD have been twin studies. <BR><BR>"It's very hard to do family studies on PTSD because typically only single individuals, not whole families, are exposed to a particular trauma," he said. "In our study, we were able to avert this problem since all the subjects were exposed to the same severe trauma at the same time." <BR><BR>In fact, he said, the 200 participants all saw destroyed buildings throughout Gumri, 90 percent witnessed dead bodies left lying in the streets and 92 percent witnessed severely injured people.</DIV>
<DIV> </DIV>
<DIV>The findings are promising for the next step in understanding the underlying biology of these disorders, which is locating the specific genes involved, Goenjian said.</DIV>
<DIV> </DIV>
<DIV>Other authors on the paper included Julia N. Bailey, Ida S. Karayana, Ernest P. Noble and Terry Ritchie, all of UCLA; David P. Walling from the Collaborative Neuroscience Network; and Haig A. Goenjian from the Tulane University School of Medicine. <BR><BR>Funding for the study was provided by the Collaborative Neuroscience Network. The researchers report no conflicts of interest.</DIV>
<DIV> <SPAN style="FONT-WEIGHT: bold"></SPAN><SPAN style="FONT-WEIGHT: bold"></SPAN> <BR><A href="http://www.psychiatry.ucla.edu/"><SPAN style="FONT-WEIGHT: bold">The UCLA Department of Psychiatry and Biobehavioral Sciences</SPAN></A> within the David Geffen School of Medicine is home to faculty who are experts in the origins of and treatments for disorders of complex human behavior. The department is part of the Semel Institute for Neuroscience and Human Behavior at UCLA, a world-leading interdisciplinary research and education institute devoted to the understanding of complex human behavior and the causes and consequences of neuropsychiatric disorders.<BR><BR>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.<BR></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=98486" height="1" width="1" />]]></description><pubDate>Fri, 19 Dec 2008 08:00:00 GMT</pubDate></item><item><author>Amy Albin</author><title>Volunteers and their dogs to go caroling at UCLA children's hospital</title><link>http://newsroom.ucla.edu/portal/ucla/dogs-and-owners-to-carol-through-76949.aspx?link_page_rss=76949</link><guid>http://newsroom.ucla.edu/portal/ucla/dogs-and-owners-to-carol-through-76949.aspx</guid><description><![CDATA[<DIV><EM>(Note to Editors: Depending on the number of media outlets that attend, please be prepared to take turns filming inside hospital rooms due to limited space in patient care areas.)</EM></DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>WHAT:</STRONG></DIV>
<DIV>A group of volunteers and their dogs, all members of UCLA's People-Animal Connection (PAC), will hold their annual holiday caroling event. Dressed in holiday gear, the canine volunteer teams will stroll through the pediatric unit and playroom of Mattel Children's Hospital UCLA, singing songs and bringing holiday cheer to patients and staff.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>WHEN:</STRONG></DIV>
<DIV>10 a.m., Sunday, Dec. 21</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>WHERE:</STRONG></DIV>
<DIV>Mattel Children's Hospital UCLA (757 Westwood Blvd., Los Angeles, Calif. 90095)</DIV>
<UL>
<LI>10 a.m.: PAC volunteers will meet at the entrance to Mattel Children's Hospital to dress in holiday gear. 
<LI>10:10–11 a.m.: Caroling on the pediatric patient floor and playroom.</LI></UL>
<DIV>&nbsp;</DIV>
<DIV><STRONG>BACKGROUND:</STRONG></DIV>
<DIV>UCLA's PAC is an animal-assisted therapy program that brings trained volunteers and their dogs to UCLA hospital patients in order to provide a more humane environment for patients, family and staff and to help in the patient recovery process. Started in 1994 with one canine team, PAC has since grown to more than 50 teams that visit more than 40 diverse units of the hospital and more than 450 patients each month. The program is supported solely by donations. For more information, contact PAC director Jack Barron at 310-267-8184 or visit <A href="http://www.uclahealth.org/PAC">www.uclahealth.org/PAC</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>MEDIA CONTACT:</STRONG> </DIV>
<DIV>Amy Albin, UCLA Health Sciences Media Relations, 310-794-8672 (office) or 310-597-5765 (cell).</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>PARKING:</STRONG></DIV>
<DIV>Media trucks may park in the yellow loading zone on Gayley Avenue. All other vehicles can obtain a parking pass at Lot 1, located on Gayley Avenue. Passes will be under "Dog Caroling Event."</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=97789" height="1" width="1" />]]></description><pubDate>Wed, 17 Dec 2008 08:00:00 GMT</pubDate></item><item><author>Gwendolyn Driscoll</author><title>Nearly 6.4 million Californians lack health insurance, report shows</title><link>http://newsroom.ucla.edu/portal/ucla/nearly-6-4-million-californians-72721.aspx?link_page_rss=72721</link><guid>http://newsroom.ucla.edu/portal/ucla/nearly-6-4-million-californians-72721.aspx</guid><description><![CDATA[<DIV>Nearly one-fifth of all Californians under age 65 were without health insurance for all or some of 2007, according to a policy brief released today by the UCLA Center for Health Policy Research. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Drawing on comprehensive new data from the California Health Interview Survey (CHIS), the policy brief's authors found that 6.4 million Californians lacked any health insurance coverage for all or some of 2007, the most recent year for which comprehensive statewide data is available.</DIV>
<DIV>&nbsp;</DIV>
<DIV>This number represents 19.5 percent of all Californians under age 65, which is slightly lower than the uninsured rate of 20.2 percent in 2005. However, the gains were small and are now likely to be reversed by the current recession,&nbsp;according to&nbsp;the authors of the brief, "<A href="http://www.healthpolicy.ucla.edu/">Nearly 6.4 Million Californians Lacked Health Insurance in 2007</A><SPAN style="FONT-STYLE: italic">.</SPAN>"</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We're looking at the final year of an economic expansion and yet the gains in coverage were small," said lead author E. Richard Brown, director of the Center for Health Policy Research. "If the employer-based system can't increase health insurance in good times, how will they do it in bad? The answer is: they can't. Only comprehensive health care reform will change the equation." </DIV>
<DIV>&nbsp;</DIV>
<DIV>In 2003, the state's unemployment rate rose to 6.8 percent, which was a main driver of the decline in employment-based insurance from 56.4 percent&nbsp;in 2001 to 53.8 percent&nbsp;in 2003. Today in California, the statewide unemployment rate is more than 8 percent&nbsp;and is predicted to rise. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"It suggests we are now in for an even more severe decline in employment-based insurance than in 2003," said co-author and senior research associate Shana Alex Lavarreda. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Funded by grants from the California Endowment and the California Wellness Foundation, the policy brief brief draws on the latest comprehensive data from the CHIS, the largest state health survey in the nation. That data was collected from more than 50,000 Californians, including adults, teenagers and children, on a range of health topics. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"Our current system of health coverage locks too many families out," said Dr. Robert K. Ross, president and chief executive officer of the California Endowment. "We desperately need a system that ensures all Californians have access to health coverage, regardless of heath status, income and employment."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Easily searchable CHIS data on uninsurance and other topics by state, region and county can be found at <A href="http://www.askchis.com/">www.askchis.com</A>. A quick summary of health insurance statistics by county or region&nbsp;is available at the Center for Health Policy&nbsp;Research's&nbsp;updated <A href="http://www.healthsnapshots.org/profile.asp?groupid=1">Health SNAPSHOTS</A>. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"This policy brief is another example of the critical information that the UCLA Center for Health Policy Research is able to provide through analysis of data from the California Health Interview Survey," said Gary L. Yates, president and CEO of the California Wellness Foundation. "It is difficult to overestimate the relevance of this data source in times like these, when so many Californians lack adequate health coverage."</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.calendow.org/"><STRONG>The California Endowment</STRONG></A>, a private, statewide health foundation, was established in 1996 to expand access to affordable, quality health care for underserved individuals and communities and to promote fundamental improvements in the health status of all Californians.</DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.tcwf.org/"><STRONG>The California Wellness Foundation</STRONG></A> is an independent, private foundation created in 1992 with a mission to improve the health of the people of California by making grants for health promotion, wellness education and disease prevention.</DIV>
<DIV>&nbsp;</DIV>
<DIV>
<DIV><A href="http://www.askchis.com/"><SPAN style="FONT-WEIGHT: bold">The California Health Interview Survey (CHIS)</SPAN></A> is one of the largest health surveys in the United States. The CHIS is conducted by the UCLA Center for Health Policy Research in collaboration with the California Department of Public Health, the Department of Health Care Services and the Public Health Institute.</DIV></DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.healthpolicy.ucla.edu/"><SPAN style="FONT-WEIGHT: bold">The UCLA Center for Health Policy Research</SPAN></A> is of the nation's leading health policy research centers and the premier source of health-related information on Californians. </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=96964" height="1" width="1" />]]></description><pubDate>Mon, 15 Dec 2008 17:00:00 GMT</pubDate></item><item><author>Gwendolyn Driscoll</author><title>Obesity among state's low-income teens nearly triple that of more affluent peers</title><link>http://newsroom.ucla.edu/portal/ucla/obesity-among-california-s-low-72532.aspx?link_page_rss=72532</link><guid>http://newsroom.ucla.edu/portal/ucla/obesity-among-california-s-low-72532.aspx</guid><description><![CDATA[<DIV>California's low-income teenagers have a lot in common: Sugary soda. Fast-food restaurants. Too much television. Not enough exercise. The result: Low-income teenagers are almost three times more likely to be obese than teens from more affluent households, according to new research from the UCLA Center for Health Policy Research. </DIV>
<DIV>&nbsp;</DIV>
<DIV>In California, 21 percent of teenagers living in low-income families are obese, according to the new policy brief, "<A href="http://www.healthpolicy.ucla.edu/">Low-Income Adolescents Face More Barriers to Healthy Weight</A>." Low-income is defined as having income of less than $19,971 for a family of four or $12,755 for a family of two, according to federal poverty guidelines. In contrast, only 8 percent of teenagers living in families making more than $59,913 (family of four) or $38,265 (family of two) are obese. </DIV>
<DIV>&nbsp;</DIV>
<DIV>California is home to about 480,000 obese adolescents from all income levels. But the high rate of obesity among low-income teens suggests that barriers to healthy behaviors, healthy foods and physical activity not only continue to exist but have grown even larger. Those barriers include high numbers of neighborhood fast-food restaurants and low numbers of parks and other opportunities for physical activity. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"Our neighborhoods are literally making us fat," said Susan H. Babey, one of the policy brief's authors. "We need better strategies and more thoughtful urban planning if we are going to make our towns and cities livable, not just places where we live." </DIV>
<DIV>&nbsp;</DIV>
<DIV>Among other recommendations to combat teen obesity, the policy brief's authors urge city planners to consider zoning ordinances to regulate the number of fast-food restaurants while providing incentives to attract grocery stores&nbsp;and other&nbsp;outlets that stock fresh fruits and vegetables. The Los Angeles City Council recently used data from the UCLA Center for Health Policy Research to support such a moratorium on new fast-food restaurants in South Los Angeles. </DIV>
<DIV>&nbsp;</DIV>
<DIV>The policy brief's authors also called for greater opportunities for physical activity and education, as well as campaigns to promote family dinners and discourage excessive television viewing. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"The disparity in teen obesity prevalence among low-income and more affluent communities should serve as a wake-up call to policymakers," said Dr. Robert K. Ross, president and chief executive officer of The California Endowment, which funded the policy brief. "Where we live plays a critical role in shaping our health status. Elected officials can help improve the environmental factors that contribute to the poor health of Californians through local ordinances and statewide policy."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Among the findings of the policy brief:</DIV>
<DIV style="FONT-SIZE: 4px">&nbsp;</DIV>
<UL>
<LI>More sugary soda: 67 to 71 percent of low-income teens reported having at least one glass or can of soda on the previous day, compared with 55 percent of more affluent teens. </LI></UL>
<UL>
<LI>More fast food: 46 to 49 percent of low-income teens reported eating fast food on the previous day, compared with 37 percent of more affluent teens. </LI></UL>
<UL>
<LI>Fewer family meals: Up to 11 percent of low-income teens reported that they had never eaten dinner with a parent or guardian during the previous week. The rate is twice that of more affluent teens. </LI></UL>
<UL>
<LI>Fewer opportunities for organized sports: 36 to 37 percent of low-income teens were on a school sports team in the previous year, compared with 49 percent of more affluent teens. </LI></UL>
<UL>
<LI>Less physical activity: Nearly one in five, or 18 percent, of low-income teens did not get at least 60 minutes of physical activity in a week — the minimum amount of physical activity recommended by the 2005 federal Dietary Guidelines for Americans. </LI></UL>
<UL>
<LI>More television: 56 percent of low-income teens watch more than two hours of television per day, compared with 46 percent of more affluent teens. </LI></UL>
<UL></UL>
<DIV><B></B></DIV>
<DIV><STRONG></STRONG>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.healthpolicy.ucla.edu/">The UCLA Center for Health Policy Research</A> </STRONG>is of the nation's leading health policy research centers and the premier source of health-related information on Californians. </DIV>
<DIV><BR><STRONG><A href="http://www.askchis.com/">The California Health Interview Survey (CHIS)</A></STRONG>, is the nation's largest state health survey and one of the largest health surveys in the United States. </DIV>
<DIV><B></B></DIV>
<DIV>&nbsp;</DIV>
<DIV><B><A href="http://www.calendow.org/">The California Endowment</A></B>, a private, statewide health foundation, was established in 1996 to expand access to affordable, quality health care for underserved individuals and communities and to promote fundamental improvements in the health status of all Californians. </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=93893" height="1" width="1" />]]></description><pubDate>Wed, 10 Dec 2008 08:00:00 GMT</pubDate></item><item><author>Amy Albin</author><title>Multifaith event at medical center to showcase variety of holiday traditions</title><link>http://newsroom.ucla.edu/portal/ucla/multi-faith-event-at-reagan-ucla-72611.aspx?link_page_rss=72611</link><guid>http://newsroom.ucla.edu/portal/ucla/multi-faith-event-at-reagan-ucla-72611.aspx</guid><description><![CDATA[<DIV><SPAN style="FONT-WEIGHT: bold">WHAT: </SPAN></DIV>
<DIV>The Spiritual Care Department at Ronald Reagan UCLA Medical Center will host its 11th annual multicultural, multifaith exhibit, a fun and educational event that helps enrich people's understanding of a wide variety of religious and cultural holiday traditions. Holidays represented include Bodhi Day, Hanukkah, Christmas, Kwanzaa, Ramadan and Yule/Winter solstice. </DIV>
<DIV> </DIV>
<DIV>Visitors can sample the traditional holiday foods of each culture and learn about religious symbols, spiritual practices and prayers associated with each of these tradition's holiday celebrations.</DIV>
<DIV> </DIV>
<DIV><STRONG>WHO:</STRONG></DIV>
<DIV>Patients, their families and friends, medical center staff, and the general public are invited to participate.</DIV>
<DIV><SPAN style="FONT-WEIGHT: bold"></SPAN> </DIV>
<DIV><SPAN style="FONT-WEIGHT: bold">WHEN: </SPAN></DIV>
<DIV>11:30 a.m.–1:30 p.m., Thursday, Dec. 11</DIV>
<DIV> </DIV>
<DIV><SPAN style="FONT-WEIGHT: bold">WHERE: </SPAN></DIV>
<DIV>Ronald Reagan UCLA Medical Center, B-Level lower lobby </DIV>
<DIV>(757 Westwood Plaza, Los Angeles, Calif. 90095) </DIV>
<DIV> </DIV>
<DIV><SPAN style="FONT-WEIGHT: bold">BACKGROUND: </SPAN></DIV>
<DIV>UCLA's Spiritual Care Department offers a diverse program that includes multifaith spiritual care for patients, families and staff, and clinical pastoral education and training. </DIV>
<DIV> </DIV>
<DIV><SPAN style="FONT-WEIGHT: bold">MEDIA CONTACT: </SPAN></DIV>
<DIV>Amy Albin, UCLA Health Sciences Media Relations, 310-794-8672</DIV>
<DIV> </DIV>
<DIV><SPAN style="FONT-WEIGHT: bold">R.S.V.P. & PARKING: </SPAN></DIV>
<DIV>
<DIV>Please call media contact to R.S.V.P. and arrange parking.</DIV></DIV>
<DIV> </DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=91821" height="1" width="1" />]]></description><pubDate>Fri, 05 Dec 2008 08:00:00 GMT</pubDate></item><item><author>Amy Albin</author><title>UCLA signs historic memorandum with pediatric institution in Tokyo</title><link>http://newsroom.ucla.edu/portal/ucla/mattel-children-s-hospital-ucla-72613.aspx?link_page_rss=72613</link><guid>http://newsroom.ucla.edu/portal/ucla/mattel-children-s-hospital-ucla-72613.aspx</guid><description><![CDATA[<DIV>As part of a new initiative to create partnerships with pediatric research institutions around the globe, Mattel Children's Hospital UCLA has signed a memorandum of understanding with the department of pediatrics at Tokyo's Jikei University School of Medicine.</DIV>
<DIV><BR>The memorandum is the first among Mattel Children's Hospital's many planned agreements with leading institutions throughout Asia and Latin America. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Signed last month, the UCLA–Jikei University pact is a broad agreement in which both institutions express the intention of engaging in cooperative research and collaborating on a variety of other academic activities. The historic memorandum will help create a network&nbsp;through which physicians, scholars and administrators can&nbsp;exchange information on developments in pediatric education and research and help facilitate the translation of research into practice for pediatric diseases.<BR><BR>"By expanding our network throughout the Americas, Pacific Rim, India and beyond, we have the opportunity to exchange ideas and collaborate on cutting-edge research that will benefit children both at home and abroad," said Dr. Edward McCabe, physician-in-chief of Mattel Children's Hospital. "As a result, children everywhere will benefit from an improved quality of life."<BR><BR>In&nbsp;general terms, the memorandum of understading is an agreement to engage in the following types of activities:</DIV>
<DIV style="FONT-SIZE: 4px">&nbsp;</DIV>
<UL>
<LI>
<DIV>Develop visits and informal exchanges of faculty, scholars and administrators in specific areas of education, research and outreach.</DIV></LI>
<LI>
<DIV>Explore ways to cooperate in postgraduate education and training.</DIV></LI>
<LI>
<DIV>Organize joint conferences and scientific meetings on subjects of mutual interest.</DIV></LI>
<LI>
<DIV>Exchange academic information and materials.</DIV></LI>
<LI>
<DIV>Pursue avenues for student exchanges.</DIV></LI></UL>
<DIV><BR>
<DIV><B>Mattel Children's Hospital UCLA</B>, one of the highest-rated children's hospitals in Southern California, is a vital component of UCLA Medical Center, ranked by U.S. News &amp; World Report as the third best hospital in nation and best in the western United States for the past 19 years. Mattel Children's Hospital offers a full spectrum of primary and specialized medical care for infants, children and adolescents. The hospital's mission is to provide state&#8209;of-the-art treatment for children in a compassionate atmosphere, as well as to improve the understanding and treatment of pediatric diseases. For more information, visit <A href="http://www.uclahealth.org/mattel">www.uclahealth.org/mattel</A>. </DIV><BR>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.<BR></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=91464" height="1" width="1" />]]></description><pubDate>Fri, 05 Dec 2008 08:00:00 GMT</pubDate></item><item><author>Roxanne Moster</author><title>Shapiro family donates $2M to establish two chairs at Geffen School of Medicine</title><link>http://newsroom.ucla.edu/portal/ucla/shapiro-family-charitable-foundation-72525.aspx?link_page_rss=72525</link><guid>http://newsroom.ucla.edu/portal/ucla/shapiro-family-charitable-foundation-72525.aspx</guid><description><![CDATA[<DIV>The Shapiro Family Charitable Foundation has pledged $2 million to The UCLA Foundation to fund two endowed chairs, both of which will greatly enhance the research, teaching, patient care and public service mission of the David Geffen School of Medicine at UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The endowed Shapiro Family Chair in Child Development Studies and Cerebral Palsy, funded by a $1 million endowment, will support the teaching and research activities of a distinguished faculty member in the department of pediatrics who is dedicated to improving outcomes for children with developmental and behavioral problems. Examples would include working with children who have cerebral palsy, those who have parents with substance abuse problems and those who have experienced environmental deprivation. Studies will evaluate the developmental status of children from birth through 5 years of age in inpatient and outpatient settings. Presenting conditions may include high-risk status for developmental problems, as well as demonstrated delays in motor, cognitive, language and/or social-emotional development. The department is in the process of identifying a distinguished individual as chair holder.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The establishment of this chair will provide vital resources to promote innovative research and education in child development studies and cerebral palsy&nbsp;— and result in better treatments and programs for pediatric patients at Mattel Children's Hospital UCLA," said Dr. Edward R.B. McCabe, physician-in-chief of Mattel Children's Hospital UCLA and executive chair of the department of pediatrics at the David Geffen School of Medicine at UCLA. "We are grateful for this very generous gift from the Shapiro family."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Peter William Shapiro Chair for the Center for Cerebral Palsy will reside in the department of orthopaedic surgery at the Geffen School of Medicine. The creation of this chair supplies important resources to further promote and strengthen clinical services, professional and consumer education, and relevant research to meet the needs of people with cerebral palsy.</DIV>
<DIV>&nbsp;</DIV>
<DIV>William L. Oppenheim, director of the UCLA/Orthopaedic Hospital Center for Cerebral Palsy, said, "We at the Center for Cerebral Palsy are extremely grateful for Shirley, Ralph and Peter Shapiro's committed support to promote and enhance our teaching and clinical investigations, as they clearly understand our goal to emphasize ability over disability."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Peter Shapiro is especially dedicated to this area of medicine and plays a key role in helping to underwrite the Center for Cerebral Palsy's programs.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Eileen Fowler, the newly named holder of the chair, is the&nbsp;Center for Cerebral Palsy's&nbsp;director of research and education. She also is director of the Kameron Gait and Motion Analysis Laboratory and a faculty member&nbsp;at the Tarjan Center at UCLA, a University Center of Excellence.&nbsp;Fowler's research covers a variety of areas, including the effect of exercise and pharmacological agents on movement ability in persons with cerebral palsy and Duchenne muscular dystrophy. She was lead investigator&nbsp;of a multicenter study that demonstrated the benefits of exercise on strength, endurance and function in children with cerebral palsy. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Fowler completed her physical therapy degree at Northeastern University in Boston, worked as a physical therapist at Orthopaedic Hospital in Los Angeles for five years and received her Ph.D. from the physiological science department (formerly kinesiology) at UCLA, with a major in biomechanics and a minor in motor control. She was the director of the UCLA Rehabilitation Department's Functional Assessment Laboratory before joining the department of orthopaedic surgery, where she is currently associate professor. Fowler was integral to the development of the Center for Cerebral Palsy.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The Shapiros' generous gift to UCLA's pediatric and orthopaedic programs will help lead to exciting breakthroughs in child development and cerebral palsy," said Dr. Gerald S. Levey, vice chancellor for UCLA Medical Sciences and dean of the David Geffen School of Medicine at UCLA. "We applaud their commitment to support the work of our dedicated researchers and improve the lives of both pediatric and adult patients in need of lifesaving medical treatments."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Currently, Ralph Shapiro is chair of Avondale Investment Partners. He is on the board of advisors of the UCLA School of Law, is a member of the executive board for UCLA Medical Sciences, serves on the board of directors of The UCLA Foundation and is a member of the advisory board of the California NanoSystems Institute at UCLA. He also serves on the boards of directors of the United Cerebral Palsy Research and Education Foundation and the Spastic Children's Endowment Foundation and is a trustee of the Scripps Research Institute.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Shapiro earned his bachelor's degree in business administration in 1953 and his J.D. in 1958, both from UCLA. He and his wife, Shirley, who received her bachelor's degree from UCLA in 1959, have three children. The Shapiros are the founders of the Shapiro Family Charitable Foundation, and their son Peter William Shapiro is the current president. Between the foundation, personal giving and associated entities, they are credited with more than $24 million in gifts to UCLA.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Shirley Shapiro serves on the boards of directors of Women &amp; Philanthropy and the Royce Center Circle and on&nbsp;the board of visitors of&nbsp;UCLA's School of the Arts and Architecture. A prominent campus landmark, the Shirley and Ralph Shapiro Fountain at the top of Janss Steps, was named in recognition of the couple's longstanding commitment to the university.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Endowed chairs and professorships continue to play an increasingly crucial role in the recruitment and retention of outstanding university faculty. Reserved for the most distinguished scholars and teachers, including the best junior faculty, endowed chairs provide vital funds for the support of the chair holder's research, teaching and service activities. Donors continue to provide thoughtful and generous support for endowed chairs with the knowledge that their gifts supply a solid foundation for the enrichment of university programs and the recognition of academic excellence.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>The UCLA Department of Pediatrics</STRONG> was founded in 1950, and construction on the Marion Davies Children's Health Center was completed in 1962. Since that time, the pediatrics department has grown to include affiliations with Harbor–UCLA Medical Center, Martin Luther King Jr.–Harbor Hospital, Cedars–Sinai Medical Center and Olive View–UCLA Medical Center, and outpatient sites have expanded in the community. In 1998, UCLA's children's hospital was renamed Mattel Children's Hospital UCLA in recognition of a major gift by Mattel Inc.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>The UCLA Department of Orthopaedic Surgery</STRONG> provides consultation and treatment for disorders of the musculoskeletal system. Its faculty members provide comprehensive services for such specialties as joint replacement and reconstructive surgery, microvascular surgery, sports medicine, arthroscopy, foot and ankle surgery, hand surgery, pediatric orthopaedics, spinal diseases, orthopaedic trauma, orthopaedic oncology and metabolic bone disease. In 1998, UCLA and Los Angeles Orthopaedic Hospital formed a strategic alliance through which Orthopaedic Hospital was integrated with UCLA in the replacement facility for Santa Monica–UCLA Medical Center and Orthopaedic Hospital.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more information about UCLA's pediatric and orthopaedic surgery programs, please visit <A href="http://www.uclahealth.org/">www.uclahealth.org</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=90025" height="1" width="1" />]]></description><pubDate>Wed, 03 Dec 2008 08:00:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>Can you hear me now? How the inner ear's sensors are made</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-reveal-how-sensors-72148.aspx?link_page_rss=72148</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-scientists-reveal-how-sensors-72148.aspx</guid><description><![CDATA[<DIV><EM>(Editors: Images of normal and abnormal ear sensors in zebrafish are available upon request.)</EM></DIV>
<DIV>&nbsp;</DIV>
<DIV>A UCLA study shows for the first time how microscopic crystals form sound and gravity sensors inside the inner ear. Located at the ends of cilia&nbsp;— tiny cellular hairs in the ear that move and transmit signals&nbsp;— these crystals play an important role in detecting sound, maintaining balance and regulating movement.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Dislodged ear crystals are to blame for the most common form of vertigo.&nbsp;Known as&nbsp;benign paroxysmal positional vertigo, the disorder plagues up to 10 percent of people older than 60 and causes 20 percent of patients' dizziness complaints.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers' findings, published Nov. 30 in the advance online edition of the journal Nature, suggest a potential gene target for the treatment of&nbsp;people suffering from common hearing and balance problems related to cilia disorders.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"People have known for a long time about the importance of cilia for propelling sperm up the uterus and moving mucus out of the lungs,"&nbsp;said Kent Hill, associate professor of microbiology, immunology and molecular genetics at the David Geffen School of Medicine at UCLA&nbsp;and the UCLA College of Letters and Science. "Our study illustrates that cilia perform many additional jobs that are essential to how our bodies develop and work."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Hill's team employed high-speed, high-definition video imaging to watch cilia moving in real-time inside the developing ears of embryonic zebrafish. These small, bony fish undergo stages of development similar to humans and other vertebrates, making them useful models for research.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The researchers labeled cilia in the fish with fluorescent probes and used video microscopy to visualize the cilia and other inner ear structures. In&nbsp;the&nbsp;control group of fish, long cilia beat like tiny oars, causing tiny particles to circle in a vortex around them. The tornado of whirling particles accumulated at the proper location to form the inner ear's crystalline sensors.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We next blocked expression of a gene that controls dynein&nbsp;— a tiny molecular motor that drives cilia movement," said Hill. "When we examined the embryos, we saw that cilia movement came to a halt. As a result, the particles did not assemble in the correct site. So not only did ear crystals form in the wrong place, but they were misshapen and abnormally sized."</DIV>
<DIV>&nbsp;</DIV>
<DIV>"While it's been suggested that cilia movement contributes to the formation of ear crystals, this idea had never been tested before," he said. "Our findings show that cilia in the ear do move and demonstrate that cilia movement is needed for ear crystals to assemble in the right place."</DIV>
<DIV>&nbsp;</DIV>
<DIV>According to Hill, the findings offer promise for the treatment of patients with hearing disorders and people with ciliopathies, disorders marked by poor cilia function. These conditions include sperm-related infertility, polycystic kidney disease, lung and respiratory disorders, swelling of the brain, and reversal of the internal organs' sites from one side of the body to the other.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The idea that physical movement can influence vertebrate development is very provocative," Hill said. "Scientists typically look at whether a particular gene is switched on or off, or if a particular protein is activated that determines if a tissue develops normally. In this case, microscopic currents in the fluid surrounding developing tissue are affecting its development. We need to understand more details of this process and determine how common it is during development."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study was supported by grants from the National Institutes of Health, the National Science Foundation, the Human Frontier Science Program and the Arnold and Mabel Beckman Foundation.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Hill's collaborators included co-first coauthor Jessica Colantonio, Adam Langenbacher and Jau-Nian Chen of the David Geffen School of Medicine at UCLA, and co-first author Julien Vermot, David Wu and Scott Fraser of the Beckman Institute at the California Institute of Technology.</DIV>
<DIV>&nbsp;</DIV>
<DIV>
<DIV><B>UCLA</B> is California's largest university, with an enrollment of nearly 38,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 323 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize. For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=88501" height="1" width="1" />]]></description><pubDate>Sun, 30 Nov 2008 18:00:00 GMT</pubDate></item><item><author>Amy Albin</author><title>Pediatric patients, families to enjoy Thanksgiving meal at UCLA</title><link>http://newsroom.ucla.edu/portal/ucla/pediatric-patients-families-to-72147.aspx?link_page_rss=72147</link><guid>http://newsroom.ucla.edu/portal/ucla/pediatric-patients-families-to-72147.aspx</guid><description><![CDATA[<DIV><B>WHAT: </B></DIV>
<DIV>UCLA pediatric patients and their families will enjoy a delicious Thanksgiving meal at Mattel Children's Hospital UCLA thanks to a generous donation from Lawry's Prime Rib Restaurant of Beverly Hills, Calif. The traditional meal allows families to enjoy a meaningful holiday experience together.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>FILMING&nbsp;| PHOTO OPPORTUNITIES: </B></DIV>
<DIV>Children too ill to leave the hospital for the holidays and their families will enjoy the meal, which is&nbsp;being prepared&nbsp;for 150 people.&nbsp;Individual meals will include prime rib and/or a turkey sandwich, cranberry sauce, salad, chips and brownies. </DIV>
<DIV>&nbsp;</DIV>
<DIV><B>WHEN: </B></DIV>
<DIV>11 a.m.–1 p.m., Wednesday, Nov. 26</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>WHERE:</B></DIV>
<DIV>Child Life Playroom, fifth floor of Mattel Children's Hospital UCLA (757 Westwood Blvd., Los Angeles)</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>BACKGROUND:</STRONG></DIV>
<DIV>Lawry's has a history with Mattel Children's Hospital UCLA; the restaurant&nbsp;donated&nbsp;Christmas Day meals to patients and families in 2007 and&nbsp;has hosted&nbsp;pediatric patients&nbsp;at the annual Lawry's Beef Bowl event prior to the Rose Bowl game.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B>MEDIA CONTACT: </B></DIV>
<DIV>Amy Albin, UCLA Health Sciences Media Relations, 310-794-0777</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>R.S.V.P. &amp;</STRONG> <B>PARKING:</B></DIV>
<DIV>Please call media contact to R.S.V.P. and arrange parking.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=87777" height="1" width="1" />]]></description><pubDate>Tue, 25 Nov 2008 08:00:00 GMT</pubDate></item><item><author>Gwen Driscoll</author><title>San Joaquin Valley center of emerging health crisis among elderly</title><link>http://newsroom.ucla.edu/portal/ucla/new-report-san-joaquin-valley-71966.aspx?link_page_rss=71966</link><guid>http://newsroom.ucla.edu/portal/ucla/new-report-san-joaquin-valley-71966.aspx</guid><description><![CDATA[<DIV>Senior citizens in California's Central Valley region have the worst health in the state and may provide a snapshot of the challenges California faces over the next two decades&nbsp;— a time in which the elderly population is projected to double.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Diabetes, obesity and falls, as well as low mammography rates and sedentary lifestyles, are all more acute among older adults&nbsp;in the San Joaquin Valley than elsewhere in the state, according to a new report, "<A href="http://www.healthpolicy.ucla.edu/">Trends in the Health of Older Californians</A>," by the UCLA Center for Health Policy Research.</DIV>
<DIV>&nbsp;</DIV>
<DIV><B></B></DIV>
<DIV>Throughout the state, older adults are increasingly likely to report cancer, obesity, diabetes, high blood pressure, high cholesterol and the need for help with emotional problems. The use of medical care services has also risen,&nbsp;with&nbsp;increases in&nbsp;the percentage of older adults who went to the emergency room&nbsp;and&nbsp;those who&nbsp;made monthly or more frequent doctor visits.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This is a bad way to start the new century," said Steven P. Wallace, the report's author and associate director of the Center for Health Policy Research. "Unless there is an increased focus on the prevention and management of chronic diseases, the promise of a healthy and happy retirement will be unattainable for millions of Californians."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The report did note some positive trends, including improved screening rates for several types of cancer and a drop in the number of older women taking hormone-replacement therapy drugs, which&nbsp;have been linked to an increased risk of cardiovascular disease and breast cancer.</DIV>
<DIV>&nbsp;</DIV>
<DIV>This last change is linked to significant new information provided to doctors and their older patients about the dangers of hormone replacement therapy.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"It's an example of a concerted prevention effort that will have a long-term payoff in terms of better health and fewer health care costs," Wallace said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In the heavily Latino San Joaquin Valley, such doctor-patient prevention efforts may be harder due to problems in the health care system, language and cultural barriers, and limited community resources. In addition, a fear of using government health services&nbsp;because of&nbsp;immigration concerns, even among documented residents and U.S. citizens, remains a significant barrier to preventative health care, Wallace said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The proportion of older adults reporting diabetes in the San Joaquin Valley&nbsp;region increased from one in six in 2001 — just above the state average — to the highest in the state, with one in four reporting&nbsp;having diabetes in 2005. The San Joaquin Valley is also the only region of the state where mammography rates worsened between 2001 and 2005. In every other region, the proportion of older women&nbsp;who had undergone&nbsp;a recent mammogram increased.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The San Joaquin Valley also has particularly high rates of sedentary lifestyle, obesity and falls.</DIV>
<DIV>&nbsp;</DIV>
<DIV>California's elderly population is&nbsp;expected to become majority non-Caucasian&nbsp;by 2030, with Latinos&nbsp;among the largest ethnic groups.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The report looked at data gathered by the California Health Interview Survey (CHIS)&nbsp;over three different time periods: 2001, 2003 and 2005. </DIV>
<DIV>&nbsp;</DIV>
<DIV>Among the findings:</DIV>
<DIV style="FONT-SIZE: 4px">&nbsp;</DIV>
<UL>
<LI>The San Joaquin Valley region's elderly population&nbsp;has the highest rates of diabetes (25.7 percent)&nbsp;and reported high blood pressure (63.9 percent) in the state.</LI></UL>
<DIV></DIV>
<UL>
<LI>In 2005, 41.8 percent&nbsp;of older women in the San Joaquin Valley region reported having had&nbsp;no mammogram&nbsp;over the previous 12 months. The rate was nearly 10 points higher than all other regions and a 19-percent&nbsp;change for the worse since 2001. </LI></UL>
<DIV></DIV>
<UL>
<LI>After Imperial County, Kern and Stanislaus counties had California's highest rates of diabetes among the elderly: 30.6 percent&nbsp;in Kern and 31.3 percent&nbsp;in Stanislaus. </LI></UL>
<DIV></DIV>
<UL>
<LI>23&nbsp;percent&nbsp;of the San Joaquin Valley's elderly population is obese&nbsp;— more than three points higher than all other regions.</LI></UL>
<DIV></DIV>
<UL>
<LI>15.3 percent&nbsp;of the elderly population in the San Joaquin Valley reported having experienced a fall in the previous 12 months&nbsp;— more than three points higher than all other regions.</LI></UL>
<DIV></DIV>
<UL>
<LI>
<DIV>Almost one-quarter (23.9 percent) of low-income older adults in the San Joaquin Valley are food insecure, meaning they have trouble during the month obtaining sufficient nutritionally adequate food. This is particularly troubling given the fact that the&nbsp;region is among the most productive agricultural areas in the country.</DIV></LI></UL>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.chis.ucla.edu/main/default.asp?timeout=1">The California Health Interview Survey</A></STRONG>, conducted every two years by the UCLA Center for Health Policy&nbsp;Research, is the nation's largest state health survey and one of the largest health surveys in the United States. </DIV>
<DIV>&nbsp;</DIV>
<DIV><A href="http://www.healthpolicy.ucla.edu/"><STRONG>The UCLA Center for Health Policy Research</STRONG></A>&nbsp;is one of the nation's leading health policy research centers and the premier source of health-related information on Californians.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=85716" height="1" width="1" />]]></description><pubDate>Thu, 20 Nov 2008 08:00:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Red, red wine: How it fights Alzheimer's</title><link>http://newsroom.ucla.edu/portal/ucla/red-red-wine-how-if-fights-alzheimer-71974.aspx?link_page_rss=71974</link><guid>http://newsroom.ucla.edu/portal/ucla/red-red-wine-how-if-fights-alzheimer-71974.aspx</guid><description><![CDATA[<DIV>Scientists call it the "French paradox" — a&nbsp;society that, despite consuming food high&nbsp;in cholesterol and saturated fats, has long had low death rates from heart disease. Research has suggested it is the red wine consumed with all that fatty food that may be beneficial —&nbsp;and not only&nbsp;for cardiovascular health but&nbsp;in warding off certain tumors and even Alzheimer's disease.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Now, Alzheimer's researchers at UCLA, in collaboration with Mt. Sinai School of Medicine in New York, have discovered how red wine may reduce the incidence of the disease. Reporting in the Nov. 21 issue of the Journal of Biological Chemistry, David Teplow, a UCLA professor of neurology, and colleagues show how naturally occurring compounds in red wine called polyphenols block the formation of&nbsp;proteins that build the toxic plaques thought to destroy brain cells, and further, how they reduce the toxicity of existing plaques, thus reducing cognitive deterioration.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Polyphenols comprise a chemical class with&nbsp;more than&nbsp;8,000 members, many of which are found in high concentrations in wine, tea, nuts, berries, cocoa and&nbsp;various plants.&nbsp;Past&nbsp;research has suggested that such polyphenols may inhibit or prevent the buildup of toxic fibers composed primarily of two&nbsp;proteins — Aß40 and Aß42 — that deposit in the brain and form the plaques which have long been associated with Alzheimer's. Until now, however, no one understood the mechanics of how polyphenols worked.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Teplow's lab has been studying how amyloid beta (Aß) is involved in causing Alzheimer's. In this work,&nbsp;researchers monitored how&nbsp;Aß40 and Aß42&nbsp;proteins folded up and stuck to each other to produce aggregates that killed nerve cells in mice. They then treated the proteins with a polyphenol compound extracted from grape seeds. They&nbsp;discovered that polyphenols carried a one-two punch: They blocked the formation of the toxic aggregates of&nbsp;Aß&nbsp;and also decreased toxicity when they were combined with&nbsp;Aß before it was added to brain cells.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"What we found is pretty straightforward," Teplow said. "If the Aß proteins can't assemble, toxic aggregates can't form, and thus there is no toxicity. Our work in the laboratory, and Mt. Sinai's Dr. Giulio Pasinetti's work in mice, suggest that administration of the compound to Alzheimer's patients might block the development of these toxic aggregates, prevent disease development and also ameliorate existing disease."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Human clinical trials are next. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"No disease-modifying treatments of Alzheimer's&nbsp;now exist, and initial clinical trials of a number of different candidate drugs have been disappointing," Teplow said. "So we believe that this is an important next step."</DIV>
<DIV>&nbsp;</DIV>
<DIV>This work was supported by the National Institutes of Health; the Department of Veterans Affairs; the James J. Peters Veterans Affairs Medical Center Geriatric Research Education Clinical Center Program, Polyphenolics (to Giulio Pasinetti); grants from the Japan Human Science Foundation and the Mochida Memorial Foundation for Medical and Pharmaceutical Research; grants from the Alzheimer's Association; and the Jim Easton Consortium for Alzheimer's Drug Discovery and Biomarkers at UCLA (to David Teplow). Teplow reports no conflict of interests.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>The UCLA Department of Neurology</STRONG> encompasses more than a dozen research, clinical and teaching programs. These programs cover brain mapping and neuroimaging, movement disorders, Alzheimer's disease, multiple sclerosis, neurogenetics, nerve and muscle disorders, epilepsy, neuro-oncology, neurotology, neuropsychology, headaches and migraines, neurorehabilitation, and neurovascular disorders. The department ranks first among its peers nationwide in National Institutes of Health funding. For more information,&nbsp;visit <A href="http://neurology.medsch.ucla.edu/">http://neurology.medsch.ucla.edu</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=86345" height="1" width="1" />]]></description><pubDate>Thu, 20 Nov 2008 08:00:00 GMT</pubDate></item><item><author>Amy Albin</author><title>Harley bikers kick off holidays with toy run at Mattel Children's Hospital UCLA</title><link>http://newsroom.ucla.edu/portal/ucla/harley-bikers-kick-off-the-holidays-71915.aspx?link_page_rss=71915</link><guid>http://newsroom.ucla.edu/portal/ucla/harley-bikers-kick-off-the-holidays-71915.aspx</guid><description><![CDATA[<DIV><B>WHAT:</B> </DIV>
<DIV>For the 19th consecutive year, more than 100 motorcyclists and friends from the Southern California Anaheim-Fullerton H.O.G. (Harley Owner's Group) chapter will caravan on their bikes to deliver hundreds of holiday gifts for pediatric patients at Mattel Children's Hospital UCLA. Hospital staff and young patients will greet the bikers and get a chance to see and even sit on the Harleys. Bikers will form a "love line" to unload hundreds of toys, which&nbsp;will be distributed to pediatric patients&nbsp;during the holiday season and at other special&nbsp;times throughout the year.</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>WHEN: </B></DIV>
<DIV>9:15 a.m., Sunday, Nov. 23.</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>WHERE:</B> </DIV>
<DIV>Mattel Children's Hospital UCLA (757 Westwood Blvd., Los Angeles, CA 90095) </DIV>
<DIV>The event is at the Mattel Hospital entrance, located&nbsp;at Gayley Avenue and Charles E. Young Drive.</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>PARKING: </B></DIV>
<DIV>Media trucks&nbsp;may park in the yellow loading zone on Gayley Avenue. All other vehicles can obtain a parking pass&nbsp;at Lot 1, located on Gayley Avenue. Passes will be under "Harley Biker Toy Run."</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>PHOTO &amp; INTERVIEW OPPORTUNITIES:</B></DIV>
<UL>
<LI>9:15–9:30 a.m.: Motorcyclists begin arriving in waves at Mattel Children's Hospital UCLA; pediatric patients and medical staff will be there to greet them.</LI>
<LI>10 a.m.: Motorcyclists will form a "love line" to unload the toys from a truck.</LI>
<LI>10:30 a.m.:<STRONG> </STRONG>Hospital officials and pediatric patients will thank event organizer Joyce Savisky-Chance and bikers.</LI></UL>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>BACKGROUND: </B></DIV>
<DIV>Joyce Savisky-Chance, whose young son Johnnie was a patient at UCLA many years ago, started the annual event in his memory after he died following a long battle with cancer. UCLA's Child Life department distributes the toys to hospitalized children's parents, who often do not have the time or funds to shop for holiday gifts. Gifts are also distributed throughout the year to help celebrate patient's birthdays or after medical procedures. To view a video of last year's toy run, visit <A href="http://www.newsroom.ucla.edu/portal/ucla/electronicplay.aspx?fid=16537&amp;id=E0C5478">www.newsroom.ucla.edu/portal/ucla/electronicplay.aspx?fid=16537&amp;id=E0C5478</A>.</DIV>
<DIV><B></B>&nbsp;</DIV>
<DIV><B>MEDIA CONTACT:</B> </DIV>
<DIV>Amy Albin, Mattel Children's Hospital UCLA Media Relations, 310-794-8672 (office) or 310-597-5765 (cell)</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=85243" height="1" width="1" />]]></description><pubDate>Tue, 18 Nov 2008 08:00:00 GMT</pubDate></item><item><author>Elaine Schmidt</author><title>UCLA study reveals smoking's effect on nurses' health, death rates</title><link>http://newsroom.ucla.edu/portal/ucla/new-ucla-study-reveals-smoking-71590.aspx?link_page_rss=71590</link><guid>http://newsroom.ucla.edu/portal/ucla/new-ucla-study-reveals-smoking-71590.aspx</guid><description><![CDATA[<DIV>A new UCLA School of Nursing study is the first to reveal the devastating consequences of smoking on the nursing profession. Published in the November–December edition of the journal Nursing Research, the findings describe smoking trends and death rates among U.S. nurses and emphasize the importance of supporting smoking cessation programs in the nursing field.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Nurses witness firsthand how smoking devastates the health of their patients with cancer and respiratory and cardiovascular diseases," said principal investigator Linda Sarna, D.N.Sc, a professor at the UCLA School of Nursing. "Yet nurses struggle with nicotine addiction like the rest of the 45 million smokers in America. We are concerned that nurses who smoke may be less apt to support tobacco-control programs or encourage their patients to quit."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Sarna led a team of researchers who analyzed data from the Nurses' Health Study, a historic study on women's health. Launched at Brigham and Women's Hospital in the mid-1970s, the study relied upon surveys completed every two years by 237,648 female registered nurses about their health, including smoking habits.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The Nurses' Health Study is the largest study of women's health in the world," Sarna said. "From a workforce perspective, however, the findings also hold a mirror up to the well-being of nurses, the largest group of health care professionals in the country."</DIV>
<DIV>&nbsp;</DIV>
<DIV>The current UCLA research explored changes in smoking trends and death rates among female nurses enrolled in the Nurses' Health Study between 1976 and 2003, a span of 27 years.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Sarna and her colleagues&nbsp;compared the differences in death rates among nurses who never smoked, former smokers and current smokers. In all age groups, roughly twice as many current smokers had died in comparison to nurses who never smoked.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Quitting smoking made a big difference in enhancing longevity, especially among nurses in their late 70s," Sarna said. "Death rates among former smokers that age were 1.5 times higher than those of non-smokers, while current smokers were 2.3 times more likely to have died by that age than nurses who never smoked."</DIV>
<DIV>&nbsp;</DIV>
<DIV>According to the most recent data, the smoking rate among registered nurses nationwide is nearly 12 percent.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The rate of smoking among women in the Nurses' Health Study declined from 33.2 percent in 1976 to 8.4 percent in 2003. The number of cigarettes smoked per day also dropped. However, the daily number among current smokers still averaged more than 15 cigarettes, or over half a pack.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"When the Nurses' Health Study began in 1976, nursing education gave limited attention to smoking's effect on health. Today, the amount of time devoted to tobacco cessation in the curriculum remains inadequate," Sarna said.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"Nurses in the study demonstrated behavior patterns similar to women in the general population," she added. "For example, the younger nurses in the study began smoking before entering the profession, a pattern reflected by American women starting smoking at younger ages in general. Being a nurse did not make these women immune to nicotine addiction."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Although data from the Nurses' Health Study has been used by the U.S. Surgeon General, researchers and health care providers to craft health policy, the findings have rarely been directed to the nursing community itself.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"It is encouraging to see that fewer and fewer nurses are smoking, but we can't declare the problem solved," said Michelle Larkin, senior program officer for the Robert Wood Johnson Foundation, which funded the UCLA team's research. "The devastating effects of smoking are all too real for those nurses who still smoke. We need research to learn about the factors that lead them to smoke and more resources to help them quit."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Sarna's co-authors included Stella Bialous, Dr.P.H., president of Tobacco Policy International; Hee-Jin Jun, Sc.D., M.P.H., and Diane Feskanich, Sc.D., both&nbsp;of Brigham and Women's Hospital and Harvard University&nbsp;Medical School; Mary Ellen Wewers, Ph.D., M.P.H., professor and associate dean for research at the College of Public Health at Ohio State University; and Mary Cooley, Ph.D., a nurse scientist at the Dana-Farber Cancer Institute.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Nurses' Health Study was established by Dr. Frank Speizer at Brigham and Women's Hospital with funding from the National Institutes of Health.</DIV>
<DIV>&nbsp;</DIV>
<DIV>
<DIV><STRONG>UCLA</STRONG> is California's largest university, with an enrollment of nearly 38,000 undergraduate and graduate students. The UCLA College of Letters and Science and the university's 11 professional schools feature renowned faculty and offer more than 323 degree programs and majors. UCLA is a national and international leader in the breadth and quality of its academic, research, health care, cultural, continuing education and athletic programs. Four alumni and five faculty have been awarded the Nobel Prize. For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>. </DIV></DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=83407" height="1" width="1" />]]></description><pubDate>Thu, 13 Nov 2008 05:01:00 GMT</pubDate></item><item><author>Enrique Rivero</author><title>Researchers use chemical from medicinal plant to fight HIV</title><link>http://newsroom.ucla.edu/portal/ucla/researchers-use-chemical-from-71498.aspx?link_page_rss=71498</link><guid>http://newsroom.ucla.edu/portal/ucla/researchers-use-chemical-from-71498.aspx</guid><description><![CDATA[<DIV>Like other kinds of cells, immune cells lose the ability to divide as they age because a part of their chromosomes known as a telomere becomes progressively shorter with cell division. As a result, the cell changes in many ways, and its disease fighting ability is compromised.</DIV>
<DIV>&nbsp;</DIV>
<DIV>But a new UCLA AIDS Institute study has found that a chemical from the Astragalus root, frequently used in Chinese herbal therapy, can prevent or slow this progressive telomere shortening, which could make it a key weapon in the fight against HIV.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This has the potential to be either added to or possibly even replace the HAART (highly active antiretroviral therapy), which is not tolerated well by some patients and is also costly," said study co-author Rita Effros, a professor of pathology and laboratory medicine at the David Geffen School of Medicine at UCLA and member of the UCLA AIDS Institute.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study, to be published in the Nov. 15 print edition of the Journal of Immunology, is available online at <A href="http://www.jimmunol.org/cgi/content/full/181/10/7400">www.jimmunol.org/cgi/content/full/181/10/7400</A>. </DIV>
<DIV>&nbsp;</DIV>
<DIV>A telomere is a region at the end of every cell chromosome that contains repeated DNA sequences but no genes; telomeres act to protect the ends of the chromosomes and prevent them from fusing together&nbsp;— rather like the plastic tips that keep shoelaces from unraveling. Each time a cell divides, the telomeres get shorter, eventually causing the cell to reach a stage called replicative senescence, when it can no longer divide. This seems to indicate that the cell has reached an end stage, but, in fact, the cell has changed into one with new genetic and functional characteristics.</DIV>
<DIV>&nbsp;</DIV>
<DIV>A great deal of cell division must take place within the immune system for the system to function properly. For example, the so-called "killer" CD8 T-cells that help fight infection have unique receptors for particular antigens. When a virus enters the body, the killer T-cells whose receptors recognize that virus create, through division, versions of themselves that fight the invader.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Generally, the telomeres in cells are sufficiently long that they can divide many times without a problem. Moreover, when fighting infections, T-cells can turn on an enzyme called telomerase, which can prevent the telomeres from shortening.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The problem is that when we're dealing with a virus that can't be totally eliminated from the body, such as HIV, the T-cells fighting that virus can't keep their telomerase turned on forever," Effros said. "They turn off, and telomeres get shorter and they enter this stage of replicative senescence."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Previous studies have shown that injecting the telomerase gene into T-cells can keep the telomeres from shortening, enabling them to maintain their HIV-fighting function for much longer. This gene-therapy approach, however, is not a practical way to treat the millions of people living with HIV.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For the present study, rather than utilizing gene therapy, the researchers used a chemical called TAT2, which was originally identified from plants used in traditional Chinese therapy and which enhances telomerase activity in other cell types.</DIV>
<DIV>&nbsp;</DIV>
<DIV>They tested TAT2 in several ways. First, they exposed the CD8 T-cells from HIV-infected persons to TAT2 to see if the chemical not only slowed the shortening of the telomeres but improved the cells' production of soluble factors called chemokines and cytokines, which had previously been shown to inhibit HIV replication. It did.</DIV>
<DIV>&nbsp;</DIV>
<DIV>They then took blood samples from HIV-infected individuals and separated out the CD8 T-cells and the CD4 T-cells&nbsp;— those infected with HIV. They treated the CD8 T-cells with TAT2 and combined them with the CD4 T-cells in the dish and found that the treated CD8 cells inhibited production of HIV by the CD4 cells.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"The ability to enhance telomerase activity and antiviral functions of CD8 T-lymphocytes suggests that this strategy could be useful in treating HIV disease, as well as immunodeficiency and increased susceptibility to other viral infections associated with chronic diseases or aging," the researchers write.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to Effros, researchers were Steven Russell Fauce, Beth D. Jamieson, Ronald T. Mitsuyasu, Stan T. Parish, Christina M. Ramirez Kitchen and Otto O. Yang, all of UCLA, and Allison C. Chin and Calvin B. Harley of the Geron Corp.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Geron Corp., TA Therapeutics Ltd., the National Institutes of Health and the Frank Jernigan Foundation funded this study.<B> </B></DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG><A href="http://www.uclaaidsinstitute.org/">The UCLA AIDS Institute</A></STRONG>, established in 1992, is a multidisciplinary think tank drawing on the skills of top-flight researchers in the worldwide fight against HIV and AIDS, the first cases of which were reported in 1981 by UCLA physicians. Institute members include researchers in virology and immunology, genetics, cancer, neurology, ophthalmology, epidemiology, social sciences, public health, nursing and disease prevention. Their findings have led to advances in treating HIV, as well as other diseases, such as hepatitis B and C, influenza and cancer.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=81669" height="1" width="1" />]]></description><pubDate>Fri, 07 Nov 2008 08:00:00 GMT</pubDate></item><item><author>Mark Wheeler</author><title>Study IDs three effective treatments for child anxiety</title><link>http://newsroom.ucla.edu/portal/ucla/study-identifies-three-effective-70918.aspx?link_page_rss=70918</link><guid>http://newsroom.ucla.edu/portal/ucla/study-identifies-three-effective-70918.aspx</guid><description><![CDATA[<DIV>Treatment&nbsp;that combines&nbsp;a certain type of psychotherapy with an antidepressant medication is most likely to help children with anxiety disorders,&nbsp;but&nbsp;each treatment alone&nbsp;is also effective, according to a new study funded by the National Institute of Mental Health (NIMH), part of the National Institutes of Health.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study&nbsp;is currently available online in the New England Journal of Medicine.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Anxiety disorders are among the most common mental disorders affecting children and adolescents. Untreated anxiety can undermine a child's success in school, jeopardize his or her relationships with family and inhibit social functioning. </DIV>
<DIV>&nbsp;</DIV>
<DIV>"This study represents a significant advance in the treatment of children and adolescents with anxiety disorders," said study author Dr. John Piacentini, a professor of psychiatry and director of&nbsp;UCLA's Child OCD, Anxiety and Tic Disorders Program. UCLA was one of six study sites.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The Child/Adolescent Anxiety Multimodal Study randomly assigned 488 children between the ages of 7&nbsp;and 17 to one of the following four treatment options for a 12-week period:</DIV>
<DIV style="FONT-SIZE: 4px">&nbsp;</DIV>
<UL>
<LI>
<DIV>Cognitive behavioral therapy —&nbsp;a specific type of therapy that, for this study, taught children about anxiety and helped them face and master their fears by guiding them through structured tasks</DIV>
<LI>The antidepressant sertraline (Zoloft), a selective serotonin reuptake inhibitor 
<LI>Cognitive behavioral therapy&nbsp;combined with sertraline 
<LI>A placebo (sugar pill)</LI></UL>
<DIV>&nbsp;</DIV>
<DIV>The children, recruited from six regionally dispersed sites throughout the United States, all had moderate to severe separation anxiety disorder, generalized anxiety disorder or social phobia. Many also had coexisting disorders, including other anxiety disorders, attention-deficit hyperactivity disorder and behavioral problems.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Piacentini and colleagues found that 81 percent of the children and adolescents&nbsp;who received the combination treatment improved, compared&nbsp;with 60 percent in the therapy-only group, 55 percent in the sertraline-only group and 24 percent in the placebo group.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Results also showed that the treatments were safe. Children taking sertraline alone showed no more side effects than the children taking the placebo, and few children discontinued the trial due to side effects. In addition, no child attempted suicide —&nbsp;a rare side effect sometimes associated with antidepressant medications in children.</DIV>
<DIV>&nbsp;</DIV>
<DIV>The study&nbsp;findings echo previous studies in which sertraline and other&nbsp;selective serotonin reuptake inhibitors&nbsp;were found to be effective in treating childhood anxiety disorders. The study's results also&nbsp;provide further&nbsp;evidence that high-quality cognitive behavioral therapy, with or without medication, can effectively treat anxiety disorders in children, according to the researchers.</DIV>
<DIV>&nbsp;</DIV>
<DIV>In addition to&nbsp;UCLA, study sites&nbsp;included Duke University; Columbia University/New York University; Johns Hopkins University; Temple University/University of Pennsylvania; and the Western Psychiatric Institute and Clinic at the University of Pittsburgh Medical Center.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Faculty within the <STRONG>UCLA Department of Psychiatry and Biobehavioral Sciences</STRONG> are experts in the origins of and treatments for disorders of complex human behavior. The department is an integral part of the Semel Institute for Neuroscience and Human Behavior at UCLA, an interdisciplinary research and education institute devoted to the understanding of complex human behavior and the causes and consequences of neuropsychiatric disorders.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=80338" height="1" width="1" />]]></description><pubDate>Tue, 04 Nov 2008 08:00:00 GMT</pubDate></item><item><author>Amy Albin</author><title>Study finds fears of HIV transmission within families</title><link>http://newsroom.ucla.edu/portal/ucla/ucla-rand-harvard-study-finds-69055.aspx?link_page_rss=69055</link><guid>http://newsroom.ucla.edu/portal/ucla/ucla-rand-harvard-study-finds-69055.aspx</guid><description><![CDATA[<DIV>Despite ongoing efforts to educate the public about HIV, a new study by researchers from UCLA, the RAND Corp., Harvard University and Children's Hospital Boston has found that two-thirds of families with an HIV-infected parent experience fears about spreading HIV in the home.<BR><BR>The qualitative study is the first to interview multiple family members, including minor children, in families with an HIV-infected parent about their concerns over HIV transmission in the household. The findings will be published in the November issue of the peer-reviewed journal Pediatrics.<BR><BR>"We found that many of the worries were based on misconceptions about how HIV is spread," said lead study author Burt Cowgill, a staff researcher at the UCLA|RAND Center for Adolescent Health Promotion. "We also learned that HIV-infected parents had legitimate concerns about contracting infections such as a cold, flu or chicken pox while caring for a sick child. This knowledge could help pediatricians to address children's specific fears about HIV transmission as well as help clinicians who care for the HIV-infected parents."<BR><BR>Between March 2004 and March 2005, the team conducted interviews with 33 HIV-infected parents, 27 of their minor children (ages 9 to 17), 19 adult children and 15 caregivers (spouses, partners, grandparents or friends). All HIV-infected parents had previously participated in the RAND Corp.'s HIV Cost and Services Utilization Study, a national probability sample of people over 18 with known HIV infection.<BR><BR>Interview questions were open-ended and broad to elicit a detailed description of family members' experiences. In addition, follow-up questions focused on whether respondents' fears subsided over time and what was done in the household to address them.<BR><BR>In a majority of the families, participants reported HIV transmission-related fears in the household. Concerns included acquiring HIV through contact with blood from a parent's cut, through saliva by sharing a bathroom or kissing, or by sharing food or beverages. HIV-infected parents were also concerned about catching an opportunistic infection from a sick child or other family member, and they were especially concerned about caring for a child with chicken pox, a cold or the flu.<BR><BR>Families addressed their fears by educating children about how HIV is spread and establishing household rules and taking precautions to reduce risks. However, some of the fears were based on incorrect information and beliefs.<BR><BR>"Fears about disease may substantially affect the relationship between the HIV-infected parent and child," said senior author Dr. Mark Schuster, chief of general pediatrics at Children's Hospital Boston and professor of pediatrics at Harvard Medical School. "It is critical not only to provide children with age-appropriate information on how the disease is transmitted, but also to clear up any misconceptions."</DIV>
<DIV>&nbsp;</DIV>
<DIV>Schuster is also with the RAND Corp.</DIV>
<DIV>&nbsp;</DIV>
<DIV>Findings from this paper and others coming from the qualitative study will inform researchers of the specific needs of families with an HIV-infected parent and aid in the development of interventions aimed at addressing their needs.<BR><BR>This research was supported by the National Institute of Child Health and Human Development and the Centers for Disease Control and Prevention. The authors have no financial ties to disclose.<BR><BR>In addition to Cowgill and Schuster, study authors included Laura M. Bogart, Rosalie Corona and Gery Ryan.<BR><BR><STRONG><A href="http://www.rand.org/health/centers/adolescent/">The UCLA|RAND Center for Adolescent Health Promotion</A></STRONG>, a collaboration between the UCLA School of Public Health, the UCLA Department of Pediatrics and the RAND Corp., is a Prevention Research Center funded by the Centers for Disease Control and Prevention to conduct research on health-related issues relevant to children, adolescents and families.</DIV>
<DIV>&nbsp;</DIV>
<DIV>For more news, visit the <A href="http://www.newsroom.ucla.edu/">UCLA Newsroom</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=80013" height="1" width="1" />]]></description><pubDate>Mon, 03 Nov 2008 08:00:00 GMT</pubDate></item><item><author>Roxanne Moster</author><title>Pediatric patients celebrate Halloween at Mattel Children's Hospital UCLA</title><link>http://newsroom.ucla.edu/portal/ucla/pediatric-patients-at-mattel-children-70862.aspx?link_page_rss=70862</link><guid>http://newsroom.ucla.edu/portal/ucla/pediatric-patients-at-mattel-children-70862.aspx</guid><description><![CDATA[<DIV><B>WHAT:</B></DIV>
<DIV>Despite being in the hospital, pediatric patients at Mattel Children's Hospital UCLA will still get to celebrate Halloween this year, by dressing up in costumes, decorating pumpkins and watching a magic show. In addition, canine teams from UCLA's People-Animal Connection (PAC) program will don costumes and accompany the kids while they trick-or-treat through the hospital hallways. </DIV>
<DIV> </DIV>
<DIV><B>WHEN: </B></DIV>
<DIV>11 a.m.–1:30 p.m., Friday, Oct. 31 </DIV>
<UL>
<LI>11 a.m.: Creative arts, including crafts, face-painting and pumpkin-decorating 
<LI>11:45 a.m.: Magic show 
<LI>12:30 p.m.: PAC dogs greet kids, trick-or-treat parade begins</LI></UL>
<DIV><B></B> </DIV>
<DIV><B>WHERE:</B></DIV>
<DIV>Child Life Playroom, on the fifth floor of Mattel Children's Hospital UCLA (757 Westwood Blvd., Los Angeles)</DIV>
<DIV> </DIV>
<DIV><STRONG>BACKGROUND:</STRONG></DIV>
<DIV>The annual Halloween party is hosted by the hospital's Child Life/Child Development department in an effort to make sure kids and their siblings experience a memorable celebration. For the second year, Spirit Halloween, the country's largest seasonal Halloween retailer, has generously donated all costumes and accessories for pediatric families at UCLA's Westwood and Santa Monica hospitals. Art of Elysium, a nonprofit organization that facilitates creative arts activities with pediatric patients and families will organize Halloween crafts and face-painting, and Pun the Magician will host his annual magic show.</DIV>
<DIV> </DIV>
<DIV><B>MEDIA CONTACT: </B></DIV>
<DIV>Roxanne Moster, UCLA Health Sciences Media Relations, 310-794-0777</DIV>
<DIV> </DIV>
<DIV><STRONG>R.S.V.P. & PARKING:</STRONG></DIV>
<DIV>Please call media contact to R.S.V.P. and arrange parking.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=76147" height="1" width="1" />]]></description><pubDate>Thu, 30 Oct 2008 07:00:00 GMT</pubDate></item><item><author>Roxanne Moster</author><title>Blue Shield of California and UCLA reach an agreement</title><link>http://newsroom.ucla.edu/portal/ucla/blue-shield-of-california-and-69199.aspx?link_page_rss=69199</link><guid>http://newsroom.ucla.edu/portal/ucla/blue-shield-of-california-and-69199.aspx</guid><description><![CDATA[<DIV>After several months of negotiations, Blue Shield of California and the UCLA Health System have agreed to new contract terms. Both parties are pleased to announce a three-year agreement, providing for services through Dec. 31, 2011. </DIV>
<DIV>&nbsp;</DIV>
<DIV>The contract will allow for care to Blue Shield HMO and PPO members through all of the UCLA Hospital System facilities&nbsp;and will provide Blue Shield PPO members immediate access to the wide network of UCLA Medical Group primary care and subspecialty providers. (UCLA and other University of California employees are offered health insurance by Blue&nbsp;Cross but not currently by Blue Shield&nbsp;of California.)<SPAN style="COLOR: blue"><STRONG>&nbsp;</STRONG></SPAN><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p></DIV>
<DIV>&nbsp;</DIV>
<DIV>This agreement reflects Blue Shield and UCLA's joint commitment to provide Southern California communities with broad access to outstanding physicians and health care facilities. Members, including those from the California Public Employee Retirement System (CalPERS) and the Motion Picture Association, will benefit from UCLA's comprehensive offerings.</DIV>
<DIV>&nbsp;</DIV>
<DIV>"We are delighted to have UCLA hospitals and physicians back in our network," said Juan C. Davila, Blue Shield's vice president of network management. "Our nearly 595,000 members in Los Angeles County will have broader access to quality medical care as a result of this agreement. Now that we have concluded this agreement, we are looking forward to jointly growing our membership in the Greater Los Angeles area."</DIV>
<DIV>&nbsp;</DIV>
<DIV>"This was a very welcome event for all participants, who have worked hard and long to come to an&nbsp;agreement," said Dr. Thomas E. Sibert, president of the&nbsp;UCLA Faculty Practice Group. "Most important, however, in any resolution like this is the chance to once again restore a full relationship between families and individuals in Blue Shield who need medical services and the UCLA Health System. We deeply regret any disruption in that relationship and look forward to helping our Blue Shield patients with their health care."</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>Blue Shield of California</STRONG>, an independent member of the Blue Shield Association, is a not-for-profit health plan dedicated to providing Californians with access to high-quality care at a reasonable price. Founded in 1939, it now has 3.4 million members, 4,700 employees, one of the largest provider networks and more than 20 office locations, providing a wide range of commercial and government products throughout the state. The company has contributed $100 million over the past three years to the Blue Shield of California Foundation to fund nonprofit organizations that improve access to quality health care in California. Contact your local agent or broker for more information about Blue Shield products and services, or visit the Blue Shield of California website at <A href="http://www.blueshieldca.com/">www.blueshieldca.com</A>.</DIV>
<DIV>&nbsp;</DIV>
<DIV><STRONG>The UCLA Health System</STRONG>, composed of the UCLA Hospital System and&nbsp;the UCLA Medical Group and its affiliates, has provided the best in health care and&nbsp;the most advanced treatment options to the people of Los Angeles and the world for more than half a century. UCLA's preeminence in health care —&nbsp;a strength that comes from the union of research, teaching and excellence in patient care —&nbsp;continues to be recognized nationally, internationally and in numerous forums. The clinical programs of Ronald Reagan UCLA Medical Center, Santa Monica–UCLA Medical Center and Orthopaedic Hospital, the Resnick Neuropsychiatric Hospital at UCLA,&nbsp;and Mattel Children's Hospital UCLA&nbsp;comprise a system of hospital care that is unparalleled in California. Ronald Reagan UCLA Medical&nbsp;Center is&nbsp;consistently ranked one of the top five hospitals in the nation and the best in the western United States by U.S.&nbsp;News &amp; World Report<EM>.</EM> At the same time, the UCLA Medical Group has been ranked among the best in Southern California for four successive years by the Integrated Healthcare Association. UCLA physicians and hospitals will continue to be world leaders in the full range of care, from maintaining the health of families to the diagnosis and treatment of complex illnesses. For more information about the UCLA Health System, visit <A href="http://www.uclahealth.org/">www.uclahealth.org</A>.</DIV> <img src="http://newsroom.ucla.edu/rss.ashx?id=74131" height="1" width="1" />]]></description><pubDate>Fri, 24 Oct 2008 07:00:00 GMT</pubDate></item></channel></rss>